WorldWideScience

Sample records for antigen psa isoforms

  1. Differentiation of lethal and non lethal prostate cancer:PSA and PSA isoforms and kinetics

    Institute of Scientific and Technical Information of China (English)

    H Ballentine Carter

    2012-01-01

    Prostate-specific antigen (PSA) testing for the early diagnosis of prostate cancer has led to a decrease in cancer mortality.However,the high prevalence of low-grade prostate cancer and its long natural history,competing causes of death in older men and treatment patterns of prostate cancer,have led to dramatic overtreatment of the disease.Improved markers of prostate cancer lethality are needed to reduce the overtreatment of prostate cancer that leads to a reduced quality of life without extending life for a high proportion of men.The PSA level prior to treatment is routinely used in multivariable models to predict prostate cancer aggressiveness.PSA isoforms and PSA kinetics have been associated with more aggressive phenotypes,but are not routinely employed as part of prediction tools prior to treatment.PSA kinetics is a valuable marker of lethality post treatment and routinely used in determining the need for salvage therapy.

  2. Prostate-specific antigen (PSA) blood test

    Science.gov (United States)

    Prostate-specific antigen; Prostate cancer screening test; PSA ... PSA testing is an important tool for detecting prostate cancer, but it is not foolproof. Other conditions can cause a rise in PSA, including: A larger prostate ...

  3. Proteolytic activity of prostate-specific antigen (PSA towards protein substrates and effect of peptides stimulating PSA activity.

    Directory of Open Access Journals (Sweden)

    Johanna M Mattsson

    Full Text Available Prostate-specific antigen (PSA or kallikrein-related peptidase-3, KLK3 exerts chymotrypsin-like proteolytic activity. The main biological function of PSA is the liquefaction of the clot formed after ejaculation by cleavage of semenogelins I and II in seminal fluid. PSA also cleaves several other substrates, which may explain its putative functions in prostate cancer and its antiangiogenic activity. We compared the proteolytic efficiency of PSA towards several protein and peptide substrates and studied the effect of peptides stimulating the activity of PSA with these substrates. An endothelial cell tube formation model was used to analyze the effect of PSA-degraded protein fragments on angiogenesis. We showed that PSA degrades semenogelins I and II much more efficiently than other previously identified protein substrates, e.g., fibronectin, galectin-3 and IGFBP-3. We identified nidogen-1 as a new substrate for PSA. Peptides B2 and C4 that stimulate the activity of PSA towards small peptide substrates also enhanced the proteolytic activity of PSA towards protein substrates. Nidogen-1, galectin-3 or their fragments produced by PSA did not have any effect on endothelial cell tube formation. Although PSA cleaves several other protein substrates, in addition to semenogelins, the physiological importance of this activity remains speculative. The PSA levels in prostate are very high, but several other highly active proteases, such as hK2 and trypsin, are also expressed in the prostate and may cleave protein substrates that are weakly cleaved by PSA.

  4. Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements

    Science.gov (United States)

    McJimpsey, Erica L.

    2016-02-01

    The prostate-specific antigen (PSA) assays currently employed for the detection of prostate cancer (PCa) lack the specificity needed to differentiate PCa from benign prostatic hyperplasia and have high false positive rates. The PSA calibrants used to create calibration curves in these assays are typically purified from seminal plasma and contain many molecular forms (intact PSA and cleaved subforms). The purpose of this study was to determine if the composition of the PSA molecular forms found in these PSA standards contribute to the lack of PSA test reliability. To this end, seminal plasma purified PSA standards from different commercial sources were investigated by western blot (WB) and in multiple research grade PSA ELISAs. The WB results revealed that all of the PSA standards contained different mass concentrations of intact and cleaved molecular forms. Increased mass concentrations of intact PSA yielded higher immunoassay absorbance values, even between lots from the same manufacturer. Standardization of seminal plasma derived PSA calibrant molecular form mass concentrations and purification methods will assist in closing the gaps in PCa testing measurements that require the use of PSA values, such as the % free PSA and Prostate Health Index by increasing the accuracy of the calibration curves.

  5. Generation of monoclonal antibodies against prostate specific antigen (PSA) for the detection of PSA and its purification

    International Nuclear Information System (INIS)

    The prostate cancer in Cuba is a problem of health (2672 diagnosed cases and 2769 deaths in 2007). Various diagnostic methods have been implemented for the detection and management of this disease, emphasizing among them (PSA) prostate-specific antigen serological determination. At this work was generated and characterized a panel of 11 antibodies (AcMs) monoclonal IgG1 detected with high affinity described major epitopes of the PSA, both in solution and attached to the test plate. From the panel obtained AcMs was the standardization of an essay type ELISA for the detection of serum total PSA (associated and free) equimolar, based on antibody monoclonal CB-PSA.4 in the coating and the CB-PSA.9 coupled with biotin as liner, with a detection limit of 0.15 ng/mL. Similarly, standardized system for detection in serum free PSA, based on the AcMs CB-PSA.4 (coating) and CB-PSA.2 coupled with biotin (liner), with a detection limit of 0.5 ng/mL. Finally, with the purpose of using PSA as standard in trials type ELISA, developed a simple method of inmunopurificación based on the AcM, CB-PSA.2, which was obtained the PSA with a purity exceeding 90%. Immunoassay Centre on the basis of the AcMs panel and the results of this study, developed and recorded two diagnostic systems for the detection of PSA in human serum. (author)

  6. Arraying prostate specific antigen PSA and Fab anti-PSA using light-assisted molecular immobilization technology

    Science.gov (United States)

    Parracino, Antonietta; Neves-Petersen, Maria Teresa; di Gennaro, Ane Kold; Pettersson, Kim; Lövgren, Timo; Petersen, Steffen B

    2010-01-01

    We here report for the first time the creation of prostate specific antigen (PSA) and Fab anti-PSA biosensor arrays using UV light-assisted molecular immobilization (LAMI), aiming at the detection and quantification of PSA, a cancer marker. The technology involves formation of free, reactive thiol groups upon UV excitation of protein aromatic residues located in spatial proximity of disulphide bridges, a conserved structural feature in both PSA and Fab molecules. The created thiol groups bind onto thiol reactive surfaces leading to oriented covalent protein immobilization. Protein activity was confirmed carrying out immunoassays: immobilized PSA was recognized by Fab anti-PSA in solution and immobilized Fab anti-PSA cross-reacted with PSA in solution. LAMI technology proved successful in immobilizing biomedically relevant molecules while preserving their activity, highlighting that insight into how light interacts with biomolecules may lead to new biophotonic technologies. Our work focused on the application of our new engineering principles to the design, analysis, construction, and manipulation of biological systems, and on the discovery and application of new engineering principles inspired by the properties of biological systems. PMID:20665692

  7. A portable chemiluminescence imaging immunoassay for simultaneous detection of different isoforms of prostate specific antigen in serum.

    Science.gov (United States)

    Liu, Anran; Zhao, Fang; Zhao, Yuewu; Shangguan, Li; Liu, Songqin

    2016-07-15

    A multianalyte chemiluminescence (CL) imaging immunoassay strategy for sensitive detection of different isoforms of prostate specific antigen (PSA) was developed. The microtiter plates were fabricated by simultaneously immobilizing of free-PSA (f-PSA) and total-PSA (t-PSA) capture antibody on nitrocellulose (NC) membrane. Each of the array were spotted in replicates of six spots within a spacing of 2mm. 16 or 48 detection wells were integrated on a single NC membrane and each well could be used as a microreactor and microanalysis chamber. Under a sandwiched immunoassay, the CL signals on each sensing site were collected by a charge-coupled device (CCD), presenting an array-based chemiluminescence imaging. Soybean peroxidase (SBP) was used to label f-PSA or t-PSA monoclonal antibody. With the amplification effects of two enhancers, 3-(10'-phenothiazinyl) propane-1-sulfonate (SPTZ) and 4-morpholinopyridine (MORP), the CL intensity could significantly enhanced, which improved the sensing sensitivity and detection limit. Under the optimal conditions, the linear response to the analyte concentration ranged from 0.01-36.7ng/mL and 0.02-125ng/mL for f-PSA and t-PSA, respectively. The results for the detection of forty serum samples from prostate cancer patients and cancer-free patients showed good agreement with the clinical data, suggesting that the proposed assay had acceptable accuracy. The proposed CL imaging immunoassay possess high throughput and acceptable reproducibility, stability and accuracy, which made it great potential to available to distinguish different isoforms of PSA in serum samples. PMID:26922048

  8. A population study of fasting time and serum prostate-speciifc antigen (PSA) level

    Institute of Scientific and Technical Information of China (English)

    Cheryl K Lau; Maggie Guo; Jeannine A Viczko; Christopher T Naugler

    2014-01-01

    Prostate cancer is one of the most common cancers in men. Traditional screening and diagnostic methods include digital rectal examinations(DREs), biopsies and serum prostate‑speciifc antigen(PSA) tests, with the latter being the more popular. PSA is a biomarker for prostate cancer; however, it is highly sensitive to external factors as well as other prostate diseases. As such, the reliability of of the serum PSA level as a sole screening and diagnostic tool for prostate cancer is controversial. Recently, it has been shown that fasting extremes can affect concentrations of serum chemistry analytes, thus raising the question of whether or not fasting has an effect on the highly sensitive PSA biomarker. Patients testing for serum PSA levels are often concomitantly submitting to other tests that require fasting, subjecting certain patients to a fasting PSA level while others not. The objective of this study was to investigate whether this discrepancy in fasting state translates into an effect on serum PSA levels. Serum PSA levels and fasting time records for 157276 men who underwent testing at Calgary Laboratory Services(CLS; Calgary, Alberta, Canada) between 01January 2010 and 31March 2013 were accessed. Linear regression models of mean PSA levels and fasting times revealed a statistically important relationship at certain fasting times. Applying a dynamic mathematical model to explore the clinical effect of fasting suggests minimal impact on serum PSA result interpretation. Thus, patients can be tested for serum PSA levels regardless of their fasting state.

  9. Impact of capillary conditioning and background electrolyte composition on capillary electrophoresis analysis of prostate specific antigen isoforms.

    Science.gov (United States)

    Farina-Gomez, Noemi; Puerta, Angel; Gonzalez, Monica; Diez-Masa, Jose Carlos; de Frutos, Mercedes

    2016-04-22

    Glycoproteins expressed in the human body can experience modifications as result of pathological situations. Detection of those changes can be useful as disease biomarkers. As a result of these modifications, size and/or electrical charge of the glycoprotein can be altered. Migration in capillary zone electrophoresis (CZE) is governed by the size to charge ratio of the analyte and therefore this separation technique can be used to monitor those modifications. At its turn, the alteration of the electrophoretical pattern of a given glycoprotein could be used as disease biomarker. To this aim, high repeatability for separation of a large number of peaks for a given glycoprotein is desirable. For prostate cancer, new markers are needed to decrease the high number of false positive results provided by the biomarkers currently used in clinics. In this sense, CZE methods for analysis of the several prostate specific antigen (PSA) peaks which this glycoprotein exhibit, called isoforms and containing one or more glycoforms, could be useful to study the PSA pattern as prostate cancer marker. In this study two complementary strategies to achieve both lot-to-lot capillary repeatability and high resolution of a large number of PSA isoforms are developed. Better performance and precision have been obtained for capillaries conditioned with HCl than for those conditioned with NaOH. Optimization of the background electrolyte (BGE) pH value to 8.0 and inclusion of 3M urea on its composition were the two factors of highest impact for enhancing resolution of the highest number of PSA peaks. Under the optimized conditions for capillary conditioning and BGE pH and composition, long-term resolution of 10 isoforms of PSA was achieved. Inter-day (n=3) %RSD was 0.55 for the ratio tm/tEOF, 1.15 for μeff, and 5.02 for % Acorr of the PSA peaks. PMID:27018191

  10. Portable smartphone quantitation of prostate specific antigen (PSA) in a fluoropolymer microfluidic device

    OpenAIRE

    Barbosa, Ana I.; Gehlot, Poonam; Sidapra, Kalpita; Edwards, Alexander D.; Reis, Nuno M.

    2015-01-01

    We present a new, power-free and flexible detection system named MCFphone for portable colorimetric and fluorescence quantitative sandwich immunoassay detection of prostate specific antigen (PSA). The MCFphone is composed by a smartphone integrated with a magnifying lens, a simple light source and a miniaturised immunoassay platform, the Microcapillary Film (MCF). The excellent transparency and flat geometry of fluoropolymer MCF allowed quantitation of PSA in the range 0.9 to 60 ng/ml with < ...

  11. Contribution of allelic variability in prostate specific antigen (PSA & androgen receptor (AR genes to serum PSA levels in men with prostate cancer

    Directory of Open Access Journals (Sweden)

    Sushant V Chavan

    2014-01-01

    Full Text Available Background & objectives: Wide variability in serum prostate specific antigen (PSA levels exists in malignant conditions of the prostate. PSA is expressed in normal range in 20 to 25 per cent of prostate cancer cases even in presence of high grade Gleason score. This study was aimed to assess the influence of genetic variants exhibited by PSA and androgen receptor (AR genes towards the variable expression of PSA in prostate cancer. Methods: Pre-treatment serum PSA levels from 101 prostate cancer cases were retrieved from medical record. PSA genotype analysis in promoter region and AR gene microsatellite Cytosine/Adenine/Guanine (CAG repeat analysis in exon 1 region was performed using DNA sequencing and fragment analysis techniques. Results: A total of seven single nucleotide polymorphisms (SNPs in the PSA promoter region were noted. Only two SNPs viz., 158G/A (P<0.001 in the proximal promoter region and -3845G/A (P<0.001 in enhancer region showed significant association with serum PSA levels. The carriers of homozygous GG genotype (P<0.001 at both of these polymorphic sites showed higher expression of PSA whereas homozygous AA genotype (P<0.001 carriers demonstrated lower PSA levels. The combination effect of PSA genotypes along with stratified AR CAG repeats lengths (long, intermediate and short was also studied. The homozygous GG genotype along with AR long CAG repeats and homozygous AA genotype along with AR short CAG repeats at position -3845 and -158 showed strong interaction and thus influenced serum PSA levels. Interpretation & conclusions: The genetic variants exhibited by PSA gene at positions -3845G/A and -158G/A may be accountable towards wide variability of serum PSA levels in prostate cancer. Also the preferential binding of G and A alleles at these polymorphic sites along with AR long and short CAG repeats may contribute towards PSA expression.

  12. Postoperative monitoring of prostate-specific antigen (PSA after treatment with high-intensive focused ultrasound (HIFU

    Directory of Open Access Journals (Sweden)

    Blyumberg B.I.

    2012-12-01

    Full Text Available Research objective: to estimate efficiency of treatment of prostate cancer using high-intensive focused ultrasound on the basis of laboratory analysis of postoperative level prostate-specific antigen (PSA. Objects of research. Objects of research consisted of 110 patients treated in urological clinic of Hospital n.a. S. R. Mirotvortsev (Saratov State Medical University during the period February, 2009 — March, 2012. Patients took 110 sessions of primary operative treatment of prostate cancer by HIFU therapy method. Technique and research methods. Concentration of PSA in blood changed in all patients every 1,5 month within 6 months after operation, irrespective of its kind (including after repeated HIFU, further — after every 3 month till one year, and later on after 6 months. We were guided by references of the International Consensus, which considers PSA level more than 0,5 ng/ml in blood after 3 months of treatment to be unsatisfactory result. We also headed for PSA level before treatment and oncological risk degree. Results. Median nadir formed 0,5 ng/ml PSA by 3 months after treatment. Patients demonstrated different indicators of PSA dynamics depending on oncological risk, stage and hormonal therapy management. Patients with low oncological risk had initially lower PSA concentration, further PSA concentration reached nadir level faster. At patients with widespread forms of prostate cancer accurate dependence of PSA concentration according to prevalence of process was traced. Time of PSA nadir amount did not differ and was marked as 12-14 weeks on average. At patients received hormonal therapy, lower value of PSA nadir was marked. The conclusion. Monitoring of PSA concentration (PSA nadir by 3 months, dynamics of PSA concentration change is of great importance in early revealing of relapse after prostate HIFU therapy. High level of PSA nadir and PSA growth according to time period are important prognostic factors.

  13. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA screening

    Directory of Open Access Journals (Sweden)

    Black Amanda

    2011-04-01

    Full Text Available Abstract Background Despite the recent publication of results from two randomized clinical trials, prostate specific antigen (PSA screening for prostate cancer remains a controversial issue. There is lack of agreement across studies that PSA screening significantly reduces prostate cancer mortality. In spite of these facts, the widespread use of PSA testing in the United States leads to overdetection and overtreatment of clinically indolent prostate cancer, and its associated harms of incontinence and impotence. Discussion Given the inconclusive results from clinical trials and incongruent PSA screening guidelines, the decision to screen for prostate cancer with PSA testing is an uncertain one for patients and health care providers. Screening guidelines from some health organizations recommend an informed decision making (IDM or shared decision making (SDM approach for deciding on PSA screening. These approaches aim to empower patients to choose among the available options by making them active participants in the decision making process. By increasing involvement of patients in the clinical decision-making process, IDM/SDM places more of the responsibility for a complex decision on the patient. Research suggests, however, that patients are not well-informed of the harms and benefits associated with prostate cancer screening and are also subject to an assortment of biases, emotion, fears, and irrational thought that interferes with making an informed decision. In response, the IDM/SDM approaches can be augmented with strategies from the philosophy of libertarian paternalism (LP to improve decision making. LP uses the insights of behavioural economics to help people better make better choices. Some of the main strategies of LP applicable to PSA decision making are a default decision rule, framing of decision aids, and timing of the decision. In this paper, we propose that applying strategies from libertarian paternalism can help with PSA

  14. 3D label-free prostate specific antigen (PSA) immunosensor based on graphene-gold composites.

    Science.gov (United States)

    Jang, Hee Dong; Kim, Sun Kyung; Chang, Hankwon; Choi, Jeong-Woo

    2015-01-15

    Highly sensitive and label-free detection of the prostate specific antigen (PSA) remains a challenge in the diagnosis of prostate cancer. Here, a novel three-dimensional (3D) electrochemical immunosensor capable of sensitive and label-free detection of PSA is reported. This unique immunosensor is equipped with a highly conductive graphene (GR)-based gold (Au) composite modified electrode. The GR-based Au composite is prepared using aerosol spray pyrolysis and the morphology of the composite is the shape of a crumpled GR ball decorated with Au nanoparticles. Unlike the previous research, this novel 3D immunosensor functions very well over a broad linear range of 0-10 ng/mL with a low detection limit of 0.59 ng/mL; furthermore, it exhibits a significantly increased electron transfer and high sensitivity toward PSA. The highest rate of current change with respect to the PSA concentration is 5 μA/(ng/mL). Satisfactory selectivity, reproducibility, and stability of the 3D immunosensor are also exhibited. PMID:25150936

  15. Prostate-specific antigen (PSA) screening: has the pendulum swung too far?

    Institute of Scientific and Technical Information of China (English)

    Jason M Phillips; E David Crawford

    2011-01-01

    @@ Prostate-specific antigen (PSA) along with digital rectal exam has been the standard for prostate cancer screening in the United States for the past 20 years.1 During this time period,the improved detection of prostate cancer decreased related mortality more than 30%? In fact,metastases and their comorbidities have decreased more than 75% since the early 1990s,resulting in a higher incidence of early organ-confined disease.While it is clear that prostate cancer mortality statistics have improved,it is unclear whether men are overscreened.

  16. Power-free chip enzyme immunoassay for detection of prostate specific antigen (PSA) in serum.

    Science.gov (United States)

    Adel Ahmed, Heba; Azzazy, Hassan M E

    2013-11-15

    A power-free, portable "Chip EIA" was designed to render the popular Enzyme Linked Immunosorbent Assay (ELISA) more suitable for point-of-care testing. A number of microfluidic platforms have enabled miniaturization of the conventional microtitre plate ELISA, however, they require external pumping systems, valves, and electric power supply. The Chip EIA platform has eliminated the need for pumps and valves through utilizing a simple permanent magnet and magnetic nanoparticles. The magnetic nanoparticles act as solid support to capture the target and are then moved through chambers harboring different reagents necessary to perform a sandwich ELISA. The use of magnetic nanoparticles increases the volume-to-surface ratio reducing the assay time to 30 min. Changing the color of horseradish peroxidase (HRP) substrate to green indicates a positive result. In addition, a quantitative read-out was obtained through the use of cellphone camera imaging and analyzing the images using Matlab®. Cell phones, including smart ones, are readily available almost everywhere. The Chip EIA device was used to assay total prostate specific antigen (tPSA) in 19 serum samples. The PSA Chip EIA was tested for accuracy, precision, repeatability, and the results were correlated to the commercial Beckman Colter, Hybritech immunoassay® for determination of tPSA in serum samples with a Pearson correlation coefficient (R(2)=0.96). The lower detection limit of the PSA Chip EIA was 3.2 ng/mL. The assay has 88.9% recovery and good reproducibility (% CV of 6.5). We conclude that the developed Chip EIA can be used for detection of protein biomarkers in biological specimens.

  17. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs

    Science.gov (United States)

    Petitdidier, Elodie; Pagniez, Julie; Papierok, Gérard; Vincendeau, Philippe; Lemesre, Jean-Loup; Bras-Gonçalves, Rachel

    2016-01-01

    Preventive vaccination is a highly promising strategy for interrupting leishmaniasis transmission that can, additionally, contribute to elimination. A vaccine formulation based on naturally excreted secreted (ES) antigens was prepared from L. infantum promastigote culture supernatant. This vaccine achieved successful results in Phase III trials and was licensed and marketed as CaniLeish. We recently showed that newly identified ES promastigote surface antigen (PSA), from both viable promastigotes and axenically-grown amastigotes, represented the major constituent and the highly immunogenic antigen of L. infantum and L. amazonensis ES products. We report here that three immunizations with either the recombinant ES LaPSA-38S (rPSA) or its carboxy terminal part LaPSA-12S (Cter-rPSA), combined with QA-21 as adjuvant, confer high levels of protection in naive L. infantum-infected Beagle dogs, as checked by bone marrow parasite absence in respectively 78.8% and 80% of vaccinated dogs at 6 months post-challenge. The parasite burden in infected vaccinated dogs was significantly reduced compared to placebo group, as measured by q-PCR. Moreover, our results reveal humoral and cellular immune response clear-cut differences between vaccinated and control dogs. An early increase in specific IgG2 antibodies was observed in rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs only. They were found functionally active in vitro and were highly correlated with vaccine protection. In vaccinated protected dogs, IFN-γ and NO productions, as well as anti-leishmanial macrophage activity, were increased. These data strongly suggest that ES PSA or its carboxy-terminal part, in recombinant forms, induce protection in a canine model of zoonotic visceral leishmaniasis by inducing a Th1-dominant immune response and an appropriate specific antibody response. These data suggest that they could be considered as important active components in vaccine candidates. PMID:27223609

  18. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA Induce Protective Immune Responses in Dogs.

    Directory of Open Access Journals (Sweden)

    Elodie Petitdidier

    2016-05-01

    Full Text Available Preventive vaccination is a highly promising strategy for interrupting leishmaniasis transmission that can, additionally, contribute to elimination. A vaccine formulation based on naturally excreted secreted (ES antigens was prepared from L. infantum promastigote culture supernatant. This vaccine achieved successful results in Phase III trials and was licensed and marketed as CaniLeish. We recently showed that newly identified ES promastigote surface antigen (PSA, from both viable promastigotes and axenically-grown amastigotes, represented the major constituent and the highly immunogenic antigen of L. infantum and L. amazonensis ES products. We report here that three immunizations with either the recombinant ES LaPSA-38S (rPSA or its carboxy terminal part LaPSA-12S (Cter-rPSA, combined with QA-21 as adjuvant, confer high levels of protection in naive L. infantum-infected Beagle dogs, as checked by bone marrow parasite absence in respectively 78.8% and 80% of vaccinated dogs at 6 months post-challenge. The parasite burden in infected vaccinated dogs was significantly reduced compared to placebo group, as measured by q-PCR. Moreover, our results reveal humoral and cellular immune response clear-cut differences between vaccinated and control dogs. An early increase in specific IgG2 antibodies was observed in rPSA/QA-21- and Cter-rPSA/QA-21-immunized dogs only. They were found functionally active in vitro and were highly correlated with vaccine protection. In vaccinated protected dogs, IFN-γ and NO productions, as well as anti-leishmanial macrophage activity, were increased. These data strongly suggest that ES PSA or its carboxy-terminal part, in recombinant forms, induce protection in a canine model of zoonotic visceral leishmaniasis by inducing a Th1-dominant immune response and an appropriate specific antibody response. These data suggest that they could be considered as important active components in vaccine candidates.

  19. Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy

    OpenAIRE

    Shalini Agnihotri; Mittal, R. D.; Kapoor, R; Anil Mandhani

    2014-01-01

    Background & objectives: The characteristics of prostate specific antigen (PSA) for trans-rectal ultrasonography guided prostate biopsy in men with lower urinary tract symptoms (LUTS) are not well defined. This study was carried out to analyse the threshold of PSA for biopsy in symptomatic men in India. Methods: From January 2000 to June 2011, consecutive patients who had digital rectal examination (DRE) and PSA testing done for LUTS were included in this study. PSA was done with ELISA te...

  20. Possible factors influencing high serum Prostate-specific Antigen (PSA in Indonesian patients with Benign Prostatic Hyperplasia (BPH

    Directory of Open Access Journals (Sweden)

    Djoko Rahardjo

    2001-03-01

    Full Text Available Benign prostatic hyperplasia (BPH cases in Indonesia frequently associated with high serum prostate specific antigen (PSA. To explore possible factors that could increase serum PSA level, we performed a retrospective, cross-sectional study on 805 consecutive patients in Sumber Waras and Dr. Cipto Mangunkusumo Hospitals from 1994 to 1997. Clinical manifestations were evaluated and prostate biopsies were performed if indicated. Complete histopathological data were only available in 82 BPH patients with no urinary retention from 1998-1999 and a thin section of paraffin blocks of BPH patients which still could be found from 1994-1999 was analyzed using flow cytometer to obtain the S-phase fraction as a parameter of proliferative activity, From 805 patients, 461 (57% presented with urinary retention and need to be catheteized. Catheteization significantly increased PSA level if compared to noncatheterized patients (16.3 vs. 6,8 ng/mL, p= 0,000. Another data of 82 uncatheteized patients from 1998-1999 has revealed that 79 patients (96.3% had chronic prostatitis and 19 (23.2% showed the presence of prostatic-intraepithelial neoplasia (PIN with an increase of PSA level (5.4 ng/mL. The S-phase fraction of BPH without PIN cases was significantly higher in cases with PSA > 4 ng/ml than patients with PSA ≤ 4 ng/ml (I3.1% vs. 8.9%, p=0,008. As conclusion, the high serum PSA level was mostly due to urethral catheteization and increased prostate volume. There was a tendency of increasing PSA in subclinical inflammation and PIN. Cases with high PSA also showed high proliferative activities which is suggestive of mitogenic activity. (Med J Indones 2001; 10:22-8Keywords: BPH, high PSA, PIN, proliferative activity, s-phase fraction

  1. Prostate-specific antigen (PSA) velocity: a test of controversial benefit in the era of increased prostate cancer screening

    Institute of Scientific and Technical Information of China (English)

    Michael S Borofsky; Danil V Makarov

    2011-01-01

    @@ Determining the need for prostate biopsy remains one of the most controversial questions in urology.Over the past 10 years, practice guidelines have changed dramatically, especially among asymptomatic men with low prostate-specific antigen (PSA) and negative digital rectal exam.Thompson et al.Found that nearly 15% of men with PSA <4.0 had evidence of prostate cancer on biopsy;1 however, the clinical significance of these tumors is unclear.PSAvelocity (PSAV) has been suggested as a measurement to discriminate between aggressive and indolent cancers.Both the NCCN2 and AUA3 guidelines recommend considering prostate biopsy for men with PSA <4.0 and high PSAV (0.35 and 0.4 ng/ml/year, respectively); however, a recent article by Vickers et al.4 has called these recommendations into question, suggesting that PSAV adds little predictive accuracy to the standard risk factor assessment for prostate cancer.

  2. Squamous cell carcinoma antigen isoforms in serum from cervical cancer patients

    NARCIS (Netherlands)

    Roijer, E; de Bruijn, HWA; Dahlen, U; ten Hoor, K; Lundin, M; Nilsson, K; Soderstrom, K; Nilsson, O

    2006-01-01

    Squamous cell carcinoma antigen (SCCA) is a serological marker of squamous cell carcinomas (SCC). To study whether any of the SCCA isoforms would provide additional and more specific/sensitive clinical information than total SCCA, immunoassays specific for the different forms of SCCA (free SCCA2, to

  3. The preoperative serum ratio of total prostate specific antigen (PSA to free testosterone (FT, PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy

    Directory of Open Access Journals (Sweden)

    Antonio B. Porcaro

    2016-03-01

    Full Text Available Objectives: To evaluate associations of preoperative total prostate specific antigen (PSA to free testosterone (FT, the PSA/FT index ratio, with features of pathology prostate cancer (PCA and to investigate its prognostic potential in clustering the PCA population. Patients and methods: After excluding criteria, the records of 220 patients who underwent radical prostatectomy (RP were retrospectively reviewed. Serum samples of PSA, total testosterone (TT and FT were collected at 8.00 A.M., one month after biopsies and before RP. The PSA/FT ratio was computed in the population of patients who were clustered in groups according to ranking intervals of the PSA/FT ratio which identified at least 4 clusters which were coded as A, B, C, and D. The independent associations of the PSA/FT index ratio were assessed by statistical methods and a two-sided P < 0.05 was considered to indicate statistical significance. Results: TT correlated to FT which was a significant predictor of PSA in the population of patients who were subsequently clustered, according to increasing interval values of the PSA/FT index ratio, in groups that showed a stronger linear association of FT with PSA. The PSA/FT index ratio significantly associated with pathology features of prostate cancer such as pathology Gleason score (pGS, invasion of the seminal vesicles (pT3b, proportion of positive cores (P+ and proportion of cancer involving the volume of the prostate. In the population of patients, TT, PSA/FT index ratio and P+ independently associated with pGS ≥ 7 and pT3b; moreover, the odds ratio (OR of the PSA/FT index ratio resulted 9.11 which was stronger than TT (OR = 1.11 and P+ (OR = 8.84. In the PCA population, TT, PSA/FT index ratio and P+ also independently associated with pT3b PCA; interestingly, the OR of PSA/FT index resulted 54.91 which was stronger than TT (OR = 1.31 and P+ (26.43. Conclusions: Preoperative PSA/FT index ratio is an independent strong factor which

  4. Prostate-specific antigen (PSA) rate of decline post external beam radiotherapy predicts prostate cancer death

    International Nuclear Information System (INIS)

    Background and purpose: To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality. Materials and methods: All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 Patients treated by definitive EBRT with more than one PSA recorded in the two year post-treatment were included. We calculated PSAV by linear regression. Results: The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAVs across quartiles (Q1–Q4) were −4.17, −1.29, −0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1–Q4 hazard ratios (HR) being 3.82 (1.46–10.00), 3.07 (1.10–8.58), 1, 5.15 (1.99–13.30) respectively. HR for all cause mortality in a similar model were 1.79 (1.07–2.98), 1.55 (0.93–2.59), 1.00 and 1.74 (1.04–2.90) for Q1 to Q4 respectively. A rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM. Conclusion: A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of the need for additional therapies

  5. PsaA Antigen Expression of Y.pestis and Its Antibody Development and Application%鼠疫菌PsaA抗原的表达及抗体制备和应用

    Institute of Scientific and Technical Information of China (English)

    洪文艳; 王浩然; 王津; 郭兆彪; 周蕾; 杨瑞馥

    2011-01-01

    Objective: To develop the PsaA antigen of Y.Pestis and its antibody, and to develop the fast detection assays, and to detect the positive ratio of PsaA antibody in 18 plague monkey serum samples. Methods: The PsaA gene was amplificated by PCR method. The production was cloned and expressed using an E. coli expression system, purified with the Ni-NTA affinity chromatography,and renatured the inclusion body expressed proteins using a urea gradient dialysis method. The corresponding polyclonal antibody was prepared by immunizing rabbits using the conventional method. Bloods were obtained from rabbits for collection of sera and purification of specific immunoglobulin G (IgG) with a caprylic acid-saturated ammonium sulfate precipitation method. Then both indirect ELISA method and Up-converting Phospher Technology (UPT) lateral flow assay were developed to detect PsaA antibodies of samples. Lastly,18 monkey serum samples were tested. Results: The data showed that the positive ratio of the PsaA antibody in plague monkey serum samples was 62%(8/13). Conclusion: The fast detection assays were successfully developed for the PsaA antibody test. And the positive ratio of the antibody in plague monkey serum samples was 62%.%目的:制备鼠疫菌PsaA抗原及抗体,建立针对PsaA抗体的快速检测方法,并检测鼠疫感染猴血清标本中的PsaA抗体的阳性率.方法:利用PCR方法扩增出PsaA蛋白基因片段,在大肠杆菌原核表达系统中表达出重组PsaA抗原,以镍柱亲和层析纯化包涵体形式的表达蛋白,以尿素梯度透析复性成可溶蛋白.再以表达蛋白为免疫原,常规免疫家兔,收集兔血清制备多抗,并以正辛酸-硫酸铵法提纯获得PsaA抗体IgG.利用得到的PsaA抗原和抗体为材料,建立两种检测PsaA抗体的快速检测方法,即间接ELISA法和上转换发光(Up-converting Phospher Technology,UPT)免疫层析试纸条法.最后利用这两种方法检测18份猴血清标本中的PsaA抗体.

  6. Impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) on prostate-specific antigen (PSA) testing by Dutch general practitioners

    NARCIS (Netherlands)

    Van der Meer, Saskia; Kollen, Boudewijn J.; Hirdes, Willem H.; Steffens, Martijn G.; Hoekstra-Weebers, Josette E. H. M.; Nijman, Rien M.; Blanker, Marco H.

    2013-01-01

    Objective To determine the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC) publication in 2009 on prostate-specific antigen (PSA) level testing by Dutch general practitioners (GPs) in men aged 40 years. Materials and Methods Retrospective study with a Dutch insurance

  7. The Leishmania promastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity to L. major

    DEFF Research Database (Denmark)

    Kemp, M; Handman, E; Kemp, K;

    1998-01-01

    The promastigote surface antigen-2 (PSA-2) is a Leishmania parasite antigen, which can induce Th1-mediated protection against murine leishmaniasis when used as a vaccine. To evaluate PSA-2 as a human vaccine candidate the specific T-cell response to PSA-2 was characterised in individuals immune...... to cutaneous leishmaniasis. Peripheral blood mononuclear cells from Sudanese individuals with a past history of self-healing cutaneous leishmaniasis proliferated vigorously in response to PSA-2 isolated from Leishmania major, whereas the antigen did not activate cells from presumably unexposed Danes...... and that these cells were the major source of interferon-gamma. The results show that Th1-like cells recognising PSA-2 are expanded during infection by L. major and that they maintain their Th1-like cytokine profile upon reactivation in vitro. Since immunity to cutaneous leishmaniasis is mediated by antigen...

  8. Importance of prostate-specific antigen (PSA as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens

    Directory of Open Access Journals (Sweden)

    Nelson Gianni de Lima

    2013-06-01

    Full Text Available OBJECTIVE: To evaluate the concordance between the Gleason scores of prostate biopsies and radical prostatectomy specimens, thereby highlighting the importance of the prostate-specific antigen (PSA level as a predictive factor of concordance. METHODS: We retrospectively analyzed 253 radical prostatectomy cases performed between 2006 and 2011. The patients were divided into 4 groups for the data analysis and dichotomized according to the preoperative PSA, <10 ng/mL and ≥10 ng/mL. A p-score <0.05 was considered significant. RESULTS: The average patient age was 63.3±7.8 years. The median PSA level was 9.3±4.9 ng/mL. The overall concordance between the Gleason scores was 52%. Patients presented preoperative PSA levels <10 ng/mL in 153 of 235 cases (65% and ≥10 ng/mL in 82 of 235 cases (35%. The Gleason scores were identical in 86 of 153 cases (56% in the <10 ng/mL group and 36 of 82 (44% cases in the ≥10 ng/mL group (p = 0.017. The biopsy underestimated the Gleason score in 45 (30% patients in the <10 ng/mL group and 38 (46% patients in the ≥10 ng/mL (p = 0.243. Specifically, the patients with Gleason 3 + 3 scores according to the biopsies demonstrated global concordance in 56 of 110 cases (51%. In this group, the patients with preoperative PSA levels <10 ng/dL had higher concordance than those with preoperative PSA levels ≥10 ng/dL (61% x 23%, p = 0.023, which resulted in 77% upgrading after surgery in those patients with PSA levels ≥10 ng/dl. CONCLUSION: The Gleason scores of needle prostate biopsies and those of the surgical specimens were concordant in approximately half of the global sample. The preoperative PSA level was a strong predictor of discrepancy and might improve the identification of those patients who tended to be upgraded after surgery, particularly in patients with Gleason scores of 3 + 3 in the prostate biopsy and preoperative PSA levels ≥10 ng/mL.

  9. Técnica para obtenção do aparelho geniturinário e dosagem do PSA (Prostate Specific Antigen) no hamster sírio, Mesocricetus auratus Technique for collecting blood for PSA (Prostate Specific Antigen) dosing and genitourinary system obtaining in syrian hamster, Mesocricetus auratus

    OpenAIRE

    Dimas José Araújo Vidigal; Alcino Lázaro da Silva; Luiz Mauro Andrade da Fonseca; Dilermando Fazito de Rezende

    2004-01-01

    Objetivo: Expor a técnica utilizada na colheita de sangue para dosagem do PSA ( Prostate Specific Antigen ) e retirada do aparelho geniturinário no hamster sírio, Mesocricetus auratus, e correlacionar os achados do PSA com as alterações histológicas dos anexos sexuais desse roedor. Métodos: Foram usados no experimento trinta (n= 30) Hamsters: dez (n=10) animais considerados jovens com idade média no momento da morte de 47,5 dias e vinte (n=20) animais considerados adultos com idade superior à...

  10. Permanent 125I-seed prostate brachytherapy: early prostate specific antigen value as a predictor of PSA bounce occurrence

    Directory of Open Access Journals (Sweden)

    Mazeron Renaud

    2012-03-01

    Full Text Available Abstract Purpose To evaluate predictive factors for PSA bounce after 125I permanent seed prostate brachytherapy and identify criteria that distinguish between benign bounces and biochemical relapses. Materials and methods Men treated with exclusive permanent 125I seed brachytherapy from November 1999, with at least a 36 months follow-up were included. Bounce was defined as an increase ≥ 0.2 ng/ml above the nadir, followed by a spontaneous return to the nadir. Biochemical failure (BF was defined using the criteria of the Phoenix conference: nadir +2 ng/ml. Results 198 men were included. After a median follow-up of 63.9 months, 21 patients experienced a BF, and 35.9% had at least one bounce which occurred after a median period of 17 months after implantation (4-50. Bounce amplitude was 0.6 ng/ml (0.2-5.1, and duration was 13.6 months (4.0-44.9. In 12.5%, bounce magnitude exceeded the threshold defining BF. Age at the time of treatment and high PSA level assessed at 6 weeks were significantly correlated with bounce but not with BF. Bounce patients had a higher BF free survival than the others (100% versus 92%, p = 0,007. In case of PSA increase, PSA doubling time and velocity were not significantly different between bounce and BF patients. Bounces occurred significantly earlier than relapses and than nadir + 0.2 ng/ml in BF patients (17 vs 27.8 months, p Conclusion High PSA value assessed 6 weeks after brachytherapy and young age were significantly associated to a higher risk of bounces but not to BF. Long delays between brachytherapy and PSA increase are more indicative of BF.

  11. Técnica para obtenção do aparelho geniturinário e dosagem do PSA (Prostate Specific Antigen no hamster sírio, Mesocricetus auratus Technique for collecting blood for PSA (Prostate Specific Antigen dosing and genitourinary system obtaining in syrian hamster, Mesocricetus auratus

    Directory of Open Access Journals (Sweden)

    Dimas José Araújo Vidigal

    2004-12-01

    Full Text Available Objetivo: Expor a técnica utilizada na colheita de sangue para dosagem do PSA ( Prostate Specific Antigen e retirada do aparelho geniturinário no hamster sírio, Mesocricetus auratus, e correlacionar os achados do PSA com as alterações histológicas dos anexos sexuais desse roedor. Métodos: Foram usados no experimento trinta (n= 30 Hamsters: dez (n=10 animais considerados jovens com idade média no momento da morte de 47,5 dias e vinte (n=20 animais considerados adultos com idade superior à um ano. Após serem anestesiados com cloridrato de quetamina e diazepam, foi colhido diretamente da veia cava, em nível de abdome superior, cerca de 1,5mL a 2,0mL de sangue para dosagem do PSA totalpelo método ELISA, com antígeno humano. Morriam após colheita do sangue. Constatado a morte do animal, fazia-se a laparotomia retirando-se em monobloco todo aparelho geniturinário para estudo histológico dos anexos sexuais. Correlacionou-se o PSA com as alterações histológicas encontradas. Resultados: Os animais após serem anestesiados com cloridrato de quetamina e diazepam intraperitonealmente, obteve-se um excelente plano anestésico, que possibilitou colher via trans-dérmica da veia cava inferior em abdome superior sangue para dosagem do PSA. O animal morria após colheita do sangue. Fazia-se a laparotomia, com retirada em monobloco do aparelho geniturinário para estudo histológico e comparação das alterações encontradas nos anexos sexuais com o PSA dosado. Entre os Hamsters Jovens a média do PSA encontrado foi de 0,252ng/mL. Desvio Padrão (DP = 0,36. Entre os Hamsters adultos esta média foi de 0,325 ng/mL, DP= 0,12 . Quando comparou-se as médias do PSA entre os dois grupos de jovens e adultos obteve-se p= 0,0427. Dentre os Hamsters jovens, três apresentaram PSA não detectado. A análise histológica mostrou que, entre os animais jovens, não foi identificada qualquer alteração das estruturas microscópicas da próstata, ves

  12. Prostate Health Index (Phi and Prostate Cancer Antigen 3 (PCA3 significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

    Directory of Open Access Journals (Sweden)

    Matteo Ferro

    Full Text Available Many efforts to reduce prostate specific antigen (PSA overdiagnosis and overtreatment have been made. To this aim, Prostate Health Index (Phi and Prostate Cancer Antigen 3 (PCA3 have been proposed as new more specific biomarkers. We evaluated the ability of phi and PCA3 to identify prostate cancer (PCa at initial prostate biopsy in men with total PSA range of 2-10 ng/ml. The performance of phi and PCA3 were evaluated in 300 patients undergoing first prostate biopsy. ROC curve analyses tested the accuracy (AUC of phi and PCA3 in predicting PCa. Decision curve analyses (DCA were used to compare the clinical benefit of the two biomarkers. We found that the AUC value of phi (0.77 was comparable to those of %p2PSA (0.76 and PCA3 (0.73 with no significant differences in pairwise comparison (%p2PSA vs phi p = 0.673, %p2PSA vs. PCA3 p = 0.417 and phi vs. PCA3 p = 0.247. These three biomarkers significantly outperformed fPSA (AUC = 0.60, % fPSA (AUC = 0.62 and p2PSA (AUC = 0.63. At DCA, phi and PCA3 exhibited a very close net benefit profile until the threshold probability of 25%, then phi index showed higher net benefit than PCA3. Multivariable analysis showed that the addition of phi and PCA3 to the base multivariable model (age, PSA, %fPSA, DRE, prostate volume increased predictive accuracy, whereas no model improved single biomarker performance. Finally we showed that subjects with active surveillance (AS compatible cancer had significantly lower phi and PCA3 values (p<0.001 and p = 0.01, respectively. In conclusion, both phi and PCA3 comparably increase the accuracy in predicting the presence of PCa in total PSA range 2-10 ng/ml at initial biopsy, outperforming currently used %fPSA.

  13. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.

    NARCIS (Netherlands)

    Watson, E.; Hewitson, P.; Brett, J.; Bukach, C.; Evans, R.; Edwards, A.; Elwyn, G.; Cargill, A.; Austoker, J.

    2006-01-01

    OBJECTIVE: To examine the impact of a brief patient decision aid (pDA) on men's knowledge, attitudes and intention to have a prostate specific antigen (PSA) test. To explore the important predictors of intention to be tested in men who received the brief pDA. METHODS: A brief pDA designed to facilit

  14. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

    OpenAIRE

    Perambakam, Supriya; Xie, Hui; Edassery, Seby; Peace, David J.

    2011-01-01

    Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum...

  15. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)

    OpenAIRE

    Perambakam, Supriya; Xie, Hui; Edassery, Seby; Peace, David J.

    2010-01-01

    Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum...

  16. Cytochemical localization of ATP diphosphohydrolase from Leishmania (Viannia) braziliensis promastigotes and identification of an antigenic and catalytically active isoform.

    Science.gov (United States)

    Rezende-Soares, F A; Carvalho-Campos, C; Marques, M J; Porcino, G N; Giarola, N L L; Costa, B L S; Taunay-Rodrigues, A; Faria-Pinto, P; Souza, M A; Diniz, V A; Corte-Real, S; Juliano, M A; Juliano, L; Vasconcelos, E G

    2010-04-01

    An ATP diphosphohydrolase (EC 3.6.1.5) activity was identified in a Leishmania (Viannia) braziliensis promastigotes preparation (Lb). Ultrastructural cytochemical microscopy showed this protein on the parasite surface and also stained a possible similar protein at the mitochondrial membrane. Isolation of an active ATP diphosphohydrolase isoform from Lb was obtained by cross-immunoreactivity with polyclonal anti-potato apyrase antibodies. These antibodies, immobilized on Protein A-Sepharose, immunoprecipitated a polypeptide of approximately 48 kDa and, in lower amount, a polypeptide of approximately 43 kDa, and depleted 83% ATPase and 87% of the ADPase activities from detergent-homogenized Lb. Potato apyrase was recognized in Western blots by IgG antibody from American cutaneous leishmaniasis (ACL) patients, suggesting that the parasite and vegetable proteins share antigenic conserved epitopes. Significant IgG seropositivity in serum samples diluted 1:50 from ACL patients (n=20) for Lb (65%) and potato apyrase (90%) was observed by ELISA technique. Significant IgG antibody reactivity was also observed against synthetic peptides belonging to a conserved domain from L. braziliensis NDPase (80% seropositivity) and its potato apyrase counterpart (50% seropositivity), in accordance with the existence of shared antigenic epitopes and demonstrating that in leishmaniasis infection the domain r82-103 from L. braziliensis NDPase is a target for the human immune response. PMID:19961654

  17. Lassen Veränderungen des Prostata-spezifischen Antigen- (PSA- Spiegels nach Prostatastanzbiopsie Rückschlüsse auf das pathologische Ergebnis zu?

    Directory of Open Access Journals (Sweden)

    Volkmer BG

    2004-01-01

    Full Text Available Einleitung: Die diagnostische Biopsie der Prostata führt bekanntermaßen zum Anstieg des Serum-PSA-Spiegels. Diese prospektive Untersuchung sollte die Frage klären, ob die Änderungen des Serum-PSA-Spiegels nach Stanzbiopsie Rückschlüsse auf das histologische Ergebnis zulassen und so als Entscheidungshilfe bei der Frage der Rebiopsie dienen können. Patienten und Methoden: Insgesamt 79 konsekutive Patienten mit klinischem Verdacht auf das Vorliegen eines Prostatakarzinoms (PCA und einem Gesamt-PSA 50 ng/ml wurden in die Studie eingeschlossen. Ausschlußkriterien waren klinische Hinweise für eine Prostatitis und Prostatabiopsie innerhalb der letzten 3 Monate. Die Serum-PSA-Werte wurden mit einem ultrasensitiven Enzymimmunoassay bestimmt. Die Bestimmung des Gesamt-PSA und des freien PSA im Serum erfolgte unmittelbar vor und 60 Minuten nach der Biopsie. Die Spiegel des Gesamt-PSA und freien PSA, sowie die f/t-PSA-Ratio vor und nach Biopsie wurden in Korrelation zum histologischen Ergebnis gesetzt. Ergebnisse: 86 Biopsieserien wurden bei 79 Patienten durchgeführt. 38 Biopsieserien diagnostizierten ein PCA, 48 eine benigne Prostatahyperplasie (BPH. Die abschließende Histologie nach wiederholter Biopsie war PCA und BPH in je 43 Fällen. Insgesamt fand sich ein Anstieg des durchschnittlichen Gesamt-PSA von 18,39 ng/ml auf 107,8 ng/ml, des durchschnittlichen freien PSA von 3,43 ng/ml auf 33,7 ng/ml und der durchschnittlichen f/t PSA-Ratio von 18,1 % auf 52,0 %. Es fand sich keine Korrelation zwischen dem Anstieg dieser Parameter und der Anzahl der Biopsiezylinder (4–51. Bezüglich des histologischen Befundes ergaben sich statistisch signifikante Unterschiede für das Gesamt-PSA vor und die f/t PSA-Ratio vor und nach Stanzbiopsie. Schlußfolgerung: Die Analyse der PSA-Parameter nach Stanzbiopsie bietet keine zusätzliche Information über die konventionellen PSA-Parameter vor der Biopsie hinaus. Sie korrelieren vor allem nicht mit falsch

  18. Soluble human leukocyte antigen-G isoforms in maternal plasma in early and late pregnancy

    DEFF Research Database (Denmark)

    Rizzo, Roberta; Andersen, Anita Sylvest; Lassen, Michael Rud;

    2009-01-01

    detectable plasma HLA-G5 compared with that of the control group (P = 0.013, P(C) = 0.04; Mann-Whitney). Similar findings were not observed in women with gestational hypertension or existing hypertension continuing into pregnancy. Furthermore, there was a trend toward lower maternal plasma sHLA-G1 in a group......PROBLEM: Human Leukocyte Antigen (HLA)-G is a class Ib gene located in the human major histocompatibility complex (MHC). Several lines of investigation indicate that the HLA-G molecule is involved in the maternal acceptance of the semi-allogenic fetus during pregnancy and in the development...... of tolerance. Expression of soluble HLA-G (sHLA-G) is positively correlated with successful in vitro fertilization (IVF) treatments, and aberrant expression of HLA-G in certain complications of pregnancy, such as pre-eclampsia and spontaneous abortion, has been reported. The main purpose of this study...

  19. Differential recognition of the multiple banded antigen isoforms across Ureaplasma parvum and Ureaplasma urealyticum species by monoclonal antibodies.

    Science.gov (United States)

    Aboklaish, Ali F; Ahmed, Shatha; McAllister, Douglas; Cassell, Gail; Zheng, Xiaotian T; Spiller, Owen B

    2016-08-01

    Two separate species of Ureaplasma have been identified that infect humans: Ureaplasma parvum and Ureaplasma urealyticum. Most notably, these bacteria lack a cell wall and are the leading infectious organism associated with infection-related induction of preterm birth. Fourteen separate representative prototype bacterial strains, called serovars, are largely differentiated by the sequence of repeating units in the C-terminus of the major surface protein: multiple-banded antigen (MBA). Monoclonal antibodies that recognise single or small groups of serovars have been previously reported, but these reagents remain sequestered in individual research laboratories. Here we characterise a panel of commercially available monoclonal antibodies raised against the MBA and describe the first monoclonal antibody that cross-reacts by immunoblot with all serovars of U. parvum and U. urealyticum species. We also describe a recombinant MBA expressed by Escherichia coli which facilitated further characterisation by immunoblot and demonstrate immunohistochemistry of paraffin-embedded antigens. Immunoblot reactivity was validated against well characterised previously published monoclonal antibodies and individual commercial antibodies were found to recognise all U. parvum strains, only serovars 3 and 14 or only serovars 1 and 6, or all strains belonging to U. parvum and U. urealyticum. MBA mass was highly variable between strains, consistent with variation in the number of C-terminal repeats between strains. Antibody characterisation will enable future investigations to correlate severity of pathogenicity to MBA isoform number or mass, in addition to development of antibody-based diagnostics that will detect infection by all Ureaplasma species or alternately be able to differentiate between U. parvum, U. urealyticum or mixed infections. PMID:27208664

  20. Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154

    Directory of Open Access Journals (Sweden)

    Supriya Perambakam

    2010-01-01

    Full Text Available Twenty-eight HLA-A2+ patients with high-risk, locally advanced or metastatic, hormone-sensitive prostate cancer were immunized with a peptide homologue of prostate-specific antigen, PSA146-154, between July 2002 and September 2004 and monitored for clinical and immune responses. Fifty percent of the patients developed strong PSA146-154-peptide-specific delayed-type hypersensitivity skin responses, tetramer and/or IFN-γ responses within one year. Thirteen patients had stable or declining serum levels of PSA one year post-vaccination. A decreased risk of biochemical progression was observed in patients who developed augmented tetramer responses at six months compared to pre-vaccination levels (P=.02. Thirteen patients have died while 15 patients remain alive with a mean overall survival of 60 months (95% CI, 51 to 68 months per Kaplan-Meier analysis. A trend towards greater overall survival was detected in men with high-risk, hormone-sensitive CaP who developed specific T-cell immunity following vaccination with PSA146-154 peptide.

  1. Identification, cloning and functional characterization of novel sperm associated antigen 11 (SPAG11 isoforms in the rat

    Directory of Open Access Journals (Sweden)

    Petrusz Peter

    2006-04-01

    Full Text Available Abstract Background Sperm binding proteins and their C-terminal peptides of the Sperm Associated Antigen 11 (SPAG11 family were found to play an important role in epididymal innate immunity in addition to their role in sperm maturation. However, the expression of Spag11 transcripts in rodents is not well documented. Methods Computational analysis was employed to identify novel Spag11 isoforms in the rat. RT-PCR analyses were carried out on RNAs isolated from the male reproductive tract tissues of rat using gene specific primers for Spag11c and Spag11t. The identities of PCR products were confirmed by sequencing. Tissue distribution, developmental expression and androgen regulation of Spag11t and Spag11c were studied using RT-PCR. The antimicrobial activities of recombinant Spag11t and Spag11c were tested against E coli in a colony forming unit assay. Results In this study, we identified two novel Spag11 transcripts, namely, Spag11t and Spag11c derived from the long arm of chromosome 16 in the rat (Rattus norvegicus, using both in silico and molecular biology approaches. Spag11c is expressed in all three regions of the epididymis, in testis and in ovary but is absent from the seminal vesicle. Spag11t expression is confined to the caput and it is not expressed in the testis, seminal vesicle or ovary. Age dependent expression of Spag11t and Spag11c was observed in the epididymides of rats (10–60 day old. Their expression was found to be most abundant in the adult rat (60 day suggesting roles in mature reproductive function. Further, both Spag11t and Spag11c expression was down regulated in castrated rat epididymides and the expression was maintained in the testosterone replaced castrated rats. SPAG11C is a potent antibacterial agent. SPAG11T also displayed bactericidal capacity although weaker than SPAG11C and SPAG11E. Conclusion The abundant expression of Spag11t and Spag11c in the male reproductive tract suggests an important role in male

  2. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?

    LENUS (Irish Health Repository)

    Duffy, Michael J

    2012-02-01

    Although widely used, the value of prostate-specific antigen (PSA) in screening asymptomatic men for prostate cancer is controversial. Reasons for the controversy relate to PSA being less than an ideal marker in detecting early prostate cancer, the possibility that screening for prostate cancer may result in the overdetection and thus overtreatment of indolent disease and the lack of clarity as to the definitive or best treatment for men diagnosed with localized prostate cancer. Although the results from some randomized prospective trials suggest that screening with PSA reduces mortality from prostate cancer, the overall benefit was modest. It is thus currently unclear as to whether the modest benefit of reduced mortality outweighs the harms of overdetection and overtreatment. Thus, prior to undergoing screening for prostate cancer, men should be informed of the risks and benefits of early detection. Newly emerging markers that may complement PSA in the early detection of prostate cancer include specific isoforms of PSA and PCA3.

  3. The diagnostic values of serum prostate specific antigen and transrectal contrast-enhanced ultrasonography of prostate cancer%血清 PSA 指标与经直肠超声造影对前列腺癌的诊断

    Institute of Scientific and Technical Information of China (English)

    朱林; 黄君; 詹洁群; 贾天利; 刘灿

    2015-01-01

    目的:探讨血清前列腺特异性抗原(PSA)指标,游离前列腺特异性抗原(f-PSA)、总前列腺特异性抗原(T-PSA),前列腺特异性抗原密度(PSAD)与经直肠前列腺超声造影对前列腺癌(Prostate Cancer,PCa)的诊断价值。方法:获取59例血清 PSA 升高的患者的 fPSA 及 T-PSA、前列腺体积的三个径(L、W、H),所有病例均经直肠超声造影检查,并在超声引导下进行前列腺穿刺。结果:前列腺癌组患者的发病年龄要比良性前列腺增生(Benign prostate hyperplasia,BPH)组大,PSAD 比 BPH 组高。前列腺癌组的 f/T-PSA 比良性前列腺增生组低。前列腺癌组患者的显影时间、达峰时间、加速时间较良性前列腺增生组患者短,绝对增强强度较良性前列腺增生组高。前列腺癌组患者的强度减半时间比良性前列腺增生组患者短。结论:前列腺癌组的前列腺造影结果表现为“快进快出”。血清 f/T-PSA、PSAD 及经直肠超声造影技术对前列腺良恶性病变的鉴别诊断具有一定的临床价值。%Aim:To study the value of serum PSA indicator (f/T-PSA,PSAD)and CETRUS (con-trast-enhanced transrectal ultrasound)in diagnosis of prostate cancer.Methods:Fifty-nine patients were elevated with serum PSA had fPSA (free prostate specific antigen)and T-PSA (total prostate specific an-tigen),three size (Long,Wide,Height),the 59 patients carry through CETRUS (contrast-enhanced transrectal ultrasound)and biopsy.Results:Prostate cancer patients’age of onset are older than benign prostate hyperplasia group,PSAD in prostate cancer group are higher than that of benign prostate hyper-plasia group,f/T-PSA in prostate cancer group are lower than that of benign prostate hyperplasia group. AT (arrival time),TTP (time to peak),ACT (acceleration time)in prostate cancer group are shorter than those of benign prostate hyperplasia group,absolute enhance intense (△PI =PI

  4. [5ARI and PSA: open questions.

    Science.gov (United States)

    Tubaro, Andrea; Puccini, Federica; De Nunzio, Cosimo

    2014-09-23

    No consensus has ever been reached on the predictive value of serum prostate specific antigen(PSA) for the diagnosis of prostate cancer. Limitations of PSA testing in clinical practice have beenoften discussed in the peer-reviewed literature following data derived from clinical trials such as theProstate Cancer Prevention Trial (PCPT) and the Reduction by Dutasteride of Prostate Cancer Events(REDUCE) study that showed a linear rise in the risk of prostate cancer with increasing PSA levels.Benign prostatic hyperplasia is a known confounding factor for the use of PSA as a marker of prostatecancer. Increased prostate volume observed with ageing, urinary retention, acute and chronicinflammatory conditions of the prostate, sexual activity and digital rectal examination may all cause anincrease of PSA values. Both finasteride and dutasteride, 5-alpha reductase inhibitors (5ARI) used inthe treatment of BPH, are known to induce a significant decrease of serum PSA levels close to 50%.The observed change in PSA values following 5ARI treatment has raised questions about the accuracyof PSA testing for the early diagnosis of prostate cancer in patients on finasteride/dutasteride treatment.Careful analysis of data from various clinical trials on pharmacological treatment of LUTS due toBPH suggested that the accuracy of PSA testing is not just maintained but rather increased following5ARI use. Then, the question of PSA accuracy during 5ARI treatment can be considered closed. PMID:25350562

  5. Determination of the Normal Prostate Specific Antigen (PSA) Value in Iraqi Society and its Relation to Bacterial Urinary Tract Infection (UTI)

    International Nuclear Information System (INIS)

    The study was carried out by radioimmunoassay and immuno radiographic analysis in the Iraqi Ministry of Health, within the research plan of Kurdistan institution for strategic study and scientific research. A total of 793 serum samples were collected in which 50 patient samples have biopsy with positive bacterial UTI. The other 743 samples were obtained from normal healthy volunteers all were over 45 years old. The samples were gathered randomly from three regions in Iraq namely, from north (Sulaymaniyah, Erbil and Dohuk), from the middle (Baghdad and Diyala) and from south (Basra, Missan and Najaf). The total PSA was measured and the results were subjected to statistical analysis based on statistical package social science (SPSS) method. The obtained data showed that the normal PSA values are function of the age of the donors. The results were grouped and clarified that PSA was less than 3.8 ng/ml for the age 45-55 years, while it was less than 4.8 ng/ml for the volunteers from 56-65 years old and the values lower than 5.9 ng/ml for group aged 66-75 years old. On the other hand, the obtained data illustrated that there were non-significant variations in PSA values as a function of the geographic regions. The PSA values for the 50 male positive bacterial UTI samples were within the same grouping previously stated for the normal healthy volunteers. Seven cases of the 743 samples showed abnormal high PSA values (i.e. greater than 9 ng/ml) which represent 0.93% of the healthy collected samples. It could be concluded that the PSA has non-significance relation to the bacterial UTI. In addition, the radioimmunoassay has a sensitivity of about 99.04% for the normal cases and specificity of 0.96% for prostate cancer.

  6. African-American (AA) men with local-regional prostate cancer (PC) present with higher prostate specific antigen (PSA) levels than whites: results of RTOG 94-12

    International Nuclear Information System (INIS)

    Purpose/Objective: To use pretreatment serum PSA levels as an20), gleason score (2-5,6-7,7-10), race (whites and AAs), and two interactions viz (a) PSA by race (p=0.0012) and (b) PSA by total gleason score (p=0.0001). When race was replaced by educational status, or income, or both, the fits (0.8246,0.8197, and 0.7815, respectively) were not as good as the fit with race in the model. Conclusion: The findings of this nation-wide prospective registration study with a high percentage of AA patient participation confirms previous, smaller, geographically-limited studies (1,2,3) results that AA patients with non-metastatic PC present with a higher mean PSA values than whites. The multivariate findings imply that, for each level of total gleason score, there is a higher percentage of whites with PSA levels 20. Education and/or income as surrogates of sociological status could not completely explain the racial differences. Other reasons for health-care barriers among AAs need to be identified

  7. Lassen Veränderungen des Prostata-spezifischen Antigen- (PSA-) Spiegels nach Prostatastanzbiopsie Rückschlüsse auf das pathologische Ergebnis zu?

    OpenAIRE

    Volkmer BG; Gottfried H-W; Herkommer K; Küfer R; Neßlauer T

    2004-01-01

    Einleitung: Die diagnostische Biopsie der Prostata führt bekanntermaßen zum Anstieg des Serum-PSA-Spiegels. Diese prospektive Untersuchung sollte die Frage klären, ob die Änderungen des Serum-PSA-Spiegels nach Stanzbiopsie Rückschlüsse auf das histologische Ergebnis zulassen und so als Entscheidungshilfe bei der Frage der Rebiopsie dienen können. Patienten und Methoden: Insgesamt 79 konsekutive Patienten mit klinischem Verdacht auf das Vorliegen eines Prostatakarzinoms (PCA) und einem Gesamt...

  8. Putting PSA to work

    International Nuclear Information System (INIS)

    The IAEA has, during the last three years, been working intensively on PSA applications. The draft TECDOC prepared during these activities, ''PSA Applications'' is summarized in this paper. Actual events at nuclear facilities provide an important basis to compare PSAs with reality. PSA based operational event analysis therefore can be used to evaluate the importance of operational events from a risk perspective but also can contribute to validating and enhancing PSAs and to continuously check whether or not the PSA models are adequate, appropriate and complete. The work of the IAEA in this area is therefore summarized as well. In a companion paper, titled ''Towards a credible PSA fit for applications'', two specific aspects regarding the quality of the PSA to be used are discussed in detail, namely the Living PSA concept, which ensures that the PSA reflects actual design and operational features and Quality Assurance for PSA. (author)

  9. THE CLINICAL SIGNIFICANCE OF PERCENT FREE PSA IN DIFFERENTIATING PROSTATE CANCER AND BENIGN PROSTATE HYPERPLASIA

    Institute of Scientific and Technical Information of China (English)

    王子明; 张鹏; 种铁; 赵丽华

    2004-01-01

    Objective To evaluate using prostate specific antigen (PSA) and percent free PSA(fPSA) for the diagnosis of prostate cancer(Pca) and benign prostate hyperplasia(BPH). Methods 315 men with BPH and 55 men with Pca were randomly chosen, serum fPSA and total PSA were determined by ELISA and then we compared the sensitivity and specificity of PSA and percent fPSA for the diagnosis of Pca. Results While using PSA and percent fPSA for the diagnosis of prostate cancer, the sensitivity was similar (89.8% vs. 94.5%, P>0.05), but the specificity was significanty different (52.7% vs. 89.8%, P<0.005). Conclusions Using percent fPSA might decrease false-positive and avoid 37.1% negative biopsies as compared with PSA, it is very valuable for the diagnosis of Pca.

  10. Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer

    DEFF Research Database (Denmark)

    Ulmert, David; Vickers, Andrew J; Scher, Howard I;

    2012-01-01

    The utility of conventional prostate-specific antigen (PSA) measurements in blood for monitoring rapid responses to treatment for prostate cancer is limited because of its slow elimination rate. Prior studies have shown that free PSA (fPSA), intact PSA (iPSA) and human kallikrein-related peptidas...

  11. Molekulare Formen des PSA in der Diagnostik des Prostatakarzinoms

    Directory of Open Access Journals (Sweden)

    Lein M

    2003-01-01

    Full Text Available Das prostataspezifische Antigen ist die wichtigste Kenngröße in der Diagnostik und Therapieüberwachung des Prostatakarzinoms. Zur besseren Abgrenzung zwischen Männern mit und ohne Prostatakarzinom, aber auch zur Früherkennung, haben sich die molekularen Formen des PSA als wertvolle Entscheidungshilfen erwiesen. Es wird eine Übersicht über bisher vorliegende Informationen zur Aussagekraft des freien PSA, des an alpha 1-Antichymotrypsin gebundenen PSA und des komplexierten PSA (cPSA zusammen mit eigenen Resultaten gegeben. Der Quotient aus freiem und Gesamt-PSA hat sich als eine wichtige Entscheidungsgröße in der urologischen Praxis etabliert, mit der Sensitivität und Spezifität der Prostatakarzinomdiagnostik verbessert werden. Die Zahl von Prostatastanzbiopsien im Gesamt-PSA-Bereich von 4–10 ng/ml kann damit reduziert werden. Ein diagnostischer Vorteil der alleinigen Bestimmung des komplexierten PSA bzw. der entsprechenden Quotienten im Vergleich zum Gesamt-PSA und des Quotienten freies PSA zu Gesamt-PSA konnte bisher nicht sicher nachgewiesen werden.

  12. Antigenic characterization of an abnormal isoform of prion protein using a new diverse panel of monoclonal antibodies

    International Nuclear Information System (INIS)

    We established a panel of monoclonal antibodies (mAbs) against prion protein (PrP) by immunizing PrP gene-ablated mice with the pathogenic isoform of prion protein (PrPSc) or recombinant prion protein (rPrP). The mAbs could be divided into at least 10 groups by fine epitope analyses using mutant rPrPs and pepspot analysis. Seven linear epitopes, lying within residues 56-90, 119-127, 137-143, 143-149, 147-151, 163-169, and 219-229, were defined by seven groups of mAbs, although the remaining three groups of mAbs recognized discontinuous epitopes. We attempted to examine whether any of these epitopes are located on the accessible surface of PrPSc. However, no mAbs reacted with protease-treated PrPSc purified from scrapie-affected mice, even when PrPSc was dispersed into a detergent-lipid protein complex, to reduce the size of PrPSc aggregates. In contrast, denaturation of PrPSc by guanidine hydrochloride efficiently exposed all of the epitopes. This suggests that any epitope recognized by this panel of mAbs is buried within the PrPSc aggregates. Alternatively, if the corresponding region(s) are on the surface of PrPSc, the region(s) may be folded into conformations to which the mAbs cannot bind. The reactivity of a panel of mAb also showed that the state of PrPSc aggregation influenced the denaturation process, and the sensitivity to denaturation appeared to vary between epitopes. Our results demonstrate that this new panel of well-characterized mAbs will be valuable for studying the biochemistry and biophysics of PrP molecules as well as for the immuno-diagnosis of prion diseases

  13. Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor.

    Directory of Open Access Journals (Sweden)

    Mathilda Eriksson

    Full Text Available Virus-like particles (VLPs consist of capsid proteins from viruses and have been shown to be usable as carriers of protein and peptide antigens for immune therapy. In this study, we have produced and assayed murine polyomavirus (MPyV VLPs carrying the entire human Prostate Specific Antigen (PSA (PSA-MPyVLPs for their potential use for immune therapy in a mouse model system. BALB/c mice immunized with PSA-MPyVLPs were only marginally protected against outgrowth of a PSA-expressing tumor. To improve protection, PSA-MPyVLPs were co-injected with adjuvant CpG, either alone or loaded onto murine dendritic cells (DCs. Immunization with PSA-MPyVLPs loaded onto DCs in the presence of CpG was shown to efficiently protect mice from tumor outgrowth. In addition, cellular and humoral immune responses after immunization were examined. PSA-specific CD4(+ and CD8(+ cells were demonstrated, but no PSA-specific IgG antibodies. Vaccination with DCs loaded with PSA-MPyVLPs induced an eight-fold lower titre of anti-VLP antibodies than vaccination with PSA-MPyVLPs alone. In conclusion, immunization of BALB/c mice with PSA-MPyVLPs, loaded onto DCs and co-injected with CpG, induces an efficient PSA-specific tumor protective immune response, including both CD4(+ and CD8(+ cells with a low induction of anti-VLP antibodies.

  14. Sensitivity improvement of a sandwich-type ELISA immunosensor for the detection of different prostate-specific antigen isoforms in human serum using electrochemical impedance spectroscopy and an ordered and hierarchically organized interfacial supramolecular architecture.

    Science.gov (United States)

    Gutiérrez-Zúñiga, Gabriela Guadalupe; Hernández-López, José Luis

    2016-01-01

    A gold millielectrode (GME) functionalized with a mixed (16-MHA + EG3SH) self-assembled monolayer (SAM) was used to fabricate an indirect enzyme-linked immunosorbent assay (ELISA) immunosensor for the sensitive detection of prostate-specific antigen (PSA), a prostate cancer (PCa) biomarker, in human serum samples. To address and minimize the issue of non-specific protein adsorption, an organic matrix (amine-PEG3-biotin/avidin) was assembled on the previously functionalized electrode surface to build up an ordered and hierarchically organized interfacial supramolecular architecture: Au/16-MHA/EG3SH/amine-PEG3-biotin/avidin. The electrode was then exposed to serum samples at different concentrations of a sandwich-type immunocomplex molecule ((Btn)Ab-AgPSA-(HRP)Ab), and its interfacial properties were characterized using electrochemical impedance spectroscopy (EIS). Calibration curves for polarization resistance (RP) and capacitance (1/C) vs. total and free PSA concentrations were obtained and their analytical quality parameters were determined. This approach was compared with results obtained from a commercially available ELISA immunosensor. The results obtained in this work showed that the proposed immunosensor can be successfully applied to analyze serum samples of patients representative of the Mexican population.

  15. DIAGNOSTIC AND PROGNOSTIC UTILITY OF SERUM PSA IN BREAST CANCER

    Institute of Scientific and Technical Information of China (English)

    张淑群; 强水云; 李妙羡; 纪宗正

    2004-01-01

    Objective To investigate the diagnostic and prognostic value of total and free prostate-specific antigen (PSA) in breast cancer women. Methods Using the microparticle enzyme immunoassay system, we measured the concentrations of these markers in the sera of 85 women with breast cancer and in 30 healthy women.Results Free PSA levels were significantly higher in women with breast cancer than healthy women (P <0. 05 ).The percentage of free PSA predominant subjects was 37. 6% in breast cancer patients and 3. 3% in healthy women.In women with breast cancer,total PSA positivity was 23.5% and free PSA positivity was 27. 1%. When compared to negatives,total PSA positive patients had a higher percentage of lymph node involvement tamours ( P >0. 05).However, patients with predominant free PSA had a higher percentage of early stage than patients with predominant PSA-ACT. Conclusion This study indicate clinical significance of preoperative measurement of serum total and free PSA in diagnosis and prognosis of women with breast cancer. The expression of KLKs is correlated with carcinogenesis of breast cancer.

  16. Randomized studies of PSA screening: an opinion

    Institute of Scientific and Technical Information of China (English)

    Oliver Sartor

    2011-01-01

    @@ The issue of prostate cancer screening with prostate-specific antigen (PSA) has been contentious for nearly two decades due to lack of data from randomized trials, but that has now changed.A brief review of the available data is warranted as there is finally some clarity on this critically important topic.Knowing what to ignore, as well as what to focus on, is critical for understanding the current data.

  17. Prostate-Specific Antigen (PSA) Test

    Science.gov (United States)

    ... Understanding Laboratory Tests Prostate Cancer—Patient Version Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Tumor Markers Understanding Prostate Changes: A Health Guide for Men ...

  18. Babesiosis PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-04-25

    This 60 second PSA describes babesiosis, a preventable and treatable tickborne disease, including the signs and symptoms of infection and ways to prevent it.  Created: 4/25/2012 by Center for Global Health, Division of Parasitic Diseases and Malaria.   Date Released: 4/26/2012.

  19. Probabilistic safety analyses (PSA)

    International Nuclear Information System (INIS)

    The guide shows how the probabilistic safety analyses (PSA) are used in the design, construction and operation of light water reactor plants in order for their part to ensure that the safety of the plant is good enough in all plant operational states

  20. Development of an MHC class I Ld-restricted PSA peptide-loaded tetramer for detection of PSA-specific CD8+ T cells in the mouse

    OpenAIRE

    Lemke, Caitlin D.; Graham, Jessica B.; Lubaroff, David M.; Salem, Aliasger K.

    2011-01-01

    Objectives We set out to develop a prostate specific antigen (PSA) peptide-loaded tetramer for enumeration of PSA-specific CD8+ T cells in the Balb/c mouse model. Methods A candidate MHC class I PSA peptide (HPQKVTKFML188–197) was selected based on its ability to restimulate PSA-specific CD8+ T cells to secrete IFN-γ in our assays. Next, H-2Ld-restricted peptide-loaded and fluorescently labeled tetramers were produced in conjunction with the NIH Tetramer Core Facility. This tetramer was then ...

  1. PSA velocity may not be of value in prostate cancer detection

    Institute of Scientific and Technical Information of China (English)

    Derrick Johnston; Martha K Tetris

    2011-01-01

    @@ Prostate cancer is the most prevalent nonskin cancer and is the third leading cause of cancer death in the United States.It is estimated to affect millions of men worldwide and is a significant cause of morbidity and mortality.1 The detection and treatment of prostate cancer has changed significantly since the discovery of prostate-specific antigen (PSA) in the 1970s and the development of the first PSA serum assay in the 1980s.PSA testing has been implemented as a tumor marker and as a screening instrument for prostate cancer.Much data have been generated regarding the properties and usefulness of PSA in both roles.PSA velocity (PSAV), or the rate of increase in serum PSA levels over time, has been discussed and studied for many years as an adjunct to PSA alone in predicting prostate cancer.

  2. Evaluation of the effect of PSA inter-assay variability on nomograms for prostate cancer prediction

    OpenAIRE

    Siemßen, Kerstin

    2012-01-01

    Purpose: To evaluate the suitability of published nomograms for prostate cancer (PCa) risk prediction, in particular considering the prostate specific antigen (PSA) inter-assay variability. Patients and Methods: Total (tPSA) and free PSA were determined with five different assays in 780 biopsy-referred men. Together with age, prostate volume and digital rectal examination (DRE) status these data were applied to five published nomograms for PCa detection. The criteria discrimina...

  3. FDA Approves Test to Aid Post-PSA Biopsy Decisions | Division of Cancer Prevention

    Science.gov (United States)

    The Food and Drug Administration (FDA) has approved a test to help men with elevated prostate-specific antigen (PSA) test scores decide whether to have a biopsy to test for prostate cancer. The Access Hybritech p2PSA test is approved for use in men aged 50 or older who have a PSA test score between 4 and 10 ng/ml but who show no signs of cancer during a digital rectal exam. |

  4. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer

    DEFF Research Database (Denmark)

    See, W; Iversen, P; Wirth, M;

    2003-01-01

    To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.......To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer....

  5. Binge Drinking PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-10-05

    This PSA is based on the October, 2010 CDC Vital Signs report which indicates that drinking too much, including binge drinking, causes more than 79,000 deaths in the U.S. each year and is the third leading preventable cause of death.  Created: 10/5/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 10/5/2010.

  6. Whooping Cough PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2015-01-22

    This 30 second PSA encourages pregnant women to get the whooping cough vaccine, called Tdap, during the third trimester of each pregnancy in order to pass antibodies to their babies so they are born with protection against this serious disease.  Created: 1/22/2015 by National Center for Immunization and Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), Meningitis and Vaccine Preventable Diseases Branch (MVPDB).   Date Released: 1/22/2015.

  7. PSA data development for Novovoronezh unit 5 level 1 PSA

    International Nuclear Information System (INIS)

    This paper presents the approach used in developing data for the level-1 Probabilistic Safety Analysis (PSA) of the Novovoronezh Unit 5 nuclear power plant (NVNPP-5), the first Russian VVER-1000 reactor. The NVNPP-5 PSA is being carried out within the framework of the joint Russian-Swiss project (i.e., SWISRUS). This paper describes briefly approaches and results of PSA data analysis done in respect to various PSA data required for the PSA model quantification including: Initiating event frequencies; Component reliability parameters; Component unavailabilities due to maintenance and common cause failures; Human error probabilities. Specifically, both generic and plant-specific data on initiating event frequencies and reliability parameters for system components (pumps, valves, diesel generators, etc.) were developed on the basis of available initial statistical data ('raw' data) with usage of the Bayesian updating methodology. Samples of final data are provided. The problems and insights dealt with processing the statistical data and parameters definition are identified in the paper. The insights obtained from Human Reliability Analysis (HRA) and component Common Cause Failure (CCF) analysis, as well as the effect of various types of PSA data on PSA results are discussed. Also, plans and procedures for PSA data updating for Living PSA purposes are discussed in this paper. (authors)

  8. PSA Screening Has Led to Overtreatment of Many Prostate Cancers

    Science.gov (United States)

    Screening for prostate cancer with the prostate-specific antigen (PSA) test has led to overtreatment of many prostate cancers, including aggressive treatments in older men considered to be at low risk for progression of the disease according to a study published in the July 26, 2010 Archives of Internal Medicine.

  9. Lifestyle and Clinical Health Behaviors and PSA Tests

    Science.gov (United States)

    Norris, Cynthia; McFall, Stephanie

    2006-01-01

    This study assessed the association of lifestyle and clinical health behaviors with prostate specific antigen (PSA) tests. The study used cross-sectional data from the 2002 Behavioral Risk Factor Surveillance System (BRFSS). We used Stata 8.0 to take into account the complex sample design in analyses. Both lifestyle and clinical health behaviors…

  10. Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.

    Science.gov (United States)

    Schlack, Katrin; Krabbe, Laura-Maria; Fobker, Manfred; Schrader, Andres Jan; Semjonow, Axel; Boegemann, Martin

    2016-01-01

    The purpose of this study was to evaluate the prognostic ability of early changes of total prostate specific antigen (tPSA), free PSA (fPSA), [-2]proPSA and the Prostate Health Index (PHI) following initiation of Abiraterone-therapy in men with castration resistant prostate cancer (mCRPC). In 25 patients, PSA-subforms were analyzed before and at 8-12 weeks under therapy as prognosticators of progression-free-survival (PFS) and overall survival (OS). Comparing patients with a PFS 15 months of OS there was a non-significant trend for a difference in the relative-median-change of fPSA (17.0% vs. -46.3%; p = 0.06). In Kaplan-Meier analyses, declining fPSA and [-2]proPSA were associated with a longer median PFS (13 months, 95% confidence interval (CI): 9.6-16.4 vs. 10 months, 95% CI: 3.5-16.5; p = 0.11), respectively. Correspondingly, decreasing fPSA and [-2]proPSA values indicated an OS of 32 months (95% CI: not reached (NR)) compared to 21 months in men with rising values (95% CI: 7.7-34.3; p = 0.14), respectively. We concluded that the addition of fPSA- and [-2]proPSA-changes to tPSA-information might be further studied as potential markers of early Abiraterone response in mCRPC patients. PMID:27618028

  11. PSA Update Procedures, an Ultimate Need for Living PSA

    International Nuclear Information System (INIS)

    Nuclear facilities by their complex nature, change with time. These changes can be both physical (plant modification, etc.), operational (enhanced procedures, etc.) and organizational. In addition, there are also changes in our understanding of the plant, due to operational experience, data collection, technology enhancements, etc. Therefore, it is imperative that PSA model must be frequently up-dated or modified to reflect these changes. Over the last ten years. these has been a remarkable growth of the use of Probabilistic Safety Assessments (PSAs). The most rapidly growing area of the PSA Applications is their use to support operational decision-making. Many of these applications are characterized by the potential for not only improving the safety level but also for providing guidance on the optimal use of resources and reducing regulatory burden. To enable a wider use of the PSA model as a tool for safety activities it is essential to maintain the model in a controlled state. Moreover, to fulfill requirements for Living PSA, the PSA model has to be constantly updated and/or monitored to reflect the current plant configuration. It should be noted that the PSA model should not only represent the plant design but should also represent the operational and emergency procedures. To keep the PSA model up-to-date several issues should be clearly defined including: - Responsibility should be divided among the PSA group, - Procedures for implementing changes should be established, and - QA requirements/program should be established to assure documentation and reporting. (author)

  12. Prostate Cancer Screening: the role of biopsy, PSA, PSA dynamics and isoforms

    NARCIS (Netherlands)

    P.F.J. Raaijmakers (René)

    2009-01-01

    textabstractIn the beginning of the past century, A. Astraldi urologist from Buenos Aires, Argentina, recognized the importance of early detection of prostate cancer and was unsatisfied with the available diagnostic tools he had to his disposal. The only diagnostic means for the urologist at that ti

  13. Der Stellenwert verschiedener PSA-abhängiger Parameter zur Optimierung der präoperativen Diagnostik bei Patienten mit symptomatischer Prostatahyperplasie

    OpenAIRE

    Zey, Silke

    2003-01-01

    Es wurden bei 558 Patienten (148 Prostatakarzinom; 410 benigne Prostatahyperplasie) die Sensitivität und Spezifität folgender Parameter untersucht: Prostataspezifisches Antigen, freies Prostataspezifisches Antigen, Volumendichte des PSA und Volumendichte des freien PSA. Für die bekannten Parameter zeigten sich die in anderen Studien ermittelten Sensitivitäten und Spezifitäten, für die Volumendichte des freien PSA konnten keine signifikanten Ergebnisse gefunden werden und dient som...

  14. Nonprostatic sources of prostate-specific antigen.

    Science.gov (United States)

    Diamandis, E P; Yu, H

    1997-05-01

    The name prostate-specific antigen has been given to a protein that now is known not to be prostate-specific; however, prostatic tissue does produces extremely high levels of PSA and secrets it into the seminal plasma. Seminal plasma contains about 1 million micrograms/L of PSA and is the richest source of PSA reported. The biologic fluid with the second highest PSA concentration, however, is nipple aspirate fluid from the female breast (up to about 5000 micrograms/L), and the third is milk from lactating women (up to 300 micrograms/L). Male serum PSA is usually less than 4 micrograms/L. In nonprostatic tissues, PSA exists mainly in its free molecular form, but PSA-ACT complex is also present in most of the fluids that contain PSA, such as breast secretions and amniotic fluid. The gene expression and protein production of PSA in nonprostatic tissues are under the regulation of steroid hormones via their receptors. Androgens, glucocorticoids, and progestins up-regulate the PSA gene expression, resulting in an increase of protein production. Estrogen by itself seems to have no effect on PSA regulation, but it can impair PSA production induced by androgen. It remains unknown whether PSA is enzymatically active and what is the physiologic role of PSA in nonprostatic tissues. It is speculated that PSA may be involved in the regulation of growth factors. Measuring PSA in breast cancer cytosol, breast-nipple aspirate fluid, and female serum may have potential clinical utilities, including breast cancer prognosis, breast cancer risk assessment, and evaluation of androgen excess. Further studies are needed to identify the exact function and regulation of PSA in nonprostatic tissues and to explore the clinical application of this protein. PMID:9126224

  15. The Relationship of PSA, PSAD and Clinicopathological Stage in Patients with Prostate Cancer

    Institute of Scientific and Technical Information of China (English)

    2007-01-01

    OBJECTIVE To investigate the relationship between the clinicopathological stage and serum prostate specific antigen (PSA) concentration and PSA density (PSAD) in patients with prostate cancer.METHODS The clinicopathological stage was determined on the basis of a pathological examination and clinical data in 65 prostate cancer patients treated by radical prostatectomy. PSA and PSAD were measured before the operation. The Spearman rank correlation was applied to evaluate the relationship between the clinicopathological stage, serum PSA concentration and PSAD.RESULTS Patients with higher PSA and PSAD were significantly more likely to have higher clinical stages, a higher Gleason score, positive surgical margins, capsular penetration, and seminal vesicle invasion (each P<0.05).But there was no significant association between PSA and lymph node metastasis (P=0.053). The levels of serum PSA concentration and PSAD were significantly correlated with the clinical stage (P<0.05) in the prostate cancer patients.CONCLUSION The level of both PSA and PSAD were significantly correlated with the clinical stage (P<0.05) in the prostate cancer patients. But PSAD may be a more powerful predictor of clinical stage and prognosis than PSA.

  16. Human behaviour in PSA

    International Nuclear Information System (INIS)

    Based on the current international state of the art of methodology for evaluation of human errors for PSA, many research projects have been initiated by the competent departments of the BMU and the BfS (Federal Min. of the Environment and Reactor Safety, Federal Radiation Protection Office). Three major areas of the research activities are discussed: Database: - Specific investigations into the applicability of generic data (THERP) to other than the original cases, possibly elaboration of approaches for application-specific modification, further evaluation of operating results; - general enhancement of insight into human performance and errors, e.g. with respect to causes of error and application areas (influence of organisation, cognitive performance); interviews with experts as a supplementary approach for data verification and database enhancement. Sensitivity analysis: - Identification of information describing human errors essentially contributing to frequency of occurrence of incidents and system non-availability; - establishment of relevance rating system, methodology for uncertainty analysis. Further development of methodology: - Modelling of repair activities and knowledge-based behaviour. (orig./CB)

  17. EVALUATION OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN RATIO IN THE DIAGNOSIS OF PROSTATE CANCER

    Institute of Scientific and Technical Information of China (English)

    2000-01-01

    @@ It's reported that free to total prostate specific antigen ration (f/tPSA) can provide more benefit than the single use of prostate specific antigen (PSA) in the diagnosis of prostate cancer (PCa). We measured serum PSA and fPSA levels in 62 cases of benign prostatic hyperplasia (BPH) and 40 cases of PCa using radioimmunoassay, with patients' age range 59y~ 89y.

  18. Does the size matter?: Prostate weight does not predict PSA recurrence after radical prostatectomy.

    Science.gov (United States)

    Davidson, Darrell D; Koch, Michael O; Lin, Haiqun; Jones, Timothy D; Biermann, Katharina; Cheng, Liang

    2010-04-01

    Previous studies suggest that low prostate weight is a significant negative prognostic factor for prostate cancer. In the current study, the data for 431 men who underwent radical retropubic prostatectomy between 1990 and 1998 were analyzed for association between prostate weight and various clinical and pathologic parameters. These included age, preoperative prostate-specific antigen (PSA) level, PSA recurrence, pathologic stage, Gleason grade, extraprostatic extension, positive surgical margins, tumor volume, associated high-grade prostatic intraepithelial neoplasia, perineural invasion, and lymph node metastasis. Potential associations were probed by using Cox regression model analysis. A significant positive correlation was found between prostate weight and increasing patient age or increasing preoperative PSA level. There was no significant independent association between prostate weight and any of the other variables examined. No association was found between prostate weight and PSA recurrence. Although increasing prostate weight correlates with increased patient age and higher preoperative PSA level, it does not independently predict postoperative cancer recurrence.

  19. Survey of Dynamic PSA Methodologies

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Hansul; Kim, Hyeonmin; Heo, Gyunyoung [Kyung Hee University, Yongin (Korea, Republic of); Kim, Taewan [KEPCO International Nuclear Graduate School, Ulsan (Korea, Republic of)

    2015-05-15

    Event Tree(ET)/Fault Tree(FT) are significant methodology in Probabilistic Safety Assessment(PSA) for Nuclear Power Plants(NPPs). ET/FT methodology has the advantage for users to be able to easily learn and model. It enables better communication between engineers engaged in the same field. However, conventional methodologies are difficult to cope with the dynamic behavior (e.g. operation mode changes or sequence-dependent failure) and integrated situation of mechanical failure and human errors. Meanwhile, new possibilities are coming for the improved PSA by virtue of the dramatic development on digital hardware, software, information technology, and data analysis.. More specifically, the computing environment has been greatly improved with being compared to the past, so we are able to conduct risk analysis with the large amount of data actually available. One method which can take the technological advantages aforementioned should be the dynamic PSA such that conventional ET/FT can have time- and condition-dependent behaviors in accident scenarios. In this paper, we investigated the various enabling techniques for the dynamic PSA. Even though its history and academic achievement was great, it seems less interesting from industrial and regulatory viewpoint. Authors expect this can contribute to better understanding of dynamic PSA in terms of algorithm, practice, and applicability. In paper, the overview for the dynamic PSA was conducted. Most of methodologies share similar concepts. Among them, DDET seems a backbone for most of methodologies since it can be applied to large problems. The common characteristics sharing the concept of DDET are as follows: • Both deterministic and stochastic approaches • Improves the identification of PSA success criteria • Helps to limit detrimental effects of sequence binning (normally adopted in PSA) • Helps to avoid defining non-optimal success criteria that may distort the risk • Framework for comprehensively considering

  20. Result of salvage radiotherapy for post-operative PSA failure of prostate cancer. Evaluation of predictive factors

    International Nuclear Information System (INIS)

    Fifty-five patients with prostate specific antigen (PSA) failure were treated with salvage radiotherapy. Post-operative and post-radiotherapy PSA failure was defined as the PSA elevation (nadir +0.2 ng/ml) or the initiation of hormone therapy. The median follow-up period after salvage radiotherapy was 32 months (range; 1-67 months). The 3-yrs biochemical free survival and overall survival rate was 66.7% and 100%. Result of salvage radiotherapy for post-operation PSA failure is good and only the dose was significant predictive factor (60 Gy vs > 64 Gy; 53.9% vs 86.2%). (author)

  1. Cancer of the prostate - role of PSA

    International Nuclear Information System (INIS)

    Since 1979 when prostate specific antigen (PSA), found in the cytoplasm of benign and malignant prostatic cells, was first purified, it has attained world wide popularity in prostate cancer detection. It is also a sensitive test for skeletal meta states from carcinoma of the prostate. Prostate cancer has become the number one cancer in men and constitutes 11% of all cancers. Approximately 50% of men over 50 years have symptoms referable to the lower urinary tract. 50% or more of patients at Ibadan present an advanced stage of the disease and are therefore not curable. Thus, lacking the skill to manage advanced manifestations, early detection and screening programs are the best means to reduce mortality due to prostate cancer

  2. DETERMINATION OF PSA REFERENCE LEVEL FOR COMMON PROSTATIC DISEASE PATIENTS IN SUDAN

    OpenAIRE

    Yousef, Mohamed; ALIOMER, MOHAMMED A.

    2013-01-01

    This study aimed to determine the reference prostate specific antigen (PSA) range for different types prostatic disease patients in Sudanese men,A total of 50 patients, age ranged from 46-96 years with various types of prostatic disorders were enrolled into this study. The analyses included patients referred to RIA lab at RICK ,a biopsy was taken in those to exclude prostate cancer. The collected data included: PSA amount, diagnosis, habits, Age, residence and Races (tribe). The collected dat...

  3. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.

    Science.gov (United States)

    Alsahebfosoul, Fereshteh; Zavaran Hosseini, Ahmad; Salehi, Rasoul; Etemadifar, Masood; Esmaeil, Nafiseh; Jamshidian, Azam

    2015-06-01

    Soluble forms of nonclassical human leukocyte antigen (HLA)-G have recently been suggested as immunomodulatory factors in multiple sclerosis (MS). HLA-G inhibits the effecter function of T cells and natural killer (NK) cells. Also regulatory T cells (Treg) are considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of HLA-G molecules and Treg cells in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and compare it to healthy controls. Patients with RRMS (n=205, mean age=31.32±8.53) and healthy subjects (n=205, mean age=32.2±7.48) were studied. The patients subgrouped to untreated and treated with Interferon beta. Then sHLA-G levels (sHLA-G1 and sHLA-G5) were measured using ELISA method. Treg (CD4+ CD25+ Foxp3+) cells in patients who had sHLA-G>10 U/ml were characterized by using flow cytometry. Our data showed that there was no significant differences between RRMS patients and healthy controls in sHLA-G concentration (p>0.05). Treg cell frequencies were higher in the patients who had sHLA-G >10 U/ml compared to healthy subjects (pTreg cells in treated RRMS patients and healthy individuals. It seems that high level sHLA-G has been instrumental in raising frequency of Treg cells in treated patients and could be associated with remission of MS disease. PMID:26546899

  4. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis

    Directory of Open Access Journals (Sweden)

    Fereshteh Alsahebfosoul

    2015-10-01

    Full Text Available Soluble forms of nonclassical human leukocyte antigen (HLA-G have recently been suggested as immunomodulatory factors in multiple sclerosis (MS. HLA-G inhibits the effecter function of T cells and natural killer (NK cells. Also regulatory T cells (Treg are considered as pivotal players in MS pathogenesis. Thus, we aimed to evaluate the presence of HLA-G molecules and Treg cells in Relapsing-Remitting Multiple Sclerosis (RRMS patients and compare it to healthy controls.Patients with RRMS (n=205, mean age=31.32±8.53 and healthy subjects (n=205, mean age=32.2±7.48 were studied. The patients subgrouped to untreated and treated with Interferon  beta.  Then  sHLA-G  levels  (sHLA-G1  and  sHLA-G5  were measured  using ELISA method. Treg (CD4+CD25+  Foxp3+ cells in patients who had sHLA-G>10 U/ml were characterized by using flow cytometry.Our data showed that there was no significant differences between RRMS patients and healthy controls in  sHLA-G concentration (p>0.05. Treg cell frequencies were higher in the patients who had sHLA-G >10 U/ml compared to healthy subjects (p<0.05.Collectively, there was significant correlation between sHLA-G and frequency of Treg cells in treated RRMS patients and healthy individuals. It seems that high level sHLA-G has been  instrumental  in  raising  frequency  of  Treg  cells  in  treated  patients  and  could  be associated with remission of MS disease.

  5. fPSA、tPSA、 PAP、fPSA/tPSA值联合99m Tc-MDP骨扫描在前列腺癌诊断中的价值%The value of combination serum tumor marker measurement fPSA,tPSA, PAP, the ratio of fPSA/tPSA with 99mTC-MDP bone scanning in the patients with prostate cancer

    Institute of Scientific and Technical Information of China (English)

    王婵; 冯雪凤; 刘万红

    2013-01-01

    Objective: To study the value of combination"mTc- MDP bone scanning with serum tumor marker free prostate specific antigen (fPSA ) , total prostate specific antigen (tPSA) , prostatic acid phosphatase ( PAP) , the ratio of fPSA/tPSA measurement in the patients with prostate cancer. Methods: 99mTc-MDP whole-body bone scanning was performed in 175 patients with prostate cancer,the serum fPSA,tPSA and PAP were measured,and calculating the ratio of fPSA/tPSA. Results: In 175 patients with prostate cancer, the average value of fPSA,tPSA and PAP were significantly higher than the control group (P 50 ng·ml-1 ,it was 58. 97%. Conclusion; Combining fPSA,tPSA,PAP and fPSA/tPSA <0. 20 could increase the sensitivity of diagnosis prostate cancer. 99mTc-MDP whole-body bone scanning is considerable screening method in diagnosis osseous metastasis in the patients with prostate cancer, when tPSA increasing, the positive ratio of bone scanning in the patients with prostate cancer is higher and higher.%目的:研究肿瘤标记物fPSA、tPSA、PAP、fPSA/tPSA值联合99mTc-MDP骨扫描在前列腺癌中的诊断价值.方法:对175例初诊前列腺癌患者行99mTc-MDP骨扫描,检测fPSA、tPSA和PAP,并计算出fPSA/tPSA值.结果:在175例前列腺癌患者中,fPSA、tPSA、PAP均高于正常人,fPSA/tPSA值低于正常人,差异有统计学意义(P <0.01);fPSA、tPSA、PAP和fPSA/tPSA<0.20诊断前列腺癌的灵敏度分别为57.71%、69.14%、38.29%和66.29%,fPSA、tPSA和fPSA/tPSA<0.20三项联合检测灵敏性可达87.50%.99mTc-MDP骨扫描阳性病例占36.57% (64/175),阴性病例占63.43%(111/175).骨扫描阳生病例组的fPSA、tPSA和PAP均高于骨扫描阴性病例组(P<0.01).当tPSA< 10 ng·ml-1时,骨扫描阳性病例数占29.87%,当tPSA> 50 ng·ml-1,骨扫描阳性病例数高达58.97%.结论:fPSA、tPSA、PAP和fPSA/tPSA<0.20联合检测可提高诊断前列腺癌的灵敏性.99mTc-MDP核素骨扫描可作为前列腺癌骨

  6. World AIDS Day PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-11-16

    December 1 is World AIDS Day. In this PSA, communities are encouraged to get tested for HIV.  Created: 11/16/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 11/16/2011.

  7. Hepatitis Awareness Month PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2011-05-11

    May is National Hepatitis Awareness Month. This 30 second PSA discusses hepatitis and encourages listners to talk to their health care professional about getting tested.  Created: 5/11/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 5/11/2011.

  8. Raccoon Roundworm Infection PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-08-27

    This 60 second PSA describes the signs and symptoms of and ways to prevent Baylisascaris infection, a parasitic roundworm infection that is spread through raccoon feces.  Created: 8/27/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/28/2012.

  9. Development of a PSA information management system

    Energy Technology Data Exchange (ETDEWEB)

    Ho, Seok; Dong Kyu, Kim; Sun Koo, Kang [Korea Power Engineering Company, Inc (Korea, Republic of)

    2007-07-01

    In general, Probabilistic Safety Agreement (PSA) is a very complicated work that uses and generates a lot of resources such as reports, procedures, drawings, assumptions, calculation sheets, PSA model, and so on. In many PSAs, however, the data, materials and knowledge considered and generated during performing PSA are scattered in many documents so that overall structure of PSA and information relationship between documents and models cannot easily be understood. To organize and manage all documents related to PSA, to capture knowledge of analysts, and finally to improve the quality of PSA, a PSA information management system (PIMS) was developed. The PIMS can manage all the documents of a PSA in a database and connect the causal relation between one information to another in the scattered documents via link. The PIMS can manage all the assumptions and technical basis used in PSA, and it can keep the record of the design changes the revision of PSA model. It can also control the review results of PSA models. The link of the PIMS can explicitly describe and reveal the expertise of the PSA analysts, and it enables the users to capture the knowledge and to understand the structure and contents of a PSA with ease. We are planning to apply the PIMS to the PSA of Shin Kori Units 1 and 2 as feasibility study and then to all the PSAs of the nuclear power plants in Korea. The PIMS is expected to contribute to enhancing the quality and confidence of PSA and reducing the efforts and costs of maintenance and update of PSA. (authors)

  10. FATORES DEMOGRÁFICOS ASSOCIADOS À REALIZAÇÃO DO ANTÍGENO PROSTÁTICO ESPECÍFICO (PSA EM MUNICÍPIO SUL BRASILEIRO

    Directory of Open Access Journals (Sweden)

    Willian Augusto Melo

    2012-12-01

    Full Text Available The Prostate Specific Antigen (PSA is considered the most important marker to detect, monitor and internship prostate cancer. This study aimed to characterize the men who were examined for measurement of PSA in 2009 in a basic health unit of Maringá-PR. Were collected information about age, race, PSA test result and place of residence. The independent variable was PSA values (normal or abnormal. Were used descriptive statistics of the variables through the frequencies and bivariate analysis by Fisher's Exact Test. Was reached that 53.5% of men who underwent PSA testing were younger than 60 years, where these, 1.2% had their PSA level abnormal or above 4.01 Ng-mL. Being over 70 years was statistically significant PSA changes. It is concluded that age is a triggering factor for benign and malignant prostatic abnormalities.

  11. PSA bounce after {sup 125}I-brachytherapy for prostate cancer as a favorable prognosticator

    Energy Technology Data Exchange (ETDEWEB)

    Engeler, Daniel S.; Schwab, Christoph; Schmid, Hans-Peter [Cantonal Hospital St. Gallen, Department of Urology, St. Gallen (Switzerland); Thoeni, Armin F. [Lindenhofspital Berne, Department of Radiation Oncology, Berne (Switzerland); Hochreiter, Werner [Hirslanden Klinik Aarau, Department of Urology, Aarau (Switzerland); Prikler, Ladislav [Klinik Uroviva Buelach, Department of Urology, Buelach (Switzerland); Suter, Stefan [Cantonal Hospital Zug, Department of Urology, Zug (Switzerland); Stucki, Patrick [Cantonal Hospital Lucerne, Department of Urology, Lucerne (Switzerland); Schiefer, Johann; Plasswilm, Ludwig; Putora, Paul Martin [Cantonal Hospital St. Gallen, Department of Radiation Oncology, St. Gallen (Switzerland)

    2015-10-15

    Permanent low-dose-rate brachytherapy (BT) with iodine 125 is an established curative treatment for localized prostate cancer. After treatment, prostate-specific antigen (PSA) kinetics may show a transient rise (PSA bounce). Our aim was to investigate the association of PSA bounce with biochemical control. Patients treated with BT in Switzerland were registered in a prospective database. Only patients with a follow-up of at least 2 years were included in our analysis. Clinical follow-up and PSA measurements were assessed after 1.5, 3, 6, and 12 months, and annually thereafter. If PSA increased, additional follow-up visits were scheduled. Cases of PSA bounce were defined as a rise of at least 0.2 ng/ml above the initial PSA nadir with a subsequent decline to or below the initial nadir without treatment. Biochemical failure was defined as a rise to nadir + 2 ng/ml. Between March 2001 and November 2010, 713 patients with prostate cancer undergoing BT with at least 2 years of follow-up were registered. Median follow-up time was 41 months. Biochemical failure occurred in 28 patients (3.9 %). PSA bounce occurred in 173 (24.3 %) patients; only three (1.7 %) patients with PSA bounce developed biochemical failure, in contrast to 25 (4.6 %) patients without previous bounce (p < 0.05). The median time to bounce was 12 months, the median time to biochemical failure was 30 months. The median bounce increase was 0.78 ng/ml. Twenty-eight patients with bounce (16.5 %) had a transient PSA rise of + 2 ng/ml above the nadir. In most cases, an early increase in PSA after BT indicates PSA bounce and is associated with a lower risk of biochemical failure. (orig.) [German] Die permanente Low-dose-rate-Brachytherapie (BT) mit {sup 125}I ist ein etabliertes kuratives Verfahren bei lokalisiertem Prostatakarzinom. Posttherapeutisch koennen die PSA-Konzentrationen einen voruebergehenden Anstieg zeigen (Bounce-Phaenomen). Untersucht werden sollte ein moeglicher Zusammenhang mit der

  12. High-sensitivity detection of PSA by time-resolved fluorometry with Europium chelate

    Science.gov (United States)

    Nahm, Kie B.; Jeong, Jin H.; Kim, Byoung C.; Kim, Jae H.; Kim, Young M.; Jeong, Dong S.; Oh, Sang W.; Choi, Eui Y.; Ko, Dong S.

    2006-01-01

    Prostate-specific antigen (PSA) is an androgen-dependent glycoprotein protease (M.W. 33 kDa) and a member of kallikrein super-family of serine protease, and has chymotrypsin-like enzymatic activity. It is synthesized by the prostate epithelial cells and found in the prostate gland and seminal plasma as a major protein. It is widely used as a clinical marker for diagnosis, screening, monitoring and prognosis of prostate cancer. In normal male adults, the concentration of PSA in the blood is below 4 ng/ml and this value increases in patients with the prostate cancer or the benign prostatic hyperplasia (BPH) due to its leakage into the circulatory system. As such, systematic monitoring of the PSA level in the blood can provide critical information about the progress of the prostatic disease. We have fabricated a bread-board time resolved fluorescence system that could detect a concentration of Prostate Specific Antigen t-PSA) at clinically meaningful level in plasma as well as in whole blood sample. We chose Europium chelates as the fluorescence markers to attach to the PSA for its long decay lifetime and relative photostability. We have simplified the electronic circuits considerably by employing a MCS. With this setup, we have successfully proved that PSA concentration of 4pg/mL can be detected with acceptable reliability.

  13. Prostate-Specific Antigen Nadir and Time to Prostate-Specific Antigen Nadir Following Maximal Androgen Blockade Independently Predict Prognosis in Patients with Metastatic Prostate Cancer

    OpenAIRE

    Hong, Seok Young; Cho, Dae Sung; Kim, Sun Il; Ahn, Hyun Soo; Kim, Se Joong

    2012-01-01

    Purpose To evaluate the influence of prostate-specific antigen (PSA) kinetics following maximal androgen blockade (MAB) on disease progression and cancer-specific survival in patients with metastatic, hormone-sensitive prostate cancer. Materials and Methods One hundred thirty-one patients with metastatic, hormone-sensitive prostate cancer treated with MAB at our institution were included in this study. Patients' characteristics, PSA at MAB initiation, PSA nadir, time to PSA nadir (TTN), and P...

  14. Towards a credible PSA fit for applications

    International Nuclear Information System (INIS)

    Probabilistic Safety Assessment (PSA) is an effective tool to enhance plant safety, and to operate nuclear facilities in the most efficient manner. However, a PSA that is to be used as a day to day tool for decision making at NPPs has to reflect the actual design and operational features of the plant as accurate as possible and it must be of high quality. The first requirement can best be fulfilled with the Living PSA Concept, while the latter considerably depends on the Quality Assurance for the PSA project. The IAEA has made a considerable effort to support the development of technical capabilities for PSA in Member States and in writing technical oriented procedures for carrying out PSA. However, PSA reviews show that there are still some aspects, such as quality assurance, that need to be stressed further. With his background in mind, the IAEA has, during the last two years, been working on Living PSA and Quality Assurance for PSA. The draft TECDOCs prepared during these activities, ''Requirements for Living PSA'' and ''A framework for a Quality Assurance programme for PSA'' are summarized in this paper. (author)

  15. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes.

    Science.gov (United States)

    Llop, Esther; Ferrer-Batallé, Montserrat; Barrabés, Sílvia; Guerrero, Pedro Enrique; Ramírez, Manel; Saldova, Radka; Rudd, Pauline M; Aleixandre, Rosa N; Comet, Josep; de Llorens, Rafael; Peracaula, Rosa

    2016-01-01

    New markers based on PSA isoforms have recently been developed to improve prostate cancer (PCa) diagnosis. However, novel approaches are still required to differentiate aggressive from non-aggressive PCa to improve decision making for patients. PSA glycoforms have been shown to be differentially expressed in PCa. In particular, changes in the extent of core fucosylation and sialylation of PSA N-glycans in PCa patients compared to healthy controls or BPH patients have been reported. The objective of this study was to determine these specific glycan structures in serum PSA to analyze their potential value as markers for discriminating between BPH and PCa of different aggressiveness. In the present work, we have established two methodologies to analyze the core fucosylation and the sialic acid linkage of PSA N-glycans in serum samples from BPH (29) and PCa (44) patients with different degrees of aggressiveness. We detected a significant decrease in the core fucose and an increase in the α2,3-sialic acid percentage of PSA in high-risk PCa that differentiated BPH and low-risk PCa from high-risk PCa patients. In particular, a cut-off value of 0.86 of the PSA core fucose ratio, could distinguish high-risk PCa patients from BPH with 90% sensitivity and 95% specificity, with an AUC of 0.94. In the case of the α2,3-sialic acid percentage of PSA, the cut-off value of 30% discriminated between high-risk PCa and the group of BPH, low-, and intermediate-risk PCa with a sensitivity and specificity of 85.7% and 95.5%, respectively, with an AUC of 0.97. The latter marker exhibited high performance in differentiating between aggressive and non-aggressive PCa and has the potential for translational application in the clinic. PMID:27279911

  16. Improvement of Prostate Cancer Diagnosis by Detecting PSA Glycosylation-Specific Changes

    Science.gov (United States)

    Llop, Esther; Ferrer-Batallé, Montserrat; Barrabés, Sílvia; Guerrero, Pedro Enrique; Ramírez, Manel; Saldova, Radka; Rudd, Pauline M.; Aleixandre, Rosa N.; Comet, Josep; de Llorens, Rafael; Peracaula, Rosa

    2016-01-01

    New markers based on PSA isoforms have recently been developed to improve prostate cancer (PCa) diagnosis. However, novel approaches are still required to differentiate aggressive from non-aggressive PCa to improve decision making for patients. PSA glycoforms have been shown to be differentially expressed in PCa. In particular, changes in the extent of core fucosylation and sialylation of PSA N-glycans in PCa patients compared to healthy controls or BPH patients have been reported. The objective of this study was to determine these specific glycan structures in serum PSA to analyze their potential value as markers for discriminating between BPH and PCa of different aggressiveness. In the present work, we have established two methodologies to analyze the core fucosylation and the sialic acid linkage of PSA N-glycans in serum samples from BPH (29) and PCa (44) patients with different degrees of aggressiveness. We detected a significant decrease in the core fucose and an increase in the α2,3-sialic acid percentage of PSA in high-risk PCa that differentiated BPH and low-risk PCa from high-risk PCa patients. In particular, a cut-off value of 0.86 of the PSA core fucose ratio, could distinguish high-risk PCa patients from BPH with 90% sensitivity and 95% specificity, with an AUC of 0.94. In the case of the α2,3-sialic acid percentage of PSA, the cut-off value of 30% discriminated between high-risk PCa and the group of BPH, low-, and intermediate-risk PCa with a sensitivity and specificity of 85.7% and 95.5%, respectively, with an AUC of 0.97. The latter marker exhibited high performance in differentiating between aggressive and non-aggressive PCa and has the potential for translational application in the clinic. PMID:27279911

  17. Prostate-Specific Antigen Velocity Before and After Elimination of Factors That Can Confound the Prostate-Specific Antigen Level

    Energy Technology Data Exchange (ETDEWEB)

    Park, Jessica J., E-mail: park16@fas.harvard.edu [Department of Radiation Oncology, Brigham and Women' s Hospital and Dana-Farber Cancer Institute, Boston, MA (United States); Chen, Ming-Hui [Department of Statistics, University of Connecticut, Storrs, CT (United States); Loffredo, Marian; D' Amico, Anthony V. [Department of Radiation Oncology, Brigham and Women' s Hospital and Dana-Farber Cancer Institute, Boston, MA (United States)

    2012-03-01

    Purpose: Prostate-specific antigen (PSA) velocity, like PSA level, can be confounded. In this study, we estimated the impact that confounding factors could have on correctly identifying a patient with a PSA velocity >2 ng/ml/y. Methods and Materials: Between 2006 and 2010, a total of 50 men with newly diagnosed PC comprised the study cohort. We calculated and compared the false-positive and false-negative PSA velocity >2 ng/ml/y rates for all men and those with low-risk disease using two approaches to calculate PSA velocity. First, we used PSA values obtained within 18 months of diagnosis; second, we used values within 18 months of diagnosis, substituting the prebiopsy PSA for a repeat, nonconfounded PSA that was obtained using the same assay and without confounders. Results: Using PSA levels pre-biopsy, 46% of all men had a PSA velocity >2 ng/ml/y; whereas this value declined to 32% when substituting the last prebiopsy PSA for a repeat, nonconfounded PSA using the same assay and without confounders. The false-positive rate for PSA velocity >2 ng/ml/y was 43% as compared with a false-negative rate of PSA velocity >2 ng/ml/y of 11% (p = 0.0008) in the overall cohort. These respective values in the low-risk subgroup were 60% and 16.7% (p = 0.09). Conclusion: This study provides evidence to explain the discordance in cancer-specific outcomes among groups investigating the prognostic significance of PSA velocity >2 ng/ml/y, and highlights the importance of patient education on potential confounders of the PSA test before obtaining PSA levels.

  18. Programmable automation systems in PSA

    International Nuclear Information System (INIS)

    The Finnish safety authority (STUK) requires plant specific PSAs, and quantitative safety goals are set on different levels. The reliability analysis is more problematic when critical safety functions are realized by applying programmable automation systems. Conventional modeling techniques do not necessarily apply to the analysis of these systems, and the quantification seems to be impossible. However, it is important to analyze contribution of programmable automation systems to the plant safety and PSA is the only method with system analytical view over the safety. This report discusses the applicability of PSA methodology (fault tree analyses, failure modes and effects analyses) in the analysis of programmable automation systems. The problem of how to decompose programmable automation systems for reliability modeling purposes is discussed. In addition to the qualitative analysis and structural reliability modeling issues, the possibility to evaluate failure probabilities of programmable automation systems is considered. One solution to the quantification issue is the use of expert judgements, and the principles to apply expert judgements is discussed in the paper. A framework to apply expert judgements is outlined. Further, the impacts of subjective estimates on the interpretation of PSA results are discussed. (orig.) (13 refs.)

  19. Qualification of calculation aids for PSA

    International Nuclear Information System (INIS)

    In Germany Probabilistic Safety Analysis (PSA) are part of the evaluation of a nuclear power plants safety. The German PSA guide stipulates that the used software must enable a PSA according to the state of the art. This software must be qualified to assure that its features, mathematic methods and its performance enable a PSA like this. In this research work specifications and requirements are developed, which allow the testing of software. A procedure was developed to qualify PSA software according to the PSA guide and the experiences of users of PSA. Setting up a procedure, a tool for a systematic and uniform examination was crated. Additionally the options, mathematic fundamentals and performance of PSA-programs were analyzed. According to this all programs that were analyzed are capable to sovle their original task, that is the calculation of the safety of high available system based on high available components. Against that the requirements of modern PSA, e.g. to handle less available functions, HRA and fire analyses, based on the use of modern software and the implementation of new developments in the field of PSA are not supported adequately by all programs. (orig.)

  20. Incorporating Level-2 PSA Feature of CONPAS into AIMS-PSA Software

    International Nuclear Information System (INIS)

    CONPAS (CONtainment Performance Analysis System) utilizes a methodology to treat containment phenomena in detail like APET but in simple way. In mid 2000's, KAERI has developed very fast cut set generator FTREX and PC's OS (Operating system) has changed into Windows 95. Thus, KAERI has developed new Level-1 PSA software, called AIMS-PSA (Advanced Information Management System for PSA) to replace KIRAP. Recently, KAERI has been developing an integrated PSA platform, called OCEANS (On-line Consolidator and Evaluator of All mode risk for Nuclear System), for the risk assessment of all power modes and all hazards. CONPAS for Level-2 PSA was developed in 1990's using the Visual Basic 6.0 compiler which is not supported any more. It needs to be updated for the integrated PSA software framework. This paper describes a study to incorporate the features of CONPAS into AIMS-PSA. The basic idea is to follow the approach of CONPAS, but in the integrated way. Various approaches for Level-2 PSA have been used since WASH-1400. APET approach of NUREG-1150 study would be most comprehensive and complex methodology for containment event tree analysis. CONPAS is the Level-2 PSA software to utilize an approach to treat containment phenomena in detail like APET but in simple way. But, new Level-2 PSA software is required to develop more integrated PSA framework. A modified approach of CONPAS is developed and incorporated in AIMS-PSA software that can handle Level-1 and Level-2 PSA in the integrated way (from the viewpoint of event tree and fault tree). AIMS-PSA combines whole Level-2 PSA model to produce a One Top fault tree and to generate cut sets in the same way as Level-1 PSA. Quantification results of Level-2 PSA such as frequency for each STC can be calculated from the minimal cut sets

  1. Incorporating Level-2 PSA Feature of CONPAS into AIMS-PSA Software

    Energy Technology Data Exchange (ETDEWEB)

    Han, Sang Hoon; Lim, Hogon; Ahn, Kwang Il [Korea Atomic Energy Research Institute, Daejeon (Korea, Republic of)

    2014-05-15

    CONPAS (CONtainment Performance Analysis System) utilizes a methodology to treat containment phenomena in detail like APET but in simple way. In mid 2000's, KAERI has developed very fast cut set generator FTREX and PC's OS (Operating system) has changed into Windows 95. Thus, KAERI has developed new Level-1 PSA software, called AIMS-PSA (Advanced Information Management System for PSA) to replace KIRAP. Recently, KAERI has been developing an integrated PSA platform, called OCEANS (On-line Consolidator and Evaluator of All mode risk for Nuclear System), for the risk assessment of all power modes and all hazards. CONPAS for Level-2 PSA was developed in 1990's using the Visual Basic 6.0 compiler which is not supported any more. It needs to be updated for the integrated PSA software framework. This paper describes a study to incorporate the features of CONPAS into AIMS-PSA. The basic idea is to follow the approach of CONPAS, but in the integrated way. Various approaches for Level-2 PSA have been used since WASH-1400. APET approach of NUREG-1150 study would be most comprehensive and complex methodology for containment event tree analysis. CONPAS is the Level-2 PSA software to utilize an approach to treat containment phenomena in detail like APET but in simple way. But, new Level-2 PSA software is required to develop more integrated PSA framework. A modified approach of CONPAS is developed and incorporated in AIMS-PSA software that can handle Level-1 and Level-2 PSA in the integrated way (from the viewpoint of event tree and fault tree). AIMS-PSA combines whole Level-2 PSA model to produce a One Top fault tree and to generate cut sets in the same way as Level-1 PSA. Quantification results of Level-2 PSA such as frequency for each STC can be calculated from the minimal cut sets.

  2. PSA Velocity Does Not Improve Prostate Cancer Detection | Division of Cancer Prevention

    Science.gov (United States)

    A rapid increase in prostate-specific antigen (PSA) levels is not grounds for automatically recommending a prostate biopsy, according to a study published online February 24 in the Journal of the National Cancer Institute. |

  3. Infographic: Benefits and Harms of PSA Screening for Prostate Cancer | Division of Cancer Prevention

    Science.gov (United States)

    As more has been learned about the benefits and harms of prostate-specific antigen (PSA) screening, organizations have begun to recommend against routine screening. Screening is a personal decision that, according to most experts, a man should make in consultation with his doctor, after he has been informed in detail about the potential benefits and harms. |

  4. Prostate-Specific Antigen fluctuation: what does it mean in diagnosis of prostate cancer?

    Directory of Open Access Journals (Sweden)

    Jun Seok Kim

    2015-04-01

    Full Text Available Objective To investigate whether prostate-specific antigen (PSA fluctuation correlates with a prostate cancer and to assess whether PSA fluctuation could be used for diagnosis of prostate cancer. Materials and Methods Our study included 229 patients who were performed a prostate biopsy (non-cancer group, 177; prostate cancer group, 52. Enrolled patients were provided twice PSA tests within 6 months. PSA fluctuation (%/month was defined as a change rate of PSA per a month. Independent t test was used to compare between two groups. Receiver operator characteristic curve was used to assess the availability as a differential diagnostic tool and the correlation. Simple linear regression was performed to analyze a correlation between PSA fluctuation and other factors such as age, PSA, PSA density, and prostate volume. Results There were significant differences in PSA, PSA density, percentage of free PSA, and PSA fluctuation between two groups. PSA fluctuation was significantly greater in non-cancer group than prostate cancer group (19.95±23.34%/month vs 9.63±8.57%/month, P=0.004. The most optimal cut-off value of PSA fluctuation was defined as 8.48%/month (sensitivity, 61.6%; specificity, 59.6%; AUC, 0.633; P=0.004. In a simple linear regression model, only PSA level was significantly correlated with PSA fluctuation. Conclusion Patients with wide PSA fluctuations, although baseline PSA levels are high, might have a low risk of diagnosis with prostate cancer. Thus, serial PSA measurements could be an option in patients with an elevated PSA level.

  5. Small Numbers and Use of PSA

    Energy Technology Data Exchange (ETDEWEB)

    Jae, Moosung [Hanyang University, Seoul (Korea, Republic of)

    2015-10-15

    It is not perfect because it depends on many incomplete factors such as assumptions, theories, hypotheses, scope, information handling limitations, and analysts. However it is the best method available nowadays. Until a better methodology comes out, we are often advised to use PSA to make the best decisions in assessing and managing the risk of nuclear power plants. PSA people need to pay sincere attention to the quality of PSA including those factors described above in order for us to use PSA as important input to our risk assessment and management. PSA is not perfect because it depends on many incomplete factors such as assumptions, theories, hypotheses, scope, information handling limitations, and analysts. However it is the best method available nowadays until a better methodology comes out. Now it appears that the USNRC and NRA in Japan are exhibiting more interests in upgrading the use of PSA than before.

  6. PKC Isoform Expression in Modeled Microgravity

    Science.gov (United States)

    Risin, Diana; Sundaresan, Alamelu; Pellis, Neal R.; Dawson, David L. (Technical Monitor)

    1999-01-01

    Our previous studies showed that modeled (MMG) and true (USA Space Shuttle Missions STS-54 and STS-56) microgravity (MG) inhibit human lymphocyte locomotion, Modeled MG also suppressed polyclonal and antigen-specific lymphocyte activation. Activation of PKC by phorbol myristate acetate (PMA) restored the microgravity-inhibited lymphocyte locomotion as well as activation by phytohaemagglutinin (PHA), whereas calcium ionophore (ionomycin) was unable to restore these functions. Based on these results we hypothesized that MG-induced changes in lymphocyte functions are caused by a fundamental defect in signal transduction mechanism. This defect may be localized either at the PKC level or upstream of PKC, most likely, at the cell membrane level. In this study we examined the expression of PKC isoforms alpha, epsilon and delta in PBMC cultured in rotating wall vessel bioreactor, developed at NASA JSC, which models microgravity by sustaining cells in continuous free fall. The assessment of the isoforms was performed by FACS analysis following cell permeabilization. A decrease in the expression of isoforms epsilon and delta, but not isoform a, was observed in PBMC cultured in microgravity conditions. These data suggest that MMG might selectively affect the expression of Ca2+ independent isoforms of PKC Molecular analysis confirm selective suppression of Ca2+ independent isoforms of PKC.

  7. Development and perspectives of PSA in Cuba

    International Nuclear Information System (INIS)

    During the last decade the GDA/PSA has carried out the pre-operational PSA task for the Juragua Nuclear Power Plant. Since 1991 the work has been accomplished in the frames of the IAEA Technical Assistance Project CUB/9/008. The paper describes the stages of this study, (concluding with the Final Report of the pre-operational Level 1 PSA Rev. O), its assumptions, limitations and the main results and concluding remarks

  8. Factors prompting PSA-testing of asymptomatic men in a country with no guidelines: a national survey of general practitioners.

    LENUS (Irish Health Repository)

    Drummond, Frances J

    2009-01-01

    BACKGROUND: Increased use of prostate specific antigen (PSA) has been associated with increased prostate cancer incidence. Ireland is estimated to have one of the highest prostate cancer incidences in Europe and has no national guidelines for prostate cancer screening. GPs have a pivotal role in influencing PSA testing, therefore, our aim was to describe GP testing practices and to identify factors influencing these. METHODS: A postal survey, including questions on clinical practice and experience, knowledge and demographics was distributed to all GPs (n = 3,683). The main outcomes were (i) PSA testing asymptomatic men and (ii) "inappropriate" PSA testing, defined as testing asymptomatic men aged < 50 or > 75 years. Factors associated with these outcomes were identified using logistic regression. RESULTS: 1,625 GPs responded (response rate corrected for eligibility = 53%). Most respondents (79%) would PSA test asymptomatic men. Of these, 34% and 51% would test asymptomatic men < 50 and > 75 years, respectively. In multivariate analyses, GPs were more likely to test asymptomatic men if they were >or= 50 years, in practice >or= 10 years, female or less knowledgeable about PSA efficacy. Male GPs who would have a PSA test themselves were > 8-times more likely to PSA test asymptomatic men than GPs who would not have a test. GPs who had an asymptomatic patient diagnosed with prostate cancer following PSA testing, were > 3-times more likely to test asymptomatic men. Practice-related factors positively associated with testing included: running \\'well man\\' clinics, performing occupational health checks and performing other tests routinely with PSA. Factors positively associated with \\'inappropriate\\' testing included; being male and willing to have a PSA test, having worked\\/trained in the UK and supporting annual PSA testing. 91% of respondents supported the development of national PSA testing guidelines. CONCLUSION: Our findings suggest that widespread PSA testing

  9. Too Much Sodium PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-02-07

    This 60 second PSA is based on the February 2012 CDC Vital Signs report. Ninety percent of Americans age two and older eat too much sodium which can increase your risk for high blood pressure and often leads to heart disease and stroke, two leading causes of death in the US. Learn several small steps you can take to reduce the amount of sodium in your diet.  Created: 2/7/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 2/7/2012.

  10. Model engineering in a modular PSA

    International Nuclear Information System (INIS)

    For the purpose of PSA (Probabilistic Safety Analysis) for complex industrial systems, often PSA models in the form of fault and event trees are developed to model the risk of unwanted situations (hazards). While the recent decades, PSA models have gained high acceptance and have been developed massively. This lead to an increase in model sizes and complexity. Today, PSA models are often difficult to understand and maintain. This manuscript presents the concept of a modular PSA. A modular PSA tries to cope with the increased complexity by the techniques of modularization and instantiation. Modularization targets to treat a model by smaller pieces (the 'modules') to regain control over models. Instantiation aims to configure a generic model to different contexts. Both try to reduce model complexity. A modular PSA proposes new functionality to manage PSA models. Current model management is rather limited and not efficient. This manuscript shows new methods to manage the evolutions (versions) and deviations (variants) of PSA models in a modular PSA. The concepts of version and variant management are presented in this thesis. In this context, a model comparison and fusion of PSA models is precised. Model comparison provides important feedback to model engineers and model fusion kind of combines the work from different model engineers (concurrent model engineering). Apart from model management, methods to understand the content of PSA models are presented. The methods focus to highlight the dependencies between modules rather than their contents. Dependencies are automatically derived from a model structure. They express relations between model objects (for example a fault tree may have dependencies to basic events). To visualize those dependencies (for example in form of a model cartography) can constitute a crucial aid to model engineers for understanding complex interrelations in PSA models. Within the scope of this thesis, a software named 'Andromeda' has been

  11. Status and use of PSA in Sweden

    International Nuclear Information System (INIS)

    The performance and use of PSA:s in Sweden goes back about two decades. During all of this time, the field of PSA has been developing intensively, both internationally and within Sweden. The latest years have been characterised by an increased use of PSA models and results, and by major extensions of existing PSA models. The aim of this document is to describe PSA in Sweden with respect to development, scope and maturity, as well as to the contents of the analyses and the use of results. PSA activities will be described from the point of view of both the authorities and the utilities. The report gives an overview of the development within the area of PSA in Sweden both its history and current trends. The aim has been to include a reasonable amount of detail, both on the methods and results in PSA:s performed and on the numerous supporting research programs dealing with various aspects of PSA. 39 refs 39 refs

  12. Arraying prostate specific antigen PSA and Fab anti-PSA using light assisted molecular immobilization technology

    DEFF Research Database (Denmark)

    Parracino, Antonietta; Neves Petersen, Teresa; Gennaro, Ane Kold Di;

    2010-01-01

    Continuous 295nm excitation of bovine apo-α-lactalbumin (apo-bLA) results in an increase of tryptophan fluorescence quantum yield and in a progressive red-shift in tryptophan fluorescence emission. Furthermore, 295nm excitation in apo-bLA leads to disulphide bridges breakage, leading to free thiol...... a putative isosbestic point is observed in tryptophan fluorescence emission spectra, suggesting equilibrium between two pools of molecules: one with intact disulphide bridges and low fluorescence quantum yield, and another pool with disrupted disulphide bridges, high fluorescence quantum yield and red...... in many fluorescence spectroscopy studies of proteins. Prolonged illumination of any disulphide bridge containing protein will have photochemical consequences, such as disulphide bond disruption. We may not be able to observe proteins using UV light without perturbing them....

  13. Decision criteria in PSA applications

    Energy Technology Data Exchange (ETDEWEB)

    Holmberg, J.E.; Pulkkinen, U.; Rosqvist, T.; Simola, K. [VTT Automation (Finland)

    2001-11-01

    Along with the adoption of risk informed decision making principles, the need for formal probabilistic decision rule or criteria has been risen. However, there are many practical and theoretical problems in the application of probabilistic criteria. One has to think what is the proper way to apply probabilistic rules together with deterministic ones and how the criteria are weighted with respect to each other. In this report, we approach the above questions from the decision theoretic point of view. We give a short review of the most well known probabilistic criteria, and discuss examples of their use. We present a decision analytic framework for evaluating the criteria, and we analyse how the different criteria behave under incompleteness or uncertainty of the PSA model. As the conclusion of our analysis we give recommendations on the application of the criteria in different decision situations. (au)

  14. Dosagem e correlação do antígeno prostático específico com as alterações histológicas dos anexos sexuais do hamster sírio Prostate specific antigen-psa dosage and correlation with syrian hamster sexual addiction histologic alterations

    Directory of Open Access Journals (Sweden)

    Dimas José Araújo Vidigal

    2005-06-01

    Full Text Available OBJETIVO: Verificar os níveis de PSA total no Hamster Sírio, Mesocricetus auratus, jovem e adulto e demonstrar possíveis correlações entre esses níveis com as alterações histológicas dos anexos sexuais: próstata, vesículas seminais e testículos. MÉTODO: Foram examinados dez (n=10 Hamsters jovens, com idade inferior a sete semanas de vida e vinte (n=20 Hamsters com idade superior a um ano. Fez-se a dosagem do PSA e estudo histológico dos anexos sexuais em ambos os grupos e procurou-se a correlação entre o PSA encontrado e as alterações histológicas. RESULTADOS: A média de idade para os animais jovens, (grupo controle, foi de 46,7 dias (Desvio-Padrão-DP=1,16. Nos animais adultos, (grupo experimental, a média de idade não foi determinada, embora todos apresentassem idade acima de um ano no momento da morte. A média do peso dos animais jovens quando foram mortos foi de 57kg e dos animais adultos 126,5g. O PSA foi dosado no plasma de todos os animais adultos e em sete dos animais jovens. Em três animais do grupo jovem o PSA não foi detectado. A média do PSA nos animais jovens foi de 0,252ng/mL (nanogramo por mililitro e nos animais adultos de 0,325ng/mL. Os animais jovens não apresentaram alterações histológicas nos anexos sexuais examinados. Entre os Hamsters adultos, quatorze (70% animais apresentaram alguma alteração nos anexos sexuais: dez (50% apresentaram Hiperplasia Benigna da Próstata (HBP; um (5% apresentou HBP, prostatite e inflamação das vesículas seminais; um (5% inflamação supurativa das vesículas seminais; um (5% apresentou infarto testicular e prostatite; um (5% apresentou inflamação das vesículas seminais, sem HBP e prostatite. Não se detectou relação estatística entre os níveis de PSA e a ocorrência de HBP, embora os portadores da hiperplasia prostática exibissem médias de PSA bastante superiores às apresentadas pelos não portadores de hiperplasia. Não foram também determinadas

  15. Low Power and Shutdown PSA Modeling using AIMS-PSA and SIMA Script

    Energy Technology Data Exchange (ETDEWEB)

    Han, Sang Hoon; Lim, Ho Gon; Park, Jin Hee; Joon Eon [Korea Atomic Energy Research Institute, Daejeon (Korea, Republic of)

    2011-10-15

    KAERI has been developing an integrated PSA (Probabilistic Safety Assessment) software package, called OCEANS. OCEANS includes software for Level- 1, 2 and 3 PSAs, fire PSA, seismic PSA, and shutdown PSA. OCEANS is being developed to simplify and automate the modeling and quantification procedures in PSA. The AIMS-PSA software plays a key role in OCEANS, which takes charge of the event tree and fault tree modeling, as well as automates the quantification procedure. The first low power and shutdown (LPSD) PSA in Korea was performed for the purpose of estimating the risk during the LPSD operation for YGN 5 and 6 in 2000. The LPSD PSA requires a lot of time and effort for the following 2 reasons: 1) The risk is analyzed for 14 POSs (Plant Operating States). A PSA for each POS corresponds to a full power PSA. The size of a LPSD PSA can be as large as 14 times a full power PSA. 2) The states of systems/components are changed for every overhaul. The LPSD PSA should be revised for every overhaul to reflect the overhaul schedule. Another study was performed to improve the quality and enhance the methodology for the LPSD PSA in 2006. A method to use the conditioning gate was introduced for the purpose of handling a change in the state of a component. This approach has a benefit compared with the previous one, but still requires modifying the model manually. An approach has been developed in this study to simply the modeling of the LPSD PSA by using a script, called SIMA (Script Interpreter for Mapping Algorithm), in conjunction with AIMS-PSA. The SIMA script consists of a series of script commands to describe the changes in the fault tree model, which enables modifying the system fault trees of a full power PSA automatically to incorporate the situation of LPSD, so as not to modify the fault tree manually. The approach developed in this study was tested and verified for the LPSD PSA model developed in 2006

  16. Lycopene, Tomato Products, and Prostate Cancer Incidence: A Review and Reassessment in the PSA Screening Era

    Directory of Open Access Journals (Sweden)

    Melissa Y. Wei

    2012-01-01

    Full Text Available Lycopene has been proposed to protect against prostate cancer through various properties including decreased lipid oxidation, inhibition of cancer cell proliferation, and most notably potent antioxidant properties. Epidemiologic studies on the association between lycopene and prostate cancer incidence have yielded mixed results. Detection of an association has been complicated by unique epidemiologic considerations including the measurement of lycopene and its major source in the diet, tomato products, and assessment of prostate cancer incidence and progression. Understanding this association has been further challenging in the prostate-specific antigen (PSA screening era. PSA screening has increased the detection of prostate cancer, including a variety of relatively indolent cancers. This paper examines the lycopene and prostate cancer association in light of epidemiologic methodologic issues with particular emphasis on the effect of PSA screening on this association.

  17. Polymorphisms in the AR and PSA genes as markers of susceptibility and aggressiveness in prostate cancer

    DEFF Research Database (Denmark)

    Kuasne, Hellen; Rodrigues, Iara Sant'Ana; Fuganti, Paulo Emílio;

    2010-01-01

    The study of genes involved in androgen pathway can contribute to a better knowledge of prostate cancer. Our aim was to examine if polymorphisms in prostate-specific antigen (PSA) and androgen receptor (AR) genes were involved in prostate cancer risk and aggressiveness. Genotypes were determined...... by PCR-RFLP (PSA) or using a 377 ABI DNA Sequencer (AR). PSA(G/G) genotype (OR = 1.78, 95% CI = 1.06–2.99) and AR short CAG repeats (OR = 1.89, 95% CI = 1.21–2.96) increased risk for prostate cancer and were related with tumor aggressiveness. About 38.3% of tumors showed microsatellite instability...

  18. PSA as a tool for decision making

    International Nuclear Information System (INIS)

    The question on ''How safe is safe enough'' is being responded presently by deterministic criteria. Probabilistic criteria in support to more rational and less emotional decisions in regulatory and licensing issues, rationalization of resource allocation and research prioritization, among others, have a potential which is only marginally being explored. This paper discussed PSA limitations and proposes three areas for the use of PSA in decision making, namely: preventing accidents, mitigating accidents, and defining regulatory requirements. Current activities of the International Atomic Energy Agency in these areas are mentioned. PSA studies depict clearly the uncertainties and this is viewed as a positive aspect, which is unique to the use of probabilistic methods. (orig.)

  19. Overview of level 2 PSA and Overview of level 3 PSA

    International Nuclear Information System (INIS)

    The paper presents the PSA framework and an overview of PSA level 2 and 3. The PSA level 2 covers the extension of the PSA level 1, confinement event tree analysis, source term analysis and supporting tasks: structural analysis, equipment and survivability analysis. The Plant Damage States (PDS) are the starting point for the level 2 analysis. Example PDS parameters - containment status; RCS status secondary status; safety injection, containment spray and an example radiological source term table are given. The structural analysis shows that for WWER 440/213 the critical locations appear to be: bubbler tower corners, SG room wall/floor junction, hatches, mechanical and electric penetrations. For WWER 1000 critical locations are similar to PWR - liner tear near airlocks. The PSA level 3 processes are presented and examples for the results (early fatalities, latent cancer fatalities) are shown. The use of PSA in the emergency planning and the effectiveness of the emergency response actions are discussed

  20. Correlation Between MRS and Serum PSA in the Diagnosis of Local Recurrence After Radical Prostatectomy

    Directory of Open Access Journals (Sweden)

    M Ghafuri

    2012-08-01

    Full Text Available Background: Multifocality, multicentricity and extension beyond the prostate capsule are all characteristics of prostatic adenocarcinoma that may escape diagnosis by conventional CT scanning or MRI. This study was designed to assess the diagnostic value of magnetic resonance spectroscopy (MRS in prostatic carcinoma and its compatibility with prostatic specific antigen (PSA as the conventional method.Methods: In this cross-sectional study, we recruited 139 patients with previous radical prostatectomy referring to Radiology department of Hazrate-e-Rasul Hospital during the first half of 2011 for the evaluation of local recurrence. Traditionally, local recurrence is defined as serum PSA concentration >0.2 ng/dl. We used 1.5-tesla Siemens Avanto MRI unit with endorectal coil and measured creatine, choline and citrate levels before calculating choline-creatine/citrate ratio. Correlation between MRS findings with PSA concentration was evaluated in regards to the multiple levels of the previously mentioned ratio.Results: Local recurrence was found in 107 (77% patients based on PSA levels. The mean values for serum PSA levels and creatine-choline/citrate ratio were significantly different in patients with and without local recurrence. Creatine-choline/citrate ratios greater than 50, 100 and 150 (as different cut-off points of recurrence were respectively seen in 104, 102 and 97 patients and agreement ratio between MRS and PSA in these levels were 94.1%, 94.4% and 85.1%, respectively. Correlation coefficient between these two methods was 0.481.Conclusion: MRS is a valuable tool for evaluating recurrence inpatients with prostate cancer treated by radical prostatectomy and it is in good agreement with serum PSA levels.

  1. A preliminary investigation of PSA validation methods

    International Nuclear Information System (INIS)

    This document has been prepared to support the initial phase of the Atomic Energy Control Board's program to review and evaluate Probabilistic Safety Assessment (PSA) studies conducted by nuclear generating station designers and licensees. The document provides (1) a review of current and prospective applications of PSA technology in the Canadian nuclear power industry; (2) an assessment of existing practices and techniques for the review or risk and hazard identification studies in the international nuclear power sector and other technological sectors; and (3) proposed analytical framework in which to develop systematic techniques for the scrutiny and evaluation of a PSA model. These frameworks are based on consideration of the mathematical structure of a PSA model and are intended to facilitate the development of methods to evaluate a model relative to intended end-uses. (author). 34 refs., 10 tabs., 3 figs

  2. IAEA work with guides for PSA quality

    International Nuclear Information System (INIS)

    IAEA has a project on development of a TECDOC 'PSA Quality for Various Applications'. The project develops the guidance document in stages with intermediate meetings with exchange of ideas, thoughts and experience. Draft versions are being produced successively. The objective with the project is to use attributes to describe the quality of different elements of a PSA (Analysis of initiating events, accident progression, system, data, human reliability, etc) making the PSA suitable for application in various risk informed activities. Two of the meetings in this project took place in February 2004 and in July 2004. The February meeting discussed different aspects of PSA quality in relation to applications and a draft of the TECDOC was reviewed. The meeting made recommendations for preparation of a final document and set priorities for further work in the area. The July meeting elaborated the document further in a small working group and a new draft version was prepared. A final version is expected to be published during 2005. The project has come to the conclusion that it is a limited number of PSA element attributes that are specific for a certain application. Most of the attributes concern plant specificity, realism and level of detail in a general manner, how plant specific is the model, how realistic and how detailed? Many attributes have the characteristic that they are good to have, but not necessarily needed to do the job. This last statement is valid both for a baseline PSA and a PSA application. The IAEA project has identified a limited number of attributes that are necessary to describe characteristics needed for specific applications. The PSA scope needed for a specific application is not covered by the project/document, even though it is obvious that different applications will need different scope or approaches to handle scope limitations. The guidance on performing a PSA available today is old. It is a need to review these guides and update with regard

  3. Proceedings of the 10th Korea-Japan joint workshop on PSA. For Asian PSA network

    International Nuclear Information System (INIS)

    The tenth Korea-Japan Joint Workshop on Probabilistic Safety Assessment (PSA) was held in the Jeju island of Korea, on May 18-20, 2009 organized by Korea Atomic Energy Research Institute (KAERI). The purpose of the workshop was to provide a forum for presentation and discussions on experiences and technical achievements related to PSA, risk-informed and performance-based approach, and other relevant issues in both countries. Since the first Korea-Japan Joint Workshop on PSA started in 1992, the workshops have provided an important and timely opportunity for exchange and discussion of the relevant information to all PSA practitioners and users of risk information in the industry, research, academia and regulatory arena. This was the tenth anniversary of the Joint Workshop with the main theme of 'For Asian PSA Network' and participants included those from China, Taiwan and the United States of America besides Korea and Japan. Two keynote speeches were presented by the former chairmen of this workshop, Prof. Chang-Sun Kang of Seoul National University and Prof. emeritus Shunsuke Kondo of Tokyo University. We had two special lectures, 70 papers presented by experts at 10 technical sessions related PSA, the special session on the status of PSA in Korea, Japan, China and Taiwan and panel discussion on their cooperation in PSA. This report provides the summary of each session, and all the presentation materials presented in the 10th Korea-Japan Joint Workshop on PSA. (author)

  4. External hazards in PSA program for VVER 440/213

    International Nuclear Information System (INIS)

    The basic PSA study for the Dukovany NPP was completed in 1995. Since then a Living PSA program has come into force. All the PSA related activities are undertaken under the umbrella called Living PSA. They include support of risk management, data collection and information transfer, maintenance and improvement of PSA models. To support regulatory decision making the full scope PSA is under development. External hazards identified are: earthquake initiators, aircraft crushes and extreme rainfalls. Seismic PSA is not scheduled for near future, but team is being build up and a test example of seismic event impact is being modelled for trial evaluation

  5. Extent of disease in recurrent prostate cancer determined by [{sup 68}Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

    Energy Technology Data Exchange (ETDEWEB)

    Verburg, Frederik A.; Mottaghy, Felix M. [RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands); Pfister, David; Heidenreich, Axel [RWTH University Hospital Aachen, Department of Urology, Aachen (Germany); Vogg, Andreas; Drude, Natascha I.; Behrendt, Florian F. [RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen (Germany); Voeoe, Stefan [Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht (Netherlands)

    2016-03-15

    To examine the relationship between the extent of disease determined by [{sup 68}Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [{sup 68}Ga]PSMA-HBED-CC PET/CT. PET/CT was positive in 44 %, 79 % and 89 % of patients with PSA levels of ≤1, 1 - 2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95 %) had a positive scan and 12 (60 %) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36 %) had a positive scan and 1 (7 %) had M1a disease. [{sup 68}Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [{sup 68}Ga]PSMA-HBED-CC PET/CT. (orig.)

  6. Extent of disease in recurrent prostate cancer determined by [68Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score

    International Nuclear Information System (INIS)

    To examine the relationship between the extent of disease determined by [68Ga]PSMA-HBED-CC-PET/CT and the important clinical measures prostate-specific antigen (PSA), PSA doubling time (PSAdt) and Gleason score. We retrospectively studied the first 155 patients with recurrent prostate cancer (PCA) referred to our university hospital for [68Ga]PSMA-HBED-CC PET/CT. PET/CT was positive in 44 %, 79 % and 89 % of patients with PSA levels of ≤1, 1 - 2 and ≥2 ng/ml, respectively. Patients with high PSA levels showed higher rates of local prostate tumours (p < 0.001), and extrapelvic lymph node (p = 0.037) and bone metastases (p = 0.013). A shorter PSAdt was significantly associated with pelvic lymph node (p = 0.026), extrapelvic lymph node (p = 0.001), bone (p < 0.001) and visceral (p = 0.041) metastases. A high Gleason score was associated with more frequent pelvic lymph node metastases (p = 0.039). In multivariate analysis, both PSA and PSAdt were independent determinants of scan positivity and of extrapelvic lymph node metastases. PSAdt was the only independent marker of bone metastases (p = 0.001). Of 20 patients with a PSAdt <6 months and a PSA ≥2 ng/ml, 19 (95 %) had a positive scan and 12 (60 %) had M1a disease. Of 14 patients with PSA <1 ng/ml and PSAdt >6 months, only 5 (36 %) had a positive scan and 1 (7 %) had M1a disease. [68Ga]PSMA-HBED-CC PET/CT will identify PCA lesions even in patients with very low PSA levels. Higher PSA levels and shorter PSAdt are independently associated with scan positivity and extrapelvic metastases, and can be used for patient selection for [68Ga]PSMA-HBED-CC PET/CT. (orig.)

  7. Decision-Making Processes among Prostate Cancer Survivors with Rising PSA Levels: Results from a Qualitative Analysis1

    Science.gov (United States)

    Shen, Megan Johnson; Nelson, Christian J.; Peters, Ellen; Slovin, Susan F.; Hall, Simon J.; Hall, Matt; Herrera, Phapichaya Chaoprang; Leventhal, Elaine A.; Leventhal, Howard; Diefenbach, Michael A.

    2014-01-01

    Background Prostate cancer survivors with a rising prostate specific antigen (PSA) level have few treatment options, experience a heightened state of uncertainty about their disease trajectory that might include the possibility of cancer metastasis and death, and often experience elevated levels of distress as they have to deal with a disease they thought they had conquered. Guided by self-regulation theory, the present study examined the cognitive and affective processes involved in shared decision making between physician and patients who experience a rising PSA after definitive treatment for prostate cancer. Methods In-depth interviews were conducted with 34 prostate cancer survivors who had been diagnosed with a rising PSA (i.e., biochemical failure) within the past 12 months. Survivors were asked about their experiences and affective responses after being diagnosed with a rising PSA and while weighing potential treatment options. In addition, patients were asked about their decision-making process for the initial prostate cancer treatment. Results Compared to the initial diagnosis, survivors with a rising PSA reported increased negative affect following their diagnosis, concern about the treatability of their disease, increased planning and health behavior change, heightened levels of worry preceding doctor’s appointments (especially prior to the discussion of PSA testing results), and a strong reliance on physicians’ treatment recommendations. Conclusions Prostate cancer survivors’ decision-making processes for the treatment of a rising PSA are markedly different from those of the initial diagnosis of prostate cancer. Because patients experience heightened distress and rely more heavily on their physicians’ recommendations with a rising PSA, interactions with the health care provider provide an excellent opportunity to address and assist patients with managing the uncertainty and distress inherent with rising PSA levels. PMID:25385751

  8. Penile Metastases of Recurrent Prostatic Adenocarcinoma without PSA Level Increase: A Case Report

    OpenAIRE

    Antonio Pierro; Savino Cilla; Cinzia Digesù; Morganti, Alessio G

    2012-01-01

    We report a case of penile metastases from recurrent prostatic adenocarcinoma that was the first sign of a widespread metastatic disease in the absence of any increase in prostate-specific antigen (PSA) level. In April 2011, an 80-year-old man presented to our Radiotherapy Unit with multiple palpable hard nodules in the penis, dysuria, and moderate perineal pain, 7 years after he had received radiotherapy for prostate cancer. Nodules in the penis had appeared in February 2011. The ultrasound ...

  9. Prognostic Significance of PSA, Gleason Score, Bone Metastases in Patients with Metastatic Prostate Cancer Under Palliative Androgen Deprivation Treatment

    International Nuclear Information System (INIS)

    Objective: The aim of this study was to evaluate the prognostic significance of each of the following in the development and progression of hormonal refractory disease in patients with metastatic prostate cancer under hormonal palliative treatment: The initial serum level prostate specific antigen (PSA), the Gleason score (GS), the presence of bone metastases with or without visceral metastases, and the PSA decline. Patients and Methods: During the time period from January 2005 to December 2008, a total of 92 patients with newly diagnosed, histologically confirmed metastatic prostate cancer (MPC) were under palliative androgen deprivation therapy. The age range was 52 to 85 years with a mean age of 66.2±7.9 years. MPC was diagnosed histologically after transrectal ultrasonography guided biopsy. The Gleason score assessment was determined by low power microscopic examination. Metastases were confirmed by positive bone scintigraphy with 925 MBq 99mTc-MDP using a tomographic gamma camera, computerized axial tomography or magnetic resonance imagining. Measurements of PSA levels were conducted by the radioimmunoassay method. The influences of the following prognostic factors were evaluated: The initial serum level of prostate specific antigen (PSA), the Gleason score (GS), the presence of bone metastases with or without visceral metastases, and the PSA decline, on the time to disease progression. Results: The time to progression was significantly delayed in patients with initial PSA level £50 ng/ml (median: 32 months), Gleason Score £7 (median: 33 months), bone metastases only (median: 30 months) and PSA level normalization within 6 months (median: 30 months) compared to that of patients with initial PSA level >50 ng/ml (median: 24 months), Gleason Score >7 (median: 24 months), bone, distant lymph nodes and/or visceral metastases (median: 24 months), PSA level decline (median: 18 months) (p-values were 0.002, 6 sites bone metastases (median: 28 months) (p=0

  10. A method for determining a prostate-specific antigen cure after radiation therapy for clinically localized prostate cancer

    International Nuclear Information System (INIS)

    Purpose: A method that allows the determination of a prostate-specific antigen (PSA) cure after definitive management for prostate carcinoma with radiation therapy is presented and tested. Methods and Materials: The method involves a calculation of the patient's theoretical baseline PSA prior to the development of prostate cancer by using three serial rising PSA determinations obtained prior to the institution of therapy. The rate of rise of the PSA prior to therapy and the rate of decline of the PSA posttherapy are calculated, using an exponential model. Two criteria must be satisfied to define a PSA cure. First, the PSA nadir after treatment should be less than the calculated theoretical baseline PSA. Second, the rate of decline of PSA posttreatment should be greater than the rate of rise of the PSA prior to treatment. Results: Applying these two criteria to the patient data base (n 16) at a median follow-up of 19 months enabled the accurate prediction of 6 out of 6 (100%) of patients with documented PSA failure and 7 out of 10 (70%) of patients without PSA failure. Therefore, despite short follow-up, all six patients with PSA failure were predicted. Further follow-up is needed to ascertain if the seven patients predicted to be cured will remain PSA failure free and if the three patients currently without PSA failure in whom the model predicts failure, will subsequently fail. Conclusion: Therefore, using each patient's PSA history as the natural control may eliminate the error that is introduced with defining a PSA cure by using a single value for the PSA nadir at a specified time after radiation therapy

  11. Evaluation of prostate cancer prevalence in Iranian male population with increased PSA level, a one center experience

    International Nuclear Information System (INIS)

    This study was conducted to evaluate the incidence of prostate cancer (PCa) in Iranian male patients with increased prostate-specific antigen (PSA), and normal or abnormal digital rectal examination (DRE) that underwent prostate biopsy. From March 2006 to April 2009, a total of 346 consecutive males suspected of having PCa due to increased PSA levels underwent transrectal ultrasonography (TRUS)-guided sextant biopsy of the prostate. The total PSA (tPSA), demographic data, incidence of PCa, benign prostate hyperplasia (BPH), and prostatitis were assessed. The patients were divided into two groups according to their PSA values (group A serum tPSA level, 4–10 ng/mL; group B serum tPSA level, 10.1–20.0 ng/mL). Of the 346 biopsied cases, 193 cases (56%) had PCa, 80 cases (23%) had BPH, and 73 cases (21%) had prostatitis. The mean PSA and the age of the carcinoma group were significantly higher than those of the benign group (P < 0.01). The biopsy results were grouped as PCa, BPH, and prostatitis. Incidence of PCa for group A and group B cases were 115 cases (51%), and 78 cases (65%), respectively. In the case of PCa, BPH, and prostatitis, the mean PSAs were 10.02 ng/mL, 8.76 ng/mL, and 8.41 ng/mL, respectively (P < 0.40). TRUS-guided prostate biopsy and interpretation by a skilled team is highly recommended for early detection of PCa or its ruling-out. It seems that a PSA cutoff value of 4 ng/mL may be applied to the Iranian population. Although the chance of PCa is high in the PSA levels of 4–10 ng/mL, the combination of some data, like age and prostate volume, can decrease the rate of unnecessary prostate biopsies. We recommend prostate biopsy when PSA and/or DRE is elevated in symptomatic patients with obstructive and/or irritative lower urinary tract symptoms (LUTS) such as dysuria, frequency, or nocturia. Due to the very high incidence of PCa in the patients with PSA greater than 10 ng/mL, TRUS-guided biopsy is indicated, whatever the findings on DRE and

  12. Imprinted gold 2D nanoarray for highly sensitive and convenient PSA detection via plasmon excited quantum dots.

    Science.gov (United States)

    Song, Hong Yan; Wong, Ten It; Sadovoy, Anton; Wu, Lin; Bai, Ping; Deng, Jie; Guo, Shifeng; Wang, Yi; Knoll, Wolfgang; Zhou, Xiaodong

    2015-01-01

    We designed and fabricated two new nanostructured biosensing chips, with which the sensitive detection of prostate specific antigen (PSA) as low as 100 pg ml(-1) can be achieved, by measuring the plasmon enhanced fluorescence through a conventional dark field microscope. The gold nanostructure arrays, one with gold nanopillars of 140 nm, the other with gold nanoholes of 140 nm, were fabricated via nanoimprinting onto glass substrate, as localized surface plasmon resonance (LSPR) generators to enhance the fluorescent emission of fluorophore, e.g. quantum dot (QD). A sandwich bioassay of capture anti-PSA antibody (cAb)/PSA/detection anti-PSA (dAb) labeled by QD-655 was established on the nanostructures, and the perfect LSPR excitation distance (10-15 nm) between the nanostructure and QD-655 was simulated and controlled by a cleft cAb fragment and streptavidin modified QD. QD was chosen in this study due to its photo stability, broad Stokes shift, and long lifetime. As far as we know, this is the first time that QD is applied for PSA detection on the uniform nanostructured sensing chips based on the LSPR enhanced fluorescence. Due to the miniaturized nanoarray sensing chip (1.8 mm × 1.8 mm), the convenience and specificity for the detection of PSA via the sandwich assay, and the high optical detection sensitivity, the platform has great potential for the development of a portable point-of-care (POC) system for outpatient diagnosis and treatment monitoring. PMID:25360665

  13. Dosagem e correlação do antígeno prostático específico com as alterações histológicas dos anexos sexuais do hamster sírio Prostate specific antigen-psa dosage and correlation with syrian hamster sexual addiction histologic alterations

    OpenAIRE

    Dimas José Araújo Vidigal; Alcino Lázaro da Silva; Luiz Mauro Andrade da Fonseca; Dilermando Fazito de Rezende

    2005-01-01

    OBJETIVO: Verificar os níveis de PSA total no Hamster Sírio, Mesocricetus auratus, jovem e adulto e demonstrar possíveis correlações entre esses níveis com as alterações histológicas dos anexos sexuais: próstata, vesículas seminais e testículos. MÉTODO: Foram examinados dez (n=10) Hamsters jovens, com idade inferior a sete semanas de vida e vinte (n=20) Hamsters com idade superior a um ano. Fez-se a dosagem do PSA e estudo histológico dos anexos sexuais em ambos os grupos e procurou-se a corr...

  14. A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol

    Directory of Open Access Journals (Sweden)

    Griffiths Jeff

    2007-10-01

    Full Text Available Abstract Background Informed decision making is the theoretical basis in the UK for men's decisions about Prostate Specific Antigen (PSA testing for prostate cancer testing. The aim of this study is to evaluate the effect of a web-based PSA decision-aid, Prosdex, on informed decision making in men. The objective is to assess the effect of Prosdex on six specific outcomes: (i knowledge of PSA and prostate cancer-related issues – the principal outcome of the study; (ii attitudes to testing; (iii decision conflict; (iv anxiety; (v intention to undergo PSA testing; (vi uptake of PSA testing. In addition, a mathematical simulation model of the effects of Prosdex will be developed. Methods A randomised controlled trial with four groups: two intervention groups, one viewing Prosdex and the other receiving a paper version of the site; two control groups, the second controlling for the potential Hawthorn effect of the questionnaire used with the first control group. Men between the ages of 50 and 75, who have not previously had a PSA test, will be recruited from General Practitioners (GPs in Wales, UK. The principal outcome, knowledge, and four other outcome measures – attitudes to testing, decision conflict, anxiety and intention to undergo testing – will be measured with an online questionnaire, used by men in three of the study groups. Six months later, PSA test uptake will be ascertained from GP records; the online questionnaire will then be repeated. These outcomes, and particularly PSA test uptake, will be used to develop a mathematical simulation model, specifically to consider the impact on health service resources. Trial registration Current Controlled Trial: ISRCTN48473735.

  15. Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer

    DEFF Research Database (Denmark)

    Jessen, Kasper; Søndergaard, Jens; Larsen, Pia Veldt;

    2013-01-01

    Background. The use of prostate-specific antigen test has markedly increased in Danish general practice in the last decade. Despite the national guidelines advice against PSA screening, opportunistic screening is supposed to be the primary reason for this increased number of PSA tests performed. ...

  16. A Microfluidic Love-Wave Biosensing Device for PSA Detection Based on an Aptamer Beacon Probe

    Directory of Open Access Journals (Sweden)

    Feng Zhang

    2015-06-01

    Full Text Available A label-free and selective aptamer beacon-based Love-wave biosensing device was developed for prostate specific antigen (PSA detection. The device consists of the following parts: LiTaO3 substrate with SiO2 film as wave guide layer, two set of inter-digital transducers (IDT, gold film for immobilization of the biorecongniton layer and a polydimethylsiloxane (PDMS microfluidic channels. DNA aptamer, or “artificial antibody”, was used as the specific biorecognition probe for PSA capture. Some nucleotides were added to the 3'-end of the aptamer to form a duplex with the 3'-end, turning the aptamer into an aptamer-beacon. Taking advantage of the selective target-induced assembly changes arising from the “aptamer beacon”, highly selective and specific detection of PSA was achieved. Furthermore, PDMS microfluidic channels were designed and fabricated to realize automated quantitative sample injection. After optimization of the experimental conditions, the established device showed good performance for PSA detection between 10 ng/mL to 1 μg/mL, with a detection limit of 10 ng/mL. The proposed sensor might be a promising alternative for point of care diagnostics.

  17. A Microfluidic Love-Wave Biosensing Device for PSA Detection Based on an Aptamer Beacon Probe.

    Science.gov (United States)

    Zhang, Feng; Li, Shuangming; Cao, Kang; Wang, Pengjuan; Su, Yan; Zhu, Xinhua; Wan, Ying

    2015-06-11

    A label-free and selective aptamer beacon-based Love-wave biosensing device was developed for prostate specific antigen (PSA) detection. The device consists of the following parts: LiTaO3 substrate with SiO2 film as wave guide layer, two set of inter-digital transducers (IDT), gold film for immobilization of the biorecongniton layer and a polydimethylsiloxane (PDMS) microfluidic channels. DNA aptamer, or "artificial antibody", was used as the specific biorecognition probe for PSA capture. Some nucleotides were added to the 3'-end of the aptamer to form a duplex with the 3'-end, turning the aptamer into an aptamer-beacon. Taking advantage of the selective target-induced assembly changes arising from the "aptamer beacon", highly selective and specific detection of PSA was achieved. Furthermore, PDMS microfluidic channels were designed and fabricated to realize automated quantitative sample injection. After optimization of the experimental conditions, the established device showed good performance for PSA detection between 10 ng/mL to 1 μg/mL, with a detection limit of 10 ng/mL. The proposed sensor might be a promising alternative for point of care diagnostics.

  18. Age-specific PSA reference ranges in Chinese men without prostate cancer

    Institute of Scientific and Technical Information of China (English)

    Zhi-Yong Liu; Ying-Hao Sun; Chuan-Liang Xu; Xu Gao; Luo-Man Zhang; Shan-Cheng Ren

    2009-01-01

    This study is to determine age-specific prostate-specific antigen (PSA) distributions in Chinese men without prostate cancer (PC) and to recommend reference ranges for this population after comparison with other studies.From September 2003 to December 2006,9 374 adult men aged from 18 to 96 years agreed to participate in the study.After all cases of PC were excluded,8 422 adult men participated in statistical analysis and were divided into five age groups.Simple descriptive statistical analyses were carried out and quartiles and 95th percentiles were calculated for each age group.The age-specific PSA reference ranges are as follows:40-49 years,2.15 ng mL-1;50-59 years,3.20 ng mL-1;60-69 years,4.10 ng mL-1;70-79 years,5.37 ng mL-1.The results indicate that the ethnic differences in PSA levels are obvious.The currently adopted Oesterling's age-specific PSA reference ranges are not appropriate for Chinese men.The reference ranges of this study should be more suitable to Chinese men.

  19. Analysis of results related to the percent free prostate specific antigen among men without prostate diseases in Xi'an area

    Institute of Scientific and Technical Information of China (English)

    Peng Zhang; Ziming Wang; Tie Chong; Lihua Zhao

    2007-01-01

    Objective: To measure the percent of free prostate specific antigen (fPSA) among men without prostate diseases in Xi'an area, and to study the relationship of percent fPSA with age and pathological grade, clinical stage of prostate cancer (PCa) with percent fPSA, and to analyze the difference between the data in China and theoverseas data to determine appropriate reference range for Chinese male. Methods: A total of 713 participants were enrolled into the study, with PSA, fPSA in serum measured and the percent fPSA calculated. Out of 713 cases, 679 without prostate diseases were divided into 5 groups by age, and then the relationships of PSA, fPSA and percent fPSA with age were studied, respectively. The relationship of pathological grade and clinical stage with percent fPSA of the 34 participants with PCa was also studied. With the help of the related data of men without prostate disease, the appropriate reference range for Chinese male was established. Results: The increases in PSA or fPSA were correlated with age, while there was no significant correlation between age and percent fPSA. The percent fPSA was also correlated with pathological grade and clinical stage of PCa. The percent fPSA of men without prostate disease in Xi'an area was significantly lower than that in the related overseas data. The reference range of percent fPSA for Chinese male was≥15%. Conclusion: Percent fPSA might be more useful than PSA in the detection of prostate cancer. As the percent fPSA is decreased, the pathological grade is decreased, and the clinical stage is increased, the malignant degree is increased. The reference range of≥15% is more appropriate for Chinese male.

  20. Seminal plasma PSA in spinal cord injured men

    DEFF Research Database (Denmark)

    Brasso, K; Sønksen, J; Sommer, P;

    1998-01-01

    The aim of the study was to evaluate the impact of spinal cord injury on seminal plasma PSA concentration.......The aim of the study was to evaluate the impact of spinal cord injury on seminal plasma PSA concentration....

  1. The Serum Level of Prostate Specific Antigen in Polycystic Ovary Syndrome

    International Nuclear Information System (INIS)

    To determine whether serum prostate specific antigen (PSA) level are increased in polycystic ovary syndrome (PCOS), 40 patients with PCOS, and 50 healthy control subjects were enrolled in the study.The subjects were compared by means of serum PSA T SHBG DHEA-S levels. The correlations between PSA and T SHBG DHEA-S were evaluated.Serum PSA levels were found to be significantly higher in PCOS (PSA: 15.64±3.36 pg/mL, in PCOS; PSA: 3.56±0.44pg/mL, in control; P<0.01). Positive correlations between PSA and T (r=0.467, P<0.01) and between PSA and DHEA-S (r=, 0.205 P<0.05) were found. A negative correlation between PSA and SHBG was apparent (r=-0.260, P<0.05). Females with PCOS tended to have higher PSA than females without PCOS (P<0.01). PSA appears to be a promising marker of androgen excess in females suffering from PCOS. (authors)

  2. Cloning and sequence analysis of the isoforms H11-4 of the vaccine candidate antigen H11 from Haemonchus contortus%捻转血矛线虫ZJ株疫苗候选抗原H11亚型基因H11-4的克隆及序列分析

    Institute of Scientific and Technical Information of China (English)

    段丽君; 周前进; 张红丽; 杨怡; 闫宝龙; 杜爱芳

    2013-01-01

    微粒体氨肽酶H11天然提取物是目前捻转血矛线虫(Haemonchus contortus)防治研究中最好的疫苗候选抗原之一,但其重组形式均不能提供有效的免疫保护效果;同时报道H11蛋白存在多种亚型,推测其某种亚型或亚型组合可能在天然提取物参与免疫保护中起了关键作用.本试验参考NCBI公布的H.contortus H11-4基因序列,设计2对特异性引物,以H.contortus ZJ株总RNA为模板,利用RT-PCR技术分段扩增出该基因的部分片段,并进行T-A克隆.测序正确后,利用含有不同片段的阳性质粒经BamH Ⅰ/Nco Ⅰ消化,连接后获得H11-4基因的全长cDNA序列.测序结果显示成功获得H11 4基因,开放阅读框大小为2 916 bp,与NCBI中公布的核苷酸序列同源性为97.8%,氨基酸序列同源性为97.6%.生物信息学分析,已获得的H11-4与H11 (H11-3)亚型氨基酸序列高度同源,且具有保守糖基化位点、相对保守的跨膜区与微粒体氨肽酶活性中心锌指基序.为进一步分析H11天然提取物各亚型在参与免疫保护的机制和角色分工奠定了基础.%The recombinant microsomal aminopeptidase H11 antigen has not shown highly protective efficacy against Haemonchus contortus compared to its native extract which is considered to be the most efficient vaccine candidate antigen. It is reported that there exist several isoforms of native H11 and it was supposed that one or combined isoforms of native H11 play a key role in immune protection. Fragments of H11-4 gene were amplified by reverse transcription polymerase chain reaction (RT-PCR) with two pairs of primers designed according to the published gene sequence from NCBI. Then the fragments of H11-4 gene were ligated to the T-A cloning vector pMD18-T and sequenced. Positive clones representative the different two fragments were digested with BamH Ⅰ / Nco Ⅰ and then ligated to obtain the full-length cDNA. Sequence analysis shows that with 2 916 bp, H11-4 gene

  3. STD Awareness PSA - College 1 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA, targeted to college-aged youth and young adults, encourages listeners to get tested for STDs.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  4. STD Awareness PSA - Male Announcer 2 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA encourages listeners to get tested for STDs. Target - Men who have sex with other men.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  5. STD Awareness PSA - College 2 (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-04-22

    This PSA, targeted to college-aged youth and young adults, encourages listeners to get tested for STDs.  Created: 4/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/22/2010.

  6. Screen for Life: Meryl Streep PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2013-05-16

    In this 30 second PSA, Academy Award®-winning actress Meryl Streep urges viewers to get screened for colorectal cancer.  Created: 5/16/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/16/2013.

  7. Screen for Life: Meryl Streep PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2013-05-16

    In this 60 second PSA, Academy Award®-winning actress Meryl Streep urges viewers to get screened for colorectal cancer.  Created: 5/16/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/16/2013.

  8. Assessment of Atorvastatin Effectiveness on Serum PSA Level in Hypercholesterolemic Males

    Directory of Open Access Journals (Sweden)

    Darya Khosropanah

    2011-12-01

    Full Text Available The previous large retrospective studies demonstrated that treatment with Statins reduces both the incidence of prostate cancer by 50% and serum Prostate Specific Antigen (PSA level up to 40%. However the main problem in those studies was the absence of control groups of men with hypercholesterolemia without Statin treatment. We performed a small prospective controlled clinical trial to assess the influence of the treatment with Atorvastatin on serum PSA in men with hypercholesterolemia referred to our educational and treatment center from October 2007 to March 2008. In this study, among the newly diagnosed males with hypercholesterolemia (LDL > 130 mg/dl, 40 patients with LDL more than 190 mg/dl were selected as a case group and were treated with Atorvastatin (20 mg/day. Among the same population and in the same period, another 40 patients with LDL between 130 and 190 mg/dl were selected as first control group and were treated only with low fat diet. Another 40 patients with normal serum cholesterol and without any treatment were selected as second control group. The lipid profile and serum PSA level of patients of all groups were tested at the first and third months after the therapy. After completion of data, the mean serum lipids and PSA level were measured in both visits and compared with each other by paired t-test. Also the mean PSA change in two visits between three groups was compared by ANOVA and Tukey HSD test. There was not any significant difference in mean baseline PSA between hypercholesterolemic and normocholesterolemic patients (P=0.547. In case group, mean PSA and LDL was reduced by 14.1% (P=0.0001 and 30% (P=0.0001 respectively by second visit. In first control group, mean PSA was not changed significantly (P=0.337, whereas mean LDL in this group was reduced by 9.6% (P= 0.0001. Similarly in the second control group mean PSA was not changed significantly (P=0.309 by second visit. In addition, mean change of PSA in case group

  9. PSA procedure guide for MOX fuel fabrication facilities

    International Nuclear Information System (INIS)

    This document is a procedure guide developed by Japan Atomic Energy Agency for PSA (Probabilistic Safety Assessment) of MOX fuel Fabrication Facilities. The procedure guide consists of two parts. The first part describes the procedure of PSA. The second part shows the practical examples of PSA of a typical facility with information applicable to the practical assessment. (author)

  10. PSA levels of 4.0 - 10 ng/ml and negative digital rectal examination: antibiotic therapy versus immediate prostate biopsy

    Directory of Open Access Journals (Sweden)

    Avraham Shtricker

    2009-10-01

    Full Text Available Purpose: The management of mildly elevated (4.0-10.0 ng/ml prostate specific antigen (PSA is uncertain. Immediate prostate biopsy, antibiotic treatment, or short term monitoring PSA level for 1-3 months is still in controversy. Material and Methods: We conducted a retrospective chart review of patients in a large community practice (2003 - 2007 who had PSA levels between 4.0-10 ng/mL without any further evidence of infection. Data was gathered regarding patient's age, whether standard antibiotic therapy (10-14 days of ofloxacin or ciprofloxacin had been administered before the second PSA measurement, results of a second PSA test performed at 1- to 2-month intervals, whether a prostate biopsy was performed and its result. Results: One-hundred and thirty-five men met the study inclusion criteria with 65 (48.1% having received antibiotics (group 1; the PSA levels decreased in 39 (60% of which, sixteen underwent a biopsy which demonstrated prostate cancer in 4 (25%. Twenty-six (40% patients of group 1 exhibited no decrease in PSA levels; seventeen of them underwent a biopsy that demonstrated cancer in 2 (12%. The other 70 (51.9% patients were not treated with antibiotics (group 2; the PSA levels decreased in 42 (60% of which, thirteen underwent a biopsy which demonstrated prostate cancer in 4 (31%. In the other 28 (40% patients of group 2 there was no demonstrated decrease in PSA, nineteen of these subjects underwent a biopsy that demonstrated cancer in 8 (42%. Conclusions: There appears to be no advantage for administration of antibacterial therapy with initial PSA levels between 4-10 ng/mL without overt evidence of inflammation.

  11. False positives observed on the Seratec® PSA SemiQuant Cassette Test with condom lubricants.

    Science.gov (United States)

    Bitner, Sara E

    2012-11-01

    In the course of the validation of a new component of the prostate-specific antigen (PSA) SemiQuant Cassette Test marketed by Seratec(®) , a false-positive reaction was observed when testing samples collected from the surface of unused, lubricated condoms. A variety of personal lubricants and condoms were tested to determine the frequency of the false positive, as well as its potential source. Samples were extracted in both water and the manufacturer-provided buffer, and the test was performed according to the manufacturer's suggested protocol. The false positive was observed intermittently, but occurred consistently with samples containing nonoxynol-9, a strong detergent utilized as a spermicide. The reaction may be attributable to the combination of latex and nonoxynol-9. Because of the unreliability of the test to confirm the presence of PSA in samples collected from condoms, the PSA cassette is an unsuitable method for confirming the presence of seminal fluid in condoms. PMID:22494324

  12. PSA as a tool of RBMK upgrading efficiency analysis

    International Nuclear Information System (INIS)

    RBMK reactors being channel-type graphite moderated reactors required updating of ''PSA standard methodology''. RBMK PSA concept was developed when performing Ignalina NPP study which resulted in a full scope level 1 PSA. Findings of the study on the plant weaknesses allowed to compose a list of proposals which lead to core damage risk reduction from 2E-4 to 6E-5 1/year. For the Leningrad NPP a simplified method of PSA was used in order to evaluate existing safety improvement measures. Each measure was weighted in terms of risk to rank them according to their importance. However, the results should be specified by the full scope PSA

  13. Quantitative mathematical modeling of PSA dynamics of prostate cancer patients treated with intermittent androgen suppression

    Institute of Scientific and Technical Information of China (English)

    Yoshito Hirata; Koichiro Akakura; Celestia S.Higano; Nicholas Bruchovsky; Kazuyuki Aihara

    2012-01-01

    If a mathematical model is to be used in the diagnosis,treatment,or prognosis of a disease,it must describe the inherent quantitative dynamics of the state.An ideal candidate disease is prostate cancer owing to the fact that it is characterized by an excellent biomarker,prostate-specific antigen (PSA),and also by a predictable response to treatment in the form of androgen suppression therapy.Despite a high initial response rate,the cancer will often relapse to a state of androgen independence which no longer responds to manipulations of the hormonal environment.In this paper,we present relevant background information and a quantitative mathematical model that potentially can be used in the optimal management of patients to cope with biochemical relapse as indicated by a rising PSA.

  14. Predictive simulations and optimization of nanowire field-effect PSA sensors including screening

    KAUST Repository

    Baumgartner, Stefan

    2013-05-03

    We apply our self-consistent PDE model for the electrical response of field-effect sensors to the 3D simulation of nanowire PSA (prostate-specific antigen) sensors. The charge concentration in the biofunctionalized boundary layer at the semiconductor-electrolyte interface is calculated using the propka algorithm, and the screening of the biomolecules by the free ions in the liquid is modeled by a sensitivity factor. This comprehensive approach yields excellent agreement with experimental current-voltage characteristics without any fitting parameters. Having verified the numerical model in this manner, we study the sensitivity of nanowire PSA sensors by changing device parameters, making it possible to optimize the devices and revealing the attributes of the optimal field-effect sensor. © 2013 IOP Publishing Ltd.

  15. Expression System Based on an MTIIa Promoter to Produce hPSA in Mammalian Cell Cultures.

    Science.gov (United States)

    Santos, Anderson K; Parreira, Ricardo C; Resende, Rodrigo R

    2016-01-01

    Because of the limitations of standard culture techniques, the development of new recombinant protein expression systems with biotechnological potential is a key challenge. Ideally, such systems should be able to effectively and accurately synthesize a protein of interest with intrinsic metabolic capacity. Here, we describe such a system that was designed based on a plasmid vector containing promoter elements derived from the metallothionein MTIIa promoter, as well as processing and purification elements. This promoter can be induced by heavy metals in a culture medium to induce the synthesis of human prostate-specific antigen (hPSA), which has been modified to insert elements for purification, proteolysis, and secretion. We optimized hPSA production in this system by comparing the effects and contributions of ZnCl2, CdCl2, and CuSO4 in HEK293FT, HeLa, BHK-21, and CHO-K1 cells. We also compared the effectiveness of three different transfection agents: multi-walled carbon nanotubes, Lipofectamine 2000, and X-tremeGENE HP Reagent. hPSA production was confirmed via the detection of enhanced green fluorescent protein fluorescence, and cell viability was determined. The expression of hPSA was compared with that of the native protein produced by LNCaP cells, using enzyme-linked immunosorbent assay and sodium dodecyl sulfate polyacrylamide gel electrophoresis. X-tremeGENE reagent, the BHK-21 cell line, and CuSO4 showed the highest hPSA production rates. Furthermore, BHK-21 cells were more resistant to the oxidative stress caused by 100 μM CuSO4. These results suggest that the proposed optimized inducible expression system can effectively produce recombinant proteins with desired characteristics for a wide range of applications in molecular biology. PMID:27582737

  16. Expression System Based on an MTIIa Promoter to Produce hPSA in Mammalian Cell Cultures

    Science.gov (United States)

    Santos, Anderson K.; Parreira, Ricardo C.; Resende, Rodrigo R.

    2016-01-01

    Because of the limitations of standard culture techniques, the development of new recombinant protein expression systems with biotechnological potential is a key challenge. Ideally, such systems should be able to effectively and accurately synthesize a protein of interest with intrinsic metabolic capacity. Here, we describe such a system that was designed based on a plasmid vector containing promoter elements derived from the metallothionein MTIIa promoter, as well as processing and purification elements. This promoter can be induced by heavy metals in a culture medium to induce the synthesis of human prostate-specific antigen (hPSA), which has been modified to insert elements for purification, proteolysis, and secretion. We optimized hPSA production in this system by comparing the effects and contributions of ZnCl2, CdCl2, and CuSO4 in HEK293FT, HeLa, BHK-21, and CHO-K1 cells. We also compared the effectiveness of three different transfection agents: multi-walled carbon nanotubes, Lipofectamine 2000, and X-tremeGENE HP Reagent. hPSA production was confirmed via the detection of enhanced green fluorescent protein fluorescence, and cell viability was determined. The expression of hPSA was compared with that of the native protein produced by LNCaP cells, using enzyme-linked immunosorbent assay and sodium dodecyl sulfate polyacrylamide gel electrophoresis. X-tremeGENE reagent, the BHK-21 cell line, and CuSO4 showed the highest hPSA production rates. Furthermore, BHK-21 cells were more resistant to the oxidative stress caused by 100 μM CuSO4. These results suggest that the proposed optimized inducible expression system can effectively produce recombinant proteins with desired characteristics for a wide range of applications in molecular biology. PMID:27582737

  17. Is extended biopsy protocol justified in all patients with PSA ≥ 20 ng/mL?

    Institute of Scientific and Technical Information of China (English)

    Xiaojun Deng; Jian Chu; Bo Yang; Feng Liu; Weifeng Wang; Jidong Hao; Jiansheng Wan; Hui Liu

    2014-01-01

    Objective: The aim of this study was to investigate whether it was necessary to increase the number of cores at initial prostate biopsy with patients of prostate-specific antigen (PSA) ≥ 20 ng/mL and to explore an appropriate individual-ized transrectal ultrasonograhpy (TRUS)-guided prostate biopsy for the detection of prostate cancer in men suspicious of prostate cancer.Methods:A total of 115 patients with PSA ≥ 20 ng/mL and suspicious of prostate cancer were prospectively randomized to perform TRUS-guided biopsy. Patients were randomized to a “6 + X” cores or a “10 + X” cores protocol. The primary end point was cancer detection rate. Secondary end points were cancer characteristics, rate of complications and the level of pain experienced by patients during TRUS-guided prostate biopsy.Results:Preoperative variables were similar in both groups. The overal prostate cancer detection rate was 73.9%. The “10 + X” cores strategy increased cancer detection rate only 9.7% in patients with PSA ≥ 20 ng/mL but < 50 ng/mL, while there was no diference between the two strategies for cancer detection in patients with PSA ≥ 50.1 ng/mL. The number of extended biopsy cores and pain score of extended biopsy in prostate cancer patients increased significantly (P < 0.001).Conclusion:Our findings suggest that there is no significant advantage in using extended biopsy protocol in al patients with PSA ≥ 20 ng/mL.

  18. Expression system based on an MTIIa promoter to produce hPSA in mammalian cell cultures

    Directory of Open Access Journals (Sweden)

    Anderson K Santos

    2016-08-01

    Full Text Available Because of the limitations of standard culture techniques, the development of new recombinant protein expression systems with biotechnological potential is a key challenge. Ideally, such systems should be able to effectively and accurately synthesize a protein of interest with intrinsic metabolic capacity. Here, we describe such a system that was designed based on a plasmid vector containing promoter elements derived from the metallothionein MTIIa promoter, as well as processing and purification elements. This promoter can be induced by heavy metals in a culture medium to induce the synthesis of human prostate-specific antigen (hPSA, which has been modified to insert elements for purification, proteolysis, and secretion. We optimized hPSA production in this system by comparing the effects and contributions of ZnCl2, CdCl2, and CuSO4 in HEK293FT, HeLa, BHK-21, and CHO-K1 cells. We also compared the effectiveness of three different transfection agents: multi-walled carbon nanotubes, Lipofectamine 2000, and X-tremeGENE HP Reagent. hPSA production was confirmed via the detection of enhanced green fluorescent protein fluorescence, and cell viability was determined. The expression of hPSA was compared with that of the native protein produced by LNCaP cells, using enzyme-linked immunosorbent assay and sodium dodecyl sulphate polyacrylamide gel electrophoresis. X-tremeGENE reagent, the BHK-21 cell line, and CuSO4 showed the highest hPSA production rates. Furthermore, BHK-21 cells were more resistant to the oxidative stress caused by 100 μM CuSO4. These results suggest that the proposed optimized inducible expression system can effectively produce recombinant proteins with desired characteristics for a wide range of applications in molecular biology.

  19. Development of Integrated PSA Database and Application Technology

    International Nuclear Information System (INIS)

    The high quality of PSA is essential for the risk informed regulation and applications. The main elements of PSA are the model, methodology, reliability data, and tools. The purpose of the project is to develop the reliability database for the Korean nuclear power plants and PSA analysis and management system. The reliability database system has been developed and the reliability data has been collected for 4 types of reliability data such as the reactor trip, the piping, the component and the common cause failure. The database provides the reliability data for PSAs and risk informed applications. The FTREX software is the fastest PSA quantification engine in the world. The license agreement between KAERI and EPRI is made to sell FTREX to the members of EPRI. The advanced PSA management system AIMS- PSA has been developed. The PSA model is stored in the database and solved by clicking one button. All the information necessary for the KSNP Level-1 and 2 PSA is stored in the PSA information database. It provides the PSA users a useful mean to review and analyze the PSA

  20. A Joint Report on PSA for New and Advanced Reactors

    International Nuclear Information System (INIS)

    This report addresses the application of Probabilistic Safety Assessment (PSA) to new and advanced nuclear reactors. As far as advanced reactors are concerned, the objectives were to characterize the ability of current PSA technology to address key questions regarding the development, acceptance and licensing of advanced reactor designs, to characterize the potential value of advanced PSA methods and tools for application to advanced reactors, and to develop recommendations for any needed developments regarding PSA for these reactors. As far as the design and commissioning of new nuclear power plants is concerned, the objectives were to identify and characterize current practices regarding the role of PSA, to identify key technical issues regarding PSA, lessons learned and issues requiring further work; to develop recommendations regarding the use of PSA, and to identify future international cooperative work on the identified issues. In order to reach these objectives, questionnaires had been sent to participating countries and organisations

  1. PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study

    DEFF Research Database (Denmark)

    Karlsen, Randi V; Larsen, Signe B; Christensen, Jane;

    2013-01-01

    associations between socio-demographic or clinical characteristics and PSA testing without clinical indication. Material and methods. In the Danish Diet, Cancer and Health Cohort, we identified 1051 men with PC diagnosed in 1993-2008. Diagnostic and clinical characteristics were obtained from medical records......, and socio-demographic information was retrieved from administrative registers. We used general logistic regression analysis to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between socio-demographic or clinical characteristics and PSA testing without clinical indication. Cox......Background. Social differences in prostate cancer (PC) incidence and mortality might be related to testing for prostate-specific antigen (PSA). Although routine PSA screening is not recommended in Denmark, testing without clinical indication increased during the past decade. We evaluated...

  2. Take Charge. Take the Test. PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 30 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  3. More Adults Are Walking PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-07-31

    This 60 second PSA is based on the August 2012 CDC Vital Signs report. While more adults are walking, only half get the recommended amount of physical activity. Listen to learn how communities, employers, and individuals may help increase walking.  Created: 7/31/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/7/2012.

  4. Diagnostische Wertigkeit von PSA und DVT

    OpenAIRE

    Wolff, Carolina Johanna

    2014-01-01

    Die radiologische Diagnostik, die auf einem abgestuftem Untersuchungsschema beruht, ist heute fester Bestandteil in der Zahnärztlichen Chirurgie. Die zur Basisuntersuchung gehörende Panorama-Schichtaufnahme liefert grundlegende Informationen durch Darstellung der Organ- und Funktionseinheit und stellt somit die radiologische Grundlage für viele diagnostische Fragen dar. Durch gewissenhafte Beurteilung stellt die PSA somit ein im Hinblick auf die Therapieentscheidung wichtiges, sondern auch in...

  5. Safer Food Saves Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-11-03

    This 60 second PSA is based on the November 2015 CDC Vital Signs report. Contaminated food sent to several states can cause multistate outbreaks of foodborne illness and make a lot of people seriously ill. Learn what can be done to prevent and stop outbreaks.  Created: 11/3/2015 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 11/3/2015.

  6. Communication Can Save Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-08-04

    This 60 second public service announcement (PSA) is based on the August 2015 CDC Vital Signs report. Antibiotic-resistant germs cause at least 23,000 deaths each year. Learn how public health authorities and health care facilities can work together to save lives.  Created: 8/4/2015 by National Center for Emerging and Zoonotic Infectious Diseases (NCEZID).   Date Released: 8/4/2015.

  7. Stop C. difficile Infections PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-06

    This 60 second PSA is based on the March 2012 CDC Vital Signs report. C. difficile is a germ that causes diarrhea linked to 14,000 deaths in the US each year. This podcast helps health care professionals learn how to prevent C. difficile infections.  Created: 3/6/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/6/2012.

  8. Luminescence energy transfer detection of PSA in red region based on Mn2+-enhanced NaYF4:Yb, Er upconversion nanorods.

    Science.gov (United States)

    Zhang, Jianguo; Wang, Shaozhen; Gao, Ni; Feng, Dexiang; Wang, Lun; Chen, Hongqi

    2015-10-15

    A new turn-on luminescence energy transfer (LET) system has been designed for the detection of prostate specific antigen (PSA, a cancer marker) that utilizes Mn(2+)-enhanced long wavelength luminescence NaYF4:Yb, Er upconversion nanorods as the donor and gold nanorods as the acceptor. The Mn(2+)-doped NaYF4:Yb,Er upconversion luminescence nanorods with an emission peak located in the red region were synthesized. The presence of Mn(2+) markedly increased the luminescence intensity over that of the NaYF4:Yb, Er upconversion nanomaterials (excited by a 980 nm continuous wavelength laser). The surfaces of Mn(2+)-doped NaYF4:Yb, Er upconversion nanorods were modified with poly(acrylic acid). Antibodies against prostate specific antigen were bound to the surface of the carboxyl-functionalized upconversion nanorods, which acted as the energy donor in this LET system. Gold nanorods with an absorption band at ~666 nm were synthesized by the seed growth method, acted as the energy acceptor. The emission band of the upconversion nanorods overlapped well with the absorption band of the gold nanorods. The luminescence was quenched because of the electrostatic interactions that shortened the distance between the donor (negatively charged) and the accepter (positively charged).When the PSA antigen was added into the system, the energy acceptor and the energy donors were separated because the binding affinity between PSA and anti-PSA was greater than the electrostatic interactions, and thereby the luminescence was recovered. The linear range of detecting PSA was from 0.1172 to 18.75 ng/mL (R=0.995), with a limit of detection for PSA as low as 0.1129 ng/mL. The method was successfully applied to the sensing of PSA in human serum samples. PMID:25996781

  9. Prostate specific antigen testing policy worldwide varies greatly and seems not to be in accordance with guidelines : A systematic review

    NARCIS (Netherlands)

    Van der Meer, Saskia; Löwik, Sabine; Hirdes, Willem H.; Nijman, Rien M.; Van der Meer, Klaas; Hoekstra-Weebers, Josette E. H. M.; Blanker, Marco H.

    2012-01-01

    Background: Prostate specific antigen (PSA) testing is widely used, but guidelines on follow-up are unclear. Methods: We performed a systematic review of the literature to determine follow-up policy after PSA testing by general practitioners (GPs) and non-urologic hospitalists, the use of a cut-off

  10. Developing a follow-up strategy for patients with PSA ranging from 4 to 10 ng/ml via a new model to reduce unnecessary prostate biopsies.

    Directory of Open Access Journals (Sweden)

    Ruizhe Zhao

    Full Text Available OBJECTIVE: The aim of this study was to develop a follow-up strategy based on the new model to reduce unnecessary prostate biopsies in patients with prostate specific antigen (PSA ranging from 4 to 10 ng/ml. METHODS: A total of 436 patients with PSA ranging from 4 to 10 ng/ml who had undergone transrectal ultrasound (TRUS-guided prostate biopsy were evaluated during the first stage. Age, PSA, free PSA (fPSA, digital rectal examination (DRE findings, ultrasonic hypoechoic mass, ultrasonic microcalcifications, prostate volume (PV and PSA density (PSAD were considered as predictive factors. A multiple logistic regression analysis involving a backward elimination selection procedure was applied to select independent predictors. After a comprehensive analysis of all results, we developed a new model to assess the risk of prostate cancer and an effective follow-up strategy. RESULTS: Age, PSA, PV, fPSA, rate of abnormal DRE findings and rate of hypoechoic masses detected by TRUS were included in our model. A significantly greater area under the receiver-operating characteristic curve was obtained in our model when compared with using PSA alone (0.782 vs. 0.566. Patients were grouped according to the value of prostate cancer risk (PCaR. In the second stage of our study, patients with PCaR>0.52 were recommended to undergo biopsies immediately while the rest of the patients continued close follow-up observation. Compared with the first stage, the detection rate of PCa in the second stage was significantly increased (33.0% vs 21.1%, p = 0.012. There was no significant difference between the two stages in distribution of the Gleason score (p = 0.808. CONCLUSIONS: We developed a follow-up strategy based on the new model, which reduced unnecessary prostate biopsies without delaying patients' diagnoses and treatments.

  11. Measurement of serum zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL

    Institute of Scientific and Technical Information of China (English)

    Xiao-Meng Li; Ling Zhang; Jiang Li; Yang Li; Hong-Liang Wang; Guo-Yi Ji; Masaaki Kuwahara; Xue-Jian Zhao

    2005-01-01

    Aim: To investigate whether the measurement of serum zinc may improve the detection of prostate cancer (Pca) in men who had total prostate-specific antigen (PSA) levels higher than 4.1 ng/mL. Methods: A mass screening for Pca of 3940 men over S0 years old was undertaken using total serum PSA. Of the 190 men (4.8 %) with elevated PS A, 143(3.6 %) underwent a transrectal ultrasonography (TRUS)-guided biopsy of the prostate, and 42 men (1% of total and 29.3 % of men undergoing biopsy) were found to have cancer. The areas under the receiver operating characteristic curves (ROC-AUC) were used to compare the diagnostic power of cancer detection by means of serum zinc, and free PSA/total PSA ratio (f/t). Results: The men with levels of serum zinc that ranged from 40 ng/mL-60 ng/mL, had an age-adjusted odds ratios(OR) of 5.0. A cutoff value of 100 μg/mL forserum zinc concentration provided a sensitivity of 90.5 % and a specificity of 32.7 % in elevated PSA range, and a sensitivity of 93.3 % and specificity of 27.1% in gray zone, respectively. In the gray zone ranges of 4.1 ng/mL-10.0 ng/mL, the ROC-AUC for zinc was 73.0 %higher than 62.7 % of f/t PSA ratio and 56.7 % of total PSA. Conclusion: Pca displays a lower serum zinc concentration. The measurement of zinc levels improves Pca detection in the gray zone compared with the f/t PSA ratio and total PSA.

  12. Changes in antigenicity of porcine serum albumin in gamma-irradiated sausage extract by treatment with pepsin and trypsin

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Koth-Bong-Woo-Ri; Song, Eu-Jin [Department of Food Science and Technology/Institute of Food Science, Pukyong National University, Busan 608-737 (Korea, Republic of); Lee, So-Young [Traditional Food Research Group, Korea Food Research Institute, Seongnam 463-746 (Korea, Republic of); Park, Jin-Gyu [Radiation Food Science and Biotechnology, Advanced Radiation Technology Institute, Korea Atomic Energy Research Institute, Jeongup 580-185 (Korea, Republic of); Lee, Ju-Woon [National Federation of Fisheries Cooperatives, Fisheries Economic Institute, Seoul 138-827 (Korea, Republic of); Byun, Myung-Woo [Department of Culinary Nutrition, Woosong University, Daejon 300-718 (Korea, Republic of); Ahn, Dong-Hyun, E-mail: dhahn@pknu.ac.kr [Department of Food Science and Technology/Institute of Food Science, Pukyong National University, Busan 608-737 (Korea, Republic of)

    2011-11-15

    Pork is known as an allergenic food with porcine serum albumin (PSA, 66 kDa) representing the major allergen. This study was conducted to investigate the change in antigenicity of PSA in gamma-irradiated sausage extract treated with pepsin and trypsin. Sausage products (A and B) were irradiated at 1, 3, 10, and 20 kGy. After irradiation, sausage proteins were extracted and digested with pepsin (1:200, 30 min) and trypsin (1:300, 5, 30, 60, 90, and 120 min). The binding ability of PSA in extracts of the irradiated sausages (A and B) decreased by over 3 kGy relative to the binding ability of PSA in extracts of intact sausages and showed no notable differences when the dose of radiation ranged from 3 to 20 kGy. After treatment with pepsin and trypsin, the binding ability of PSA in extracts of the irradiated sausages was decreased more relative to that of intact sausages and showed no significant differences when the period of trypsin treatment is increased or when the dose of irradiation is increased. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that there was no visible change in the intensity of the PSA band in extracts of the irradiated sausages. After pepsin and trypsin treatment, the intensity of PSA band faded with increasing doses of irradiation. In conclusion, antigenicity of PSA in pork sausages could be reduced by gamma irradiation. - Highlights: > Change in antigenicity of PSA in irradiated sausage extract (ISE) was examined. > Binding ability of PSA in ISE was decreased compared to intact extract. > Binding ability of PSA in ISE after enzyme treatments was also further decreased. > Intensity of PSA band in ISE after enzyme treatments became weak.

  13. Changes in antigenicity of porcine serum albumin in gamma-irradiated sausage extract by treatment with pepsin and trypsin

    International Nuclear Information System (INIS)

    Pork is known as an allergenic food with porcine serum albumin (PSA, 66 kDa) representing the major allergen. This study was conducted to investigate the change in antigenicity of PSA in gamma-irradiated sausage extract treated with pepsin and trypsin. Sausage products (A and B) were irradiated at 1, 3, 10, and 20 kGy. After irradiation, sausage proteins were extracted and digested with pepsin (1:200, 30 min) and trypsin (1:300, 5, 30, 60, 90, and 120 min). The binding ability of PSA in extracts of the irradiated sausages (A and B) decreased by over 3 kGy relative to the binding ability of PSA in extracts of intact sausages and showed no notable differences when the dose of radiation ranged from 3 to 20 kGy. After treatment with pepsin and trypsin, the binding ability of PSA in extracts of the irradiated sausages was decreased more relative to that of intact sausages and showed no significant differences when the period of trypsin treatment is increased or when the dose of irradiation is increased. The sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) results indicated that there was no visible change in the intensity of the PSA band in extracts of the irradiated sausages. After pepsin and trypsin treatment, the intensity of PSA band faded with increasing doses of irradiation. In conclusion, antigenicity of PSA in pork sausages could be reduced by gamma irradiation. - Highlights: → Change in antigenicity of PSA in irradiated sausage extract (ISE) was examined. → Binding ability of PSA in ISE was decreased compared to intact extract. → Binding ability of PSA in ISE after enzyme treatments was also further decreased. → Intensity of PSA band in ISE after enzyme treatments became weak.

  14. Prostate-specific antigen bounce following stereotactic body radiation therapy for prostate cancer

    Directory of Open Access Journals (Sweden)

    Charles C. Vu

    2014-01-01

    Full Text Available Introduction: Prostate-specific antigen (PSA bounce after brachytherapy has been well-documented. This phenomenon has also been identified in patients undergoing stereotactic body radiation therapy (SBRT. While the parameters that predict PSA bounce have been extensively studied in prostate brachytherapy patients, this study is the first to analyze the clinical and pathologic predictors of PSA bounce in prostate SBRT patients. Materials and Methods: Our institution has maintained a prospective database of patients undergoing SBRT for prostate cancer since 2006. Our study population includes patients between May 2006 and November 2011 who have at least 18 months of follow-up. All patients were treated using the CyberKnife treatment system. The prescription dose was 3500-3625cGy in 5 fractions.Results: 120 patients were included in our study. Median PSA follow-up was 24 months (range 18-78 months. 34 (28% patients had a PSA bounce. The median time to PSA bounce was 9 months, and the median bounce size was 0.50ng/mL. On univariate analysis, only younger age (p = .011 was shown to be associated with an increased incidence of PSA bounce. Other patient factors, including race, prostate size, prior treatment by hormones, and family history of prostate cancer, did not predict PSA bounces. None of the tumor characteristics studied, including Gleason score, pre-treatment PSA, T-stage, or risk classification by NCCN guidelines, was associated with increased incidence of PSA bounces. Younger age was the only statistically significant predictor of PSA bounce on multivariate analysis (OR = 0.937, p = 0.009.Conclusion: PSA bounce, which has been reported after prostate brachytherapy, is also seen in a significant percentage of patients after CyberKnife SBRT. Close observation rather than biopsy can be considered for these patients. Younger age was the only factor that predicted PSA bounce.

  15. The Application of Complex PSA and Its Relative Indexes in the Detection of Prostate Cancer

    Institute of Scientific and Technical Information of China (English)

    CHENZhaohui; WUJianmin; 等

    2002-01-01

    Objective:To study the diagnostic value of complex PSA(cPSA),the calculated free/total PSA(f/t PSA) raio and total PSA(tPSA)in the differentiation of prostate cancer from benign prostate hyperplasia.Methods:The tPSA,cPSA and fPSA were measured using the Bayer ACS-180 chemiluminescence immuno-assay.152 patients(21 with prostate cancer and 131 with benign prostate hyperplasia proven by tissue pathology)whose serum total PSA ranged from 0.2-20.0ng/ml were accessed from July 2001 to May 2002 consecutively.The correlation between tPSA and cPSA was analyzed.The re-ceiver operator characteristic curves(ROC curve)were generated by plotting the sensitivity versus specificity.Areas under the curve were calculated for each assay.Logistic regression analysis was used to evaluate the ability of the indices as independent varia-bles to predict prostate cancer.Results:In the experimental group,the areas under the ROC curve of cPSA ,tPSA and fPSA/tPSA ratio were 0.811,0.799 and 0.376 respectively.The specificity for tPSA,fPSA/tPSA ratio and cPSA were 62%,57% and 4.7%,respectively,at cotoff yield-ing 95% sensitivity.Serum cPSA concentration was determined to be the best index among the three through logistic regression analy-sis.Conclusion:The serum levels of cPSA and tPSA are better indices than f/tPSA in the differentiation of prostate cancer from benign prostate hyperplasia.At the same level of sensitivity,cPSA has a higher specificity than tPSA.Serum cPSA may be a better indicator in the prediction of prostate cancer of early stage.

  16. Penile Metastases of Recurrent Prostatic Adenocarcinoma without PSA Level Increase: A Case Report

    Directory of Open Access Journals (Sweden)

    Antonio Pierro

    2012-01-01

    Full Text Available We report a case of penile metastases from recurrent prostatic adenocarcinoma that was the first sign of a widespread metastatic disease in the absence of any increase in prostate-specific antigen (PSA level. In April 2011, an 80-year-old man presented to our Radiotherapy Unit with multiple palpable hard nodules in the penis, dysuria, and moderate perineal pain, 7 years after he had received radiotherapy for prostate cancer. Nodules in the penis had appeared in February 2011. The ultrasound and magnetic resonance (MR imaging suggested the diagnosis of multiple penile metastases. A total body computed tomography scan revealed a systemic spread of the disease, with multiple metastases in the liver, bones, and lungs. PSA level was 0.126 ng/ml. A fine needle aspiration biopsy of the liver lesion was undertaken, and the histopathologic examination revealed the prostatic origin of the metastases, so androgen deprivation therapy was started. The diagnosis of metastases should be considered in a patient with prior history of prostate malignancies presenting with solid nodules in the penis, even if the PSA level is low.

  17. Empiric antibiotics therapy for mildly elevated prostate specific antigen: Helpful to avoid unnecessary biopsies?

    Directory of Open Access Journals (Sweden)

    Andrea Fandella

    2014-09-01

    Full Text Available Purpose: The management of mildly elevated (4.0-10.0 ng/ml prostate specific antigen (PSA is uncertain. Immediate prostate biopsy, antibiotic treatment, or monitoring PSA level for 1-3 months is still in controversy. Materials and Methods: We retrospectively analysed the effect of empiric antibiotics on an increased PSA in a mono-institutional study. We analysed the data of 100 patients with a PSA of 4-10 ng/ml and normal digital rectal examination undergoing their first prostate biopsy. Patients were divided in two different cohorts. One cohort was submitted to antibiotic therapy (Levoxacin 500 mg daily for 20 days and both cohort had a re-dosing of PSA before the prostate biopsy. Results: Average age of the whole group of patients was 66.48 ± 8.32 years and their average initial PSA level was 6.67 ± 1.57 ng/mL. In the treated group (N = 49 29 patients had a decreasing PSA value from mean baseline PSA value of 6.6 ± 1.54 ng/ml to the re-dosed mean PSA level of 5.4 ± 1,61 ng/ml (p = 0.7; 20 patients didn’t experience a decrease PSA value, with a mean PSA level of 6.9 ± 1.68 ng/ml. In the control group (N = 51, 30 patients had a decrease of PSA level from mean baseline PSA level of 6.5 ± 1,59 ng/ml to a re-dosed PSA level of 5.5 ± 1.57 ng/ml; 21 patients didn’t experience a decrease of PSA value, with a mean PSA level of 6.7 ± 1.71 ng/ml. Multivariate analysis of age, PSA changes, antibiotics therapy and biopsy results (presence or absence of cancer revealed no significant difference between the two cohorts. Sepsis after biopsy occurred in 3 patient in the antibiotics group (6% and in one of the control group (2%. Conclusions: The study, even with some limitations, does not seem to show an advantage due to the administration of antibacterial therapy to reduce PSA values before prostate biopsy and subsequently to reduce unnecessary prostate biopsies.

  18. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era

    Energy Technology Data Exchange (ETDEWEB)

    McGuire, Sean E., E-mail: semcguir@mdanderson.org [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (United States); Lee, Andrew K. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Cerne, Jasmina Z. [Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas (United States); Munsell, Mark F. [Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Levy, Lawrence B. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Kudchadker, Rajat J. [Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Choi, Seungtaek L.; Nguyen, Quynh N.; Hoffman, Karen E.; Pugh, Thomas J.; Frank, Steven J. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Corn, Paul G.; Logothetis, Christopher J. [Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States); Kuban, Deborah A. [Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas (United States)

    2013-01-01

    Purpose: The aim of the study was to evaluate the prognostic value of prostate-specific antigen (PSA) response to neoadjuvant androgen deprivation therapy (ADT) prior to dose-escalated radiation therapy (RT) and long-term ADT in high-risk prostate cancer. Methods and Materials: We reviewed the charts of all patients diagnosed with high-risk prostate cancer and treated with a combination of long-term ADT (median, 24 months) and dose-escalated (median, 75.6 Gy) RT between 1990 and 2007. The associations among patient, tumor, and treatment characteristics with biochemical response to neoadjuvant ADT and their effects on failure-free survival (FFS), time to distant metastasis (TDM), prostate cancer-specific mortality (PCSM) and overall survival (OS) were examined. Results: A total of 196 patients met criteria for inclusion. Median follow-up time for patients alive at last contact was 7.0 years (range, 0.5-18.1 years). Multivariate analysis identified the pre-RT PSA concentration (<0.5 vs {>=}0.5 ng/mL) as a significant independent predictor of FFS (P=.021), TDM (P=.009), PCSM (P=.039), and OS (P=.037). On multivariate analysis, pretreatment PSA (iPSA) and African-American race were significantly associated with failure to achieve a pre-RT PSA of <0.5 ng/mL. Conclusions: For high-risk prostate cancer patients treated with long-term ADT and dose-escalated RT, a pre-RT PSA level {>=}0.5 ng/mL after neoadjuvant ADT predicts for worse survival measures. Both elevated iPSA and African-American race are associated with increased risk of having a pre-RT PSA level {>=}0.5 ng/mL. These patients should be considered for clinical trials that test newer, more potent androgen-depleting therapies such as abiraterone and MDV3100 in combination with radiation.

  19. Prostate cancer in patients from rural and suburban areas – PSA value, Gleason score and presence of metastases in bone scan

    Directory of Open Access Journals (Sweden)

    Wojciech Szot

    2014-11-01

    Full Text Available [b]Introduction[/b]. Prostate cancer is the second most common neoplasm among men both worldwide and in Poland. In prostate cancer, bone metastasis is related to a poorer prognosis. A diagnosis of metastatic bone disease is important in prostate cancer patients prior to therapy. Prostate specific antigen (PSA serum value is used both as a screening tool and for staging of prostate cancer. aim. To evaluate whether there is a link between symptoms presented by patients, pain in particular, and the presence, number and location of bone metastases as assessed by bone scan scintigraphy in concordance with PSA values and Gleason scores. [b]material[/b]. A group of 186 patients (aged: 68.38±6.16 diagnosed with prostate cancer, from rural and suburban areas of Małopolska province, that was directed for bone scan scintigraphy to the Nuclear Medicine Dept, John Paul II Hospital in Kraków. [b]methods[/b]. Analysis of all laboratory findings (including PSA value and a biopsy were performed. Then, bone scan scintigraphy was done with the use of methylene disphosphonate (MDP labeled with Tc-99m. [b]results[/b]. In patients with a Gleason value ≤7 and a PSA value ≤20 ng/ml, the cutoff value for a negative bone scan with a confidence interval of 0.95 was established at a PSA value below 10 ng/ml (p<0.01. Correlations were established between PSA value and presence of metastases in bone scan (r=0.45, p=0.05, the number of metastases (r=0.66, p<0.01, and their presence in particular body regions. [b]conclusions[/b]. The correlation between PSA value and both presence and number of metastases confirms the usefulness of bone scan scintigraphy in prostate cancer staging. The cutoff value for negative bone scan with a 95% confidence interval was established at PSA = 10 ng/ml.

  20. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10–20 ng/mL and normal digital rectal examination

    Science.gov (United States)

    Chiu, Peter Ka-Fung; Teoh, Jeremy Yuen-Chun; Lee, Wai-Man; Yee, Chi-Hang; Chan, Eddie Shu-Yin; Hou, See-Ming

    2016-01-01

    Purpose We investigated the extended use of Prostate Health Index (PHI) and percentage of [-2]pro-prostate-specific antigen (%p2PSA) in Chinese men with prostate-specific antigen (PSA) 10–20 ng/mL and normal digital rectal examination (DRE). Materials and Methods All consecutive Chinese men with PSA 10–20 ng/mL and normal DRE who agreed for transrectal ultrasound (TRUS)-guided 10-core prostate biopsy were recruited. Blood samples were taken immediately before TRUS-guided prostate biopsy. The performances of total PSA (tPSA), %free-to-total PSA (%fPSA), %p2PSA, and PHI were compared using logistic regression, receiver operating characteristic, and decision curve analyses (DCA). Results From 2008 to 2015, 312 consecutive Chinese men were included. Among them, 53 out of 312 (17.0%) men were diagnosed to have prostate cancer on biopsy. The proportions of men with positive biopsies were 6.7% in PHI55 (chi-square test, pbiopsy was 0.64. Adding %p2PSA and PHI to the base model improved the AUC to 0.79 (pbiopsy rates of Gleason 7 or above prostate cancers were 2.2% for PHI55 (chi-square test, pbiopsies could be avoided. Conclusions Both PHI and %p2PSA performed well in predicting prostate cancer and high grade prostate cancer. The use of PHI and %p2PSA should be extended to Chinese men with PSA 10–20 ng/mL and normal DRE. PMID:27617315

  1. Inhibitory Effect of Matrine on the Expression of PSA and AR in Prostate Cancer Cell line LNCaP

    Institute of Scientific and Technical Information of China (English)

    Ke CHEN; Zhiquan HU; Tao WANG; Hui GUO; Zhangqun YE

    2008-01-01

    In order to investigate the inhibitory effect of matrine on the expression of prostate specific antigen (PSA) and. Androgen receptor (AR) in prostate cancer cell line LNCaP in vitro, LNCaP cells were treated with matrine at different concentrations (0.5, 1.0, 1.5, 2.0 g/L) for 12-36 h. The growth activities of cancer cells were determined by MTI" colorimetric assay, The AR level was measured by Western blotting. The expression of PSA was detected by using AXSYM system-chemical luciferase methods. The results showed that matrine could effectively inhibit the growth of androgen-dependent prostate cancer cell line LNCaP in vitro in a time- and dose-dependent manner (P<0.05). It could obviously decrease the level of AR (P<0.01) and inhibit the expression of PSA in a dose-dependent manner (P<0.05) in LNCaP cells. It was concluded that matrine could significantly suppress the growth of LNCaP cells and inhibit the expression of PSA and AR of prostate cancer cells.

  2. Joint enhancement strategy applied in ECL biosensor based on closed bipolar electrodes for the detection of PSA.

    Science.gov (United States)

    Shi, Hai-Wei; Zhao, Wei; Liu, Zhen; Liu, Xi-Cheng; Wu, Mei-Sheng; Xu, Jing-Juan; Chen, Hong-Yuan

    2016-07-01

    A highly sensitive electrogenerated chemiluminescence (ECL) biosensor was developed on the basis of a closed bipolar electrode (BPE) apparatus for the analysis of prostate specific antigen (PSA). Bipolar modifications bring up two different stages of enhancement on the same electrode. Anodic enhancement was conducted by modifying gold nanoparticles (Au NPs) to catalyze the anodic ECL reaction between luminol and hydrogen peroxide. Cathodic introduction of thionine tagged PSA antibody led to a further pertinently enhancement synchronized with the PSA amount variation, because the existence of thionine greatly increased the rate of electron gains on cathode, leading to the corresponding acceleration of anodic ECL reaction. The more thionine modified target molecules were introduced, the faster luminol was oxidized, the higher faraday current approached, and sensitive quantification was realized in correlation with the responsive ECL intensity differences. The quantification resulted in a good determination range between 0.1pg/mL and 0.1µg/mL. This strategy mainly took advantage of the special structure of closed BPE to realize a simultaneous amplification on both ends of BPE. Moreover, the platform had a potential of providing a multi-functional strategy for the realization of other bio-detections by simply substituting the PSA sandwich structure with other bio-structures. PMID:27154662

  3. Brug af undersøgelse for prostataspecifikt antigen

    DEFF Research Database (Denmark)

    Mukai, Thomas; Bro, Flemming; Pedersen, Knud Venborg;

    2010-01-01

    Introduktion: Cancer prostatae (CP) er den hyppigste kræftform blandt danske mænd, og incidensen er stigende. CP er ofte asymptomatisk, hvilket vanskeliggør klinisk diagnosticering. I udredningen for CP kan man benytte en prøve for prostataspecifikt antigen (PSA)-niveau. Dansk Urologisk Selskab har...

  4. Predictive value of prostate-specific antigen for prostate cancer

    DEFF Research Database (Denmark)

    Shepherd, Leah; Borges, Alvaro Humberto; Ravn, Lene;

    2014-01-01

    INTRODUCTION: Although prostate cancer (PCa) incidence is lower in HIV+ men than in HIV- men, the usefulness of prostate-specific antigen (PSA) screening in this population is not well defined and may have higher false negative rates than in HIV- men. We aimed to describe the kinetics and predict...

  5. Daily Pill Can Prevent HIV PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2015-11-24

    This 60 second public service announcement (PSA) is based on the November 24, 2015 CDC Vital Signs report. Preexposure prophylaxis, or PrEP, is a daily medicine that can be used to prevent getting HIV. PrEP is for people who don’t have HIV but who are at very high risk for getting it from sex or injection drug use. Unfortunately, many people who can benefit from PrEP aren’t taking it.  Created: 11/24/2015 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 11/24/2015.

  6. Impedance-Based Miniaturized Biosensor for Ultrasensitive and Fast Prostate-Specific Antigen Detection

    Directory of Open Access Journals (Sweden)

    Ganna Chornokur

    2011-01-01

    Full Text Available This paper reports the successful fabrication of an impedance-based miniaturized biosensor and its application for ultrasensitive Prostate-Specific Antigen (PSA detection in standard and real human plasma solution, spiked with different PSA concentrations. The sensor was fabricated using photolithographic techniques, while monoclonal antibodies specific to human PSA were used as primary capture antibodies. Electrochemical impedance spectroscopy (EIS was employed as a detection technique. The sensor exhibited a detection limit of 1 pg/ml for PSA with minimal nonspecific binding (NSB. This detection limit is an order of magnitude lower than commercial PSA ELISA assays available on the market. The sensor can be easily modified into an array for the detection of other biomolecules of interest, enabling accurate, ultrasensitive, and inexpensive point-of-care sensing technologies.

  7. Role of digital rectal examination and prostate specific antigen in detecting carcinoma prostate

    International Nuclear Information System (INIS)

    Objective: To investigate the ability of digital rectal examination (DRE) and prostrate specific antigen (PSA) in detecting carcinoma prostrate. Results: Digital rectal examination has shown sensitivity of 63% and specificity of 73.22%. The sensitivity of PSA was 87% and specificity was 70.8%. The positive predictive value for DRE and PSA was 57.5% and 78.04% respectively. Negative predictive value was 73.22% and 85.22% respectively. P value was statistically significant <0.037. In the second part of study a baseline serum PSA level in age-matched 200 patients without history of prostatism was estimated. Conclusion: It was concluded that PSA represent an important adjunct to DRE for detection of prostate carcinoma. (author)

  8. Applications of probabilistic safety assessment (PSA) for nuclear power plants

    International Nuclear Information System (INIS)

    This report, which compiles information on a comprehensive set of PSA applications in the areas of NPP design, operation, and accident mitigation and management, is the culmination of an IAEA project on PSA Applications and Tools to Improve NPP Safety. In this regard, the Technical Committee Meeting (TCM) held in Madrid in February 1998 allowed participants to review and provide very valuable comments for this report. Several important facts related to PSA and its applications were highlighted during this TCM: living PSAs are the basis for the risk informed approach to decision making; development and use of safety/risk monitors as tools for configuration management is spreading fast; the different uses of PSA to support NPP testing and maintenance planning and optimization are amongst the most widespread PSA applications; plant specific PSAs are being used to support the safety upgrading programmes of plants built to earlier standards; not all countries have a regulatory framework for the use of the probabilistic approach in decision making. Some countries are still far from 'risk-informed' regulation, and this means that there is still considerable work ahead, both for regulators and utilities, to clarify approaches, to establish a framework and to reach a common understanding in relation to the use of PSA in decision making. This report is based on the premise that the use of PSA can provide useful information for the decision maker. This report is intended to provide an overview of current PSA applications. Section 2 addresses the PSA application process, outlines the general requirements for PSA tools and provides a discussion on PSA aspects such as PSA level, scope and level of detail, which have to be considered when planning/performing PSA applications. Section 3 discusses the technical aspects of individual applications and is divided into three parts. Section 3.1 is dedicated to the design related PSA applications. The second part of Section 3 considers

  9. Regulatory review of probabilistic safety assessment (PSA) Level 2

    International Nuclear Information System (INIS)

    Probabilistic safety assessment (PSA) is increasingly being used as part of the decision making process to assess the level of safety of nuclear power plants. The methodologies in use are maturing and the insights gained from the PSAs are being used along with those from deterministic analysis. Many regulatory authorities consider the current state of the art in PSA to be sufficiently well developed for results to be used centrally in the regulatory decision making process-referred to as risk informed regulation. For these applications to be successful, it will be necessary for the regulatory authority to have a high degree of confidence in the PSA. However, at the 1994 IAEA Technical Committee Meeting on Use of PSA in the Regulatory Process and at the OECD Nuclear Energy Agency Committee for Nuclear Regulatory Activities (CNRA) 'Special Issues' meeting in 1997 on Review Procedures and Criteria for Different Regulatory Applications of PSA, it was recognized that formal regulatory review guidance for PSA did not exist. The senior regulators noted that there was a need to produce some international guidance for reviewing PSAs to establish an agreed basis for assessing whether important technological and methodological issues in PSAs are treated adequately and to verify that conclusions reached are appropriate. In 1997, the IAEA and OECD Nuclear Energy Agency agreed to produce, in cooperation, guidance on Regulatory Review of PSA. This led to the publication of IAEA-TECDOC-1135 on the Regulatory Review of Probabilistic Safety Assessment (PSA) Level 1, which gives advice for the review of Level 1 PSA for initiating events occurring at power plants. This TECDOC extends the coverage to address the regulatory review of Level 2 PSA.These publications are intended to provide guidance to regulatory authorities on how to review the PSA for a nuclear power plant to gain confidence that it has been carried out to an acceptable level of quality so that it can be used as the

  10. A case report of monitoring PSA level changes in two prostate cancer patients treated with Mountain Ginseng Pharmacopuncture and Sweet Bee Venom along with western anticancer therapy

    Directory of Open Access Journals (Sweden)

    Yeonhee Lee

    2011-12-01

    Full Text Available Objectives: The purpose of this report is to find out how Mountain Ginseng Pharmacopuncture(MGP and Sweet Bee Venom(SBV treatments are effective on prostate cancer patients by monitoring Prostate specific antigen(PSA values. Methods: We treated two prostate cancer patients with MGP and SBV from October 2008 to April 2011. One patient had localized prostate cancer, the other was in the terminal stage of prostate cancer with lung and bone metastasis and both had been receiving western anticancer therapy. We had monitored the changes of PSA value. Results: In case 1, MGP and SBV treatments seemed to be helpful in preventing the recurrence of localized prostate cancer. In case 2, PSA value was decreased by MGP treatment. Conclusions: It is conceivable that MGP and SBV are effective treatments for patients with prostate cancer.

  11. Prostate-specific antigen in the early detection of prostate cancer

    OpenAIRE

    Thompson, Ian M; Ankerst, Donna P.

    2007-01-01

    Throughout Canada, the United States and much of Europe, prostate-specific antigen (PSA) screening for prostate cancer has proliferated over the past 2 decades, leading to dramatic increases in detection rates of prostate cancer. Although it has unquestionably led to increased detection of cancer and a migration to lower-stage and -volume tumours, it is still unknown whether PSA screening significantly reduces mortality from prostate cancer. Often thought to be dichotomous (i.e., either norma...

  12. Prostataspecifikt antigen, sure fosfataser og rektaleksploration i diagnostik af cancer prostatae

    DEFF Research Database (Denmark)

    Andersen, B R; Knorr, U B; Brasso, K;

    1997-01-01

    prostate cancer and benign prostatic conditions. In 105 patients with newly diagnosed prostate cancer, scintigraphic evidence of osseous metastases was found in thirty-seven. No patients with a serum PSA value less than three times the upper normal limit of the assay had a positive bone scan. Isotope bone......Eleven hundred and seven patients referred for urological evaluation including measurement of serumprostate specific antigen (PSA) measurement are reviewed. Prostate cancer was diagnosed in 105 patients. PSA was found to be superior to prostatic acid phosphatase in the discrimination between...... scan can be omitted in these patients, if they are not considered candidates for curative treatment....

  13. Label-free electrochemical aptasensing of the human prostate-specific antigen using gold nanospears.

    Science.gov (United States)

    Rahi, A; Sattarahmady, N; Heli, H

    2016-08-15

    Gold nanospears were electrodeposited with the assistance of arginine as a soft template and precise selection of experimental parameters. The nanospears were then employed as a transducer to immobilize an aptamer of prostate-specific antigen (PSA) and fabrication of a label-free electrochemical aptasensor. The aptasensor was employed for the detection of PSA with a linear concentration range of 0.125-200ngmL(-1) and a limit of detection of 50pgmL(-1). The aptasensor was successfully applied to detect PSA in blood serum samples of healthy and patient persons. PMID:27260456

  14. Regulatory review of probabilistic safety assessment (PSA) level 1

    International Nuclear Information System (INIS)

    Probabilistic safety assessment (PSA) is increasingly being used as part of the decision making process to assess the level of safety of nuclear power plants. The methodologies in use are maturing and the insights gained from the PSAs are being used along with those from the deterministic analysis. Many regulatory authorities consider that the current state of the art in PSA (especially Level 1 PSA) is sufficiently well developed that it can be used centrally in the regulatory decision making process - referred to as 'risk informed regulation'. For these applications to be successful, it will be necessary for regulatory authorities to have a high degree of confidence in PSA. However, at the IAEA Technical Committee Meeting on Use of PSA in the Regulatory Process in 1994 and at the OECD Nuclear Energy Agency Committee for Nuclear Regulatory Activities (CNRA) 'Special Issues' Meeting in 1997 on Review Procedures and Criteria for Different Regulatory Applications of PSA, it was recognized that formal regulatory review guidance for PSA did not exist. The senior regulators noted that there was a need to produce some international guidance for reviewing PSAs to establish an agreed basis for assessing whether important technological and methodological issues in PSAs are treated adequately and to verify that conclusions reached are appropriate. In 1997 the IAEA and OECD Nuclear Energy Agency agreed to produce in co-operation a technical document on the regulatory review of PSA. This publication is intended to provide guidance to regulatory authorities on how to review the PSA for a nuclear power plant to gain confidence that it has been carried out to an acceptable standard so that it can be used as the basis for taking risk informed decisions within a regulatory decision making process. The document gives guidance on how to set about reviewing a PSA and on the technical issues that need to be addressed. This publication gives guidance for the review of Level 1 PSA for

  15. Quality assurance in the Juragua Nuclear Power Plant preoperational PSA

    International Nuclear Information System (INIS)

    Quality Assurance (QA) is nowadays an important requirement for the competence of any production or service, making possible to get the desired quality at the lowest cost In the case of PSA, which are multidisciplinary, very detailed and complex analysis, with many interfaces between analyst tasks, QA plays an important role as a tool for the analytical process management, and it is recognized as one of the PSA issues which require additional development In this paper the QA system developed for the Juragua NPP preoperational PSA, its antecedents and the experiences of its application are described

  16. Use of probabilistic safety assessment for operational safety. PSA '91

    International Nuclear Information System (INIS)

    Around 250 participants, representing 32 IAEA Member States and 4 international organizations, reviewed recent developments and discussed directions for future efforts in the area of probabilistic safety assessment (PSA) and particularly on its use for operational safety. During the symposium 61 papers and 27 posters were presented covering a wide spectrum of activities in areas such as: experience with ''living'' PSAs, PSA applications in decision making, the use of PSA for evaluating operating experience for operator training and for accident management, and probabilistic safety criteria. A separate abstract was prepared for each of these presentations. Refs, figs and tabs

  17. Time-resolved fluorescence imaging (TRFI) for direct immunofluorescence of PSA and alpha-1-antichymotrypsin in prostatic tissue sections.

    Science.gov (United States)

    Bjartell, A; Siivola, P; Hulkko, S; Pettersson, K; Rundt, K; Lilja, H; Lövgren, T

    1999-05-01

    We have developed a direct immunofluorescence technique utilising chelates of the lanthanide ions europium and terbium conjugated to monoclonal IgGs (Mabs) against prostate-specific antigen (PSA) and alpha-1-antichymotrypsin (ACT) for the detection and quantification on the same tissue section. Strong signals without disturbance from tissue autofluorescence were demonstrated in paraffin sections of ten benign and six malignant prostate tissue specimens. The signal intensity increased linearly with the amount of labelled Mab until epitope saturation began. The highest concentrations of bound IgG in tissue sections were 27.3 fmol/pixel for ACT and 7.2 for PSA. Time-resolved fluorescence imaging (TRFI) offers an attractive method for histochemical studies based on specific and quantitative detection of fluorescent lanthanide chelates. PMID:12496823

  18. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels

    Institute of Scientific and Technical Information of China (English)

    Dong Il Kang; Thomas L.Jang; Jeongyun Jeong; Eun Young Choi; Kelly Johnson; Dong Hyeon Lee; Wun-Jae Kim; Isaac Yi Kim1

    2011-01-01

    Active surveillance is an acceptable treatment option in men with a low-risk prostate cancer.In the present study,we have retrospectively reviewed the outcomes of 509 men who fit the criteria for active surveillance but selected radical prostatectomy.Then,the impact of varying prostate-specific antigen (PSA) levels on the risk of upstaging and upgrading in these patients was assessed.Pathological characteristics of patients who fulfilled the inclusion criteria under three active surveillance criteria-those of the University of California-San Francisco,the National Cancer Institute and the European Association of Urology-were examined.The proportion of men who were deemed candidates for active surveillance but were subsequently upstaged or upgraded was determined.Of 509 patients,186 (36.5%),132 (25.9%) and 88 (17.3%) men fulfilled the active surveillance criteria,respectively.Upgrading (Gleason scores 7-10) ranged from 32.8% to 38.6%,while upstaging ( ≥ pT3) ranged from 10.2% to 12.5%,depending on the three active surveillance criteria.After a median follow-up of 24 months,three patients developed a biochemical recurrence.When the impact of varying PSA levels was examined using a test for trend analysis in the context of PSA for each protocol,rates of upstaging were lower in men with PSA <4 ng ml-1.However,there was no impact of varying PSA levels on upgrading.In conclusion,commonly used active surveillance protocols carry the risks of upgrading and upstaging.More reliable and accurate markers are needed to better stratify the risks of men who are appropriate candidates for active surveillance.

  19. An Eight-Year Experience of HDR Brachytherapy Boost for Localized Prostate Cancer: Biopsy and PSA Outcome

    International Nuclear Information System (INIS)

    Purpose: To evaluate the biochemical recurrence-free survival (bRFS), the 2-year biopsy outcome and the prostate-specific antigen (PSA) bounce in patients with localized prostate cancer treated with an inversely planned high-dose-rate (HDR) brachytherapy boost. Materials and methods: Data were collected from 153 patients treated between 1999 and 2006 with external beam pelvic radiation followed by an HDR Ir-192 prostate boost. These patients were given a boost of 18 to 20 Gy using inverse-planning with simulated annealing (IPSA).We reviewed and analyzed all prostate-specific antigen levels and control biopsies. Results: The median follow-up was 44 months (18-95 months). When categorized by risk of progression, 74.5% of patients presented an intermediate risk and 14.4% a high one. Prostate biopsies at 2 years posttreatment were negative in 86 of 94 patients (91.5%), whereas two biopsies were inconclusive. Biochemical control at 60 months was at 96% according to the American Society for Therapeutic Radiology and Oncology and the Phoenix consensus definitions. A PSA bounce (PSA values of 2 ng/mL or more above nadir) was observed in 15 patients of 123 (9.8%). The median time to bounce was 15.2 months (interquartile range, 11.0-17.7) and the median bounce duration 18.7 months (interquartile range, 12.1-29). The estimate of overall survival at 60 months was 97.1% (95% CI, 91.6-103%). Conclusions: Considering that inverse planned HDR brachytherapy prostate boosts led to an excellent biochemical response, with a 2-year negative biopsy rate, we recommend a conservative approach in face of a PSA bounce even though it was observed in 10% of patients

  20. Advanced prostatic carcinomas with low serum levels of prostate-specific antigen

    Directory of Open Access Journals (Sweden)

    Cerović Snežana J.

    2002-01-01

    Full Text Available The serum levels of prostate-specific antigen (PSA represent a significant diagnostic and monitoring parameter of prostatic carcinoma (PC. The aim of the study was to establish correlation of serum PSA level in addition to grade, histological type, and clinical stage of PC in patients with normal or intermediary PSA serum level. In 37 untreated PC patients with preoperative serum PSA levels ranging between 0.1 and 9.6 ng/ml, paraffin-embedded tissue and serum samples were immunohistological studied and immunoassay for PSA was done. The most representative was poorly differentiated PC with D stage In serum samples from PC patients 27 (73.7% normal (≤ 4.0 ng/ml, and 10 (27.3% intermediate (4.1-10 ng/ml PSA levels were found Immunohistochemistry, in 36 PC (97.3% had demonstrated the expression of PSA. Our study results had shown low serum PSA levels in some patients with advanced poorly differentiated PC.

  1. Analysis of prostate-specific antigen transcripts in chimpanzees, cynomolgus monkeys, baboons, and African green monkeys.

    Directory of Open Access Journals (Sweden)

    James N Mubiru

    Full Text Available The function of prostate-specific antigen (PSA is to liquefy the semen coagulum so that the released sperm can fuse with the ovum. Fifteen spliced variants of the PSA gene have been reported in humans, but little is known about alternative splicing in nonhuman primates. Positive selection has been reported in sex- and reproductive-related genes from sea urchins to Drosophila to humans; however, there are few studies of adaptive evolution of the PSA gene. Here, using polymerase chain reaction (PCR product cloning and sequencing, we study PSA transcript variant heterogeneity in the prostates of chimpanzees (Pan troglodytes, cynomolgus monkeys (Macaca fascicularis, baboons (Papio hamadryas anubis, and African green monkeys (Chlorocebus aethiops. Six PSA variants were identified in the chimpanzee prostate, but only two variants were found in cynomolgus monkeys, baboons, and African green monkeys. In the chimpanzee the full-length transcript is expressed at the same magnitude as the transcripts that retain intron 3. We have found previously unidentified splice variants of the PSA gene, some of which might be linked to disease conditions. Selection on the PSA gene was studied in 11 primate species by computational methods using the sequences reported here for African green monkey, cynomolgus monkey, baboon, and chimpanzee and other sequences available in public databases. A codon-based analysis (dN/dS of the PSA gene identified potential adaptive evolution at five residue sites (Arg45, Lys70, Gln144, Pro189, and Thr203.

  2. Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging

    International Nuclear Information System (INIS)

    The purpose of this study was to evaluate fluorine-18 fluorocholine (FCH) positron emission tomography (PET)/CT for the detection of recurrent prostate cancer in relation to prostate-specific antigen (PSA) level. FCH PET/CT was performed in 50 patients with rising PSA levels at follow-up of primary treatment of prostate cancer (radical prostatectomy in 28, radiation therapy in 13, and brachytherapy in 9). PET detection rates were determined at various PSA thresholds and examined by receiver operating characteristic analysis. Findings consistent with recurrent prostate cancer were noted on FCH PET/CT in 31/50 (62%) patients, with positive findings in 17/18 (94%), and 11/13 (85%), 2/7 (29%), and 1/12 (8%) patients with PSA >4, >2-4, >0.5-2, and ≤0.5 ng/mL, respectively. These findings were indicative of local/regional recurrence in 23 cases and systemic recurrence in 8 cases, with only a single route of recurrence (id est (i.e.), either hematogenous, lymphatic, or intraprostatic) in 84% of PET scans with positive findings. Abnormal tumor activity was detected in 88% of patients with a PSA level of 1.1 ng/mL or higher, and in only 6% of patients with a PSA level below this threshold value. FCH PET/CT may serve to identify the route of tumor progression in patients with recurrent prostate cancer; however, the likelihood of tumor detection may be related to the PSA level at the time of imaging. (author)

  3. Detection of Local, Regional, and Distant Recurrence in Patients With PSA Relapse After External-Beam Radiotherapy Using 11C-Choline Positron Emission Tomography

    International Nuclear Information System (INIS)

    Purpose: An elevated serum prostate-specific antigen (PSA) level cannot distinguish between local-regional recurrences and the presence of distant metastases after treatment with curative intent for prostate cancer. With the advent of salvage treatment such as cryotherapy, it has become important to localize the site of recurrence (local or distant). In this study, the potential of 11C-choline positron emission tomography (PET) to identify site of recurrence was investigated in patients with rising PSA after external-beam radiotherapy (EBRT). Methods and Materials: Seventy patients with histologically proven prostate cancer treated with EBRT and showing biochemical recurrence as defined by American Society for Therapeutic Radiology and Oncology consensus statement and 10 patients without recurrence underwent a PET scan using 400 MBq 11C-choline intravenously. Biopsy-proven histology from the site of suspicion, findings with other imaging modalities, clinical follow-up and/or response to adjuvant therapy were used as comparative references. Results: None of the 10 patients without biochemical recurrence had a positive PET scan. Fifty-seven of 70 patients with biochemical recurrence (median PSA 9.1 ng/mL; mean PSA 12.3 ng/mL) showed an abnormal uptake pattern (sensitivity 81%). The site of recurrence was only local in 41 of 57 patients (mean PSA 11.1 ng/mL at scan), locoregionally and/or distant in 16 of 57 patients (mean PSA 17.7 ng/mL). Overall the positive predictive value and negative predictive value for 11C-choline PET scan were 1.0 and 0.44 respectively. Accuracy was 84%. Conclusions: 11C-choline PET scan is a sensitive technique to identify the site of recurrence in patients with PSA relapse after EBRT for prostate cancer.

  4. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients

    Energy Technology Data Exchange (ETDEWEB)

    Caster, Joseph M.; Falchook, Aaron D. [Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Hendrix, Laura H. [Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Chen, Ronald C., E-mail: Ronald_chen@med.unc.edu [Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States); Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (United States)

    2015-06-01

    Purpose: Radiation oncologists rely on available clinical information (biopsy Gleason score and prostate-specific antigen [PSA]) to determine the optimal treatment regimen for each prostate cancer patient. Existing published nomograms correlating clinical to pathologic extent of disease were based on patients treated in the 1980s and 1990s at select academic institutions. We used the Surveillance, Epidemiology, and End Results (SEER) database to examine pathologic outcomes (Gleason score and cancer stage) in early prostate cancer patients based on biopsy Gleason score and PSA concentration. Methods and Materials: This analysis included 25,858 patients whose cancer was diagnosed between 2010 and 2011, with biopsy Gleason scores of 6 to 7 and clinical stage T1 to T2 disease, who underwent radical prostatectomy. In subgroups based on biopsy Gleason score and PSA level, we report the proportion of patients with pathologically advanced disease (positive surgical margin or pT3-T4 disease) or whose Gleason score was upgraded. Logistic regression was used to examine factors associated with pathologic outcomes. Results: For patients with biopsy Gleason score 6 cancers, 84% of those with PSA <10 ng/mL had surgical T2 disease with negative margins; this decreased to 61% in patients with PSA of 20 to 29.9 ng/mL. Gleason score upgrading was seen in 43% (PSA: <10 ng/mL) to 61% (PSA: 20-29.9 ng/mL) of biopsy Gleason 6 patients. Patients with biopsy Gleason 7 cancers had a one-third (Gleason 3 + 4; PSA: <10 ng/mL) to two-thirds (Gleason 4 + 3; PSA: 20-29.9 ng/mL) probability of having pathologically advanced disease. Gleason score upgrading was seen in 11% to 19% of patients with biopsy Gleason 4 + 3 cancers. Multivariable analysis showed that higher PSA and older age were associated with Gleason score upgrading and pathologically advanced disease. Conclusions: This is the first population-based study to examine pathologic extent of disease and pathologic Gleason score

  5. Hiperplasia Prostática Benigna e PSA: o efeito dominó Benign prostatic hyperplasia and PSA: the domino effect Hiperplasia benigna de prostata y PSA: el efecto dominó

    Directory of Open Access Journals (Sweden)

    José Agostinho Santos

    2012-12-01

    Full Text Available

    Após a publicação de uma recomendação contra o rastreio câncer prostático pela U.S. Preventive Services Task Force, a comunidade médica não poderá desvincular-se das particularidades relacionadas com o antígeno prostático específico (PSA. O enfoque dado às guidelines da Hiperplasia Prostática surge pela possível partilha, a determinado ponto da sua abordagem, de um trilho que cursa também com a solicitação do PSA. Os resultados de dois grandes ensaios clínicos constituem o maior corpo da evidência actual e deles sobressai que o número de homens que evitaram a morte por câncer prostático após submetidos ao rastreio foi reduzido. Há evidência de que 100-200 em 1000 homens rastreados terão um falso-positivo, a maioria dos quais será biopsada, com possíveis danos psicológicos e orgânicos. O Médico de Família deverá relembrar que não é recomendado que se ofereça esta análise, sem que primeiro discuta, juntamente com o paciente, as questões inerentes ao PSA.

    After U.S. Preventive Services Task Force published a recommendation against prostate cancer screening, the medical community cannot extricate itself from all specific features associated with the prostate-specific antigen (PSA. The focus given to the guidelines of the Prostatic Hyperplasia happens for the possible sharing of a certain point of its approach with the prostatic cancer case-finding, that is the PSA test. The results of two large clinical trials represent the largest body of evidence and they say the number of men who avoided prostate cancer death after subjected to screening was reduced. There is evidence that 100-200 in 1000 screened men will have a false-positive, most of which will have a biopsy with possible psychological damage and organic. The GP should remember that it is not recommended to provide this test, without first discussing together with

  6. Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan

    Directory of Open Access Journals (Sweden)

    Yasuhide Kitagawa

    2014-12-01

    Full Text Available To clarify the recent trends in prostate-specific antigen (PSA distribution in men in Japan, we analyzed the PSA distributions of men undergoing PSA-based population screening. We summarized the annual individual data of PSA-based population screening in Kanazawa, Japan, from 2000 to 2011, and analyzed baseline serum PSA values of the participants at the first population screening. Serum PSA distributions were estimated in all participants and those excluding prostate cancer patients according to age. From 2000 to 2011, 19 620 men participated aged 54-69 years old in this screening program. Mean baseline serum PSA level of all participants at the first screening was 2.64 ng ml−1 in 2000, and gradually decreased to approximately 1.30 ng ml−1 in 2006. That of participants excluding prostate cancer patients was 1.46 ng ml−1 in 2000, and there was no remarkable change during the study period. The 95 th percentiles in the participants excluding prostate cancer patients detected at the first population screening of men aged 54-59, 60-64, and 65-69 years old were 2.90, 3.60, and 4.50 ng ml−1 , respectively. After the commencement of population screening, the proportion of prostate cancer patients with high serum PSA levels decreased. However, there were no changes in serum PSA levels in men without prostate cancer. Age-specific PSA reference level of men without prostate cancer in Japan was similar to that in China and Korea.

  7. Effect of proteasome inhibitors on expression of HLA-G isoforms.

    Science.gov (United States)

    Poláková, K; Bandzuchová, E; Bystrická, M; Pancuchárová, H; Russ, G

    2006-01-01

    HLA-G primary transcript is alternatively spliced into a number of mRNAs. In addition to full length HLA-G1 protein isoform these mRNAs might also encode truncated HLA-G protein isoforms lacking one or two extracellular domains. Whereas HLA-G1 protein isoform is regularly identified, truncated HLAG protein isoforms are not detected even if all alternative spliced mRNAs are present in cells. The absence of entire domain(s) renders the truncated HLA-G protein isoforms incapable of binding peptide and beta2-microglobulin. These features of truncated HLA-G protein isoforms may result in their rapid degradation by proteasomes. Here we show that despite the presence of all alternatively spliced HLA-G transcripts in JEG-3 cells pretreated with proteasome inhibitors only a full length HLA-G1 protein isoform was regularly detected. Interestingly, immunoblot analysis showed slight increase of HLA-G1 protein in cells pretreated with proteasome inhibitors, although the expression of HLA-G1 transcript was basically not affected. Expression of HLA-G3 transcript increased in JEG-3 cells pre-incubated with LLL, however, neither HLA-G3 nor other HLA-G short protein isoform was regularly detected. In K562 transfectants proteasome inhibitor LLL greatly enhanced expression of the HLA-G1 and -G2 transcripts as well as corresponding protein isoforms. Flow cytometry analysis showed that in cells pre-treated with proteasome inhibitors cell surface expression of HLA-G1 protein decreased but the quantity of intracellularly localized HLA-G antigens increased. Altogether our results suggest that truncated HLA-G proteins isoforms are not detected in JEG-3 cells as a result of their instability and the low translation efficiency of truncated HLA-G transcripts.

  8. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

    International Nuclear Information System (INIS)

    To evaluate the accuracy of contrast-enhanced 18F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: ≤1 ng/ml, 1 to ≤2 ng/ml, 2 to ≤4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups ≤1, 1 to ≤2, 2 to ≤4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA ≤2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt ≤6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve ≤2 ng/ml per year. PET alone was positive in 31 of 49 patients (63.3%), and of these 31 patients, CT was negative in 14 but diagnosed bone lesions in 2 patients in whom PET alone was negative. CT with the administration of intravenous contrast medium did not provide any further information. Detection rate of 18F-choline imaging is closely related to PSA and PSA kinetics. In particular, 18F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt ≤6 months and PSAve >2 ng/ml per year. CT is useful for detecting bone metastases that are not 18F-choline-avid. The use of intravenous contrast agent seems unnecessary. (orig.)

  9. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

    Energy Technology Data Exchange (ETDEWEB)

    Schillaci, Orazio [University ' ' Tor Vergata' ' , Department of Biopathology and Diagnostic Imaging, Interventional, Rome (Italy); IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy); Calabria, Ferdinando [IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy); Tavolozza, Mario; Caracciolo, Cristiana Ragano; Orlacchio, Antonio; Danieli, Roberta; Simonetti, Giovanni [University ' ' Tor Vergata' ' , Department of Biopathology and Diagnostic Imaging, Interventional, Rome (Italy); Agro, Enrico Finazzi; Miano, Roberto [University Hospital ' ' Tor Vergata' ' , Department of Urology, Rome (Italy)

    2012-04-15

    To evaluate the accuracy of contrast-enhanced {sup 18}F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: {<=}1 ng/ml, 1 to {<=}2 ng/ml, 2 to {<=}4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups {<=}1, 1 to {<=}2, 2 to {<=}4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA {<=}2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt {<=}6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve {<=}2 ng/ml per year. PET alone was positive in 31 of 49 patients (63.3%), and of these 31 patients, CT was negative in 14 but diagnosed bone lesions in 2 patients in whom PET alone was negative. CT with the administration of intravenous contrast medium did not provide any further information. Detection rate of {sup 18}F-choline imaging is closely related to PSA and PSA kinetics. In particular, {sup 18}F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt {<=}6 months and PSAve >2 ng/ml per year. CT is useful for detecting bone metastases that are not {sup 18}F-choline-avid. The use of intravenous contrast agent seems unnecessary. (orig.)

  10. Child Injury: What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-04-16

    This 60 second PSA is based on the April 2012 CDC Vital Signs report. Many childhood deaths and injuries are preventable, including those caused by crashes, suffocation, poisoning, drowning, fires, and falls. The PSA discusses ways to help prevent these deaths and injuries.  Created: 4/16/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/16/2012.

  11. Application of PSA in modifying plant technical specifications

    International Nuclear Information System (INIS)

    The Combustion Engineering Owners Group (CEOG) has undertaken an initiative to use Probabilistic Safety Analysis (PSA), in conjunction with other considerations, to obtain relief from unnecessarily restrictive aspects of plant technical specifications. This paper provides a summary of the integrated use of PSA along with deterministic and practical operational considerations in justifying AOT extensions for inoperability of one Safety Injection Tank (SIT), a single Low Pressure Safety Injection (LPSI) subtrain and one Emergency Diesel Generator (EDG)

  12. Review of APR+ Level 2 PSA. Revision 2

    Energy Technology Data Exchange (ETDEWEB)

    Lehner, John R. [Brookhaven National Lab. (BNL), Upton, NY (United States); Mubayi, Vinod [Brookhaven National Lab. (BNL), Upton, NY (United States); Pratt, W. Trevor [Brookhaven National Lab. (BNL), Upton, NY (United States); Kim, Do Sam [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Cho, Yong Jin [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Cho, Sang Jin [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of); Kim, In Goo [Korea Institute of Nuclear Safety (KINS), Daejeon (Korea, Republic of)

    2012-02-17

    Brookhaven National Laboratory (BNL) assisted the Korea Institute of Nuclear Safety (KINS) in reviewing the Level 2 Probabilistic Safety Assessment (PSA) of the APR+ Advanced Pressurized Water Reactor (PWR) prepared by the Korea Hydro & Nuclear Power Co., Ltd (KHNP) and KEPCO Engineering & Construction Co., Inc. (KEPCO-E&C). The work described in this report involves a review of the APR+ Level 2 PSA submittal [Ref. 1]. The PSA and, therefore, the review is limited to consideration of accidents initiated by internal events. As part of the review process, the review team also developed three sets of Requests for Additional Information (RAIs). These RAIs were provided to KHNP and KEPCO-E&C for their evaluation and response. This final detailed report documents the review findings for each technical element of the PSA and includes consideration of all of the RAIs made by the reviewers as well as the associated responses. This final report was preceded by an interim report [Ref. 2] that focused on identifying important issues regarding the PSA. In addition, a final meeting on the project was held at BNL on November 21-22, 2011, where BNL and KINS reviewers discussed their preliminary review findings with KHNP and KEPCO-E&C staffs. Additional information obtained during this final meeting was also used to inform the review findings of this final report. The review focused not only on the robustness of the APR+ design to withstand severe accidents, but also on the capability and acceptability of the Level 2 PSA in terms of level of detail and completeness. The Korean nuclear regulatory authorities will decide whether the PSA is acceptable and the BNL review team is providing its comments for KINS consideration. Section 2.0 provides the basis for the BNL review. Section 3.0 presents the review of each technical element of the PSA. Conclusions and a summary are presented in Section 4.0. Section 5.0 contains the references.

  13. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening

    Directory of Open Access Journals (Sweden)

    Tokudome S

    2016-05-01

    Full Text Available Shinkan Tokudome,1 Ryosuke Ando,2 Yoshiro Koda,3 1Department of Nutritional Epidemiology, National Institute of Health and Nutrition, Shinjuku-ku, Tokyo, 2Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku, Nagoya, 3Department of Forensic Medicine and Human Genetics, Kurume University School of Medicine, Kurume, Japan Abstract: The discoveries and application of prostate-specific antigen (PSA have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970. Wang et al purified the PSA in 1979, and Kuriyama et al first applied an enzyme-linked immunosorbent assay for PSA in 1980. However, the positive predictive value with a cutoff figure of 4.0 ng/mL appeared substantially low (~30%. There are overdiagnoses and overtreatments for latent/low-risk PCa. Controversies exist in the PCa mortality-reducing effects of PSA screening between the European Randomized Study of Screening for Prostate Cancer (ERSPC and the US Prostate, Lung, Colorectal, and Ovarian (PLCO Cancer Screening Trial. For optimizing PCa screening, PSA-related items may require the following: 1 adjustment of the cutoff values according to age, as well as setting limits to age and screening intervals; 2 improving test performance using doubling time, density, and ratio of free: total PSA; and 3 fostering active surveillance for low-risk PCa with monitoring by PSA value. Other items needing consideration may include the following: 1 examinations of cell proliferation and cell cycle markers

  14. Highlights of the PSA analyses performed for the RRR

    International Nuclear Information System (INIS)

    In July 2000, ANSTO signed a contract with the Argentinian company INVAP S.E. for the design, construction and commissioning of a replacement research reactor (RRR). INVAP contracted CEDIAC to prepare the Probabilistic Safety Assessment (PSA) for the RRR in support of the ANSTO application for the construction licence. The PSA is complementary to the Safety Analysis, in the sense that it asks questions such as 'What if the Postulated Initiating Events were to occur and more than one piece of equipment were to fail? What if several things were to go wrong?' The PSA attempts to determine all the possible combinations of how the plant could respond to an initiating event, group all the possible outcomes, obtain conservative estimates of the frequency, and bounding estimates of the consequences (i.e., doses to the worst exposed individual of the public). The frequency and consequence constitute the risk, and when evaluated for all possible events can be compared against the safety objectives set out in the regulatory principles. Besides the basic objective of the PSA, which is the quantitative evaluation of the risks associated with the RRR, and its comparison to the regulatory objectives, the PSA studies have been performed in parallel with the basic engineering phase of the project. Therefore, preliminary results from 'the risk point of view' were used as input to the design process, thus permitting improvements to be made to the design, and resulting in an effective reduction of the residual risk. To perform the PSA studies several methodological developments were made, in order to obtain a representative list of internal and external initiating events, to treat component and human-related failures, to consider common-cause failures, and to consider some specific aspects of the design (i.e., fail-safe components, passive systems, and lack of need for support systems). The PSA studies were performed to obtain not only quantitative estimations of the risk, but also

  15. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men.

    Science.gov (United States)

    Stephan, Carsten; Xu, Chuanliang; Cammann, Henning; Graefen, Markus; Haese, Alexander; Huland, Hartwig; Semjonow, Axel; Diamandis, Eleftherios P; Remzi, Mesut; Djavan, Bob; Wildhagen, Mark F; Blijenberg, Bert G; Finne, Patrik; Stenman, Ulf-Hakan; Jung, Klaus; Meyer, Hellmuth-Alexander

    2007-03-01

    Use of percent free PSA (%fPSA) and artificial neural networks (ANNs) can eliminate unnecessary prostate biopsies. In a total of 4,480 patients from five centers with PSA concentrations in the range of 2-10 ng/ml an IMMULITE PSA-based ANN (iANN) was compared with other PSA assay-adapted ANNs (nANNs) to investigate the impact of different PSA assays. ANN data were generated with PSA, fPSA (assays from Abbott, Beckman, DPC, Roche or Wallac), age, prostate volume, and DRE status. In 15 different ROC analyses, the area under the curve (AUC) in the PSA ranges 2-4, 2-10, and 4-10 ng/ml for the nANN was always significantly larger than the AUC for %fPSA or PSA. The nANN and logistic regression models mostly also performed better than the iANN. Therefore, for each patient population, PSA assay-specific ANNs should be used to optimize the ANN outcome in order to reduce the number of unnecessary biopsies. PMID:17333205

  16. Use of PSA to prioritize NPP walk down activities

    International Nuclear Information System (INIS)

    Full text of publication follows: an international team of experts, organized by the Institute of Risk Research of the Academic Senate of the University of Vienna, conducted a walk down assessment of the Mochovce Nuclear Power Plant (NPP) in May 1998. The Mochovce NPP is a VVER-440/213 station which has been in final construction and implementation of a safety improvement program since 1996. In preparation for the walk down, available plant design information was organized into a probabilistic safety assessment (PSA) format in order to assist in prioritizing walk down activities. The PSA was also used to understand the likely impact on core damage frequency (CDF) resulting from implementation of the safety improvement program. The PSA employed event trees from the Dukovany PSA, modified to represent the system designs at Mochovce, to assess internal hazards. External hazards were assessed based on an evaluation performed in 1995, with consideration given to upgrades planned to be implemented up to 1998. Failure events were identified directly based on the Dukovany PSA and other sources, and quantified using data from the Dukovany PSA, other non-Mochovce PSAs, and generic data. The PSA was used to identify a suite of dominant accident sequences from internal and external causes. The impact of safety improvements on these sequences was then assessed. The 'pre-fix' and 'post-fix' cases were compared to identify the change in risk due to implementation of the safety improvement program. Following the walk down, the 'post-fix' case was updated based on insights gained from the walk down. This revised case was used to aid in understanding the risk significance of issues identified during the walk down. (author)

  17. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma

    Directory of Open Access Journals (Sweden)

    Cohen Cynthia

    2010-09-01

    Full Text Available Abstract Background Prostate carcinoma is among the most common solid tumors to secondarily involve the male breast. Prostate specific antigen (PSA and prostate-specific acid phosphatase (PSAP are expressed in benign and malignant prostatic tissue, and immunohistochemical staining for these markers is often used to confirm the prostatic origin of metastatic carcinoma. PSA expression has been reported in male and female breast carcinoma and in gynecomastia, raising concerns about the utility of PSA for differentiating prostate carcinoma metastasis to the male breast from primary breast carcinoma. This study examined the frequency of PSA, PSAP, and hormone receptor expression in male breast carcinoma (MBC, female breast carcinoma (FBC, and gynecomastia. Methods Immunohistochemical staining for PSA, PSAP, AR, ER, and PR was performed on tissue microarrays representing six cases of gynecomastia, thirty MBC, and fifty-six FBC. Results PSA was positive in two of fifty-six FBC (3.7%, focally positive in one of thirty MBC (3.3%, and negative in the five examined cases of gynecomastia. PSAP expression was absent in MBC, FBC, and gynecomastia. Hormone receptor expression was similar in males and females (AR 74.1% in MBC vs. 67.9% in FBC, p = 0.62; ER 85.2% vs. 68.5%, p = 0.18; and PR 51.9% vs. 48.2%, p = 0.82. Conclusions PSA and PSAP are useful markers to distinguish primary breast carcinoma from prostate carcinoma metastatic to the male breast. Although PSA expression appeared to correlate with hormone receptor expression, the incidence of PSA expression in our population was too low to draw significant conclusions about an association between PSA expression and hormone receptor status in breast lesions.

  18. Distribution of serum prostate-specific antigen in Chinese healthy men: a population-based study

    Institute of Scientific and Technical Information of China (English)

    YUAN Xiao-dong; L(U) Jia-ju; DONG Zhi-gang; ZHANG Hui; LIN Hai-yan; SONG Xin-hong; NIU Zhi-hong; FU Qiang; LIU Shuai; SUN Zhi-jian

    2011-01-01

    Background The morbidity and mortality of prostate cancer have been increasing rapidly in recent China. There were few studies investigating prostate-specific antigen (PSA) values ranges in the healthy Chinese population. We performed this study to determine the distribution of serum PSA in a large healthy Chinese population.Methods From January 2001 to May 2008, 11 150 healthy Chinese men aged 30-79 years came to our hospital for routine health check-up. All subjects without a previous diagnosis of prostate cancer, a history of prostate surgery, or urogenital tract infection were proposed to undergo systematic serum PSA measurement and digital rectal examination (DRE). Men with normal DRE and PSA ≤4.0 ng/ml and those PSA >4.0 ng/ml or abnormal DRE but without adverse findings on prostate biopsy were included (n=9358). Age and serum PSA concentration were recorded and correlated through Logistic regression analysis.Results The 95th percentile serum PSA concentration was 1.89 ng/ml for men aged 30 to 39 years, 2.19 ng/ml for men aged 40 to 49 years, 2.88 ng/ml for men aged 50 to 59 years, 4.42 rng/ml for men aged 60 to 69 years, and 6.52 ng/ml for men aged 70 to 79 years. The serum PSA concentration correlated with age (P <0.0001) with an annual increase of 0.97% for men in 40 years, 1.58% for men in 50 years, 3.04% for men in 60 years, and 3.99% for men in 70 years.Conclusions The serum PSA level correlates directly with age in Chinese men older than 40 years, not in Chinese men younger than 40 years old. Chinese men have lower PSA level compared with white men above 60 years of age, not in those under 60 years of age.

  19. PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

    International Nuclear Information System (INIS)

    Previous studies have shown that the positive detection rate of [11C]choline positron emission tomography/computed tomography (PET/CT) depends on prostate-specific antigen (PSA) plasma levels. This study compared PSA levels and PSA doubling time (PSADT) to predict [11C]choline PET/CT findings. PSADT was retrospectively calculated in 170 prostate cancer (PCa) patients with biochemical failure after radical prostatectomy who underwent [11C]choline PET/CT. PSADT was calculated as PSADT = ln2/m, where m is the slope of the linear regression line of the natural log of PSA values. At least three PSA measurements were used (median: 4; range: 3-16), separated by at least 3 months, each with a minimum increase of 0.20 ng/ml. PET/CT findings were validated using criteria based on histological analysis and clinical and imaging data. Statistical analysis was performed using the t test, chi-square test, analysis of variance and binary logistic regression. Regression-based coefficients were used to develop a nomogram predicting the probability of positive [11C]choline PET/CT and 200 bootstrap resamples were used for internal validation. The median PSA was 1.25 ng/ml (range: 0.23-48.6 ng/ml), and the median PSADT was 7.0 months (range: 0.97-45.3 months). [11C]choline PET/CT was positive in 75 of 170 patients (44%). PET/CT findings were validated using histological criteria (11%) and clinical and imaging criteria (89%). The overall accuracy of [11C]choline PET/CT was 88%. Multivariate logistic regression showed that high PSA and short PSADT were significant (p 11C]choline PET/CT [PSA: odds ratio (OR) = 1.43; 95% confidence interval (CI): 1.15-1.78; PSADT: OR = 1.12; 95% CI: 1.04-1.21]. The percentage of patients with positive [11C]choline PET/CT was 27% for PSADT >6 months, 61% for PSADT between 3 and 6 months and 81% for PSADT 11C]choline uptake in the skeleton significantly increased (p 6 months to 52% for PSADT 11C]choline uptake in the prostatectomy bed were 0% for PSADT 6

  20. Perioperative prostate specific antigen levels among coronary artery bypass grafting patients: Does extracorporeal circulation and body temperature induce prostate specific antigen levels alterations?

    Science.gov (United States)

    Patris, Emmanuel; Giakoumidakis, Konstantinos; Patris, Vasileios; Kuduvalli, Manoj; Argiriou, Mihalis; Charitos, Christos; Kalaitzis, Christos; Touloupidis, Stavros

    2015-01-01

    Purpose: The purpose of this study is to compare the perioperative total prostate specific antigen (tPSA) levels among coronary artery bypass grafting (CABG) patients with and without extracorporeal circulation (ECC), to investigate the changes overtime of tPSA in each group separately and to determine the effect of body core temperature on tPSA levels. Materials and Methods: A prospective study was conducted. Our sample was allocated to: (a) Seven patients who underwent off pump CABG (Group I) and (b) 16 CABG patients with ECC (Group II). The levels of tPSA were measured preoperatively (baseline), intra-operatively and at the 4th postoperative day. We compared the two groups on their tPSA levels and we investigated the changes of tPSA overtime in each group separately. Results: Intra-operative serum samples were obtained in significantly lower body temperature in patients of Group II than in those of Group I (31°C vs. 36.9°C, P < 0.001). In each group separately, postoperative tPSA levels were increased significantly compared to the baseline values (2.55 ng/ml vs. 0.39 ng/ml for Group I, P = 0.005 and 4.36 ng/ml vs. 0.77 for Group II, P < 0.001). CABG patients with ECC had significantly lower intra-operative tPSA levels than the baseline values (0.67 ng/ml vs. 0.77 ng/ml, P = 0.008). We did not observe significant differences of tPSA levels between the two groups. Conclusions: CABG surgery affects similarly the perioperative tPSA independently the involvement of ECC. Although all patients had significantly higher early postoperative tPSA levels, only those who underwent CABG with ECC had exceeded normal values and significantly decreased intra-operative tPSA. Hypothermia seems to be the causal factor of tPSA reduction. PMID:25657546

  1. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer.

    Science.gov (United States)

    Pavlenko, M; Roos, A-K; Lundqvist, A; Palmborg, A; Miller, A M; Ozenci, V; Bergman, B; Egevad, L; Hellström, M; Kiessling, R; Masucci, G; Wersäll, P; Nilsson, S; Pisa, P

    2004-08-16

    Prostate-specific antigen (PSA) is a serine protease secreted at low levels by normal luminal epithelial cells of the prostate and in significantly higher levels by prostate cancer cells. Therefore, PSA is a potential target for various immunotherapeutical approaches against prostate cancer. DNA vaccination has been investigated as immunotherapy for infectious diseases in patients and for specific treatment of cancer in certain animal models. In animal studies, we have demonstrated that vaccination with plasmid vector pVAX/PSA results in PSA-specific cellular response and protection against tumour challenge. The purpose of the trial was to evaluate the safety, feasibility and biological efficacy of pVAX/PSA vaccine in the clinic. A phase I trial of pVAX/PSA, together with cytokine granulocyte/macrophage-colony stimulating factor (GM-CSF) (Molgramostim) and IL-2 (Aldesleukin) as vaccine adjuvants, was carried out in patients with hormone-refractory prostate cancer. To evaluate the biologically active dose, the vaccine was administered during five cycles in doses of 100, 300 and 900 microg, with three patients in each cohort. Eight patients were evaluable. A PSA-specific cellular immune response, measured by IFN-gamma production against recombinant PSA protein, and a rise in anti-PSA IgG were detected in two of three patients after vaccination in the highest dose cohort. A decrease in the slope of PSA was observed in the two patients exhibiting IFN-gamma production to PSA. No adverse effects (WHO grade >2) were observed in any dose cohort. We demonstrate that DNA vaccination with a PSA-coding plasmid vector, given with GM-CSF and IL-2 to patients with prostate cancer, is safe and in doses of 900 microg the vaccine can induce cellular and humoral immune responses against PSA protein. PMID:15280930

  2. Mass-sensing BioCD Protein Array towards Clinical Application: Prostate Specific Antigen Detection in Patient Sera

    CERN Document Server

    Wang, Xuefeng; Nolte, David D; Ratliff, Timothy L

    2009-01-01

    Mass-sensing biosensor arrays for protein detection require no fluorophores or enzyme labels. However, few mass biosensor protein arrays have demonstrated successful application in high background samples, such as serum. In this paper, we test the BioCD as a mass biosensor based on optical interferometry of antibodies covalently attached through Schiff-base reduction. We use the BioCD to detect prostate specific antigen (PSA, a biomarker of prostate cancer) in patient sera in a 96-well anti-PSA microarray. We have attained a 4 ng/ml detection limit in full serum and have measured PSA concentrations in three patient sera.

  3. Ni2+-Dependent and PsaR-Mediated Regulation of the Virulence Genes pcpA, psaBCA, and prtA in Streptococcus pneumoniae.

    Directory of Open Access Journals (Sweden)

    Irfan Manzoor

    Full Text Available Previous studies have shown that the transcriptional regulator PsaR regulates the expression of the PsaR regulon consisting of genes encoding choline binding protein (PcpA, the extracellular serine protease (PrtA, and the Mn2+-uptake system (PsaBCA, in the presence of manganese (Mn2+, zinc (Zn2+, and cobalt (Co2+. In this study, we explore the Ni2+-dependent regulation of the PsaR regulon. We have demonstrated by qRT-PCR analysis, metal accumulation assays, β-galactosidase assays, and electrophoretic mobility shift assays that an elevated concentration of Ni2+ leads to strong induction of the PsaR regulon. Our ICP-MS data show that the Ni2+-dependent expression of the PsaR regulon is directly linked to high, cell-associated, concentration of Ni2+, which reduces the cell-associated concentration of Mn2+. In vitro studies with the purified PsaR protein showed that Ni2+ diminishes the Mn2+-dependent interaction of PsaR to the promoter regions of its target genes, confirming an opposite effect of Mn2+ and Ni2+ in the regulation of the PsaR regulon. Additionally, the Ni2+-dependent role of PsaR in the regulation of the PsaR regulon was studied by transcriptome analysis.

  4. Natural History of Untreated Prostate Specific Antigen Radiorecurrent Prostate Cancer in Men with Favorable Prognostic Indicators

    Directory of Open Access Journals (Sweden)

    Neil E. Martin

    2014-01-01

    Full Text Available Background and Purpose. Life expectancy data could identify men with favorable post-radiation prostate-specific antigen (PSA failure kinetics unlikely to require androgen deprivation therapy (ADT. Materials and Methods. Of 206 men with unfavorable-risk prostate cancer in a randomized trial of radiation versus radiation and ADT, 53 experienced a PSA failure and were followed without salvage ADT. Comorbidity, age and established prognostic factors were assessed for relationship to death using Cox regression analyses. Results. The median age at failure, interval to PSA failure, and PSA doubling time were 76.6 years (interquartile range [IQR]: 71.8–79.3, 49.1 months (IQR: 37.7–87.4, and 25 months (IQR: 13.1–42.8, respectively. After a median follow up of 4.0 years following PSA failure, 45% of men had died, none from prostate cancer and no one had developed metastases. Both increasing age at PSA failure (HR: 1.14; 95% CI: 1.03–1.25; P=0.008 and the presence of moderate to severe comorbidity (HR: 12.5; 95% CI: 3.81–41.0; P2 years following post-radiation PSA failure appear to be good candidates for observation without ADT intervention.

  5. Velocity and doubling time of prostate-specific antigen: mathematics can matter.

    Science.gov (United States)

    Uchio, Edward; Aslan, Mihaela; Ko, John; Wells, Carolyn K; Radhakrishnan, Krishnan; Concato, John

    2016-02-01

    Changes in prostate-specific antigen (PSA) values are often reported as velocity or doubling time. We compared the association of these two calculations-at the time of PSA failure after primary treatment for prostate cancer-with prostate cancer mortality. From a source population of 1313 US Veterans with prostate cancer, including 623 treated with curative intent, the study population included 242 men experiencing biochemical failure, 81 after surgery and 161 after radiation therapy. Clinically relevant calculations of PSA velocity (linear slope) and PSA doubling time (logarithmic slope) were assessed for their association with 11-16 years of mortality from prostate cancer. Death due to prostate cancer occurred in 52/242 (21.5%) men. Among men receiving surgery, PSA velocity ≥1.0 ng/mL/year was associated with increased prostate cancer mortality (HR=4.2, p value=0.037), whereas doubling time ≤12 months did not confer risk (HR=1.0, p value=0.95). Conversely, among patients receiving radiation therapy, doubling time ≤12 months was associated with increased prostate cancer mortality (HR=2.4, p value=0.049), but velocity did not confer a statistically significant risk (HR=3.8, p value=0.19). When assessing risk of prostate cancer mortality, PSA velocity can be more predictive after surgery and PSA doubling time can be more predictive after radiation therapy.

  6. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening

    Science.gov (United States)

    Tokudome, Shinkan; Ando, Ryosuke; Koda, Yoshiro

    2016-01-01

    The discoveries and application of prostate-specific antigen (PSA) have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa) patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970. Wang et al purified the PSA in 1979, and Kuriyama et al first applied an enzyme-linked immunosorbent assay for PSA in 1980. However, the positive predictive value with a cutoff figure of 4.0 ng/mL appeared substantially low (∼30%). There are overdiagnoses and overtreatments for latent/low-risk PCa. Controversies exist in the PCa mortality-reducing effects of PSA screening between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. For optimizing PCa screening, PSA-related items may require the following: 1) adjustment of the cutoff values according to age, as well as setting limits to age and screening intervals; 2) improving test performance using doubling time, density, and ratio of free: total PSA; and 3) fostering active surveillance for low-risk PCa with monitoring by PSA value. Other items needing consideration may include the following: 1) examinations of cell proliferation and cell cycle markers in biopsy specimens; 2) independent quantification of Gleason grading; 3) developing ethnicity-specific staging nomograms based on tumor stage, PSA value, and Gleason score; 4) delineation of the natural history; 5) revisiting the significance of the androgen/testosterone hypothesis; and 6) devoting special attention to individuals with a certain genetic predisposition. Finally

  7. Discoveries and application of prostate-specific antigen, and some proposals to optimize prostate cancer screening.

    Science.gov (United States)

    Tokudome, Shinkan; Ando, Ryosuke; Koda, Yoshiro

    2016-01-01

    The discoveries and application of prostate-specific antigen (PSA) have been much appreciated because PSA-based screening has saved millions of lives of prostate cancer (PCa) patients. Historically speaking, Flocks et al first identified antigenic properties in prostate tissue in 1960. Then, Barnes et al detected immunologic characteristics in prostatic fluid in 1963. Hara et al characterized γ-semino-protein in semen in 1966, and it has been proven to be identical to PSA. Subsequently, Ablin et al independently reported the presence of precipitation antigens in the prostate in 1970. Wang et al purified the PSA in 1979, and Kuriyama et al first applied an enzyme-linked immunosorbent assay for PSA in 1980. However, the positive predictive value with a cutoff figure of 4.0 ng/mL appeared substantially low (∼30%). There are overdiagnoses and overtreatments for latent/low-risk PCa. Controversies exist in the PCa mortality-reducing effects of PSA screening between the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. For optimizing PCa screening, PSA-related items may require the following: 1) adjustment of the cutoff values according to age, as well as setting limits to age and screening intervals; 2) improving test performance using doubling time, density, and ratio of free: total PSA; and 3) fostering active surveillance for low-risk PCa with monitoring by PSA value. Other items needing consideration may include the following: 1) examinations of cell proliferation and cell cycle markers in biopsy specimens; 2) independent quantification of Gleason grading; 3) developing ethnicity-specific staging nomograms based on tumor stage, PSA value, and Gleason score; 4) delineation of the natural history; 5) revisiting the significance of the androgen/testosterone hypothesis; and 6) devoting special attention to individuals with a certain genetic predisposition. Finally

  8. Simulation and optimization of an industrial PSA unit

    Directory of Open Access Journals (Sweden)

    Barg C.

    2000-01-01

    Full Text Available The Pressure Swing Adsorption (PSA units have been used as a low cost alternative to the usual gas separation processes. Its largest commercial application is for hydrogen purification systems. Several studies have been made about the simulation of pressure swing adsorption units, but there are only few reports on the optimization of such processes. The objective of this study is to simulate and optimize an industrial PSA unit for hydrogen purification. This unit consists of six beds, each of them have three layers of different kinds of adsorbents. The main impurities are methane, carbon monoxide and sulfidric gas. The product stream has 99.99% purity in hydrogen, and the recovery is around 90%. A mathematical model for a commercial PSA unit is developed. The cycle time and the pressure swing steps are optimized. All the features concerning with complex commercial processes are considered.

  9. Prostate-specific antigen-positive extramammary Paget's disease--association with prostate cancer

    DEFF Research Database (Denmark)

    Hammer, Anne; Hager, Henrik; Steiniche, Torben

    2008-01-01

    Extramammary Paget's disease (EMPD) is a rare intraepidermal adenocarcinoma that primarily affects the anogenital region. Cases of EMPD reacting with PSA (prostate-specific antigen) have previously been associated with underlying prostate cancer. However, a recent case of EMPD in our department has...... led us to question the value of PSA as an indicator of underlying prostate cancer. Clinical and pathological data were obtained for 16 cases of EMPD. Formalin-fixed, paraffin-embedded tissue blocks from the primary skin lesions were investigated using PSA and other immunohistochemical markers. 5 of...... the 16 cases of EMPD stained positive for PSA (2 women and 3 men). However, no reactivity was seen for the prostatic marker P501S. Three of the five patients had been diagnosed with internal malignant disease-two with prostate cancer, stage 1. Immunohistochemical investigations of the tumour specimens...

  10. Inference of Isoforms from Short Sequence Reads

    Science.gov (United States)

    Feng, Jianxing; Li, Wei; Jiang, Tao

    Due to alternative splicing events in eukaryotic species, the identification of mRNA isoforms (or splicing variants) is a difficult problem. Traditional experimental methods for this purpose are time consuming and cost ineffective. The emerging RNA-Seq technology provides a possible effective method to address this problem. Although the advantages of RNA-Seq over traditional methods in transcriptome analysis have been confirmed by many studies, the inference of isoforms from millions of short sequence reads (e.g., Illumina/Solexa reads) has remained computationally challenging. In this work, we propose a method to calculate the expression levels of isoforms and infer isoforms from short RNA-Seq reads using exon-intron boundary, transcription start site (TSS) and poly-A site (PAS) information. We first formulate the relationship among exons, isoforms, and single-end reads as a convex quadratic program, and then use an efficient algorithm (called IsoInfer) to search for isoforms. IsoInfer can calculate the expression levels of isoforms accurately if all the isoforms are known and infer novel isoforms from scratch. Our experimental tests on known mouse isoforms with both simulated expression levels and reads demonstrate that IsoInfer is able to calculate the expression levels of isoforms with an accuracy comparable to the state-of-the-art statistical method and a 60 times faster speed. Moreover, our tests on both simulated and real reads show that it achieves a good precision and sensitivity in inferring isoforms when given accurate exon-intron boundary, TSS and PAS information, especially for isoforms whose expression levels are significantly high.

  11. Long distance bicycle riding causes prostate-specific antigen to increase in men aged 50 years and over.

    Directory of Open Access Journals (Sweden)

    Sandra L Mejak

    Full Text Available OBJECTIVES: To investigate whether bicycle riding alters total prostate-specific antigen (tPSA serum concentrations in healthy older men. METHODS: 129 male participants, ranging in age from 50 to 71 years (mean 55 years, rode in a recreational group bicycle ride of between 55 and 160 kilometers. Blood samples for tPSA analysis were drawn within 60 minutes before starting, and within 5 minutes after completing the ride. The pre-cycling and post-cycling tPSA values were log transformed for normality and compared using paired t-tests. Linear regression was used to assess the relationship between changes in tPSA with age and distance cycled. RESULTS: Bicycle riding caused tPSA to increase by an average of 9.5% (95% CI = 6.1-12.9; p<0.001 or 0.23 ng/ml. The number of participants with an elevated tPSA (using the standard PSA normal range cut-off of 4.0 ng/ml increased from two pre-cycle to six post-cycle (or from five to eight when using age-based normal ranges. Univariate linear regression analysis revealed that the change in tPSA was positively correlated with age and the distance cycled. CONCLUSIONS: Cycling causes an average 9.5% increase in tPSA, in healthy male cyclists ≥50 years old, when measured within 5 minutes post cycling. We considered the increase clinically significant as the number of participants with an elevated PSA, according to established cut-offs, increased post-ride. Based on the research published to date, the authors suggest a 24-48 hour period of abstinence from cycling and ejaculation before a PSA test, to avoid spurious results.

  12. Long Distance Bicycle Riding Causes Prostate-Specific Antigen to Increase in Men Aged 50 Years and Over

    Science.gov (United States)

    Mejak, Sandra L.; Bayliss, Julianne; Hanks, Shayne D.

    2013-01-01

    Objectives To investigate whether bicycle riding alters total prostate-specific antigen (tPSA) serum concentrations in healthy older men. Methods 129 male participants, ranging in age from 50 to 71 years (mean 55 years), rode in a recreational group bicycle ride of between 55 and 160 kilometers. Blood samples for tPSA analysis were drawn within 60 minutes before starting, and within 5 minutes after completing the ride. The pre-cycling and post-cycling tPSA values were log transformed for normality and compared using paired t-tests. Linear regression was used to assess the relationship between changes in tPSA with age and distance cycled. Results Bicycle riding caused tPSA to increase by an average of 9.5% (95% CI = 6.1–12.9; p<0.001) or 0.23 ng/ml. The number of participants with an elevated tPSA (using the standard PSA normal range cut-off of 4.0 ng/ml) increased from two pre-cycle to six post-cycle (or from five to eight when using age-based normal ranges). Univariate linear regression analysis revealed that the change in tPSA was positively correlated with age and the distance cycled. Conclusions Cycling causes an average 9.5% increase in tPSA, in healthy male cyclists ≥50 years old, when measured within 5 minutes post cycling. We considered the increase clinically significant as the number of participants with an elevated PSA, according to established cut-offs, increased post-ride. Based on the research published to date, the authors suggest a 24–48 hour period of abstinence from cycling and ejaculation before a PSA test, to avoid spurious results. PMID:23418500

  13. PSA and androgen-related gene (AR, CYP17, and CYP19) polymorphisms and the risk of adenocarcinoma at prostate biopsy

    DEFF Research Database (Denmark)

    dos Santos, Rodrigo Mattos; de Jesus, Carlos Márcio Nóbrega; Trindade Filho, José Carlos Souza;

    2008-01-01

    The aim of the present study was to examine the impact of polymorphisms in prostate-specific antigen (PSA) and androgen-related genes (AR, CYP17, and CYP19) on prostate cancer (PCa) risk in selected high-risk patients who underwent prostate biopsy. Blood samples and prostate tissues were obtained...... for DNA analysis. Single-nucleotide polymorphisms in the 50-untranslated regions (UTRs) of the PSA (substitution A>G at position-158) and CYP17 (substitution T>C at 50-UTR) genes were detected by polymerase chain reaction (PCR)-restriction fragment length polymorphism assays. The CAG and TTTA repeats...... in the AR and CYP19 genes, respectively, were genotyped by PCR-based GeneScan analysis. Patients with the GG genotype of the PSA gene had a higher risk of PCa than those with the AG or AA genotype (OR=3.79, p=0.00138). The AA genotype was associated with lower PSA levels (6.44 +/- 1.64 ng=mL) compared...

  14. Aberrant sialylation of a prostate-specific antigen: Electrochemical label-free glycoprofiling in prostate cancer serum samples.

    Science.gov (United States)

    Pihikova, Dominika; Kasak, Peter; Kubanikova, Petra; Sokol, Roman; Tkac, Jan

    2016-08-31

    Electrochemical detection method allowing to detect prostate-specific antigen (PSA), a biomarker of prostate cancer (PCa), with PSA glycoprofiling was applied in an analysis of PCa serum samples for the first time. Electrochemical impedance spectroscopy (EIS) as a label-free method with immobilized anti-PSA was applied for PSA detection and lectins to glycoprofile captured PSA on the same surface. A proper choice of blocking agent providing high selectivity of biosensor detection with the immobilized anti-PSA antibody was done. The biosensor could detect PSA down to 100 ag/mL with a linear concentration working range from 100 ag/mL up to 1 μg/mL, i.e. 10 orders of concentration magnitude and the sensitivity of (5.5 ± 0.2)%/decade. The results showed that a commercial carbo-free blocking solution was the best one, reducing non-specific binding 55-fold when compared to the immunosensor surface without any blocking agent applied, while allowing to detect PSA. The biosensor response obtained after addition of lectin (i.e. proportional to the amount of a particular glycan on PSA) divided by the biosensor response obtained after incubation with a sample (i.e. proportional to the PSA level in the sample) was applied to distinguish serum samples of PCa patients from those of healthy individuals. The results showed that Maackia amurensis agglutinin (MAA) recognizing α-2,3-terminal sialic acid can be applied to distinguish between these two sets of samples since the MAA/PSA response obtained from the analysis of the PCa samples was significantly higher (5.3-fold) compared to the MAA/PSA response obtained by the analysis of samples from healthy individuals. Thus, combined analysis of serological PSA levels together with PSA glycoprofiling of aberrant glycosylation of PSA (i.e. increase in the level of α-2,3-terminal sialic acid) has a potential to improve detection of PCa. PMID:27506346

  15. Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy

    International Nuclear Information System (INIS)

    Radionuclide bone scan (BS) used to be the investigation of choice for detecting osseous metastases in prostate cancer. Now, with the availability serum prostate specific antigen (PSA) testing, clinicians do have a timely, cost-effective method to determine those patients who are highly unlikely to have osseous metastases. We determine the utility of PSA for predicting the presence of skeletal metastasis on BSs in prostate cancer patients. Retrospective analysis of medical records of 322 consecutive prostate cancers patients subjected to BS during the last 3 years was done. 52 cases were excluded due to following reasons: Serum PSA not available, hormonal or other therapy given prior to serum PSA measurement, and/or BS, and symptomatic for bone metastasis. In remaining 270 cases, PSA value and BS were evaluated. BS was performed with Tc99m methylene diphosphonate (MDP) as per the standard protocol. BS was found to be positive in 153/270 (56%) and negative in 117 (46%) patients. Of the 153 positive cases, 108 (70%) had serum PSA > 100 ng/ml, 42 (28%) had PSA of 20-100 ng/ml and only 3 (2%) had PSA < 20 ng/ml. All the patients with PSA > 100 ng/ml had multiple skeletal metastasis. Of the 117 negative cases, 110 (94%) had a PSA < 20 ng/ml, 5 had between 20 and 100 ng/ml and only 2 (1.8%) had PSA > 100 ng/ml. Of the 113 patients with serum PSA < 20 ng/ml, 110 (97.4%) did not show any bony metastasis. 150/157 (95.5%) patients with PSA > 20 ng/ml had bone metastasis. Using this criterion, 110 (40.7%) scans would have been omitted. Serum PSA < 20 ng/ml have high predictive value in ruling out skeletal metastasis. Our data are in corroboration with results from previous studies that BS should be performed only if PSA > 20 ng/ml. Using this cut-off, unnecessary investigation can be avoided. Avoiding BS in this group of patients would translate into a significant cost-saving and reduction in their psychological and physical burden

  16. Prostatic specific antigen for prostate cancer screening: Going further or time over%前列腺特异性抗原筛查前列腺癌:继续深入或时代终结

    Institute of Scientific and Technical Information of China (English)

    周占松

    2013-01-01

    Prostate cancer is a popular malignant tumor in old males.Serum prostatic specific antigen (PSA) testing and digital rectal examination (DRE) have been considered the accepted method to screen prostate cancer in early stage.However,an elevated serum level of PSA can be caused not only by prostate cancer,but also by some benign prostate diseases,such as benign prostatic hyperplasia and prostatitis.Furthermore,a low level of PSA cannot exclude prostate cancer completely.In 2009,the middle-time results of two largestscale clinical trials (PLCO and ERSPC) in the world provided controversial conclusions of PSA for prostate cancer screening.From then on,the debates on PSA testing have been continued.Although the final conclusion is still unclear,it provides an opportunity to rescan the significance of PSA test.

  17. Asian and Pacific Islander HIV/AIDS Awareness PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-05-12

    In this PSA, Asians and Pacific Islanders are encouraged to talk about HIV and get tested for HIV.  Created: 5/12/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/12/2010.

  18. Reducing the Risk of Methadone Overdose PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-07-03

    This 60 second PSA is based on the July 2012 CDC Vital Signs report. Approximately 14 people die every day of overdoses related to methadone. Listen to learn how to reduce your risk of an overdose.  Created: 7/3/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/3/2012.

  19. Use of living PSA in regulatory decision making in Finland

    Energy Technology Data Exchange (ETDEWEB)

    Virolainen, R. [STUK - Radiation and Nuclear Safety Authority. Nuclear Reactor Regulation, Helsinki (Finland)

    1999-09-01

    Consideration of severe accidents beyond the traditional design basis, including full core melt accidents, has become an important ingredient of regulatory process in Finland. Increasingly, decisions are being based, at least in part, on results of plant-specific Probabilistic Safety Assessments (PSA) studies. Plant-specific level-1 and level 2 PSA studies, including internal initiators, fires, flooding and harsh weather conditions are required by STUK. These studies are used in a living fashion both at the utilities and a STUK. PSA has got an important role in the safety management at Loviisa and Olkiluoto (OL) plants and in the regulatory process of STUK. While PSA is recognised as an effective tool and review method for many different regulatory and safety management purposes, we have to acknowledge its limitations, which are often related to the level of modelling or methods, not yet mature enough for some specific applications. Hence, in context of the aforementioned activities, STUK has to use both deterministic and probabilistic reviews in parallel while controlling and regulating the issues. (au)

  20. Hand Hygiene in Healthcare Settings 2 PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-08-19

    This 30 second PSA encourages people to wash their hands often while in the hospital or visiting someone in the hospital. It also encourages them to remind their healthcare providers to wash their hands, too.  Created: 8/19/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/19/2010.

  1. Hand Hygiene in Healthcare Settings 1 PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-08-19

    This 30 second PSA encourages people to wash their hands often while in the hospital or visiting someone in the hospital. It also encourages them to remind their healthcare providers to wash their hands, too.  Created: 8/19/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/19/2010.

  2. The Inter-cultural Analysis of PSA for Disaster between China and the West

    Institute of Scientific and Technical Information of China (English)

    谭琳

    2014-01-01

    As a special and extensive type of advertising, public service advertising(PSA) has become an important cultural phe⁃nomenon. Same as commercial advertisement, PSA can also convey cultural values. Out of similar purposes, however, PSA for di⁃sasters between China and other western countries contain many differences. Aiming to reveal the cultural differences, this paper undertakes the analysis of PSA for disasters of China and other western countries from the perspective of inter-cultural communi⁃cation.

  3. PSA doubling time for prediction of [{sup 11}C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

    Energy Technology Data Exchange (ETDEWEB)

    Giovacchini, Giampiero; Garcia Parra, Rita [University of Milano-Bicocca, Center for Molecular Bioimaging, Milan (Italy); Picchio, Maria; Gianolli, Luigi [San Raffaele Scientific Institute, Department of Nuclear Medicine, Milan (Italy); Scattoni, Vincenzo; Briganti, Alberto; Montorsi, Francesco [San Raffaele Scientific Institute, Department of Urology, Milan (Italy); Messa, Cristina [University of Milano-Bicocca, Center for Molecular Bioimaging, Milan (Italy); National Research Council, Institute for Bioimaging and Molecular Physiology, Milan (Italy); San Gerardo Hospital, Department of Nuclear Medicine, Monza (Italy)

    2010-06-15

    Previous studies have shown that the positive detection rate of [{sup 11}C]choline positron emission tomography/computed tomography (PET/CT) depends on prostate-specific antigen (PSA) plasma levels. This study compared PSA levels and PSA doubling time (PSADT) to predict [{sup 11}C]choline PET/CT findings. PSADT was retrospectively calculated in 170 prostate cancer (PCa) patients with biochemical failure after radical prostatectomy who underwent [{sup 11}C]choline PET/CT. PSADT was calculated as PSADT = ln2/m, where m is the slope of the linear regression line of the natural log of PSA values. At least three PSA measurements were used (median: 4; range: 3-16), separated by at least 3 months, each with a minimum increase of 0.20 ng/ml. PET/CT findings were validated using criteria based on histological analysis and clinical and imaging data. Statistical analysis was performed using the t test, chi-square test, analysis of variance and binary logistic regression. Regression-based coefficients were used to develop a nomogram predicting the probability of positive [{sup 11}C]choline PET/CT and 200 bootstrap resamples were used for internal validation. The median PSA was 1.25 ng/ml (range: 0.23-48.6 ng/ml), and the median PSADT was 7.0 months (range: 0.97-45.3 months). [{sup 11}C]choline PET/CT was positive in 75 of 170 patients (44%). PET/CT findings were validated using histological criteria (11%) and clinical and imaging criteria (89%). The overall accuracy of [{sup 11}C]choline PET/CT was 88%. Multivariate logistic regression showed that high PSA and short PSADT were significant (p < 0.05) predictors of positive [{sup 11}C]choline PET/CT [PSA: odds ratio (OR) = 1.43; 95% confidence interval (CI): 1.15-1.78; PSADT: OR = 1.12; 95% CI: 1.04-1.21]. The percentage of patients with positive [{sup 11}C]choline PET/CT was 27% for PSADT >6 months, 61% for PSADT between 3 and 6 months and 81% for PSADT <3 months. The percentage of patients who displayed pathological [{sup 11}C

  4. Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival

    Energy Technology Data Exchange (ETDEWEB)

    Lo, Andrea C. [Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Morris, W. James, E-mail: JMorris@bccancer.bc.ca [Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Lapointe, Vincent [Department of Medical Physics, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Hamm, Jeremy [Department of Population Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Keyes, Mira; Pickles, Tom; McKenzie, Michael [Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada); Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Spadinger, Ingrid [Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia (Canada); Department of Medical Physics, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia (Canada)

    2014-01-01

    Purpose: To determine (1) the prognostic utility of prostate-specific antigen (PSA) concentration at 45 to 60 months (48mPSA) after low-dose-rate prostate brachytherapy (LDR-PB); (2) the predictors of 48mPSA; and (3) the prognostic utility of directional trends between PSA levels at 24, 36, and 48 months after LDR-PB. Methods and Materials: Between 1998 and 2008, 2223 patients with low- and intermediate-risk prostate cancer received LDR-PB monotherapy. A cohort of 1434 of these patients was identified with a documented 48mPSA and no evidence of disease relapse prior to the 48mPSA. In addition, a subset of this cohort (n=585) was identified with ≥72 months of follow-up and documented PSA values at both 24 and 36 months after implantation. Results: Median follow-up time was 76 months. Eight-year Kaplan-Meier disease-free survival (DFS) rates were 100% vs 73.4% for patients with 48mPSA ≤0.2 vs those with >0.2 ng/mL; 99.1% versus 53.8% for a 48mPSA threshold of ≤0.4 versus >0.4 ng/mL, respectively; and 97.3% versus 0% for a threshold of ≤1.0 versus >1.0 ng/mL, respectively. On multivariate analysis, the only factor predictive of DFS was 48mPSA (P<.0001). On subset analysis (n=585), 29 patients had a PSA rise (defined as >0.2 ng/mL) between 24 and 36 months, 24 patients had a rise between 36 and 48 months, and 11 patients had rises over both intervals. Failure rates in these patients were 52%, 79%, and 100%, respectively. On multivariate analysis, initial PSA, androgen deprivation therapy, and dose to 90% of the prostate significantly correlated with 48mPSA but together accounted for only ∼5% of its total variance. Conclusions: The 48mPSA after LDR-PB is highly predictive of long-term DFS. Patients with 48mPSA ≤0.4 ng/mL had a <1% risk of disease relapse at 8 years, whereas all patients with 48mPSA >1.0 ng/mL relapsed. Consecutive PSA rises of >0.2 ng/mL from 24 to 36 months and from 36 to 48 months were also highly predictive of subsequent failure.

  5. GIS Technologies For The New Planetary Science Archive (PSA)

    Science.gov (United States)

    Docasal, R.; Barbarisi, I.; Rios, C.; Macfarlane, A. J.; Gonzalez, J.; Arviset, C.; De Marchi, G.; Martinez, S.; Grotheer, E.; Lim, T.; Besse, S.; Heather, D.; Fraga, D.; Barthelemy, M.

    2015-12-01

    Geographical information system (GIS) is becoming increasingly used for planetary science. GIS are computerised systems for the storage, retrieval, manipulation, analysis, and display of geographically referenced data. Some data stored in the Planetary Science Archive (PSA), for instance, a set of Mars Express/Venus Express data, have spatial metadata associated to them. To facilitate users in handling and visualising spatial data in GIS applications, the new PSA should support interoperability with interfaces implementing the standards approved by the Open Geospatial Consortium (OGC). These standards are followed in order to develop open interfaces and encodings that allow data to be exchanged with GIS Client Applications, well-known examples of which are Google Earth and NASA World Wind as well as open source tools such as Openlayers. The technology already exists within PostgreSQL databases to store searchable geometrical data in the form of the PostGIS extension. An existing open source maps server is GeoServer, an instance of which has been deployed for the new PSA, uses the OGC standards to allow, among others, the sharing, processing and editing of data and spatial data through the Web Feature Service (WFS) standard as well as serving georeferenced map images through the Web Map Service (WMS). The final goal of the new PSA, being developed by the European Space Astronomy Centre (ESAC) Science Data Centre (ESDC), is to create an archive which enables science exploitation of ESA's planetary missions datasets. This can be facilitated through the GIS framework, offering interfaces (both web GUI and scriptable APIs) that can be used more easily and scientifically by the community, and that will also enable the community to build added value services on top of the PSA.

  6. Study on the status of breast and prostate cancers in Gazira State using (CA-15-3 and PSA) technology

    International Nuclear Information System (INIS)

    This study was conducted in Algezira State in two environmentally and economically different areas. The people in these areas were divided into two groups in the study: group (A) people who live alongside the Blue Nile bank. Group people who live away how the Blue Nile, I e in midland between the Blue Nile and White Nile which is called (AI-Bajour). The aim of the study was to recognize the normal rate of breast cancer markers(Carbohydrate Antigen 15-3), which is one of the most common cancers, and the prostate cancer (Prostate Cancer Markers), as compared with the global normal rate, in order to early detect and treat these types of cancers. The study was conducted on 336 men and 304 women, who are different in ages, work and social status. The researcher used an experimental, descriptive and analytical method, and the SPSS program for analysis. The study showed that the results of normal rate as compared with previous studies are typical to the breast cancer markers (carbohydrate antigen 15-3, ranging between (0-40) ngm/ml, where as the normal rate of the prostate cancer markers (PSA) ranges between (0-4) ngm/ml, and according to the previous African and American studies. The studies also showed that the results are different according to the group are different according to the group involved. There is an increase in normal rates of group (A) in the PSA markers. From 177 men, 49 had rated of (4-10) ng/ml, 6 had very high rates (10-20)ng/ml and extremely high rates of 2 samples (>20)ng/ml. It was noticed that the abnormal increase rate is directly proportional to the age development. The study showed high results of breast cancer markers (Carbohydrate antigen 15-3), as compared with the global normal rate (0-40)ng/ml, 6 had very high rates (60-100)ng/ml and extremely high rates (>100)ng/ml. Two women of uterus cancer died. Again the abnormal increase in the rates is directly proportional to age development. The study showed that the results of group (B) is

  7. Isolation and characterization of patatin isoforms

    NARCIS (Netherlands)

    Pots, A.M.; Gruppen, H.; Hessing, M.; Boekel, M.A.J.S. van; Voragen, A.G.J.

    1999-01-01

    Patatin has, so far, been considered a homogeneous group of proteins. A comparison of the isoforms in terms of structural properties or stability has not been reported. A method to obtain various isoform fractions as well as a comparison of the physicochemical properties of these pools is presented.

  8. Conformational difference in human IgG2 disulfide isoforms revealed by hydrogen/deuterium exchange mass spectrometry.

    Science.gov (United States)

    Zhang, Aming; Fang, Jing; Chou, Robert Y-T; Bondarenko, Pavel V; Zhang, Zhongqi

    2015-03-17

    Both recombinant and natural human IgG2 antibodies have several different disulfide bond isoforms, which possess different global structures, thermal stabilities, and biological activities. A detailed mapping of the structural difference among IgG2 disulfide isoforms, however, has not been established. In this work, we employed hydrogen/deuterium exchange mass spectrometry to study the conformation of three major IgG2 disulfide isoforms known as IgG2-B, IgG2-A1, and IgG2-A2 in two recombinant human IgG2 monoclonal antibodies. By comparing the protection factors between amino acid residues in isoforms B and A1 (the classical form), we successfully identified several local regions in which the IgG2-B isoform showed more solvent protection than the IgG2-A1 isoform. On the basis of three-dimensional structural models of IgG2, these identified regions were located on the Fab domains, close to the hinge, centered on the side where the two Fab arms faced each other in spatial proximity. We speculated that in the more solvent-protected B isoform, the two Fab arms were brought into contact by the nonclassical disulfide bonds, resulting in a more compact global structure. Loss of Fab domain flexibility in IgG2-B could limit its ability to access cell-surface epitopes, leading to reduced antigen binding potency. The A2 isoform was previously found to have disulfide linkages similar to those of the classical A1 isoform, but with different biophysical behaviors. Our data indicated that, compared to IgG2-A1, IgG2-A2 had less solvent protection in some heavy-chain Fab regions close the hinge, suggesting that the A2 isoform had more flexible Fab domains. PMID:25730439

  9. Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: A retrospective study

    Directory of Open Access Journals (Sweden)

    Chavan P

    2009-01-01

    Full Text Available Background: Need for undertaking prostate biopsies for detection of prostate cancer is often decided on the basis of serum levels of prostate specific antigen (PSA. Aim: To evaluate the case detection rate of prostate cancer among patients presenting with lower urinary tract symptoms (LUTS on the basis of PSA levels and to assess the scope of prostate biopsy in these patients. Setting and Design: A retrospective study from a tertiary care center. Materials and Methods: The clinical and histopathological data of 922 patients presenting with LUTS in the last five years was obtained from the medical record section. They had been screened for prostate cancer using PSA and /or digital rectal examination examination followed by confirmation with prostate biopsy. Statistical Analysis Used: Detection rate and receiver operating characteristic curve were performed using SPSS 16 and Medcalc softwares. Results: The detection rate of prostate cancer according to the PSA levels was 0.6%, 2.3%, 2.5%, 34.1% and 54.9% in the PSA range of 0-4, 4-10, 10-20, 20-50 and> 50 ng/ml, respectively. Maximum prostate cancer cases were detected beyond a PSA value of 20 ng/ml whereas no significant difference in the detection rate was observed in the PSA range of 0-4, 4-10 and 10-20 ng/ml. Conclusion: A low detection rate of prostate cancer observed in the PSA range of 4-20 ng/ml in LUTS patients indicates the need for use of higher cutoff values of PSA in such cases. Therefore we recommend a cutoff of 20 ng/ml of PSA for evaluation of detection rate of prostate cancer among patients presenting with LUTS.

  10. Serum concentrations of the biomarkers CA125, CA15-3, CA72-4, tPSA and PAPP-A in natural and stimulated ovarian cycles

    Institute of Scientific and Technical Information of China (English)

    Melissa Stemp; Peter Roberts; Allison McClements; Vincent Chapple; Jay Natalwala; Michael Black; Phillip Matson

    2014-01-01

    Objective:Biomarkers associated with cancer screening (CA125, CA15‐3, CA72‐4, total prostate specific antigen [tPSA]) and the monitoring of pregnancy (pregnancy associated plasma protein‐A [PAPP‐A]) were measured during natural and stimulated ovarian cycles in disease‐free non-pregnant women to determine if they could reflect normal events relating to ovulation and/or endometrial changes. Methods: A total of 73 blood samples (10 women) collected throughout the natural menstrual cycle, and 64 blood samples (11 women) taken during stimulated ovarian cycles, were analysed on the Roche Cobas e411 automated analyser. Results:Detectable levels of tPSA were measured in at least one point in the cycle in 6/10 of women in the natural cycle and 10/11 of women in stimulated cycles, and CA72-4 was detected in only 12/21 women tested. Concentrations of CA125, tPSA, CA15‐3 and CA72‐4 showed no significant difference between the natural and stimulated ovarian cycle groups. On average the mean PAPP‐A of the natural group was (2.41±0.58) mIU/L higher than the stimulated group (t=4.10, P< 0.001). CA125 and CA15‐3 results were both significantly influenced by the stage of the cycle (P<0.0001), whereas tPSA and PAPP‐A concentrations revealed no significant changes (P≥0.65). CA72‐4 was not affected by the stage of the cycle nor ovarian stimulation. Conclusion:Ovarian stimulation reduced serum PAPP‐A levels, CA125 and CA15‐3 levels were generally unaffected by ovarian stimulation but displayed cyclical changes throughout both natural and stimulated cycles, whilst tPSA and CA72-4 were not affected by the stage of the cycle or ovarian stimulation.

  11. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy

    International Nuclear Information System (INIS)

    Purpose: An identification of prostate cancer patients most likely to benefit from prostate-only radiation was made based upon the pretreatment prostate-specific antigen (PSA), biopsy Gleason score, clinical stage, percentage of positive biopsies, and the 5-year postoperative PSA outcome. Methods: Between 1989 and 2000, 2099 patients underwent radical prostatectomy for clinically localized prostate cancer. The primary end points were pathologic evidence of seminal vesicle invasion 2(SVI), extracapsular extension (ECE) with or without positive surgical margins, and the 5-year postoperative PSA outcome. Results: Pretreatment PSA, biopsy Gleason score, and clinical stage were used to assign patients to low-, intermediate-, and high-risk groups. These risk groups were stratified by the percentage of positive biopsies and the primary pathologic and biochemical outcomes examined. The rates of SVI, ECE with positive margin, and no biochemical evidence of disease (bNED) for low-risk patients with ≤50% positive biopsies were 2%, 7%, and 93%, respectively. Patients with >50% positive biopsies had higher rates of SVI and ECE (5% and 11%, respectively) and 52% bNED (p<0.0001). For intermediate-risk patients with ≤17% positive biopsies, the rates of SVI, ECE with positive margin, and bNED were 3%, 9%, and 90%, respectively. As the percentage of positive biopsies increased above 17% in intermediate-risk patients, there was a statistically significant increase in SVI and ECE and a significant decrease in bNED. Conclusions: Low-risk patients with ≤50% positive biopsies and intermediate-risk patients with ≤17% positive biopsies had a very low risk of SVI and ECE with positive surgical margins. Given that the presence of SVI and ECE with positive surgical margins was uncommon (<10%) with a ≥90% PSA failure-free survival after radical prostatectomy, these patients may be optimal candidates for radiation therapy directed at the prostate only (prostate gland + 1.5-cm margin)

  12. Investigation of contactless detection using a giant magnetoresistance sensor for detecting prostate specific antigen.

    Science.gov (United States)

    Sun, Xuecheng; Zhi, Shaotao; Lei, Chong; Zhou, Yong

    2016-08-01

    This paper presents a contactless detection method for detecting prostate specific antigen with a giant magnetoresistance sensor. In contactless detection case, the prostate specific antigen sample preparation was separated from the sensor that prevented the sensor from being immersed in chemical solvents, and made the sensor implementing in immediately reuse without wash. Experimental results showed that applied an external magnetic field in a range of 50 Oe to 90 Oe, Dynabeads with a concentration as low as 0.1 μg/mL can be detected by this system and could give an approximate quantitation to the logarithmic of Dynabeads concentration. Sandwich immunoassay was employed for preparing PSA samples. The PSA capture was implemented on a gold film modified with a self-assembled monolayer and using biotinylated secondary antibody against PSA and streptavidinylated Dynabeads. With DC magnetic field in the range of 50 to 90 Oe, PSA can be detected with a detection limit as low as 0.1 ng/mL. Samples spiked with different concentrations of PSA can be distinguished clearly. Due to the contactless detection method, the detection system exhibited advantages such as convenient manipulation, reusable, inexpensive, small weight. So, this detection method was a promising candidate in biomarker detection, especially in point of care detection. PMID:27379844

  13. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.

    Science.gov (United States)

    Tsui, Ke-Hung; Feng, Tsui-Hsia; Chung, Li-Chuan; Chao, Chun-Hsiang; Chang, Phei-Lang; Juang, Horng-Heng

    2008-01-01

    A novel prostate cancer cell line (PC-J) was isolated from an androgen independent non-prostate specific antigen (non-PSA) producing carcinoma cell line. The homologous correlation between PC-J and PC-3 was determined by short tandem repeat analysis. The PSA promoter activity was detected by transient expression assay in the PC-J and LNCaP cells but not in androgen insensitive PC-3 cells. When the PC-J cells were cotransfected with androgen receptor, androgen receptor coactivators and PSA reporter vector cells, the reporter assays indicated that nuclear receptor coactivator 4 (NCOA4) but not androgen receptor activator 24 (ARA24) increased the sensitivity and maximum stimulation of dihydrotestosterone (DHT)-inducing PSA promoter activity. The RT-PCR assays revealed that the expression of several tumor markers, including interleukin-6, prostate stem cell antigen (PSCA), prostate epithelium-specific Ets transcription factor (PDEF) and matriptase, was lower in the PC-J cells than in the PC-3 cells. This cell model elucidated the regulation of PSA expression and enabled comparison of the gene profile at different stages of metastasis in prostatic carcinoma.

  14. A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™ in Patients with Prostate Cancer

    Directory of Open Access Journals (Sweden)

    Lattime E

    2006-01-01

    Full Text Available Abstract Purpose Based on previous studies that demonstrated the safety profile and preliminary clinical activity of prostate specific antigen (PSA targeted therapeutic vaccines, as well as recent laboratory data supporting the value of the addition of co-stimulatory molecules B7-1, ICAM-1, and LFA-3 (designated TRICOM™ to these vaccines, we conducted a Phase I study to evaluate the safety and immunogenicity of a novel vaccinia and fowlpox vaccine incorporating the PSA gene sequence and TRICOM. Methods In this study, ten patients with androgen independent prostate cancer with or without metastatic disease were enrolled. Patients were treated with 2 × l08 pfu of a recombinant vaccinia virus vaccine (PROSTVAC-V followed by 1 × 109 pfu of the booster recombinant fowlpox virus (PROSTVAC-F both with gene sequences for PSA and TRICOM. The mean age of patients enrolled in the study was 70 (range 63 to 79. The mean PSA at baseline was 434 (range 9 – 1424. Results There were no deaths, and no Grade 3 or 4 adverse events. The most commonly reported adverse events, regardless of causality, were injection site reactions and fatigue. One serious adverse event (SAE occurred that was unrelated to vaccine; this patient developed progressive disease with a new sphenoid metastasis. PSA was measured at week 4 and week 8. Four patients had stable disease (with less than 25% increase in PSA through the week 8 study period. Anti-PSA antibodies were not induced with therapy: however, anti-vaccinia titers increased in all patients. Conclusion This study demonstrated that vaccination with PROSTVAC-V and PROSTVAC-F combined with TRICOM is well-tolerated and generated an immune response to vaccinia. Therefore, PROSTVAC-VF/TRICOM represents a feasible therapeutic approach for further phase II and III study in patients with prostate cancer.

  15. Predictive value of prostate specific antigen in a European HIV-positive cohort

    DEFF Research Database (Denmark)

    Shepherd, Leah; Borges, Álvaro H; Ravn, Lene;

    2016-01-01

    BACKGROUND: It is common practice to use prostate specific antigen (PSA) ≥4.0 ng/ml as a clinical indicator for men at risk of prostate cancer (PCa), however, this is unverified in HIV+ men. We aimed to describe kinetics and predictive value of PSA for PCa in HIV+ men. METHODS: A nested case...... logistic regression models investigated associations between markers and PCa. Mixed models were used to describe kinetics. Sensitivity and specificity of using tPSA >4 ng/ml to predict PCa was calculated. Receiver operating characteristic curves were used to identify optimal cutoffs in HIV+ men for total...... PSA. RESULTS: 61 HIV+ men were included with a median 6 (IQR 2-9) years follow-up. Levels of tPSA increased by 13.7% per year (95% CI 10.3, 17.3) in cases, but was stable in controls (-0.4%; 95% CI -2.5, 1.7). Elevated PSA was associated with higher odds of PCa at first (OR for twofold higher 4.7; 95...

  16. Fluorescence of prostate-specific antigen as measured with a portable 1D scanner

    Science.gov (United States)

    Kim, Byeong C.; Jeong, Jin H.; Jeong, Dong S.; Kim, Young M.; Oh, Sang W.; Choi, Eui Y.; Kim, Jae H.; Nahm, Kie B.

    2005-01-01

    Prostate-specific antigen (PSA) is an androgen-dependent glycoprotein protease (M.W. 33 kDa) and a member of kallikrein super-family of serine protease, and has chymotrypsin-like enzymatic activity. It is synthesized by the prostate epithelial cells and found in the prostate gland and seminal plasma as a major protein. It is widely used as a clinical marker for diagnosis, screening, monitoring and prognosis of prostate cancer. In normal male adults, the concentration of PSA in the blood is below 4 ng/ml and this value increases in patients with the prostate cancer or the benign prostatic hyperplasia (BPH) due to its leakage into the circulatory system. As such, systematic monitoring of the PSA level in the blood can provide critical information about the progress of the prostatic disease. We have developed a compact integral system that can quantitatively measure the concentration of total PSA in human blood. This system utilizes the fluorescence emitted from the dye molecules attached to PSA molecules after appropriate immunoassay-based processing. Developed for the purpose of providing an affordable means of fast point-of-care testing of the prostate cancer, this system proved to be able to detect the presence of the PSA at the level of 0.18 ng/ml in less than 12 minutes, with the actual measurement taking less than 2 minutes. The design concept for this system is presented together with the result for a few representative samples.

  17. Specific probe selection from landscape phage display library and its application in enzyme-linked immunosorbent assay of free prostate-specific antigen.

    Science.gov (United States)

    Lang, Qiaolin; Wang, Fei; Yin, Long; Liu, Mingjun; Petrenko, Valery A; Liu, Aihua

    2014-03-01

    Probes against targets can be selected from the landscape phage library f8/8, displaying random octapeptides on the pVIII coat protein of the phage fd-tet and demonstrating many excellent features including multivalency, stability, and high structural homogeneity. Prostate-specific antigen (PSA) is usually determined by immunoassay, by which antibodies are frequently used as the specific probes. Herein we found that more advanced probes against free prostate-specific antigen (f-PSA) can be screened from the landscape phage library. Four phage monoclones were selected and identified by the specificity array. One phage clone displaying the fusion peptide ERNSVSPS showed good specificity and affinity to f-PSA and was used as a PSA capture probe in a sandwich enzyme-linked immunosorbent assay (ELISA) array. An anti-human PSA monoclonal antibody (anti-PSA mAb) was used to recognize the captured antigen, followed by horseradish peroxidase-conjugated antibody (HRP-IgG) and o-phenylenediamine, which were successively added to develop plate color. The ELISA conditions such as effect of blocking agent, coating buffer pH, phage concentration, antigen incubation time, and anti-PSA mAb dilution for phage ELISA were optimized. On the basis of the optimal phage ELISA conditions, the absorbance taken at 492 nm on a microplate reader was linear with f-PSA concentration within 0.825-165 ng/mL with a low limit of detection of 0.16 ng/mL. Thus, the landscape phage is an attractive biomolecular probe in bioanalysis.

  18. Variability of assay methods for total and free PSA after WHO standardization.

    Science.gov (United States)

    Foj, L; Filella, X; Alcover, J; Augé, J M; Escudero, J M; Molina, R

    2014-03-01

    The variability of total PSA (tPSA) and free PSA (fPSA) results among commercial assays has been suggested to be decreased by calibration to World Health Organization (WHO) reference materials. To characterize the current situation, it is necessary to know its impact in the critical cutoffs used in clinical practice. In the present study, we tested 167 samples with tPSA concentrations of 0 to 20 μg/L using seven PSA and six fPSA commercial assays, including Access, ARCHITECT i2000, ADVIA Centaur XP, IMMULITE 2000, Elecsys, and Lumipulse G1200, in which we only measured tPSA. tPSA and fPSA were measured in Access using the Hybritech and WHO calibrators. Passing-Bablok analysis was performed for PSA, and percentage of fPSA with the Hybritech-calibrated access comparison assay. For tPSA, relative differences were more than 10 % at 0.2 μg/L for ARCHITECT i2000, and at a critical concentration of 3, 4, and 10 μg/L, the relative difference was exceeded by ADVIA Centaur XP and WHO-calibrated Access. For percent fPSA, at a critical concentration of 10 %, the 10 % relative difference limit was exceeded by IMMULITE 2000 assay. At a critical concentration of 20 and 25 %, ADVIA Centaur XP, ARCHITECT i2000, and IMMULITE 2000 assays exceeded the 10 % relative difference limit. We have shown significant discordances between assays included in this study despite advances in standardization conducted in the last years. Further harmonization efforts are required in order to obtain a complete clinical concordance.

  19. International survey of living PSA and safety indicators

    International Nuclear Information System (INIS)

    The report contains an international overview of applications of living probabilistic assessment and development of operational safety indicators. Features of an ideal living PSA tool are summarized as well as a limited survey of code systems for managing a living probabilistic safety assessment (living PSA) is included. The international survey is used as an input for planning and performance of related tasks within the nordic NKS/SIK-1 project conducted in 1990-93. The research notes are distributed to the Nordic organizations involved or interested in the subject. The report includes an overview and conclusions from technical reports and articles available and presentations and discussions related to development and use of above methods for the evaluation and management of the operational safety of nuclear power plants. A large part of this material is based on material collected and discussed in connection to international specialist meetings relating to the subject

  20. PSA for the shutdown mode for nuclear power plants

    International Nuclear Information System (INIS)

    The meeting, which was attended by more than 75 participants from 20 countries, provided a broad discussion forum where all the currently active major shutdown PSA programmes were reviewed. The meeting also addressed the issues related to actual performance of shutdown PSA studies as well as insight gained from the studies. This document, which was prepared during the TCM, contains the results of extensive discussions which were held in specific working groups. The papers presented at the meeting provide a comprehensive overview of the state of the art of shutdown risk assessment and remedial measures taken to reduce the risk in outages. It is hoped that this document will be very useful to all individuals with interest in increasing safety during outages at NPPs. Refs, figs and tabs

  1. Quantitative application of Monte Carlo simulation in Fire-PSA

    Energy Technology Data Exchange (ETDEWEB)

    Mangs, J.; Hostikka, S.; Korhonen, T. [Valtion Teknillinen Tutkimuskeskus, Espoo (Finland); Keski-Rahkonen, O.

    2007-05-15

    In a power plant a fire cell forms the basic subunit. Since the fire is initially located there, the full-scale time dependent fire simulation and estimation of target response must be performed within the fire cell. Conditional, time dependent damage probabilities in a fire cell can now be calculated for arbitrary targets (component or a subsystem) combining probabilistic (Monte Carlo) and deterministic simulation. For the latter a spectrum from simple correlations up to latest computational fluid dynamics models is available. Selection of the code is made according to the requirements form the target cell. Although calculations are numerically heavy, it is now economically possible and feasible to carry out quantitative fire-PSA for a complete plant iteratively with the main PSA. From real applications examples are shown on assessment of fire spread possibility in a relay room, and potential of fire spread on cables in a tunnel. (orig.)

  2. PSA use in accident management studies in Japan

    International Nuclear Information System (INIS)

    The safety of NPPs in Japan is secured by stringent safety regulations based on the deterministic method, minimizing the possibility a severe accident to a technologically negligible level. PSA is not required in the current regulatory procedures. Accident management based on PSA is a 'knowledge-based' action dependent on utilities' technical knowledge aimed at further reduction of the risk which is kept small enough by existing measures. The paper discusses the following three kinds of PSAs that have been conducted practically and efficiently on NPPs to provide supplemental information about their safety characteristics in addition to the deterministic evaluation used in the regulatory safety review: PSAs on typical NPPs, PSAs on all NPPs to examine candidates for accident management, and PSAs as part of periodic safety review (PSR). 1 fig., 5 tabs

  3. A COMPARATIVE STUDY OF PROSTATIC SPECIFIC ANTIGEN DENSITY AND ITS CORRELATED HISTOPATHOLOGY IN THE DIAGNOSIS OF BENIGN AND MALIGNANT PROSTATIC DISEASES

    Directory of Open Access Journals (Sweden)

    Shravan R

    2015-07-01

    Full Text Available BACKGROUND : Carcinoma of prostate gland is the most common malignancy above 65 yrs of age in men. Most patients with early - stage Ca prostate are asymptomatic. The presence of symptoms often suggests locally advanced or metastatic disease. It is important to detect Ca prostate at an early stage so that mortality due to this malignancy can be minimized. The specific threshold for prostate - specific antigen (PSA to delineate patients who are at the highest risk has been controversial. It is wiser to refine PSA by its derivative parameter like PSAD (PSA/Vol . which can be used as a better diagnostic tool in early detection of Ca Prostate.

  4. The Short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction

    OpenAIRE

    Chen, Lanfen; Chen, Zhangguo; Baker, Kristi; Halvorsen, E lizabeth M.; da Cunha, Andre Pires; Flak, Magdalena B.; Gerber, Georg; Huang, Yu-Hwa; Hosomi, Shuhei; Arthur, J anelle C.; Dery, Ken J.; Nagaishi, Takashi; Beauchemin, Nicole; Kathryn V Holmes; Joshua W K Ho

    2012-01-01

    Carcinoembryonic antigen cell adhesion molecule like I (CEACAM1) is expressed on activated T cells and signals through either a long (L) cytoplasmic tail containing immune receptor tyrosine based inhibitory motifs, which provide inhibitory function, or a short (S) cytoplasmic tail with an unknown role. Previous studies on peripheral T cells show that CEACAM1-L isoforms predominate with little to no detectable CEACAM1-S isoforms in mouse and human. We show here that this was not the case in ti...

  5. Take Charge. Take the Test. "You Know" PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 60 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  6. Recent Developments in Level 2 PSA and Severe Accident Management

    International Nuclear Information System (INIS)

    In 1997, CSNI WGRISK produced a report on the state of the art in Level 2 PSA and severe accident management - NEA/CSNI/R(1997)11. Since then, there have been significant developments in that more Level 2 PSAs have been carried out worldwide for a variety of nuclear power plant designs including some that were not addressed in the original report. In addition, there is now a better understanding of the severe accident phenomena that can occur following core damage and the way that they should be modelled in the PSA. As requested by CSNI in December 2005, the objective of this study was to produce a report that updates the original report and gives an account of the developments that have taken place since 1997. The aim has been to capture the most significant new developments that have occurred rather than to provide a full update of the original report, most of which is still valid. This report is organised using the same structure as the original report as follows: Chapter 2: Summary on state of application, results and insights from recent Level 2 PSAs. Chapter 3: Discussion on key severe accident phenomena and modelling issues, identification of severe accident issues that should be treated in Level 2 PSAs for accident management applications, review of severe accident computer codes and the use of these codes in Level 2 PSAs. Chapter 4: Review of approaches and practices for accident management and SAM, evaluation of actions in Level 2 PSAs. Chapter 5: Review of available Level 2 PSA methodologies, including accident progression event tree / containment event tree development. Chapter 6: Aspects important to quantification, including the use of expert judgement and treatment of uncertainties. Chapter 7: Examples of the use of the results and insights from the Level 2 PSA in the context of an integrated (risk informed) decision making process

  7. Teen Pregnancy - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-04-05

    This 60 second PSA is based on the April, 2011 CDC Vital Signs report. Having a child during the teen years comes at a high cost to the young mother, her child, and the community. Get tips to help break the cycle of teen pregnancy.  Created: 4/5/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 4/5/2011.

  8. Asthma - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-05-03

    This 60 second Public Service Announcement (PSA) is based on the May, 2011 CDC Vital Signs report. Children and adults can have asthma and attacks can be frightening. To help control asthma, know the warning signs of an attack, stay away from asthma triggers, and follow your health care provider's advice.  Created: 5/3/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 5/3/2011.

  9. Development of the Level 1 PSA Model for PGSFR Regulatory

    International Nuclear Information System (INIS)

    SFR (sodium-cooled fast reactor) is Gen-IV nuclear energy system, which is designed for stability, sustainability and proliferation resistance. KALIMER-600 and PGSFR (Prototype Gen-IV SFR) are under development in Korea with enhanced passive safety concepts, e.g. passive reactor shutdown, passive residual heat removal, and etc. Risk analysis from a regulatory perspective is necessary for regulatory body to support the safety and licensing review of SFR. Safety issues should be identified in the early design phase in order to prevent the unexpected cost increase and the delay of PGSFR licensing schedule. In this respect, the preliminary PSA Model of KALIMER-600 had been developed for regulatory. In this study, the development of PSA Level 1 Model is presented. The important impact factors in the risk analysis for the PGSFR, such as Core Damage Frequency (CDF), have been identified and the related safety insights have been derived. The PSA level 1 model for PGSFR regulatory is developed and the risk analysis is conducted. Regarding CDF, LOISF frequency, uncertainty parameter for passive system CCF, loss of 125V DC control center bus and damper CCF are identified as the important factors. Sensitivity analyses show that the CDF would be differentiated (lowered) according to their values

  10. Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment

    DEFF Research Database (Denmark)

    Juul, A; Müller, J; Skakkebaek, N E

    1997-01-01

    In healthy boys, the pituitary-gonadal axis exhibits diurnal variation in early puberty. Serum testosterone levels are higher during the night and low or immeasurable during the day. These fluctuating levels of circulating androgens in early pubertal boys are difficult to monitor. Prostate specific...... antigen (PSA) is a marker of the androgen-dependent prostatic epithelial cell activity and it is used in the diagnosis and surveillance of adult patients with prostatic cancer. We have measured PSA concentrations in serum from boys with precocious puberty before and during gonadal suppression with Gn......RH agonists to evaluate the effect of normal and precocious puberty on PSA levels and to study the correlation between testosterone and PSA in boys....

  11. Lycopene can reduce prostate-specific antigen velocity in a phase Ⅱ clinical study in Chinese population

    Institute of Scientific and Technical Information of China (English)

    Zhang Xin; Yang Yong; Wang Qi

    2014-01-01

    Background Epidemiological studies have shown that lycopene has anti-prostate cancer effect.In vitro tests also confirmed that it can promote apoptosis of prostate cancer cells.We investigated the effect of whole-tomato supplement lycopene on the prostate-specific antigen velocity in selected prostate cancer patients.Methods Twenty selected prostate cancer patients were given whole-tomato supplement lycopene 10 mg per day for about 6 months.Blood samples of patients were collected weekly to measure serum prostate-specific antigen (PSA) values.PSA velocity slope,which reflects the change of PSA,and the degree of change were also calculated.By comparing the values of average PSA velocity slope (rise or fall of PSA) before and after the administration of lycopene,the effect of lycopene can be evaluated.Blood chemistry analysis was regular followed as safety control.Results Three patients in the research group withdrew within 3 weeks because of inability to conform.The rest 17 patients continued for an average period of 6 months.Two patients withdrew because of cancer progression (PSA rise) who later received active treatment.The average fall in PSA was equivalent to 2.56% over (i.e.an average slope/d of -0.000 28) the first 3 months.In the last 3 months,average fall in PSA was equivalent to 31.58% (i.e.an average slope/d of-0.003 51).The Wilcoxon rank-sum test showed a statistically significant decrease of PSA velocity slope overall (P=0.000 9).Analysis of the PSA doubling time (pre-vs.post-treatment) showed a median increase over 3 months but this was not statistically significant (P=0.21).No toxic side effect was observed during the whole process.The results indicate that the average PSA change is "decline" in patients,and the degree of the decline is accelerated.Conclusion Administration of lycopene was able to reduce PSA velocity in this study group.

  12. Functional studies of sodium pump isoforms

    DEFF Research Database (Denmark)

    Clausen, Michael Jakob

    unique expression profiles and specialized functional features. We use a Two Electrode Voltage Clamp setup to determine pre-steady-state and steady-state characteristics of each isoform and design chimeras to pin-point the structural elements responsible for observed differences. With this strategy we...... and glial cells express multiple isoforms of the Na+,K+-ATPase that are sorted to different specialized subcellular compartments. We are setting up a novel assay to study the details of Na+,K+-ATPase trafficking in polarized cells. With SNAP and CLIP tagged Na+,K+-ATPase isoforms we can track newly...

  13. Analysis of common cause failure in Wolsong 2/3/4 NPPs PSA

    International Nuclear Information System (INIS)

    Wolsong 2/3/4 Nuclear Power Plants (WS 2/3/4 NPPs) are CANDU 6 type Pressurized Heavy Water Reactors (PHWRs) being built in Wolsong site of Korea by Korea Power Electric Corporation (KEPCO). WS 2/3/4 NPPs are designed by Atomic Energy of Canada Ltd. (AECL). AECL performs Probabilistic Safety Assessment (PSA) for these NPPs. In this PSA, however, the effect of Common Cause Failure (CCF) is not analyzed due to the limitation of CANDU reliability data. Since the CCF is regarded as one of the most dominant contributors to the total core damage frequency (CDF) in Pressurized Water Reactor (PWR) PSA. KEPCO and Korea Atomic Energy Research Institute (KAERI) initiated WS 2/3/4 NPPs Level 2 PSA which includes the CCF analysis and detailed HRA. In WS 2/3/4 NPPs Level 2 PSA, the authors reviewed the CCF data used in PWR PSA, and applied these data for WS 2/3/4 NPPs Level 2 PSA. The MGL method is implemented for the CCF analysis of WS 2/3/4 NPPs. The analyzed results show that the effect of CCF is not negligible in CANDU PSA as well as in PWR PSA. So the CCF data of CANDU plants should be collected and incorporated into CANDU PSA

  14. Image Guided Hypofractionated Radiotherapy by Helical Tomotherapy for Prostate Carcinoma: Toxicity and Impact on Nadir PSA

    Directory of Open Access Journals (Sweden)

    Salvina Barra

    2014-01-01

    Full Text Available Aim. To evaluate the toxicity of a hypofractionated schedule for primary radiotherapy (RT of prostate cancer as well as the value of the nadir PSA (nPSA and time to nadir PSA (tnPSA as surrogate efficacy of treatment. Material and Methods. Eighty patients underwent hypofractionated schedule by Helical Tomotherapy (HT. A dose of 70.2 Gy was administered in 27 daily fractions of 2.6 Gy. Acute and late toxicities were graded on the RTOG/EORTC scales. The nPSA and the tnPSA for patients treated with exclusive RT were compared to an equal cohort of 20 patients treated with conventional fractionation and standard conformal radiotherapy. Results. Most of patients (83% did not develop acute gastrointestinal (GI toxicity and 50% did not present genitourinary (GU toxicity. After a median follow-up of 36 months only grade 1 of GU and GI was reported in 6 and 3 patients as late toxicity. Average tnPSA was 30 months. The median value of nPSA after exclusive RT with HT was 0.28 ng/mL and was significantly lower than the median nPSA (0.67 ng/mL of the conventionally treated cohort (P=0.02. Conclusions. Hypofractionated RT schedule with HT for prostate cancer treatment reports very low toxicity and reaches a low level of nPSA that might correlate with good outcomes.

  15. The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran.

    Science.gov (United States)

    Heidari, Mohammad Hassan; Porghasem, Mohsen; Mirzaei, Nazanin; Mohseni, Jafar Hesam; Heidari, Matine; Azargashb, Eznollah; Movafagh, Abolfazl; Heidari, Reihane; Molouki, Aidin; Larijani, Leila

    2014-02-01

    Since several high level natural radiation areas (HLNRAs) exist on our planet, considerable attention has been drawn to health issues that may develop as the result of visiting or living in such places. City of Ramsar in Iran is an HNLRA, and is a tourist attraction mainly due to its hot spas. However, the growing awareness over its natural radiation sources has prompted widespread scientific investigation at national level. In this study, using an ELISA method, the level of expression of three tumor markers known as carcinoembryonic antigen (CEA), prostate-specific antigen (PSA) and carcino antigen 19-9 (CA19-9) in blood serum of 40 local men of Ramsar (subject group) was investigated and compared to 40 men from the city of Noshahr (control group). Noshahr was previously identified as a normal level natural radiation area (NLNRA) that is some 85 km far from Ramsar. According to statistical analysis, there was a significant difference in the levels of PSA and CA19-9 markers between the two groups (p < 0.001) with those of Ramsar being considerably higher. CEA level did not show any difference. Although some of the volunteers tested positive to the markers, they were in good health as confirmed by the physician. Moreover, the high number of positive markers in Noshahr was considerable. Therefore, future study is needed to further validate this result and to determine the level of positivity to tumor markers in both cities.

  16. FSH isoform pattern in classic galactosemia

    OpenAIRE

    Gubbels, Cynthia S.; Thomas, Chris M.G.; Wodzig, Will K. W. H.; Olthaar, André J.; Jaeken, Jaak; Sweep, Fred C. G. J.; Rubio-Gozalbo, M. Estela

    2010-01-01

    Female classic galactosemia patients suffer from primary ovarian insufficiency (POI). The cause for this long-term complication is not fully understood. One of the proposed mechanisms is that hypoglycosylation of complex molecules, a known secondary phenomenon of galactosemia, leads to FSH dysfunction. An earlier study showed less acidic isoforms of FSH in serum samples of two classic galactosemia patients compared to controls, indicating hypoglycosylation. In this study, FSH isoform patterns...

  17. The effect of high level natural ionizing radiation on expression of PSA, CA19-9 and CEA tumor markers in blood serum of inhabitants of Ramsar, Iran

    International Nuclear Information System (INIS)

    Since several high level natural radiation areas (HLNRAs) exist on our planet, considerable attention has been drawn to health issues that may develop as the result of visiting or living in such places. City of Ramsar in Iran is an HNLRA, and is a tourist attraction mainly due to its hot spas. However, the growing awareness over its natural radiation sources has prompted widespread scientific investigation at national level. In this study, using an ELISA method, the level of expression of three tumor markers known as carcinoembryonic antigen (CEA), prostate-specific antigen (PSA) and carcino antigen 19-9 (CA19-9) in blood serum of 40 local men of Ramsar (subject group) was investigated and compared to 40 men from the city of Noshahr (control group). Noshahr was previously identified as a normal level natural radiation area (NLNRA) that is some 85 km far from Ramsar. According to statistical analysis, there was a significant difference in the levels of PSA and CA19-9 markers between the two groups (p < 0.001) with those of Ramsar being considerably higher. CEA level did not show any difference. Although some of the volunteers tested positive to the markers, they were in good health as confirmed by the physician. Moreover, the high number of positive markers in Noshahr was considerable. Therefore, future study is needed to further validate this result and to determine the level of positivity to tumor markers in both cities. -- Highlights: • Expression of three tumor markers was examined in 80 volunteers from Ramsar. • There was a significant difference in the levels of PSA and CA19-9 markers. • Some of the volunteers from the control city of Noshahr also tested positive. • Radiation might have caused an adaptive response in people of Ramsar. • Further study is necessary to re-confirm the positivity to tumor marker

  18. Isoform Specificity of Protein Kinase Cs in Synaptic Plasticity

    Science.gov (United States)

    Sossin, Wayne S.

    2007-01-01

    Protein kinase Cs (PKCs) are implicated in many forms of synaptic plasticity. However, the specific isoform(s) of PKC that underlie(s) these events are often not known. We have used "Aplysia" as a model system in order to investigate the isoform specificity of PKC actions due to the presence of fewer isoforms and a large number of documented…

  19. Defining the appropriate radiation dose for pretreatment PSA no. <=no. 10 ng/mL prostate cancer

    International Nuclear Information System (INIS)

    Purpose: To investigate whether a dose response exists for biochemical no evidence of disease (bNED) control in prostate cancer patients with pretreatment prostate-specific antigen (PSA) no. =no. 7600 cGy. Median dose in these three groups was 7067 cGy, 7278 cGy, and 7734 cGy, respectively. Univariate analysis was performed to determine differences in bNED control (American Society for Therapeutic Radiology and Oncology [ASTRO] Consensus Guidelines definition of failure) by dose group for the entire cohort, for 310 good prognosis patients (T1-T2A, Gleason score 2-6, absence of PNI), and for 178 poor prognosis patients (T2B-T3 or Gleason score 7-10 or presence of PNI) . Multivariate analysis (MVA) was performed to determine if dose was an independent predictor of bNED control. Median follow-up was 36 months. Results: A dose response was not demonstrated for the entire group of patients with pretreatment PSA no. =no. 7600 cGy were associated with 5-year bNED control rates of 73%, 86%, and 89%, respectively (p = 0.12). MVA demonstrated prognosis group (p = 0.038) to be the only independent predictor of bNED control. Good prognosis patients had a 5-year bNED of 85% and no dose response was seen. The subgroup of poor prognosis patients demonstrated a 5-year bNED control rate of 81% and a dose response was seen for those receiving no. >=no. 7600 cGy, compared to the two lower dose groups (94% vs. 75% vs. 70%; p = 0.0062). MVA for the poor prognosis subset demonstrated dose (p = 0.01) to be the only independent predictor for improved bNED control. Conclusions: The poor prognosis subset of PSA no. <=no. 10 ng/mL prostate cancer patients benefit from dose escalation. A dose response is not demonstrated for prostate cancer patients with pretreatment PSA no. <=no. 10 ng/mL and other favorable features

  20. Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA

    Directory of Open Access Journals (Sweden)

    Leah Shepherd

    2014-11-01

    Full Text Available Introduction: Although prostate cancer (PCa incidence is lower in HIV+ men than in HIV− men, the usefulness of prostate-specific antigen (PSA screening in this population is not well defined and may have higher false negative rates than in HIV− men. We aimed to describe the kinetics and predictive value of PSA in HIV+ men. Methods: Men with PCa (n=21 and up to two matched controls (n=40 with prospectively stored plasma samples before PCa (or matched date in controls were selected. Cases and controls were matched on date of first and last sample, age, region of residence and CD4 count at first sample date. Total PSA (tPSA, free PSA (fPSA, testosterone and sex hormone binding globulin (SHBG were measured. Conditional logistic regression models investigated associations between markers and PCa. Sensitivity and specificity of using tPSA >4 µg/L to predict PCa was calculated. Mixed models were used to describe kinetics. Results: Sixty-one men were included with a median six (IQR 2–9 years follow-up. Time between last sample and PCa was seven (4–11 months. Cases and controls were well matched at first sample, with a median age of 51 (IQR 48–57 and CD4 of 437 (243–610 cells/mm3. Median tPSA [2.8 (IQR: 1.6–4.6 and 0.8 (0.5–1.2 µg/L] and fPSA [0.4 (0.2–0.8 and 0.3 (0.2–0.4 µg/L] levels were higher in cases than controls at first sample. Both tPSA and fPSA increased significantly over time in cases (Figure 1, to a median at last sample of 6.1 (4.7–9.5 and 0.9 (0.6–1.3 µg/L, respectively, but were stable in controls, with a median at last sample of 0.8 (0.5–1.4 and 0.2 (0.2–0.4 µg/L (Figure. Higher levels of tPSA and fPSA were associated with higher odds of PCa at first sample [OR for 2-fold higher 4.7 (CI: 1.7–12.9 and 5.4 (1.7–17.4]. Elevated tPSA values in cases were detectable ≥5 years before PCa (p0.7. The most informative predictor of PCa was tPSA (AUC=0.9, followed by fPSA (0.8. Testosterone (AUC = 0.5 and SHBG

  1. Prostate Cancer Detection and Dutasteride : Utility and Limitations of Prostate-Specific Antigen in Men with Previous Negative Biopsies

    NARCIS (Netherlands)

    van Leeuwen, Pim J.; Koelble, Konrad; Huland, Hartwig; Hambrock, Thomas; Barentsz, Jelle; Schroder, Fritz H.

    2011-01-01

    Context: We addressed the question whether the change of serum prostate-specific antigen (PSA) in men who use 5 alpha-reductase inhibitor (5-ARI) dutasteride is sensitive for the detection of aggressive prostate cancer (PCa). Objective: The case of a man using dutasteride diagnosed with Gleason 7 tr

  2. The Use and Results of Prostate-Specific Antigen Testing in General Practice in the Former Aarhus County

    DEFF Research Database (Denmark)

    Mukai, Thomas; Bro, Flemming; Pedersen, Knud Venborg;

    Background: Prostate Cancer (PC) is the most common type of cancer among Danish men, and the incidence is increasing. PC is often asymptomatic, making it difficult to establish a clinical diagnosis. The general practitioner can use prostate-specific antigen (PSA) testing as a tool for diagnosing ...

  3. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia

    NARCIS (Netherlands)

    Mochtar, CA; Kiemeney, LALM; van Riemsdijk, MM; Barnett, GS; Laguna, MP; Debruyne, FMJ; de la Rosette, JJMCH

    2003-01-01

    Objectives: To assess the ability of serum prostate specific antigen (PSA) to estimate prostate volume (PV) to aid in the management of patients with benign prostatic hyperplasia (BPH). Methods: From 1989 to 2002, data were collected from 2264 patients complaining of lower urinary tract symptoms (LU

  4. Long-term Prostate-specific Antigen Velocity in Improved Classification of Prostate Cancer Risk and Mortality

    DEFF Research Database (Denmark)

    Ørsted, David Dynnes; Bojesen, Stig E; Kamstrup, Pia R;

    2013-01-01

    BACKGROUND: It remains unclear whether adding long-term prostate-specific antigen velocity (PSAV) to baseline PSA values improves classification of prostate cancer (PCa) risk and mortality in the general population. OBJECTIVE: To determine whether long-term PSAV improves classification of PCa risk...

  5. Carbohydrate Biopolymers Enhance Antibody Responses to Mucosally Delivered Vaccine Antigens

    Science.gov (United States)

    Bacon, A.; Makin, J.; Sizer, P. J.; Jabbal-Gill, I.; Hinchcliffe, M.; Illum, L.; Chatfield, S.; Roberts, M.

    2000-01-01

    We have evaluated the ability of two carbohydrate biopolymers, chitosan and gellan, to enhance antibody responses to subunit influenza virus vaccines delivered to the respiratory tracts of mice. Groups of mice were vaccinated three times intranasally (i.n.) with 10 μg of purified influenza B/Panama virus surface antigens (PSAs), which consist of hemagglutinin (HA) and neuraminidase (NA), either alone or admixed with chitosan or gellan solutions. Separate groups were vaccinated subcutaneously (s.c.) with PSAs adsorbed to Alhydrogel or chitosan or gellan alone i.n. Serum antibody responses were determined by enzyme-linked immunosorbent assay (ELISA) for influenza virus-specific immunoglobulin G (IgG) and by HA inhibition (HAI) and NA inhibition (NAI) assays. The local respiratory immune response was measured by assaying for influenza virus-specific IgA antibody in nasal secretions and by enumerating nasal and pulmonary lymphocytes secreting IgA, IgG, and IgM anti-influenza virus-specific antibodies by enzyme-linked immunospotting (ELISPOT). When administered alone i.n., B/Panama PSA was poorly immunogenic. Parenteral immunization with B/Panama PSA with Alhydrogel elicited high titers of anti-B/Panama antibodies in serum but a very poor respiratory anti-B/Panama IgA response. In contrast, i.n. immunization with PSA plus chitosan stimulated very strong local and systemic anti-B/Panama responses. Gellan also enhanced the local and serum antibody responses to i.n. PSA but not to the same extent as chitosan. The ability of chitosan to augment the immunogenicity of influenza vaccines given i.n. was confirmed using PSA prepared from an influenza A virus (A/Texas H1N1). PMID:10992483

  6. Simple and robust antibody microarray-based immunoassay platform for sensitive and selective detection of PSA and hK2 toward accurate diagnosis of prostate cancer

    Directory of Open Access Journals (Sweden)

    S.W. Lee

    2015-03-01

    Full Text Available This paper reports the development of an easy to use antibody microarray-based immunoassay platform for sensitive and selective duplex detection of PSA (prostate specific antigen and hK2 (human kallikrein 2. Using PDMS wells in a 3 × 9 array on epoxy-coated glass slides 27 duplex immunoassays can be performed in parallel. Automated microarraying provided fast and reproducible antibody arraying in each assay well. To achieve highly sensitive and selective detection of each biomarker, we evaluated and optimized the density of each of the immobilized capture antibodies. The assay platform showed a limit of detection (LOD of each biomarker (PSA and hK2 of less than 10 pg/mL and a dynamic range of 104–105 orders of magnitude. Neither the PSA nor the hK2 antibody array showed any cross-reaction against each others target proteins or other plasma proteins. These results emphasize the importance of density optimization of capture antibody on the surface in order to achieve a sensitive and selective multiplex immunoassay.

  7. Electrochemiluminescence PSA assay using an ITO electrode modified with gold and palladium, and flower-like titanium dioxide microparticles as ECL labels

    International Nuclear Information System (INIS)

    We report on the synthesis of flower-like 3D titanium dioxide (fl-TiO2) using a hydrothermal method. This material possesses a large specific surface and displays an electrochemiluminescence (ECL) intensity that is much stronger than the one of TiO2 nanoparticles having smooth surfaces. It was used to label the secondary antibody in a sandwich immunoassay. A thin layer of metallic gold (Au) and palladium (Pd) was deposited on an indium tin oxide (ITO) electrode by code-position at a potential of 0.2 V in the respective chloride solutions. The Au/Pd-modified ITO electrode showed good conductivity. An ECL based immunoassay for the prostate specific antigen (PSA) was then worked out by immobilizing the first antibody on the Au/Pd layer on the ITO electrode, then exposing the electrode to a sample containing PSA, then forming the sandwich with the fl-TiO2 labeled secondary antibody, and finally measuring the intensity of ECL at a potential of −1.5 V. This ECL sensor has a response range that extends from 0.001 to 600 ng∙mL−1, a lower detection limit of 0.32 pg∙mL−1, good specificity, acceptable stability and good reproducibility. It gave satisfactory results when used for the determination of PSA in (spiked) diluted solutions of human serum. (author)

  8. Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy

    Directory of Open Access Journals (Sweden)

    Martinez Carlos A.L.

    2004-01-01

    Full Text Available OBJECTIVES: To analyze the behavior of the prostate specific antigen velocity (PSAV in localized prostate adenocarcinoma. MATERIALS AND METHODS: We conducted a retrospective study of 500 men who had localized prostate adenocarcinoma, who underwent radical retropubic prostatectomy between January 1986 and December 1999. The PSAV was calculated for each patient and subsequently, the values were correlated with 5 groups: age, initial PSA value, clinical stage, tumor volume and Gleason score. RESULTS: The behavior of PSAV presented statistic significance with an increment between 1.3 ng/mL and 9.6 ng/mL, ranging from 38.6% and 59.8% when compared with the initial PSA value (p < 0.0001, clinical stage (p = 0.0002, tumor volume (p < 0.0001 and Gleason score (p = 0.0009. CONCLUSION: PSAV up to 2.5 ng/mL/year is associated with factors of good prognosis, such as initial PSA below 10 mg/mL, clinical stage T1, tumor volume below 20% and Gleason score lower than 7.

  9. Colorectal Cancer - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-07-05

    This 60 second Public Service Announcement (PSA) is based on the July, 2011 CDC Vital Signs report. Colorectal cancer kills about 50,000 men and women every year. Screening can save lives! Screening can find abnormal growths so they can be removed before turning into cancer, and can find the cancer early, when it's easiest to treat. If you're over 50, talk to your doctor about getting screened for colorectal cancer.  Created: 7/5/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/5/2011.

  10. Application of the uncertainty analysis in the PSA

    International Nuclear Information System (INIS)

    The uncertainty of integrality and hypothesis condition while modeling, data input uncertainty is analyzed in Probability Safety Assessment, as well as the causes of said factors. Aiming at the uncertainty of the parameter input in PSA has specified the theory and method for the uncertainty analysis of Risk Spectrum Software. 13 initial events and average of core damage frequency have achieved after ration calculation to the uncertainty of input data. To token both curve of uncertainty is recommend which Probability Density Function and Cumulative Density Function

  11. Workshop on PSA applications, Sofia, Bulgaria, 7-11 October 1996. Lecturing materials

    International Nuclear Information System (INIS)

    The objective of this workshop was to present detailed, systematic and useful information about PSA-based tools and PSA applications. The first presentation of the workshop was titled ''The role of PSA in safety management''. This topic served to introduce the workshop and to highlight several concepts that were afterwards stressed during the week, i.e. the defence in depth principle and the use of deterministic and probabilistic approaches in a complementary way. This presentation provided a basis for the discussion of ''PSA applications''. As a complement to the theoretical lectures, there was a workshop during which three different exercises were run in parallel. For two of these, computer-based PSA tools were used. One of them was focused towards the analysis of design modifications and the other one towards demonstrating configuration control strategies. The objective of the third practice was to obtain Allowed Outage Times using different PSA-based approaches and to discuss the differences observed and the insights obtained. To conclude the workshop, stress was put on the importance of the quality of the PSA (the development of a high quality Living PSA should be the first step), the necessity to be cautious (before taking decisions both the qualitative and numerical results should be carefully analyzed), and the logical order for the implementation of PSA applications. Refs, figs, tabs

  12. Comparison of various methods to quantify a fault tree for Seismic PSA

    Energy Technology Data Exchange (ETDEWEB)

    Han, Sang Hoon; Park, Jin Hee; Kim, Dong San; Lim, Ho-Gon; Jang, Seung Cheol [KAERI, Daejeon (Korea, Republic of)

    2015-05-15

    Typically, quantification (evaluation of frequency) of a sequence in a PSA is performed by generating minimal cut sets and quantifying it using REA (Rare event approximation) or MCUB (Minimal cut upper bound) method. MCUB gives more exact value than REA. But, it is known that REA and MCUB method may produce very conservative value when a probability of each event is larger than 0.1 such as in seismic PSA. The PSA software AIMS-PSA and FTREX developed in KAERI use REA and MCUB method to quantify a PSA model. Thus, it is necessary to verify the quantification result for seismic PSA. There are several method/software available for the verification. ACUBE developed by EPRI quantifies the pre-generated minimal cut sets using BDD (binary decision diagram) method. FTeMC developed by KAERI is based on Monte Carlo method. FtBdd developed by KAERI is based on BDD, but it can be applied for small fault trees. In section 2, a simple example is provided to characterize various methods. The results of those methods are compared for a seismic PSA model. REA and MCUB may produce very conservative value for a seismic PSA model which includes events whose probabilities are large. It is not easy to get the exact value for every case. We should recognize the limitation of each method/software when analyzing the quantification results for PSA. To verify the results, a supporting analysis can be used using other software such as Monte Carlo method.

  13. Multiple antigen peptide dendrimer elicits antibodies for detecting rat and mouse growth hormone binding proteins

    OpenAIRE

    Aguilar, Roberto M.; Talamantes, Frank J.; Bustamante, Juan J.; Muñoz, Jesus; Treviño, Lisa R.; Martinez, Andrew O.; Haro, Luis S.

    2009-01-01

    The membrane-bound rat growth hormone receptor (GH-R) and an alternatively spliced isoform, the soluble rat GH binding protein (GH-BP), are comprised of identical N-terminal GH binding domains, however, their C-terminal sequences differ. Immunological reagents are needed to distinguish between the two isoforms in order to understand their respective roles in mediating the actions of GH. Accordingly, a tetravalent multiple antigen peptide (MAP) dendrimer with four identical branches of a C-ter...

  14. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes

    DEFF Research Database (Denmark)

    Hjertholm, Peter; Fenger-Grøn, Morten; Vestergaard, Mogens;

    2015-01-01

    Brugen af prostata-specifikt antigen (PSA) er mangedoblet i dansk almen praksis siden introduktionen i 1990’erne. Dansk Urologisk Selskab anbefaler brug af testen ved relevante symptomer og arvelig disposition, men ikke til screening. Alligevel varierer brugen af PSA-tests i almen praksis. Dette......-tests. Den mest testende fjerdedel af praksis brugte teksten 3,6 gange oftere end den mindst testende praksisgruppe. I den mest testende gruppe fik 76 % flere personer en biopsi af prostata og 37 % flere mænd blev diagnosticeret med prostatacancer sammenlignet med den mindst testende gruppe. Risikoen......,25 gange større i den mest testende gruppe sammenlignet med den mindst testende gruppe. Dødeligheden (mortaliteten) – både den over¬ordnede og den prostata-specifikke – var den samme i alle fire grupper. Resultaterne indikerer, at der er forskellig klinisk praksis for brugen af PSA-tests, og at forskellene...

  15. Prospective investigation of change in the prostate-specific antigens after various urologic procedures

    Directory of Open Access Journals (Sweden)

    Park SC

    2015-07-01

    Full Text Available Seung Chol Park,1 Yu Seob Shin,2 Li Tao Zhang,2 Dal Sik Kim,3 Sung Zoo Kim,4 Nam Cheol Park,5 Tai Young Ahn,6 Je Jong Kim,7 Sung Won Lee,8 Insuk So,9 Jong Kwan Park2,10,11 1Department of Urology, Wonkwang University School of Medicine and Hospital, Iksan, South Korea; 2Department of Urology, 3Department of Laboratory Medicine, 4Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University, Jeonju, 5Department of Urology, College of Medicine, Pusan National University Hospital, Busan, 6Department of Urology, College of Medicine, Ulsan University, Seoul, 7Department of Urology, College of Medicine, Korea University, Seoul, 8Department of Urology, Samsung Medical Center, College of Medicine, SungKyunkwan University, Seoul, 9Department of Physiology, College of Medicine, Seoul National University, Seoul, 10Research Institute of Clinical Medicine, Chonbuk National University, 11Biomedical Research Institute and Clinical Trial Center, Chonbuk National University Hospital, Jeonju, South KoreaPurpose: Prostate-specific antigen (PSA is the most important marker in the diagnosis and follow-up of patients with prostate cancer. The primary objective of this study was to evaluate the effect of various urologic procedures in prostatic area on serum free and total PSA levels.Subjects and methods: A series of 62 patients (8 after digital rectal examination [DRE], 12 after transrectal ultrasonography [TRUS], 11 after rigid cystoscopy, 13 after prostatic massage, 8 after TRUS-guided prostate biopsy, and 10 after transurethral resection of prostate [TURP] were enrolled in the study. Blood samples were taken from each patient before procedure and at 10, 30, 60, and 120 minutes after procedures.Results: Prostate massage, rigid cystoscopy, TURP, and TRUS-guided prostate biopsy caused statistically significant rise in total and free PSA levels in the serum. There was no significant increase in total and free PSA levels in the

  16. Predicting Gleason score using the initial serum total prostate-specific antigen in Black men with symptomatic prostate adenocarcinoma in Nigeria

    Directory of Open Access Journals (Sweden)

    Nnabugwu II

    2016-07-01

    Full Text Available Ikenna I Nnabugwu, Emeka I Udeh, Fredrick O Ugwumba, Francis O Ozoemena Urology Unit, Department of Surgery, College of Medicine, Enugu Campus, University of Nigeria, Enugu, Nigeria Background: Men of Black African descent are known to have the highest incidence of prostate cancer. The disease is also more aggressive in this group possibly due to biologically more aggressive tumor or late presentation. Currently, serum prostate-specific antigen (PSA assay plays a significant role in making the diagnosis of prostate cancer. However, the obtained value of serum PSA may not directly relate with the Gleason score (GS, a measure of tumor aggression in prostate cancer. This study explores the relationship between serum total PSA at presentation (iPSA and GS.Patients and methods: The iPSA of patients with histologically confirmed prostate cancer was compared with the obtained GS of the prostate biopsy specimens. The age of the patients at presentation and the prostate volumes were also analyzed with respect to the iPSA and GS. The data were analyzed retrospectively using IBM SPSS Version 20. Pearson correlation was used for numeric variables, whereas Fisher’s exact test was used for categorical variables. Significance was set at P≤0.05.Results: There were 205 patients from January 2010 to November 2013 who satisfied the inclusion criteria. iPSA as well as age at presentation and prostate volume were not found to significantly correlate with the primary Gleason grade, the secondary Gleason grade, or the GS. However, the presence of distant metastasis was identified to significantly correlate positively with GS.Conclusion: GS may not be confidently predicted by the iPSA. Higher iPSA does not correlate with higher GS and vice versa. Keywords: PSA, patient age, prostate volume, prostate adenocarcinoma, Gleason score

  17. Clinical value of ratio of f-PSA to t-PSA in the diagnosis of breast cancer%游离PSA/总PSA比值在乳腺癌诊断中的临床价值

    Institute of Scientific and Technical Information of China (English)

    曾晓华; 周洪伟; 余永康

    2004-01-01

    目的探讨血清游离前列腺特异抗原(f-PSA)/总前列腺特异抗原(t-PSA)比值对乳腺癌的诊断价值.方法用放射免疫法检测26例乳腺癌、67例乳腺增生和20例正常对照组的血清f-PSA、t-PSA,并计算f-PSA/t-PSA比值,评价其对乳腺癌的诊断价值.结果以f-PSA/t-PSA为0.15为判断上限时,其诊断敏感性为90.9%,特异性为87.5%,诊断准确性为88.6%,明显优于t-PSA和f-PSA单测结果.结论f-PSA/t-PSA比值有助于乳腺癌的诊断.

  18. Antiangiogenic VEGF Isoform in Inflammatory Myopathies

    Directory of Open Access Journals (Sweden)

    Nila Volpi

    2013-01-01

    Full Text Available Objective. To investigate expression of vascular endothelial growth factor (VEGF antiangiogenic isoform A-165b on human muscle in idiopathic inflammatory myopathies (IIM and to compare distribution of angiogenic/antiangiogenic VEGFs, as isoforms shifts are described in other autoimmune disorders. Subjects and Methods. We analyzed VEGF-A165b and VEGF-A by western blot and immunohistochemistry on skeletal muscle biopsies from 21 patients affected with IIM (polymyositis, dermatomyositis, and inclusion body myositis and 6 control muscle samples. TGF-β, a prominent VEGF inductor, was analogously evaluated. Intergroup differences of western blot bands density were statistically examined. Endomysial vascularization, inflammatory score, and muscle regeneration, as pathological parameters of IIM, were quantitatively determined and their levels were confronted with VEGF expression. Results. VEGF-A165b was significantly upregulated in IIM, as well as TGF-β. VEGF-A was diffusely expressed on unaffected myofibers, whereas regenerating/atrophic myofibres strongly reacted for both VEGF-A isoforms. Most inflammatory cells and endomysial vessels expressed both isoforms. VEGF-A165b levels were in positive correlation to inflammatory score, endomysial vascularization, and TGF-β. Conclusions. Our findings indicate skeletal muscle expression of antiangiogenic VEGF-A165b and preferential upregulation in IIM, suggesting that modulation of VEGF-A isoforms may occur in myositides.

  19. Importance of the multi-modules study in PSA

    International Nuclear Information System (INIS)

    The current approach that has taken the Probabilistic Safety Analysis (PSA) consists of doing all the APS analysis including the existence of multi-units in the nuclear power plants (NPP), this new approach seeks to analyze the risk of site, evaluating all reactors together. The main reasons for this trend are: the accident occurred on March 2011 in Fukushima Daiichi in Japan, with serious consequences in more than one reactor of the NPP and the current planning and construction of new Small Modular Reactors, which host more than one module on the same NPP and are connected to a single control room. This study analyzes how to model the risk of a multi-module NPP. In 2013, the ASME/ANS standard for advanced reactors that are not light-water reactors was published, in which the requirements to realize a PSA including multi-units or modules are shown; however, does not describe the methodology to do that. This article presents a methodology to calculate the risk of the site in a PBMR plant with two modules. This methodology consists of two models of trees of different events, one that evaluates to a single PBMR module and another that evaluates the two modules together. Both models are responsible to show their differences and compare results to finally demonstrate the need for new methodologies for risk analysis site in multi-modules and units. (Author)

  20. PSA based plant modifications and back-fits

    International Nuclear Information System (INIS)

    The mandate of Principal Working Group No. 5 - Risk Assessment states that 'The group should deal with the technology and methods for identifying contributors to risk and assessing their importance, and appropriate exchanges of information on current research'. Since being formulated in 1982, along with this mandate, the group has also endeavored to develop a common understanding of the different approaches taken in risk assessment. The focus of this report is to provide knowledge to experts on the role Probabilistic Safety Assessment (PSA) has had in safety decision making. PSA is a powerful tool for improving Nuclear Power Plant safety by identifying weaknesses in design or operation and setting priorities for plant modifications and back-fits. While the use is well recognised, it is also true that any safety decision is generally based on several elements, both probabilistic and deterministic. This document provides a general overview of insights gained from the representative set of examples collected from Member countries (Finland, France, Germany, Japan, Korea, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States). The report starts with basic types of plant modifications which were carried out (e.g. hardware or software, important or minor, etc.) and the characteristics of the PSAs used in the examples (e.g. level and scope, specific or generic, on-going or terminated, etc.). The insights gained from this small collection are then reviewed. The appendix gives a full text version of the Member country contributions

  1. Development of a PSA workstation for operational safety management

    International Nuclear Information System (INIS)

    This paper describes several efforts for the development of PSA(Probabilistic Safety Assessment) Workstation in KAERI (Korea Atomic Energy Research Institute) to manage operational safety of Nuclear Power Plants (NPPs); (1) development of PSA modeling tool, KIRAP, (2) development of a risk monitor, Risk Monster, (3) development of plant information system, EPIS, (4) development of reliability centered maintenance(RCM) tool, RAM-Pro. KIRAP supplies fault tree(FT) editor, quantification engine (Kcut), event tree(ET) editor, and database management tool(KwDBMan) in Window environment. Risk Monster supports for plant operators and maintenance schedulers to monitor plant risk and to avoid high peak risk by rearranging maintenance work schedule. EPIS (Electro Plant Information System) supplies plant information related to components such as equipment list and specification, maintenance work history data, preventive maintenance (PM) items list, spare parts information, technical specification information, design change information, and P and ID, etc. RAM-Pro help RCM by providing maintenance history data management (RAM-Hist), reliability analyzer (RAM-Rel), and RAM-RCM which are used for FFA(Functional Failure Analysis), FMEA(Failure Mode Effect Analysis) and LTA(Logical Tree Analysis) in RCM. (author)

  2. PSA based vulnerability and protectability analysis for NPPs

    International Nuclear Information System (INIS)

    Highlights: ► The paper describes the generation of location sets and protection sets. ► Vulnerability and protectability used to rank location sets and protection sets. ► Ranking helps in adequacy of protection measures employed in various locations. ► The procedure for PSA based vital area identification is demonstrated. ► This method has found practical applicability for Indian NPP. -- Abstract: Identification of vital areas in a facility involves assessing the facility and the locations, whose sabotage can result in undesirable (radiological) consequences. Probabilistic Safety Assessment (PSA) technique can find the component failures leading to core damage (a surrogate for radiological consequence) in a systematic manner, which can be extended to identification of vital areas. This paper describes the procedure for the generation of location sets (set of locations whose sabotage can lead to possible core damage) and protection sets (set of locations that must be protected to prevent possible core damage). In addition, measures such as vulnerability and protectability have been introduced, which can be used to rank location sets and protection sets.

  3. PSA results for Hanford high level waste Tank 101-SY

    International Nuclear Information System (INIS)

    Los Alamos National Laboratory has performed a comprehensive probabilistic safety assessment (PSA) that includes consideration of external events for the weapons-production wastes stored in tank number 241-SY-101, commonly known as Tank 101-SY, as configured in December 1992. This tank, which periodically releases (''burps'') a gaseous mixture of hydrogen, nitrous oxide, ammonia, and nitrogen, was analyzed because of public safety concerns associated with the potential for release of radioactive tank contents should this gas mixture be ignited during one of the burps. In an effort to mitigate the burping phenomenon, an experiment is underway in which a large pump has been inserted into the tank to determine if pump-induced circulation of the tank contents will promote a slow, controlled release of the gases. This PSA for Tank 101-SY, which did not consider the pump experiment or future tank-remediation activities, involved three distinct tasks. First, the accident sequence analysis identified and quantified those potential accidents whose consequences result in tank material release. Second, characteristics and release paths for the airborne and liquid radioactive source terms were determined. Finally, the consequences, primarily onsite and offsite potential health effects resulting from radionuclide release, were estimated, and overall risk curves were constructed. An overview of each of these tasks and a summary of the overall results of the analysis are presented in the following sections

  4. Interoperability In The New Planetary Science Archive (PSA)

    Science.gov (United States)

    Rios, C.; Barbarisi, I.; Docasal, R.; Macfarlane, A. J.; Gonzalez, J.; Arviset, C.; Grotheer, E.; Besse, S.; Martinez, S.; Heather, D.; De Marchi, G.; Lim, T.; Fraga, D.; Barthelemy, M.

    2015-12-01

    As the world becomes increasingly interconnected, there is a greater need to provide interoperability with software and applications that are commonly being used globally. For this purpose, the development of the new Planetary Science Archive (PSA), by the European Space Astronomy Centre (ESAC) Science Data Centre (ESDC), is focused on building a modern science archive that takes into account internationally recognised standards in order to provide access to the archive through tools from third parties, for example by the NASA Planetary Data System (PDS), the VESPA project from the Virtual Observatory of Paris as well as other international institutions. The protocols and standards currently being supported by the new Planetary Science Archive at this time are the Planetary Data Access Protocol (PDAP), the EuroPlanet-Table Access Protocol (EPN-TAP) and Open Geospatial Consortium (OGC) standards. The architecture of the PSA consists of a Geoserver (an open-source map server), the goal of which is to support use cases such as the distribution of search results, sharing and processing data through a OGC Web Feature Service (WFS) and a Web Map Service (WMS). This server also allows the retrieval of requested information in several standard output formats like Keyhole Markup Language (KML), Geography Markup Language (GML), shapefile, JavaScript Object Notation (JSON) and Comma Separated Values (CSV), among others. The provision of these various output formats enables end-users to be able to transfer retrieved data into popular applications such as Google Mars and NASA World Wind.

  5. A Tsunami PSA for Nuclear Power Plants in Korea

    International Nuclear Information System (INIS)

    For the evaluation of safety of NPP caused by Tsunami event, probabilistic safety assessment (PSA) method was applied in this study. At first, an empirical tsunami hazard analysis performed for an evaluation of tsunami return period. A procedure for tsunami fragility methodology was established, and target equipment and structures for investigation of Tsunami Hazard assessment were selected. A several fragility calculations were performed for equipment in Nuclear Power Plant and finally accident scenario of tsunami event in NPP was presented. Finally, a system analysis performed in the case of tsunami event for an evaluation of a CDF of Ulchin 56 NPP site. For the evaluation of safety of NPP caused by Tsunami event, probabilistic safety assessment (PSA) method was applied. A procedure for tsunami fragility methodology was established, and target equipment and structures for investigation of Tsunami Hazard assessment were selected. A several fragility calculations were performed for equipment in Nuclear Power Plant and finally accident scenario of tsunami event in NPP was presented. As a result, in the case of tsunami event, functional failure is mostly governed total failure probability of facilities in NPP site

  6. Value of contrast-enhanced sonographic micro flow imaging for prostate cancer detection with t-PSA level of 4-10 ng/mL

    Energy Technology Data Exchange (ETDEWEB)

    Guo, Yi-Fen, E-mail: guoyifen@gmail.com [Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127 (China); Li, Feng-Hua, E-mail: li_fenghua3211@163.com [Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127 (China); Xie, Shao-Wei, E-mail: shaoweixie@yahoo.cn [Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127 (China); Xia, Jian-Guo, E-mail: doctorxiajg@yahoo.com.cn [Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127 (China); Fang, Hua, E-mail: huafang12@126.com [Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127 (China); Li, Hong-Li, E-mail: lihliwl@163.com [Department of Ultrasound, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 1630 Dongfang Rd., Shanghai 200127 (China)

    2012-11-15

    Objectives: To compare the efficiency of contrast-enhanced ultrasonographic micro flow imaging (MFI) with conventional transrectal ultrasound (TRUS) in detecting prostate cancer with serum total prostate-specific antigen (t-PSA) of 4.0-10.0 ng/mL. To evaluate the value of contrast-enhanced ultrasonographic MFI in detecting prostate cancer with t-PSA in diagnostic gray zone. Methods: 47 patients with t-PSA 4.0-10.0 ng/mL underwent gray scale, power Doppler TRUS and MFI examinations before ultrasound guided biopsies. Biopsies were performed at twelve sites in the base, the mid-gland and the apex of the prostate in each patient, when there was no abnormal ultrasound finding. When an abnormality was present at MFI, the biopsy specimen from the corresponding site was directed toward the abnormal finding. With histological results of prostate biopsy as reference standards, we assessed the cancer detection of these three methods. Results: 564 specimens were collected in this study, in which 101 were prostate cancer confirmed histologically. 152 of 564 specimens were demonstrated abnormal on MFI images, in which 71 were malignant and 81 were benign confirmed histologically. The sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) for MFI in detecting prostate caner were 70.3%, 82.5%, 80.3%, 46.7% and 92.7%, respectively. The sensitivity and NPV for MFI were significantly better than gray scale (38.6%, 86.9%) and power Doppler (32.7%, 86.0%) (P < 0.001) TRUS. Conclusions: Contrast-enhanced ultrasonographic MFI could significantly improve the detection rate of prostate cancer with t-PSA in diagnostic gray zone (4-10 ng/mL) than conventional ultrasound.

  7. Treatment Outcomes in Non-Metastatic Prostate Cancer Patients With Ultra-High Prostate-Specific Antigen

    International Nuclear Information System (INIS)

    Purpose: It is commonly believed that prostate cancer patients with very high prostate-specific antigen (PSA) levels are unlikely to benefit from definitive local treatment, and patients with very high PSA are often underrepresented in, or excluded from, randomized clinical trials. Consequently, little is known about their optimal treatment or prognosis. We performed a registry-based analysis of management and outcome in this population of patients. Methods and Materials: Our provincial Cancer Registry was used to identify all men who were diagnosed with prostate cancer from 1990 to 2001. A retrospective chart review provided information on stage, Gleason score, PSA at diagnosis, and treatment. In this study, ultra-high PSA was defined as PSA of ≥50 ng/ml. For a more complete perspective, treatment outcomes of patients with PSA of 20 to 49.9 ng/ml were also studied. Results: Of the 8378 men diagnosed with prostate cancer during this period, 6,449 had no known nodal or distant metastatic disease. The median follow-up of this group was 67.2 months (range, 0–192 months). A total of 1534 patients had PSA of ≥20 ng/ml. Among the 995 patients with PSA 20 to 49.9 ng/ml, 85 had radical prostatectomy (RP), and their 5- and 10-year cause-specific survivals (CSS) were 95% and 84%, respectively. The 497 patients treated with radiotherapy (RT) had 5- and 10-year CSS of 92% and 71%. For the 332 patients with PSA 50–99.9 ng/ml, RT was associated with 5- and 10-year CSS of 81% and 55%. For the 207 patients with PSA of ≥100 ng/ml, RT was associated with 5- and 10-year CSS of 80% and 54%. Conclusions: This is the largest series in the world on non metastatic cancer patients with ultra-high PSA at diagnosis. Even in the setting of a very high presenting PSA level, prostatectomy and radiotherapy are often associated with prolonged survival.

  8. Development of a Review Guide for a Level-3 PSA of Nuclear Power Plants

    International Nuclear Information System (INIS)

    A probabilistic safety assessment (PSA) provides a systematic analysis to identify and quantify all the risks that a plant imposes to the operators, general public and the environment. The main benefits of a PSA is to provide insights into the safety aspects of a plant design, performance, and the potential environmental impacts of postulated accidents, including the identification of dominant risk contributors, and a comparison of the options for reducing a risk. Among the three levels of a PSA, a Level-3 PSA provides insights into the relative importance of a accident prevention and mitigative measures expressed in terms of the adverse consequences for the health of the public, and the contamination of land, air, water, and foodstuffs. Finally, a Level-3 PSA provides insights into the relative effectiveness of emergency response planning aspects of an off-site accident management, and into the economic impacts. Regulatory bodies are generally responsible for the specification of safety criteria which can be related to PSAs at Level-1, -2, and -3. Examples of these criteria are the frequency of a severe core damage for a Level-1, and the frequency of large releases of radionuclides for a Level-2 PSA. The most commonly used Level-3 related safety criteria are early and cancer fatality risks. The regulatory body in Korea has developed the review guides for the Level-1 and -2 PSA. And the current regulatory structure for the licensing of nuclear power plants is established for an LWR-oriented structure. However, the accomplishment of a Level-3 PSA as well as Level-1 and -2 PSA is necessary in order to establish the risk-informed and performance-based regulatory structure for the licensing of future nuclear power plants. In such a situation, the need for the accomplishment of a Level-3 PSA is increasing. Therefore, the main goal of this study is to develop a review guide for the Level-3 PSA

  9. An analysis of pretreatment characteristics and the risk of PSA failure by race and ethnicity in prostate cancer patients treated with definitive radiotherapy

    International Nuclear Information System (INIS)

    Purpose/Objective: This study was performed to: (1) determine the pretreatment characteristics of racially and ethnically diverse men who were treated with definitive radiotherapy for prostate cancer and; (2) to assess whether race or ethnicity is an independent prognostic factor for biochemical failure using the serum PSA (prostate specific antigen) as a marker of disease free status. Materials and Methods: Between 1987 and 1995, 505 men, (including 487 with pretreatment PSA determined), were treated with radiotherapy for adenocarcinoma of the prostate in the Department of Radiation Oncology at the UCSF or its affiliated hospitals and form the basis of this analysis. These patients were referred from local VA, County, HMO and private facilities in the Northern California Bay Area and represent a diverse group by race, ethnicity and social economic status. PSA failure was defined as a PSA >1.0 ng/ml or rises of ≥ 0.5 ng/ml in 1 year. Results: The median PSA for all patients was 11.5 ng/ml and the mean was 20.8 ng/ml. The mean Gleason score was 5.95, and was similar among treatment groups. Twenty percent of the patients were T1, 56% were T2 and 24% were T3/4. The maximum dose at depth (Dmax) was 71.5 in 42% of the patients. Seventy two men (14%) received neoadjuvant +/- adjuvant hormonal therapy combined with radiotherapy. With a median follow-up exceeding 2 years, 47% of the patients are disease free at 4 years. Major pretreatment characteristics by race or ethnicity are summarized below: On univariate analysis, the relative risk of PSA failure in Blacks compared to Whites was 1.04 (95% confidence interval, 0.72- 1.52, p = 0.82) and in others compared to Whites was 1.12 (95% confidence interval, 0.55 - 2.28, p = 0.77). On multivariate analysis, neither race nor ethnicity were independently significant predictors of outcome. For example, the relative risk of PSA failure in Blacks was 0.88 (95% confidence interval, 0.59 - 1.32, p = 0.53). Factors that influenced

  10. Radionuclide Bone Scan Combined with PSA, fPSA and fPSA/tPSA Ratio for Assessment of Prostatic Cancer Patients with Bone Metastasis%放射性核素骨显像联合PSA、fPSA、fPSA/tPSA评价前列腺癌骨转移

    Institute of Scientific and Technical Information of China (English)

    赵辉; 安建平; 徐晓红; 王晶

    2011-01-01

    Objective To assess the value of radionuclide bone scan combined with PSA, fPSA and fPSA/tPSA for diagnosis prostatic cancer with hone metastasis. Methods Serum levels of PSA, fPSA and fPSA/tPSA ratio were detemined in ① 35 prostatic cancer patients with definite bone metastasis lesions shown on radionucfide bone scan, ② 35 prostatic cancer patients without bone metastasis, ③ 30 patients with benign prostatic disorders and ④ 35 controls. Results The serum tumor markers levels in patients with osseous metastasis were significantly higher than those in the other three groups ( P <0.01 ). Among them,the levels in patients with more then 2 bone lesions were significantly higher than those in patients with only one or two bone lesions ( P < 0. 01 ). The serum tumor markers levels in patients without osseous metastasis were only significantly higher than those in patients with benign prostatic disorders and controls. The sensitivity of fPSA/tPSA ratio < 0.2 was highest ( 85.7%), but specificity lower ( 45.71%). The sensitivity combining tPSA/tPSA ratio and radionuclide bone scan ( ≤2 ) was lowest ( 62. 9%), but specificity was highest ( 77.14%). Conclusion PSA, fPSA and tfSA/tPSA ratio were related with osseous metastasis from prostatic cancer. Combining them was increase on diagnosis the osseous metastasis of prostatic cancer and is a valuable scheme for early detection of skeletal metastasis of prostatic cancer, especially when the results of bone scanning is equivocal. Detemination of the serum tumor markers levels would be helpful for dynamic monitoring of the extent of metastasis.%目的:评价前列腺癌患者放射性核素骨显像与血清前列腺特异抗原测定的诊断价值.方法:随机选择前列腺癌患者骨显像示骨转移与骨显像正常患者各35例,前列腺良性病患者30例及健康体检者35例,分别测定其血清中PSA、fPSA、fPSA/tPSA的含量.结果:前列腺癌无骨转移组PSA、fPSA水平较对照

  11. Ikaros isoforms:The saga continues

    Institute of Scientific and Technical Information of China (English)

    Laura; A; Perez-Casellas; Aleksandar; Savic; Sinisa; Dovat

    2011-01-01

    Through alternate splicing,the Ikaros gene produces multiple proteins.Ikaros is essential for normal hematopoiesis and possesses tumor suppressor activity.Ikaros isoforms interact to form dimers and potentially multimeric complexes.Diverse Ikaros complexes produced by the presence of different Ikaros isoforms are hypothesized to confer distinct functions.Small dominantnegative Ikaros isoforms have been shown to inhibit the tumor suppressor activity of full-length Ikaros.Here,we describe how Ikaros activity is regulated by the coordinated expression of the largest Ikaros isoforms IK-1 and IK-H.Although IK-1 is described as full-length Ikaros,IK-H is the longest Ikaros isoform.IK-H,which includes residues coded by exon 3B (60 bp that lie between exons 3 and 4),is abundant in human but not murine hematopoietic cells.Specific residues that lie within the 20 amino acids encoded by exon 3B give IK-H DNA-binding characteristics that are distinct from those of IK-1.Moreover,IK-H can potentiate or inhibit the ability of IK-1 to bind DNA.IK-H binds to the regulatory regions of genes that are upregulated by Ikaros,but not genes that are repressed by Ikaros.Although IK-1 localizes to pericentromeric heterochromatin,IK-H can be found in both pericentromeric and non-pericentromeric locations.Anti-silencing activity of gamma satellite DNA has been shown to depend on the binding of IK-H,but not other Ikaros isoforms.The unique features of IK-H,its influence on Ikaros activity,and the lack of IK-H expression in mice suggest that Ikaros function in humans may be more complex and possibly distinct from that in mice.

  12. Our Prostate Biopsy Results in The Patients with Prostate Specific Antigen Levels Below 4 ng/ml

    Directory of Open Access Journals (Sweden)

    Huseyin Aydemir

    2014-03-01

    Full Text Available Aim: The aim of this study is to evaluate the re¬sults of prostate biopsy of patients who had the prostate-specific antigen (PSA levels below 4 ng/ml. Material and Method: The medical records of 524 pa¬tients who underwent transrectal prostate biopsy be¬tween January 2010 and February 2013 in our clinic, due to suspi¬cion of prostate cancer were evaluated and histopathologic results of 43 patients whose PSA levels under 4 ng/ml were retrospectively revieved. Results: The mean age of patients was 64.63 ±7:42 and the mean level of PSA was 2.89 ±0.88ng /ml. A digital rectal examination (DRE had suspicious findings in 41(95.34% patients. Prostate adenocarcinoma was determined in 13 of (30.23% patients according to the biopsy result. The mean PSA value of these patients was 2.89 ±0.88 ng/ml and the mean gleason score of these patients was 6.41 ±0.87. The mean prostate volume of these patients was 41.46 ±11.95 cm3. Discussion: In our study, prostate cancer was identified in 30.3% of patients whose PSA levels were below 4 ng/ml. DRE, is still important for the evaluation of the prostate. According to our results, significant number of cancers can be detected in PSA below 4 ng/ml levels.

  13. The RFA regulatory sequence-binding protein in the promoter of prostate-specific antigen gene

    Institute of Scientific and Technical Information of China (English)

    2003-01-01

    To assure what sequence associated with the androgen regulation, a 15 bp region at the upstream of the ARE of prostate-specific antigen (PSA) promoter, termed RFA, was found indispensable for androgen receptor (AR)-mediated transactivation of PSA promoter. In transfection and CAT assays, some nucleotides substitution in RFA could significantly decrease the androgen inducibility for PSA promoter. The in vitro DNA binding assay demonstrated that RFA bound specifically with some non-receptor protein factors in prostate cell nucleus, but the mutant type of RFA lost this ability, so RFA might be a novel accessory cis-element. The RFA-binding proteins were isolated and purified by affinity chromatography using RFA probes. SDS-PAGE and preliminary protein identification showed these proteins possessed sequence high homology with multifunctional protein heterogeneous nuclear ribonucleoprotein A1, A2 (hnRNP A1, A2). RFA-binding proteins possibly cooperate with AR-mediated transactivation for PSA promoter as coactivator. The study results will facilitate further understanding the mechanism and tissue specificity of PSA promoter.

  14. Routine PSA Testing: An Analysis of the Controversy Concerning Its Use

    Directory of Open Access Journals (Sweden)

    Namath S. Hussain

    2005-01-01

    Full Text Available Prostate cancer is the leading cause of cancer in American males today. PSA screening has been used for over 10 years as an important diagnostic tool for the disease. Because of its lack of sensitivity and specificity, however, PSA testing should be used with caution.

  15. Review of UCN 5,6 Fire PSA Model based on ANS Fire PRA Standard

    Energy Technology Data Exchange (ETDEWEB)

    Yang, Joon Eon; Lee, Yoon Hwan

    2006-12-15

    Recently, under the de-regulation environment, nuclear industry has attempted various approaches to improve the economics of Nuclear Power Plants (NPP). This approach uses the fire risk and performance information to manage the resources effectively and efficiently that are used in the operation of NPP. In fire risk informed/performance-based decision/operation, fire PSA quality is one of the most important things. The nuclear industry and regulatory body of U.S.A have developed a measure to evaluate the quality of fire PSA. ANS (American Nuclear Society) has developed a guidance called 'ANS Fire PRA Methodology Standard'. However, in Korea, there have been no attempts to evaluate the quality of fire PSA model itself. Therefore, we cannot be sure about the quality of fire PSA whether or not the present fire PSA model can be used for the risk-informed applications such as mentioned above. We can say that the evaluation of fire PSA model quality is the basis for the fire risk informed/performance-based decision/operation. In this report, we have evaluated the quality of fire PSA model for Ulchin 5 and 6 units based on the ANS Fire PRA Standard. We, also, have derived what items are to be improved to upgrade the quality of fire PSA model and how it can be improved. This report can be used as the base of the fire risk informed/performance-based decision/operation work in Korea.

  16. Human actions treatment in the Juragua NPP pre-operational PSA

    International Nuclear Information System (INIS)

    The human reliability analysis is an important part of the Probabilistic Safety Analysis (PSA). Because Juragua NPP PSA has been accomplished during construction stage of the plant, no specific operational procedures nor experience for human reliability analysis task taking into account the worlds current methodologies in this field and the actual situation of the plant. This papers describes the approach we followed

  17. Distribution of PSA-NCAM in normal, Alzheimer's and Parkinson's disease human brain.

    Science.gov (United States)

    Murray, Helen C; Low, Victoria F; Swanson, Molly E V; Dieriks, Birger V; Turner, Clinton; Faull, Richard L M; Curtis, Maurice A

    2016-08-25

    Polysialated neural cell adhesion molecule (PSA-NCAM) is a membrane bound glycoprotein widely expressed during nervous system development. While commonly described in the neurogenic niches of the adult human brain, there is limited evidence of its distribution in other brain regions. PSA-NCAM is an important regulator of cell-cell interactions and facilitates cell migration and plasticity. Recent evidence suggests these functions may be altered in neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD). This study provides a detailed description of the PSA-NCAM distribution throughout the human brain and quantitatively compares the staining load in cortical regions and sub-cortical structures between the control, AD and PD brain. Our results provide evidence of widespread, yet specific, PSA-NCAM expression throughout the human brain including regions devoid of PSA-NCAM in the rodent brain such as the caudate nucleus (CN) and cerebellum (CB). We also detected a significant reduction in PSA-NCAM load in the entorhinal cortex (EC) of cases that was inversely correlated with hyperphosphorylated tau load. These results demonstrate that PSA-NCAM-mediated structural plasticity may not be limited to neurogenic niches and is conserved in the aged brain. We also provide evidence that PSA-NCAM is reduced in the EC, a region severely affected by AD pathology. PMID:27282086

  18. Network commercials promote legal drugs: outnumber anti-drug PSA's 45-to-1.

    Science.gov (United States)

    Fedler, F; Phillips, M; Raker, P; Schefsky, D; Soluri, J

    1994-01-01

    During the week of September 16 to 22, 1990, commercials promoting drugs and alcohol outnumbered the networks' news stories, documentaries, and PSA's about illegal drugs by a ratio of almost 39-to-1. If you consider the PSA's alone, the commercials promoting drugs and alcohol outnumbered them by a ratio of almost 45-to-1. PMID:7869221

  19. Review of UCN 5,6 Fire PSA Model based on ANS Fire PRA Standard

    International Nuclear Information System (INIS)

    Recently, under the de-regulation environment, nuclear industry has attempted various approaches to improve the economics of Nuclear Power Plants (NPP). This approach uses the fire risk and performance information to manage the resources effectively and efficiently that are used in the operation of NPP. In fire risk informed/performance-based decision/operation, fire PSA quality is one of the most important things. The nuclear industry and regulatory body of U.S.A have developed a measure to evaluate the quality of fire PSA. ANS (American Nuclear Society) has developed a guidance called 'ANS Fire PRA Methodology Standard'. However, in Korea, there have been no attempts to evaluate the quality of fire PSA model itself. Therefore, we cannot be sure about the quality of fire PSA whether or not the present fire PSA model can be used for the risk-informed applications such as mentioned above. We can say that the evaluation of fire PSA model quality is the basis for the fire risk informed/performance-based decision/operation. In this report, we have evaluated the quality of fire PSA model for Ulchin 5 and 6 units based on the ANS Fire PRA Standard. We, also, have derived what items are to be improved to upgrade the quality of fire PSA model and how it can be improved. This report can be used as the base of the fire risk informed/performance-based decision/operation work in Korea

  20. Systems Pharmacology Modeling of Prostate‐Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down‐Regulator

    Science.gov (United States)

    Mistry, HB; Young, J; Clack, G; Dickinson, PA

    2016-01-01

    First‐in‐human (FIH) studies with AZD3514, a selective androgen receptor (AR) down‐regulator, showed decreases of >30% in the prostate‐specific antigen (PSA) in some patients. A modeling approach was adopted to understand these observations and define the optimum clinical use hypothesis for AZD3514 for clinical testing. Initial empirical modeling showed that only baseline PSA correlated significantly with this biological response, whereas drug concentration did not. To identify the mechanistic cause of this observation, a mechanism‐based model was first developed, which described the effects of AZD3514 on AR protein and PSA mRNA levels in LNCaP cells with and without dihydrotestosterone (DHT). Second, the mechanism‐based model was linked to a population pharmacokinetic (PK) model; PSA effects of clinical doses were subsequently simulated under different clinical conditions. This model was used to adjust the design of the ongoing clinical FIH study and direct the backup program. PMID:27299938

  1. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir

    International Nuclear Information System (INIS)

    Patients with early stage prostate cancer have a variety of curative radiotherapy options, including conventionally-fractionated external beam radiotherapy (CF-EBRT) and hypofractionated stereotactic body radiotherapy (SBRT). Although results of CF-EBRT are well known, the use of SBRT for prostate cancer is a more recent development, and long-term follow-up is not yet available. However, rapid post-treatment PSA decline and low PSA nadir have been linked to improved clinical outcomes. The purpose of this study was to compare the PSA kinetics between CF-EBRT and SBRT in newly diagnosed localized prostate cancer. 75 patients with low to low-intermediate risk prostate cancer (T1-T2; GS 3 + 3, PSA < 20 or 3 + 4, PSA < 15) treated without hormones with CF-EBRT (>70.2 Gy, <76 Gy) to the prostate only, were identified from a prospectively collected cohort of patients treated at the University of California, San Francisco (1997–2012). Patients were excluded if they failed therapy by the Phoenix definition or had less than 1 year of follow-up or <3 PSAs. 43 patients who were treated with SBRT to the prostate to 38 Gy in 4 daily fractions also met the same criteria. PSA nadir and rate of change in PSA over time (slope) were calculated from the completion of RT to 1, 2 and 3 years post-RT. The median PSA nadir and slope for CF-EBRT was 1.00, 0.72 and 0.60 ng/ml and -0.09, -0.04, -0.02 ng/ml/month, respectively, for durations of 1, 2 and 3 years post RT. Similarly, for SBRT, the median PSA nadirs and slopes were 0.70, 0.40, 0.24 ng and -0.09, -0.06, -0.05 ng/ml/month, respectively. The PSA slope for SBRT was greater than CF-EBRT (p < 0.05) at 2 and 3 years following RT, although similar during the first year. Similarly, PSA nadir was significantly lower for SBRT when compared to EBRT for years 2 and 3 (p < 0.005). Patients treated with SBRT experienced a lower PSA nadir and greater rate of decline in PSA 2 and 3 years following completion of RT than with CF-EBRT, consistent

  2. Multi-span transmission using phase and amplitude regeneration in PPLN-based PSA.

    Science.gov (United States)

    Umeki, T; Asobe, M; Takara, H; Miyamoto, Y; Takenouchi, H

    2013-07-29

    We demonstrated multi-span transmission using a periodically poled LiNbO(3) (PPLN) based phase sensitive amplifier (PSA). An in-line PSA with a carrier recovery and phase locking system is implemented as a repeater amplifier in a recirculating loop. We achieved a PSA gain as high as + 18 dB and a high external gain of + 12 dB for the in-line PSA as a black box. The impairments caused by phase noise resulting from fiber nonlinearity and intensity noise caused by the amplified spontaneous emission (ASE) of an optical amplifier are largely suppressed using the phase and amplitude regeneration capabilities of the PSA. The ultra long-haul transmission of a 28-Gb/s binary phase shift keying (BPSK) signal over 5400 km was achieved with phase and amplitude regeneration.

  3. Updating of Initiating Events Frequencies in the UCN 3,4 PSA

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Kil Yoo; Kang, D. I.; Park, J. H.; Yang, J. E

    2005-03-15

    As the Risk Informed Regulation and Applications (RIR and A) becomes popular in the nuclear power plants, it is required that the better quality of PSA should be used in the RIR and A. Thus, for the evaluation of PSA models, ASME PSA standard or NEI PSA peer review guide was prepared. To improve the PSA of Korean Standard Nuclear Power Plants(KSNP), the frequencies of initiating events for UCN 3 and 4 were updated reflecting the new operating experience of the domestic and foreign countries, and the unsatisfactory previous methods in deriving the initiating events frequencies were upgraded. The new frequencies of initiating events for UCN 3 and 4 were updated based on NUREG/CR-5750's methodology and data, reflecting the new operating experience of the domestic nuclear plants. The new initiating events generates a little bit smaller CDF for UCN 3 and 4.

  4. Clinical Analysis of Combined Examination of Bone Scan and Serum PSA in the Diagnosis and Treatment of Prostate Carcinoma%PSA和SPECT骨显像在前列腺癌诊断治疗中的意义

    Institute of Scientific and Technical Information of China (English)

    李斌; 张海滨; 廖黎黎

    2011-01-01

    Objective:To analysis of the combined detection of radionuclide bone imaging and plasma levels of prostate specific antigen (PSA) in patients with prostate cancer. Methods: Measure the serum PSA level and conduct bone scan on all the 100 patients that had been diagnosed as prostatic cancer. Results:81 percent of patients with prostate cancer had skeleton metastasis,when PSA ≥20 μg/L ,60 percent of patients with prostate cancer had skeleton metastasis. Conclusions:The combined detection of radiouclide bone imaging and the serum PSA levels would play an important role in clinical diagnosis of bone metastases for patients with prostate cancer.%目的:研究PSA、SPECT骨显像在前列腺癌诊断及治疗中的临床意义.方法:对100例经临床确诊的前列腺癌患者全部行血清PSA测定及全身骨显像.结果:发生骨转移的患者为81%,PSA≥20 μg/L的患者发生骨转移的为60%.结论:血清PSA与骨显像联检对前列腺癌临床诊断、疗效观察及预后判定具有重要的指导意义.

  5. Lessons learnt from PSA for new and advanced reactors in Russia

    International Nuclear Information System (INIS)

    Customer requirements to probabilistic safety targets are usually stronger than existing Regulatory or IAEA ones. It appears that industry takes the lead over regulation in this case and forces the designer to find and implement appropriate means to enhance safety, which sometimes have no reference to practical experience. On the other hand, regulatory documents and the existing PSA methodology are mainly oriented to operating plants. This creates problems when developing a PSA as well as performing regulatory reviews. The scope of the PSA may be different depending on a design stage such as the development conceptual, basic or detailed design. In addition, the base case PSA is usually performed for NPP in design. However, a customer may require additional PSA applications to consider, for instance, risk monitoring. In this case the scope of the PSA should be extended to implement special attributes of the application needed that often requires specific information not available at the design stage. Lack of design information affecting PSA development may be associated with incompleteness of the design that is typical for interim design stages and communication problems caused by the involvement of many different companies in the deign activity. To deal with this issue bounding technologies and the iterative PSA development are used. However this sometimes contradicts to the ''best estimate'' approach recommended by regulatory guides. PSA development for advanced NPPs has raised some issues originated from unknown new components, processes and technologies incorporated into the design of an advanced plant. The paper addresses some issues resolved while carrying out PSAs for advanced NPPs. Some PSA results for new advanced VVER plants under construction and the first lessons learnt from the Fukushima accident are also discussed. (orig.)

  6. New isoforms of rat Aquaporin-4

    DEFF Research Database (Denmark)

    Moe, Svein Erik; Sorbo, Jan Gunnar; Søgaard, Rikke;

    2008-01-01

    an intracellular localization when expressed in cell lines and do not transport water when expressed in Xenopus oocytes. In contrast, the largest of the new isoforms, AQP4e, which contains a novel N-terminal domain, is localized at the plasma membrane in cell lines and functions as a water transporter in Xenopus...

  7. p53 isoforms change p53 paradigm

    OpenAIRE

    Bourdon, JC

    2014-01-01

    Although p53 defines cellular responses to cancer treatment it is not clear how p53 can be used to control cell fate outcome. Data demonstrate that so-called p53 does not exist as a single protein, but is in fact a group of p53 protein isoforms whose expression can be manipulated to control the cellular response to treatment.

  8. Flooding risk reduction for the ASCO NPP PSA

    International Nuclear Information System (INIS)

    Developed within the framework of the UTE (INITEC-INYPSA-Empresarios Agrupados), the Probabilistic Safety Analysis (PSA) of the Asco Nuclear Power Plant has served both as a basic tool in reducing the risk of potential internal flooding at the plant, and as a guideline for studying the optimization and feasibility of necessary plant design modifications and changes to procedures. During execution of the work, and in view of the results, a series of improvements were proposed which gave rise to design modification studies. The paper seeks to describe the effect of these modifications on reducing core damage frequency, it also includes a general description of the methodology used. Finally, it compares the results obtained in the context of similar studies performed in other PSAs. (author)

  9. The influence of seasonal characteristics in the level-3 PSA

    International Nuclear Information System (INIS)

    The variation of health effects and economic consequences resulting from the severe accidents of the YGN 3 and 4 nuclear power plants was examined for various combinations of source term release parameters and meteorological data. The release parameters and meteorological data considered in making basic scenarios are release height, heat content, release time, warning time, wind speed, rainfall rate, and atmospheric stability class. The seasonal scenarios were also made in order to estimate the seasonal variation of health effects and economic consequences by considering seasonal characteristics of Korea. According to the results, there are large differences in health effects and economic consequences from scenario to scenario although an equal amount of radioactive materials is released to the atmosphere. Also, there are large differences in health effects and economic consequences from season to season due to distinct seasonal characteristics of Korea. Therefore, it is necessary to consider seasonal characteristics in Level-3 PSA

  10. Hybrid membrane--PSA system for separating oxygen from air

    Science.gov (United States)

    Staiger, Chad L.; Vaughn, Mark R.; Miller, A. Keith; Cornelius, Christopher J.

    2011-01-25

    A portable, non-cryogenic, oxygen generation system capable of delivering oxygen gas at purities greater than 98% and flow rates of 15 L/min or more is described. The system consists of two major components. The first component is a high efficiency membrane capable of separating argon and a portion of the nitrogen content from air, yielding an oxygen-enriched permeate flow. This is then fed to the second component, a pressure swing adsorption (PSA) unit utilizing a commercially available, but specifically formulated zeolite compound to remove the remainder of the nitrogen from the flow. The system is a unique gas separation system that can operate at ambient temperatures, for producing high purity oxygen for various applications (medical, refining, chemical production, enhanced combustion, fuel cells, etc . . . ) and represents a significant advance compared to current technologies.

  11. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR

    Science.gov (United States)

    Pavlidou, Anastasia; Dalamaga, Maria; Kroupis, Christos; Konstantoudakis, George; Belimezi, Maria; Athanasas, George; Dimas, Kleanthi

    2011-01-01

    AIM: To investigate three isoforms of survivin in colorectal adenocarcinomas. METHODS: We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice variants and two common hybridization probes labeled with fluorescein and LightCycler-Red fluorophore (LC-Red 640). Real time quantitative polymerase chain reaction (PCR) was performed on cDNAs from 52 tumor specimens from colorectal cancer patients and 10 unrelated normal colorectal tissues. In the patients group, carcinoembryonic antigen (CEA) and CA19-9 tumor markers were also measured immunochemically. RESULTS: Wild type survivin mRNA isoform was expressed in 48% of the 52 tumor samples, survivin-2b in 38% and survivin-ΔΕx3 in 29%, while no expression was found in normal tissues. The mRNA expression of wild type survivin presented a significant correlation with the expression of the ratio of survivin-2b, survivin-ΔΕx3, survivin-2b/wild type survivin and survivin-ΔΕx3/wild type survivin (P < 0.001). The mRNA expression of wild-survivin and survivin-ΔΕx3 was related with tumor size and invasion (P = 0.006 and P < 0.005, respectively). A significant difference was found between survivin-2b and morphologic cancer type. Also, the ratio of survivin-ΔEx3/wild-survivin was significantly associated with prognosis. No association was observed between the three isoforms and grade, metastasis, Dukes stage and gender. The three isoforms were not correlated with CEA and CA19-9. CONCLUSION: Survivin isoforms may play a role in cell apoptosis and their quantification could provide information about clinical management of patients suffering from colorectal cancer. PMID:21472129

  12. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR

    Institute of Scientific and Technical Information of China (English)

    Anastasia Pavlidou; Maria Dalamaga; Christos Kroupis; George Konstantoudakis; Maria Belimezi; George Athanasas; Kleanthi Dimas

    2011-01-01

    AIM: To investigate three isoforms of survivin in colorectal adenocarcinomas. METHODS: We used the LightCycler Technology (Roche), along with a common forward primer and reverse primers specific for the splice variants and two common hybridization probes labeled with fluorescein and LightCycler- Red fluorophore (LC-Red 640). Real time quantitative polymerase chain reaction (PCR) was performed on cDNAs from 52 tumor specimens from colorectal cancer patients and 10 unrelated normal colorectal tissues. In the patients group, carcinoembryonic antigen (CEA) and CA19-9 tumor markers were also measured immunochemically. RESULTS: Wild type survivin mRNA isoform was expressed in 48% of the 52 tumor samples, survivin-2b in 38% and survivin-ΔΕx3 in 29%, while no expression was found in normal tissues. The mRNA expression of wild type survivin presented a significant correlation with the expression of the ratio of survivin-2b, survivin-ΔΕx3, survivin-2b/wild type survivin and survivin-ΔΕx3/wild type survivin (P < 0.001). The mRNA expression of wildsurvivin and survivin-ΔΕx3 was related with tumor size and invasion (P = 0.006 and P < 0.005, respectively). A significant difference was found between survivin-2b and morphologic cancer type. Also, the ratio of survivin-ΔEx3/ wild-survivin was significantly associated with prognosis. No association was observed between the three isoforms and grade, metastasis, Dukes stage and gender. The three isoforms were not correlated with CEA and CA19-9. CONCLUSION: Survivin isoforms may play a role in cell apoptosis and their quantification could provide information about clinical management of patients suffering from colorectal cancer.

  13. Prostate specific antigen in boys with precocious puberty before and during gonadal suppression by GnRH agonist treatment

    DEFF Research Database (Denmark)

    Juul, A; Müller, J; Skakkebaek, N E

    1997-01-01

    In healthy boys, the pituitary-gonadal axis exhibits diurnal variation in early puberty. Serum testosterone levels are higher during the night and low or immeasurable during the day. These fluctuating levels of circulating androgens in early pubertal boys are difficult to monitor. Prostate specific...... antigen (PSA) is a marker of the androgen-dependent prostatic epithelial cell activity and it is used in the diagnosis and surveillance of adult patients with prostatic cancer. We have measured PSA concentrations in serum from boys with precocious puberty before and during gonadal suppression with Gn...

  14. Application of fire PSA in enhancing NPP safety: a case study with Indian PHWRS

    International Nuclear Information System (INIS)

    Fire PSA (Probabilistic Safety Assessment) is the probabilistic analysis of fire events and their potential impact on the safety of a Nuclear Power Plant (NPP). Using probabilistic models, the fire PSA takes into account the possibility of a fire at specific plant locations and its propagation, detection and suppression of the fire; and also helps to assess the effect of the fire on safety related cables and equipment. Typically, Fire PSA involves five stages of analysis: Screening Analysis, Fire Hazard Analysis, Fire Frequency Analysis, Fire Propagation Analysis and System analysis. The probabilistic criteria used in fire PSA are based on the risk concept. Core damage frequency is a typical criterion used for PSA Level 1. Fire PSA relies on the plant response model developed for the internal initiating events. The availability of a plant model that logically examines the contributions to core damage is a prerequisite for a fire PSA. It should be pointed out that extending an internal event PSA to a fire PSA requires a considerable amount of plant specific data, such as the location of cable routes in plant compartments, fire barriers etc. The detailed fire PSA analyses was carried out for a typical Indian Nuclear Power Plant. Fire fighting system for the NPP under consideration was designed based on the prevailing standards for fire safety design. These provisions were critically analysed (after appropriate screening of fire critical areas) by using codes such as COMPBRN IIIe and Fire Dynamics Simulator (FDS). Based on the results of these studies, activities such as installation of fire barriers at critical locations, re-routing of redundant safety related cables, etc. were carried out for reducing the fire contribution to CDF. Also, suitable provisions were identified to prevent occurrence of possible core damage scenario as pointed in Fire PSA study. After retrofitting, fire PSA was re-done to quantify and ensure the reduction in the contribution of the CDF

  15. Impact of Neoadjuvant Prostate-Specific Antigen Kinetics on Biochemical Failure and Prostate Cancer Mortality: Results From a Prospective Patient Database

    Energy Technology Data Exchange (ETDEWEB)

    Foo, Marcus, E-mail: Marcus.Foo@petermac.org [Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne (Australia); Lavieri, Mariel [Department of Industrial and Operations Engineering, University of Michigan, Ann Arbor, Michigan (United States); Pickles, Tom [Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver, BC (Canada)

    2013-02-01

    Purpose: To confirm findings from an earlier report showing that neoadjuvant (NA) prostate-specific antigen (PSA) halving time (PSAHT) impacts biochemical failure (BF) rates, and to examine its association with prostate cancer-specific survival (PCSS), in a large prospective cohort of patients. Methods and Materials: A total of 502 patients were selected from a prospective database, who had localized prostate adenocarcinoma treated with 2-12 months of neoadjuvant androgen deprivation therapy (N-ADT) followed by external beam radiation therapy (EBRT) between 1994 and 2000, and had at least 2 NA PSA values. Seventy-four percent of patients had high-risk prostate cancer. Median initial PSA value, N-ADT duration, total ADT duration, and radiation therapy dose were 14 ng/mL, 6.9 months, 10.8 months, and 68 Gy, respectively. Results: At a median follow-up of 9.9 years, 210 patients have had a BF. Median PSAHT was 18 days. On univariate analysis, PSAHT was not shown to predict for BF (P=.69) or PCSS (P=.28). However, NA nadir PSA (nanPSA) and post-therapy nadir PSA (ptnPSA), when analyzed as continuous or categoric variables, predicted for BF (P<.001) and PCSS (P<.001). On multivariate analysis, nanPSA (P=.037) and ptnPSA (P<.001) continued to be significantly associated with BF. However, N-ADT duration lost significance (P=.67), and PSAHT remained a nonsignificant predictor (P=.97). For PCSS, multivariate analysis showed nanPSA (P=.049) and ptnPSA (P<.001) to be significant. Again PSAHT (P=.49) remained nonsignificant. Conclusions: In this large, prospective cohort of patients, NA PSA kinetics, expressed as PSAHT, did not predict BF or PCSS. However, nadir PSAs, in both the NA and post-therapy settings, were significant predictors of BF and PCSS. Optimization of therapy could potentially be based on early PSA response, with shorter durations of ADT for those predicted to do favorably, and intensification of therapy for those likely to have poorer outcomes.

  16. The Different Reduction Rate of Prostate-Specific Antigen in Dutasteride and Finasteride

    OpenAIRE

    Choi, Yong Hyeuk; Cho, Sung Yong; Cho, In Rae

    2010-01-01

    Purpose To compare and analyze the therapeutic effects and changes in the prostate-specific antigen (PSA) level with treatment with finasteride or dutasteride for benign prostatic hyperplasia (BPH) for 1 year. Materials and Methods We retrospectively investigated patients who suffered from BPH for 1 year between January 2005 and December 2008. For treatment groups, we divided the patients into two groups: one was treated with alfuzosin and finasteride and the other was treated with alfuzosin ...

  17. Improvement of Level-1 PSA computer code package -A study for nuclear safety improvement-

    International Nuclear Information System (INIS)

    This year is the second year of the Government-sponsored Mid- and Long-Term Nuclear Power Technology Development Project. The scope of this subproject titled on 'The Improvement of Level-1 PSA Computer Codes' is divided into three main activities : (1) Methodology development on the under-developed fields such as risk assessment technology for plant shutdown and external events, (2) Computer code package development for Level-1 PSA, (3) Applications of new technologies to reactor safety assessment. At first, in the area of PSA methodology development, foreign PSA reports on shutdown and external events have been reviewed and various PSA methodologies have been compared. Level-1 PSA code KIRAP and CCF analysis code COCOA are converted from KOS to Windows. Human reliability database has been also established in this year. In the area of new technology applications, fuzzy set theory and entropy theory are used to estimate component life and to develop a new measure of uncertainty importance. Finally, in the field of application study of PSA technique to reactor regulation, a strategic study to develop a dynamic risk management tool PEPSI and the determination of inspection and test priority of motor operated valves based on risk importance worths have been studied. (Author)

  18. Isoforms of murine and human serum amyloid P component

    DEFF Research Database (Denmark)

    Nybo, Mads; Hackler, R; Kold, B;

    1998-01-01

    Isoelectric focusing (IEF) and immunofixation of murine serum amyloid P component (SAP), purified and in serum, showed a distinct and strain-dependent isoform pattern with up to seven bands (pI 5.1-5.7). Neuraminidase treatment caused a shift of the isoforms to more basic pI values, but did...... of isoforms of human SAP required the presence of urea and higher SAP concentrations. TEF and immunofixation of SAP monomers showed five to eight isoforms, ranging from pI 4.7-5.7. IEF of SAP in human serum resulted in a less distinct pattern and more acidic isoforms. As with murine SAP, neuraminidase...

  19. Key Characteristics of Combined Accident including TLOFW accident for PSA Modeling

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Bo Gyung; Kang, Hyun Gook [KAIST, Daejeon (Korea, Republic of); Yoon, Ho Joon [Khalifa University of Science, Technology and Research, Abu Dhabi (United Arab Emirates)

    2015-05-15

    The conventional PSA techniques cannot adequately evaluate all events. The conventional PSA models usually focus on single internal events such as DBAs, the external hazards such as fire, seismic. However, the Fukushima accident of Japan in 2011 reveals that very rare event is necessary to be considered in the PSA model to prevent the radioactive release to environment caused by poor treatment based on lack of the information, and to improve the emergency operation procedure. Especially, the results from PSA can be used to decision making for regulators. Moreover, designers can consider the weakness of plant safety based on the quantified results and understand accident sequence based on human actions and system availability. This study is for PSA modeling of combined accidents including total loss of feedwater (TLOFW) accident. The TLOFW accident is a representative accident involving the failure of cooling through secondary side. If the amount of heat transfer is not enough due to the failure of secondary side, the heat will be accumulated to the primary side by continuous core decay heat. Transients with loss of feedwater include total loss of feedwater accident, loss of condenser vacuum accident, and closure of all MSIVs. When residual heat removal by the secondary side is terminated, the safety injection into the RCS with direct primary depressurization would provide alternative heat removal. This operation is called feed and bleed (F and B) operation. Combined accidents including TLOFW accident are very rare event and partially considered in conventional PSA model. Since the necessity of F and B operation is related to plant conditions, the PSA modeling for combined accidents including TLOFW accident is necessary to identify the design and operational vulnerabilities.The PSA is significant to assess the risk of NPPs, and to identify the design and operational vulnerabilities. Even though the combined accident is very rare event, the consequence of combined

  20. Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer

    DEFF Research Database (Denmark)

    Thomsen, F B; Brasso, K; Berg, K D;

    2016-01-01

    with localised PCa managed on watchful waiting. PATIENTS AND METHODS: Patients with clinically localised PCa managed observationally, who were randomised to and remained on placebo for minimum 18 months in the SPCG-6 study, were included. All patients survived at least 2 years and had a minimum of...... three PSA determinations available. The prognostic value of PSA kinetics was analysed and patients were stratified according to their PSA at consent: ≤10, 10.1-25, and >25 ng/ml. Cumulative incidences of PCa-specific mortality were estimated with the Aalen-Johansen method. RESULTS: Two hundred and sixty...

  1. Mass screening of prostate cancer in a Chinese population:the relationship between pathological features of prostate cancer and serum prostate specific antigen

    Institute of Scientific and Technical Information of China (English)

    Hong-Wen Gao; Masaaki Kuwahara; Xue-Jian Zhao; Yu-Lin Li; Shan Wu; Yi-Shu Wang; Hai-Feng Zhang; Yu-Zhuo Pan; Ling Zhang; Hiroo Tateno; Ikuro Sato

    2005-01-01

    Aim: To investigate the pathological features of the prostate biopsy through mass screening for prostate cancer in a Chinese cohort and their association with serum prostate specific antigen (PSA). Methods: A total of 12 027 Chinese men in Changchun were screened for prostate cancer by means of the serum total prostate specific antigen (tPSA) test (oy Elisa assay). Transrectal ultrasound-guided systematic six-sextant biopsies were performed on those whose serum tPSA value was >4.0 ng/mL and those who had obstructive symptoms (despite their tPSA value) and were subject to subsequent pathological analysis with the aid of the statistic software SPSS 10.0 (SPSS. Inc., Chicago. USA). Results: Of the 12 027 cases, 158 (including 137 patients whose serum tPSA values were >4.0 ng/mL and 21 patients [serum tPSA <4.0 ng/mL] who had obstructive symptoms) undertook prostate biopsy. Of the 158 biopsies, 41 cases of prostatic carcinoma were found (25.9 %, 41/158). The moderately differentiated carcinoma and poorly differentiated carcinoma accounted for 61% and 34%, respectively. A significant linear positive correlation between the serum tPSA and the Gleason scores in the 41 cases of prostatic carcinoma (r = 0.312, P < 0.01) was established. A significant linear positive correlation between the serum tPSA value of the 41 prostatic carcinoma and the positive counts of carcinoma in sextant biopsies was established (r = 0.406, P < 0.01), indicating a significant linear relationship between serum tPSA and the size of tumor.Conclusion: This study was the first to conduct mass screening for prostate cancer by testing for serum tPSA values and the first to investigate the pathological features of prostate cancer in a cohort of Chinese men. Our results reveal that the moderately differentiated carcinoma is the most common type of prostate cancer. This study also has shown that the serum tPSA value in prostate cancer is associated with the Gleason score and the size of tumor.

  2. EASI—enrichment of alternatively spliced isoforms

    OpenAIRE

    Julian P Venables; Burn, John

    2006-01-01

    Alternative splicing produces more than one protein from the majority of genes and the rarer forms can have dominant functions. Instability of alternative transcripts can also hinder the study of regulation of gene expression by alternative splicing. To investigate the true extent of alternative splicing we have developed a simple method of enriching alternatively spliced isoforms (EASI) from PCRs using beads charged with Thermus aquaticus single-stranded DNA-binding protein (T.Aq ssb). This ...

  3. BIOCARBURANTS PSA Peugeot Citroën et les biocarburants

    Directory of Open Access Journals (Sweden)

    Maurer Béatrice

    2002-09-01

    Full Text Available Les biocarburants représentent une filière essentielle pour PSA Peugeot Citroën dans le cadre de la protection de l’environnement, un axe stratégique majeur pour le groupe - de la production de ses véhicules au recyclage, de la qualité de l’air à l’effet de serre et au développement d’énergies renouvelables. Depuis plusieurs années, PSA a intégré la filière huiles végétales/biocarburants dans ses activités pour atteindre ses objectifs globaux d’innovation et de croissance. De nombreuses flottes de véhicules circulent en France avec du gazole contenant 30 % de biocarburant issu des oléagineux : une expérience réussie, qui dure depuis plus de dix ans. Le constructeur est favorable à l’utilisation de biocarburants en mélange dans les carburants pétroliers conventionnels, essence et gazole - une voie qui présente plusieurs avantages : * Un bilan CO2 global favorable (par absorption de CO2 lors de la photosynthèse de la plante-source, qui contribue à limiter « l’effet de serre ». * Une source complémentaire de carburant pour réduire les importations de pétrole (et de gazole. * Un soutien au secteur agricole (débouché supplémentaire, dans le cadre de la valorisation des terres en jachère. Issus de la transformation des céréales ou de la betterave à sucre, ou des plantes oléagineuses comme le colza, le tournesol ou le soja, les biocarburants sont par essence des énergies renouvelables. Outre leur bilan exceptionnellement favorable pour lutter contre l’effet de serre, ces carburants offrent de réelles performances environnementales, en particulier par la réduction des émissions de particules (cas des EMHV.

  4. Differential water permeability and regulation of three aquaporin 4 isoforms

    DEFF Research Database (Denmark)

    Fenton, Robert A.; Moeller, Hanne B; Zelenina, Marina;

    2010-01-01

    Aquaporin 4 (AQP4) is expressed in the perivascular glial endfeet and is an important pathway for water during formation and resolution of brain edema. In this study, we examined the functional properties and relative unit water permeability of three functional isoforms of AQP4 expressed...... in the brain (M1, M23, Mz). The M23 isoform gave rise to square arrays when expressed in Xenopus laevis oocytes. The relative unit water permeability differed significantly between the isoforms in the order of M1 > Mz > M23. None of the three isoforms were permeable to small osmolytes nor were they affected...... by changes in external K(+) concentration. Upon protein kinase C (PKC) activation, oocytes expressing the three isoforms demonstrated rapid reduction of water permeability, which correlated with AQP4 internalization. The M23 isoform was more sensitive to PKC regulation than the longer isoforms...

  5. Histocompatibility antigen test

    Science.gov (United States)

    ... more common in certain autoimmune diseases . For example, HLA-B27 antigen is found in many people (but not ... More Ankylosing spondylitis Autoimmune disorders Bone marrow transplant HLA-B27 antigen Kidney transplant Reactive arthritis Update Date 2/ ...

  6. Single chip SPR and fluorescent ELISA assay of prostate specific antigen.

    Science.gov (United States)

    Breault-Turcot, J; Poirier-Richard, H-P; Couture, M; Pelechacz, D; Masson, J-F

    2015-12-01

    A multi-channel system combining fluidics and micropatterned plasmonic materials with wavelength interrogation surface plasmon resonance (SPR) and fluorescence detection was integrated from the combination of a small and motorized fluorescence microscope mounted on a portable 4-channel SPR instrument. The SPR and fluorescent measurements were performed based on the same detection area in a multi-channel fluidic, with a sensing scheme for prostate-specific antigen (PSA) consisting of a sandwich assay with a capture anti-PSA immobilized onto the SPR sensor and a detection anti-PSA modified with horseradish peroxidase (HRP). In this dual-detection instrument, fluorescence was measured from the solution side of the micropatterned gold film, while the interface between the glass prism and the gold film served to interrogate the SPR response. The SPR sensors were comprised of microhole arrays fabricated by photolithography to enhance the instrumental response for PSA detection by approximately a factor of 2 to 3 and they were coated with a self-assembled monolayer of a peptide (3-MPA-HHHDD-OH) to minimize nonspecific adsorption. PSA was successfully detected at clinical concentrations from 10 pM to 50 nM with this integrated system in a single assay lasting 12 minutes, almost centering on the desired range for PSA diagnostic tests (>4 ng mL(-1) or >150 pM). The combination of two robust techniques in a single chip and instrument has led to a simple and effective assay that can be carried out on a small and portable instrument providing rapid biodetection of an important cancer biomarker with a dynamic range of nearly 4 orders of magnitude in the clinical range.

  7. In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.

    Directory of Open Access Journals (Sweden)

    Rym Chamakh-Ayari

    Full Text Available PSA (Promastigote Surface Antigen belongs to a family of membrane-bound and secreted proteins present in several Leishmania (L. species. PSA is recognized by human Th1 cells and provides a high degree of protection in vaccinated mice. We evaluated humoral and cellular immune responses induced by a L. amazonensis PSA protein (LaPSA-38S produced in a L. tarentolae expression system. This was done in individuals cured of cutaneous leishmaniasis due to L. major (CCLm or L. braziliensis (CCLb or visceral leishmaniasis due to L. donovani (CVLd and in healthy individuals. Healthy individuals were subdivided into immune (HHR-Lm and HHR-Li: Healthy High Responders living in an endemic area for L. major or L. infantum infection or non immune/naive individuals (HLR: Healthy Low Responders, depending on whether they produce high or low levels of IFN-γ in response to Leishmania soluble antigen. Low levels of total IgG antibodies to LaPSA-38S were detected in sera from the studied groups. Interestingly, LaPSA-38S induced specific and significant levels of IFN-γ, granzyme B and IL-10 in CCLm, HHR-Lm and HHR-Li groups, with HHR-Li group producing TNF-α in more. No significant cytokine response was observed in individuals immune to L. braziliensis or L. donovani infection. Phenotypic analysis showed a significant increase in CD4+ T cells producing IFN-γ after LaPSA-38S stimulation, in CCLm. A high positive correlation was observed between the percentage of IFN-γ-producing CD4+ T cells and the released IFN-γ. We showed that the LaPSA-38S protein was able to induce a mixed Th1 and Th2/Treg cytokine response in individuals with immunity to L. major or L. infantum infection indicating that it may be exploited as a vaccine candidate. We also showed, to our knowledge for the first time, the capacity of Leishmania PSA protein to induce granzyme B production in humans with immunity to L. major and L. infantum infection.

  8. 延边地区1627例前列腺相关疾病患者t-PSA检测分析%ANALYSIS ON T-PSA DETECTION OF 1 627 CASES OF PROSTATE RELATED DISEASES IN YANBIAN

    Institute of Scientific and Technical Information of China (English)

    李忠吉; 李素香; 朴英花

    2012-01-01

    [Objective] To investigate the early diagnosis and the predictive value of prostate disease by screening serum prostate specific antigen (t-PSA) of 1 627 male cases. [Methods] Chemiluminescence was used in detection of serum prostate specific antigen. [Results] In 1 627 cases, 27 cases (1.7%) were proved as prostate cancer, 68 cases (4.2%) were proved as prostatic hyperplasia, 51 cases (3.1%) as prostatitis. [Conclusion] Serum t-PSA is not only a diagnosis which has a higher value of tumor markers in detecting prostate cancer, but also valuable in diagnosis of benign proatatic hyperplasia, prostatitis and other prostate disease. At the same time, a preliminary understanding has done on whether the occurrence of the prostate disease is related to different ethnic groups, namely the relation of diet and lifestyle.%[目的]通过对1 627例男性血清前列腺特异抗原(t-PSA)的筛查,探讨其对前列腺疾病的早期诊断及预测价值.[方法]采用化学发光法测定血清前列腺特异抗原(t-PSA).[结果]1 627例通过血清(t-PSA)筛查发现前列腺癌27例(1.7%),前列腺增生68例(4.2%),前列腺炎51例(3.1%).[结论]男性血清(t-PSA)不仅诊断前列腺癌(Pca)有较高价值的肿瘤标志物,而且对前列腺增生.前列腺炎等前列腺疾病的诊断也有价值.与此同时初步的了解和统计了延边地区前列腺疾病与不同民族,即饮食结构与生活习惯是否有一定的关系,为今后大量普查工作做了初步的探讨.

  9. Benchmark exercise on expert judgment techniques in PSA Level 2

    International Nuclear Information System (INIS)

    This article summarizes objectives and aims of the concerted action 'Benchmark Exercise on Expert Judgment Techniques in PSA Level 2' and the results obtained within the project. The project was organized in three phases, namely a survey phase (pre-phase), a first phase devoted to parameter estimation assessment and a second phase devoted to benchmarking expert judgment methods on a scenario development case. The paper is focused on the first phase and on the results obtained by the application of five structured Expert Judgment (EJ) methodologies to the problem at hand. The results of the comparison of EJ methodologies are also provided; they are based on the use of some metrics suitably designed during the project. The context of Phase 2 and the issue to be tackled in this phase are briefly described; since this phase has been carried out only at a preliminary level (mainly after the end of the project), the results obtained are not reported here in detail but are only briefly commented on

  10. COS Imaging TA and Spectroscopic WCA-PSA/BOA offset verifications

    Science.gov (United States)

    Penton, Steven

    2013-10-01

    This program builds upon the monitoring and calibration of the FGSs (13616 - HST Cycle 21 Focal Plane Calibration (SI-FGS Alignment)). HST 13616 performs back-to-back PSA/MIRRORA & PSA/MIRRORB ACQ/IMAGES, from which all the results herein are bootstrapped.The list of proposals, cycles, and the order in which the alignment is checked is given below. 11878->12399->12781->13171->13616 C17->C18 ->C19->C20->C21 STIS->WFC3->ACS->COSThis program will be repeated every cycle and we will once again use it's COS exposures as the baseline for this program.This program performs a PSA/MIRRORA ACQ/IMAGE on a target that should already be centered in the aperture. This verifies the COS NUV PSA aperture position in the SIAF. After this PSA+MIRRORA ACQ/IMAGE, a PSA+MIRRORB ACQ/IMAGE is then performed. This exposure bootstraps the PSA+MIRRORB centering to the PSA+MIRROR SIAF verification. This allows us to monitor the properties of the PSA+MIRRORB image in a controlled way on a centered target. No spectra are taken in 13616 due to time constraints.This program extends the SIAF verification of 13616 to the other two ACQ/IMAGE combinations (BOA+MIRRORA & BOA+MIRRORB) by bootstraping from the PSA+MIRRORB verification of 13616.Visit 1 of this program begins with a PSA+MIRRORB NUV ACQ/IMAGE followed by a BOA+MIRRORA ACQ/IMAGE. Both observations are high S/N to get the most accurate centering information possible. The program then takes a PSA+MIRRORB IMAGE to ensure that we are still properly centered. We prefer that Visit 01 of this program executes within 45 days of Visit 02 of 13616, to ensure that no long term instrument or telescope focus changes impart our results.After the Imaging verification , Visit 1 of this program will obtain a S/N > 60 NUV spectrum using the most popular NUV grating (G230L, G185M, & G285M), and FUV Spectra using G130M/1309 and G140L/1280. This allows the direct verification of the NUV and FUV WCA-to-PSA cross-dispersion offsets used by ACQ/PEAKXD.Visit 02 of

  11. 美国三级 PSA 发展过程及研究进展%The Developing Process and Study Trends of Level 3 PSA in USA

    Institute of Scientific and Technical Information of China (English)

    王建华; 陈鹏; 杨杰; 苏永杰

    2015-01-01

    Public risk is an important index of Nuclear Power Plant (NPP) safety .WASH-740 ,which was is-sued in 1957 ,started introducing the concept of reactor risk analysis .In 1972 ,WASH-1400 accomplished systematically a Level 3 PSA for the first time ,and gave rise to the development of CRAC series codes .Fur-thermore ,NUREG-1550 was published in 1990 ,which indicated PSA application matured .NRC established the current framework for risk-informed regulation by issuing a PRA Policy Statement in 1995 .In 2007 ,The SOARCA project was initiated to develop best estimates of the offsite radiological health consequences for po -tential severe reactor accidents for Peach Bottom Atomic Power Station and Surry Power Station .In 2011 ,NRC proposed to perform a new full-scope comprehensive Level 3 PSA which addressed additional considerations such as multi-unit site effects and other on-site radiological sources .%公众风险是验证核电厂安全性能的重要指标。美国1957年发布的 WASH-740中开始引入反应堆风险分析的概念;1972年,WASH-1400第一次系统性地完成了三级 PSA ,并开发了 CRAC 系列分析程序;1990年,NRC 发布NUREG-1150,标志着 PSA 应用进入成熟期;1995年,正式在法规层面上确定了 PSA 地位;始于2007年的 SOARCA 研究计划在 SARP 研究基础上,结合最新研究进展利用改进的三级 PSA 工具对两个核电厂重新进行了评估;2011年,考虑最新的技术进步和福岛事故影响,计划重新启动完整三级 PSA 研究,以考虑如乏燃料水池工况、群堆工况、外部事件等新的认识。

  12. A design-phase PSA of anuclear-powered hydrogen plant

    OpenAIRE

    Flores Flores, Alain

    2007-01-01

    A probabilistic safety assessment (PSA) is being developed for a steam-methane reforming hydrogenproduction plant linked to a high-temperature gas-cooled nuclear reactor (HTGR). This work is based on the Japan Atomic Energy Research Institute's (JAERI) High Temperature Engineering Test Reactor (HTTR) prototype in Japan. The objective of this paper is to show how the PSA can be used for improving the design of the coupled plants. A simplified HAZOP study was performed to identify initiating ev...

  13. Determining the Quality of Probabilistic Safety Assessment (PSA) for Applications in Nuclear Power Plants

    OpenAIRE

    KIRCHSTEIGER Christian; KUBANYI Jozef

    2006-01-01

    Probabilistic safety assessment (PSA) of nuclear power plants (NPPs) complements the traditional deterministic analysis and is widely recognized as a comprehensive, structured approach to identifying accident scenarios and deriving numerical estimates of risks dealing with NPP operation and associated plant vulnerabilities. Increasingly, during the last years, PSA has been broadly applied to support numerous applications and risk-informed decisions on various operational and regulatory mat...

  14. The association of general practitioners’ risk attitudes, level of empathy and burnout status with PSA testing

    DEFF Research Database (Denmark)

    Pedersen, Anette Fischer; Carlsen, Anders Helles; Vedsted, Peter

    2015-01-01

    Når alment praktiserende læger sammenlignes, finder man ofte stor variation i raten af PSA-tests foretaget på mandlige patienter. Dette studie viser, at lægens risikovillighed influerer på raten af PSA-tests. Således har patienter, som er registreret hos en læge, som har mange bekymringer for fej...

  15. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy.

    Directory of Open Access Journals (Sweden)

    Tohru Nakagawa

    Full Text Available BACKGROUND: Many men develop a rising PSA after initial therapy for prostate cancer. While some of these men will develop a local or metastatic recurrence that warrants further therapy, others will have no evidence of disease progression. We hypothesized that an expression biomarker panel can predict which men with a rising PSA would benefit from further therapy. METHODOLOGY/PRINCIPAL FINDINGS: A case-control design was used to test the association of gene expression with outcome. Systemic (SYS progression cases were men post-prostatectomy who developed systemic progression within 5 years after PSA recurrence. PSA progression controls were matched men post-prostatectomy with PSA recurrence but no evidence of clinical progression within 5 years. Using expression arrays optimized for paraffin-embedded tissue RNA, 1021 cancer-related genes were evaluated-including 570 genes implicated in prostate cancer progression. Genes from 8 previously reported marker panels were included. A systemic progression model containing 17 genes was developed. This model generated an AUC of 0.88 (95% CI: 0.84-0.92. Similar AUCs were generated using 3 previously reported panels. In secondary analyses, the model predicted the endpoints of prostate cancer death (in SYS cases and systemic progression beyond 5 years (in PSA controls with hazard ratios 2.5 and 4.7, respectively (log-rank p-values of 0.0007 and 0.0005. Genes mapped to 8q24 were significantly enriched in the model. CONCLUSIONS/SIGNIFICANCE: Specific gene expression patterns are significantly associated with systemic progression after PSA recurrence. The measurement of gene expression pattern may be useful for determining which men may benefit from additional therapy after PSA recurrence.

  16. Success Criteria Analysis for PSA of Hanul Units 3 and 4: Results and Insights

    Energy Technology Data Exchange (ETDEWEB)

    Cho, Jaehyun; Park, Jin Hee; Kim, Dong-San; Lim, Ho-Gon [Korea Atomic Energy Research Institute, Daejeon (Korea, Republic of)

    2015-10-15

    In this paper, based on best-estimate TH results for exhaustive case of event tree of the Hanul units 3 and 4 PSA model, several insights were identified. It is not recommended that these issues directly apply the present PSA model because of several remain problems such as uncertainty analysis, and its impact on the core damage frequency. Major contribution of this work is to identify the problems in present PSA event tree model. Recently, the probabilistic safety assessment (PSA) model for the Hanul units 3 and 4 is being re-developed in KAERI as the one of the national project aiming at increasing and assuring the safety of the nuclear power plant (NPP). The success criteria (SC) analysis of the at-power Level 1 internal accident of the PSA model was also conducted in this project. This paper deals with the SC analysis of the Level 1 internal accident of PSA model for Hanul units 3 and 4. From the SC analysis, the valuable findings and insights were obtained.

  17. Survey on Prognostics Techniques for Updating Initiating Event Frequency in PSA

    International Nuclear Information System (INIS)

    One of the applications using PSA is a risk monito. The risk monitoring is real-time analysis tool to decide real-time risk based on real state of components and systems. In order to utilize more effective, the methodologies that manipulate the data from Prognostics was suggested. Generally, Prognostic comprehensively includes not only prognostic but also monitoring and diagnostic. The prognostic method must need condition monitoring. In case of applying PHM to a PSA model, the latest condition of NPPs can be identified more clearly. For reducing the conservatism and uncertainties, we suggested the concept that updates the initiating event frequency in a PSA model by using Bayesian approach which is one of the prognostics techniques before. From previous research, the possibility that PSA is updated by using data more correctly was found. In reliability theory, the Bathtub curve divides three parts (infant failure, constant and random failure, wareout failure). In this paper, in order to investigate the applicability of prognostic methods in updating quantitative data in a PSA model, the OLM acceptance criteria from NUREG, the concept of how to using prognostic in PSA, and the enabling prognostic techniques are suggested. The prognostic has the motivation that improved the predictive capabilities using existing monitoring systems, data, and information will enable more accurate equipment risk assessment for improved decision-making

  18. Survey on Prognostics Techniques for Updating Initiating Event Frequency in PSA

    Energy Technology Data Exchange (ETDEWEB)

    Kim, Hyeonmin; Heo, Gyunyoung [Kyung Hee University, Yongin (Korea, Republic of)

    2015-05-15

    One of the applications using PSA is a risk monito. The risk monitoring is real-time analysis tool to decide real-time risk based on real state of components and systems. In order to utilize more effective, the methodologies that manipulate the data from Prognostics was suggested. Generally, Prognostic comprehensively includes not only prognostic but also monitoring and diagnostic. The prognostic method must need condition monitoring. In case of applying PHM to a PSA model, the latest condition of NPPs can be identified more clearly. For reducing the conservatism and uncertainties, we suggested the concept that updates the initiating event frequency in a PSA model by using Bayesian approach which is one of the prognostics techniques before. From previous research, the possibility that PSA is updated by using data more correctly was found. In reliability theory, the Bathtub curve divides three parts (infant failure, constant and random failure, wareout failure). In this paper, in order to investigate the applicability of prognostic methods in updating quantitative data in a PSA model, the OLM acceptance criteria from NUREG, the concept of how to using prognostic in PSA, and the enabling prognostic techniques are suggested. The prognostic has the motivation that improved the predictive capabilities using existing monitoring systems, data, and information will enable more accurate equipment risk assessment for improved decision-making.

  19. Nanogold-functionalized g-C3N4 nanohybrids for sensitive impedimetric immunoassay of prostate-specific antigen using enzymatic biocatalytic precipitation.

    Science.gov (United States)

    Ding, Li-Li; Ge, Jing-Ping; Zhou, Wen-Quan; Gao, Jian-Ping; Zhang, Zheng-Yu; Xiong, Ya

    2016-11-15

    This work reports on a new impedimetric immunosensing strategy for sensitive detection of prostate-specific antigen (PSA) in biological fluids. The assay was carried out on monoclonal anti-PSA capture antibody-modified glassy carbon electrode with a sandwich-type detection format. Gold nanoparticles-decorated g-C3N4 nanosheets (AuNP/g-C3N4), synthesized by the wet-chemistry method, were utilized for the labeling of polyclonal anti-PSA detection antibody and horseradish peroxidase (HRP). Upon target PSA introduction, the sandwiched immunocomplex could be formed between capture antibody and detection antibody. Followed by the AuNP/g-C3N4, the labeled HRP could catalyze 4-choloro-1-naphthol into benzo-4-chlorohexadienone. The as-generated insoluble product was coated on the electrode surface, thus increasing the Faradaic impedance of Fe(CN)6(4-/3)(-) indicator between the solution and the base electrode. Under the optimal conditions, the impedance increased with the increasing target PSA in the sample, and exhibited a wide linear range from 10pgmL(-1) and 30ngmL(-1) with a detection limit of 5.2pgmL(-1). A repeatability and intermediate precision of <14% was accomplished. The specificity and method accuracy in comparison with commercial PSA ELISA kit for analysis of human serum specimens were relatively satisfactory.

  20. Cysteine-rich secretory protein 3 plays a role in prostate cancer cell invasion and affects expression of PSA and ANXA1.

    Science.gov (United States)

    Pathak, Bhakti R; Breed, Ananya A; Apte, Snehal; Acharya, Kshitish; Mahale, Smita D

    2016-01-01

    Cysteine-rich secretory protein 3 (CRISP-3) is upregulated in prostate cancer as compared to the normal prostate tissue. Higher expression of CRISP-3 has been linked to poor prognosis and hence it has been thought to act as a prognostic marker for prostate cancer. It is proposed to have a role in innate immunity but its role in prostate cancer is still unknown. In order to understand its function, its expression was stably knocked down in LNCaP cells. CRISP-3 knockdown did not affect cell viability but resulted in reduced invasiveness. Global gene expression changes upon CRISP-3 knockdown were identified by microarray analysis. Microarray data were quantitatively validated by evaluating the expression of seven candidate genes in three independent stable clones. Functional annotation of the differentially expressed genes identified cell adhesion, cell motility, and ion transport to be affected among other biological processes. Prostate-specific antigen (PSA, also known as Kallikrein 3) was the top most downregulated gene whose expression was also validated at protein level. Interestingly, expression of Annexin A1 (ANXA1), a known anti-inflammatory protein, was upregulated upon CRISP-3 knockdown. Re-introduction of CRISP-3 into the knockdown clone reversed the effect on invasiveness and also led to increased PSA expression. These results suggest that overexpression of CRISP-3 in prostate tumor may maintain higher PSA expression and lower ANXA1 expression. Our data also indicate that poor prognosis associated with higher CRISP-3 expression could be due to its role in cell invasion. PMID:26369530

  1. Continuous flow PSA system carbon dioxide gas sep aration Process. Renzoku ryu PSA hoshiki tansan gas bunri process

    Energy Technology Data Exchange (ETDEWEB)

    Kanamaru, T.; Urano, S.; Kinoshita, N.; Ota, K. (Seibu Gas Kabushiki Kaisha, Fukuoka (Japan)); Nishino, K. (Mitsubishi Petrochemical Engineering Co. Ltd., Tokyo (Japan))

    1990-10-10

    During the production process of substitute natural gas (SNG), CO {sub 2} and moisture is removed which is contained in the wet mixed gas consisting of H {sub 2}, CH {sub 4} and CO {sub 2}, etc. generated in the gas generator. As the methods to separate and remove the CO {sub 2} above, there are the liquid absorption system as the wet decarbonation technique and the pressure swing adsorption (PSA) system as the dry decarbonation technique, but either of them has various problems. The process introduced in this article is the technique which has been developed in order to solve the various problems above and separates the contunuous wet mixed gas flow (generated gas before the treatment) consisting of H {sub 2}, CH {sub 4} and CO {sub 2}, etc. generated in the gas generator into the combustible component gas flow with purity of 99% or more and the CO {sub 2} gas flow with purity of 99%, both flows being the continuous flows without fluctuation of flow rate, pressure and component, and recovers 99% of the conbustible component and CO {sub 2} both. The above process was developed by Seibu Gas Co.. Starting, stopping and load change of the plant using this system is done quickly, accurately and easily with a high degree of safety, and the one touch operation is also possible. 6 figs., 3 tabs.

  2. Monitoring of prostate cancer growth and metastasis using a PSA luciferase report plasmid in a mouse model

    Institute of Scientific and Technical Information of China (English)

    Qi-Qi; Mao; Yi-Wei; Lin; Hong; Chen; Kai; Yang; De-Bo; Kong; Hai; Jiang

    2014-01-01

    Objective:To construct a PSA luciferase report plasmid and monitor the growth and metastasis of prostate cancer after emasculation in SCID mice.Methods:PSA promoter sequence and luciferase gene were amplified by PCR and subsequently inserted into pZsCreen1-1 vector to construct pPSA-FL-Luc vector.LNCaP cells that were stably transfected with pPSA-FL-Luc were used to establish a SCID mouse xenograft model.Then,the growth and metastasis of prostate cancer were monitored via living imaging.Results:We successfully constructed a PSA luciferase piasmid,pPSA-FL-Luc.DHT enhanced lucifcrase activity in a concentration-dependent manner in 293 T cells with pPSA-FL-Luc transfection.Prostate cancer SCID mouse model was established with pPSA-FL-Luc transfected LNCaP cells.In tumor bearing mice with or without emasculation,pPSA-FL-Lue piasmid was applied to monitored tumor growth and metastasis based on bioluminescence imaging.Conclusions:We construct a pPSA-FL-Luc piasmid,which stably expresses luciferase and can be applied to monitor tumor development in a prostate SCID mouse model.

  3. Monitoring of prostate cancer growth and metastasis using a PSA luciferase report plasmid in a mouse model

    Institute of Scientific and Technical Information of China (English)

    Qi-Qi Mao; Yi-Wei Lin; Hong Chen; Kai Yang; De-Bo Kong; Hai Jiang

    2014-01-01

    Objective:To construct a PSA luciferase report plasmid and monitor the growth and metastasis of prostate cancer after emasculation in SCID mice. Methods: PSA promoter sequence and luciferase gene were amplified by PCR and subsequently inserted into pZsGreen1-1 vector to construct pPSA-FL-Luc vector. LNCaP cells that were stably transfected with pPSA-FL-Luc were used to establish a SCID mouse xenograft model. Then, the growth and metastasis of prostate cancer were monitored via living imaging. Results:We successfully constructed a PSA luciferase plasmid, pPSA-FL-Luc. DHT enhanced luciferase activity in a concentration-dependent manner in 293T cells with pPSA-FL-Luc transfection. Prostate cancer SCID mouse model was established with pPSA-FL-Luc transfected LNCaP cells. In tumor bearing mice with or without emasculation, pPSA-FL-Luc plasmid was applied to monitored tumor growth and metastasis based on bioluminescence imaging. Conclusions: We construct a pPSA-FL-Luc plasmid, which stably expresses luciferase and can be applied to monitor tumor development in a prostate SCID mouse model.

  4. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort

    Directory of Open Access Journals (Sweden)

    Shyam K. Tanguturi

    2014-01-01

    Full Text Available Purpose. We investigated whether NS-RP increased risk of PSA failure and whether PSA should be included as a selection criterion for NS. Methods. We evaluated 357 consecutive men with screen-detected PC who underwent open RP without adjuvant radiotherapy between 9/11/2001 and 12/30/2008. Criteria for NS included Gleason score ≤3 + 4, percentage of positive biopsies (PPB ≤50%, percentage of core involvement ≤50%, nonapical location, no perineural invasion, and no palpable disease on pre- or intraoperative exam but did not include a PSA threshold. Cox multivariable regression assessed whether increasing PSA or unilateral- or bilateral-NS versus non-NS-RP was associated with PSA failure adjusting for prognostic factors. Results. After a median follow-up of 3.96 years, 34 men sustained PSA failure (9.5%. Increasing PSA was significantly associated with increased risk of PSA failure in the interaction model (adjusted hazard ratio (AHR: 1.09 [95% CI: 1.03–1.16]; P=0.005, whereas unilateral (AHR: 1.24 [95% CI: 0.36–4.34]; P=0.73 or bilateral NS (AHR: 0.41 [95% CI: 0.06–2.59]; P=0.34 versus non-NS RP was not. Conclusion. NS-RP in a screened cohort did not increase risk of PSA failure using NS criteria not including PSA.

  5. Detection of prostate-specific antigen with biomolecule-gated AlGaN/GaN high electron mobility transistors

    International Nuclear Information System (INIS)

    In order to improve the sensitivity of AlGaN/GaN high electron mobility transistor (HEMT) biosensors, a simple biomolecule-gated AlGaN/GaN HEMT structure was designed and successfully fabricated for prostate specific antigen (PSA) detection. UV/ozone was used to oxidize the GaN surface and then a 3-aminopropyl trimethoxysilane (APTES) self-assembled monolayer was bound to the sensing region. This monolayer serves as a binding layer for attachment of the prostate specific antibody (anti-PSA). The biomolecule-gated AlGaN/GaN HEMT sensor shows a rapid and sensitive response when the target prostate-specific antigen in buffer solution was added to the antibody-immobilized sensing area. The current change showed a logarithm relationship against the PSA concentration from 0.1 pg/ml to 0.993 ng/ml. The sensitivity of 0.215% is determined for 0.1 pg/ml PSA solution. The above experimental result of the biomolecule-gated AlGaN/GaN HEMT biosensor suggested that this biosensor might be a useful tool for prostate cancer screening. (paper)

  6. Development of computing code system for level 3 PSA

    Energy Technology Data Exchange (ETDEWEB)

    Jeong, Jong Tae; Yu, Dong Han; Kim, Seung Hwan

    1997-07-01

    Among the various research areas of the level 3 PSA, the effect of terrain on the transport of radioactive material was investigated through wind tunnel experiment. These results will give a physical insight in the development of a new dispersion model. Because there are some discrepancies between the results from Gaussian plume model and those from field test, the effect of terrain on the atmospheric dispersion was investigated by using CTDMPLUS code. Through this study we find that the model which can treat terrain effect is essential in the atmospheric dispersion of radioactive materials and the CTDMPLUS model can be used as a useful tool. And it is suggested that modification of a model and experimental study should be made through the continuous effort. The health effect assessment near the Yonggwang site by using IPE (Individual plant examination) results and its site data was performed. The health effect assessment is an important part of consequence analysis of a nuclear power plant site. The MACCS was used in the assessment. Based on the calculation of CCDF for each risk measure, it is shown that CCDF has a slow slope and thus wide probability distribution in cases of early fatality, early injury, total early fatality risk, and total weighted early fatality risk. And in cases of cancer fatality and population dose within 48km and 80km, the CCDF curve have a steep slope and thus narrow probability distribution. The establishment of methodologies for necessary models for consequence analysis resulting form a server accident in the nuclear power plant was made and a program for consequence analysis was developed. The models include atmospheric transport and diffusion, calculation of exposure doses for various pathways, and assessment of health effects and associated risks. Finally, the economic impact resulting form an accident in a nuclear power plant was investigated. In this study, estimation models for each cost terms that considered in economic

  7. Tumorigenic properties of alternative osteopontin isoforms in mesothelioma

    Energy Technology Data Exchange (ETDEWEB)

    Ivanov, Sergey V., E-mail: Sergey.Ivanov@med.nyu.edu [Thoracic Surgery Laboratory, Cardiothoracic Surgery Department, NYU Langone Medical Center, 462 First Ave., Bellevue Hospital, Room 15N20, NY 10016 (United States); Ivanova, Alla V.; Goparaju, Chandra M.V.; Chen, Yuanbin; Beck, Amanda; Pass, Harvey I. [Thoracic Surgery Laboratory, Cardiothoracic Surgery Department, NYU Langone Medical Center, 462 First Ave., Bellevue Hospital, Room 15N20, NY 10016 (United States)

    2009-05-08

    Osteopontin (SPP1) is an inflammatory cytokine that we previously characterized as a diagnostic marker in patients with asbestos-induced malignant mesothelioma (MM). While SPP1 shows both pro- and anti-tumorigenic biological effects, little is known about the molecular basis of these activities. In this study, we demonstrate that while healthy pleura possesses all three differentially spliced SPP1 isoforms (A-C), in clinical MM specimens isoform A is markedly up-regulated and predominant. To provide a clue to possible functions of the SPP1 isoforms we next performed their functional evaluation via transient expression in MM cell lines. As a result, we report that isoforms A-C demonstrate different activities in cell proliferation, wound closure, and invasion assays. These findings suggest different functions for SPP1 isoforms and underline pro-tumorigenic properties of isoforms A and B.

  8. Developmental expression of two Haliotis asinina hemocyanin isoforms.

    Science.gov (United States)

    Streit, Klaus; Jackson, Daniel; Degnan, Bernard M; Lieb, Bernhard

    2005-09-01

    Hemocyanins are large copper-containing respiratory proteins that play a role in oxygen transport in many molluscs. In some species only one hemocyanin isoform is present while in others two are expressed. The physiological relevance of these isoforms is unclear and the developmental and tissue-specific expression of hemocyanin genes is largely unknown. Here we show that two hemocyanin genes in the gastropod Haliotis asinina, which encode H. asinina hemocyanin (HaH1) and HaH2 isoforms, are developmentally expressed. These genes initially are expressed in a small number of mesenchyme cells at trochophore and pre-torsional veliger stages, with HaH1 expression slightly preceding HaH2. These cells largely are localized to the visceral mass, although a small number of cells are present in head and foot regions. Following metamorphosis the isoforms show overlapping as well as isoform-specific expression profiles, suggesting some degree of isoform-specific function.

  9. Comorbidities and Concomitant Medication Use in Men with Prostate Cancer or High Levels of PSA Compared to Matched Controls: A GPRD Analysis

    Directory of Open Access Journals (Sweden)

    Haojie Li

    2012-01-01

    Full Text Available Comorbidity influences screening practice, treatment choice, quality of life, and survival. The presence of comorbidities and medication use could place patients at greater risks of adverse effects from certain interventions. We conducted a longitudinal cohort study in the General Practice Research Database to better understand comorbidities and medication use in men with or at risk of prostate cancer (CaP. Compared with men with similar age but no CaP, CaP patients had higher incidence of urinary tract infection, impotence and breast disorder, and 2.6-fold higher all-cause mortality. Among men with elevated prostate-specific antigen (PSA but no CaP, the mortality rates were slightly lower, and fewer differences in comorbidities and medication use were noted compared to men without elevated PSA. Many prevalent comorbidities and medications were consistent across groups and are typical of an older male population. These real-world data are broadly applicable throughout the drug development cycle and subsequent patient management.

  10. Guidance to risk-informed evaluation of technical specifications using PSA

    Energy Technology Data Exchange (ETDEWEB)

    Baeckstroem, O.; Haeggstroem, A. (Scandpower AB, Stockholm (Sweden)); Maennistoe, I. (VTT, Helsingfors (Finland))

    2010-04-15

    This report presents guidance for evaluation of Technical Specification conditions with PSA. It covers quality in PSA, how to verify that the PSA model is sufficiently robust and sufficiently complete and general requirements on methods. Acceptance criteria for evaluation of changes in the TS conditions are presented. As the probabilistic safety assessment (PSA) has developed over the years, it has demonstrated to constitute a useful tool for evaluating many aspects of the TS from a risk point of view. and in that way making the PSAs as well as the decision tools better. This also means that it will be possible to take credit for safety system overcapacity as well as inherent safety features and strength of non-safety classed systems. However, PSA is only one of the tools that shall be used in an evaluation process of TS changes (strengthening/relaxation). PSA is an excellent tool to be used to verify the importance, and thereby possibly relaxation, of TS requirements. But, since PSA is only one tool in the evaluation, it is not sufficient in itself for defining which equipment that shall or shall not have TS requirements. The purpose of this guidance document is to provide general requirements, requirements on methods and acceptance criteria on risk-informed evaluation of TS changes based on PSA. The purpose is not to provide a single solution. As part of the review of the TS conditions this guidance specify requirements on: - Quality verification of the PSA model; - Verification that the PSA model is sufficiently robust with regard to SSCs for which requirements both are and are not defined by the TS; - Verification that the SSCs, for which TS demands are to be evaluated, are modelled in a sufficient manner; - Methods for performing the evaluation; - Which evaluation criteria that shall be used (and how that is verified to be correct); - Acceptance criteria: This guidance also briefly discusses the documentation of the analysis of the TS changes. This guidance

  11. 体重指数及血脂水平与血清前列腺特异抗原的关系:一组中国50岁以下人群的研究%Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men younger than 50 years of age

    Institute of Scientific and Technical Information of China (English)

    Ming Liu; Jian-Ye Wang; Ling Zhu; Gang Wan

    2011-01-01

    This study is to assess the potential factors that could affect the serum prostate-specific antigen (PSA) level in healthy younger men.We evaluated the associations of age, body mass index (BMI) and serum lipid profile with serum PSA level in 6774 Chinese men (aged 20-49 years) who received a routine health examination. Eligible men were classified into 10-year age groups. BMI was categorized as underweight (< 18.5), normal (18.5-22.9), overweight (23.0-24.9), obese (25.0-29.9) and very obese (>30)according to the redefined World Health Organization (WHO) criteria for the Asia-Pacific region. PSA levels were compared among groups as well. In multiple linear regression analysis, PSA was positively correlated with age (P<0.0001). Negative correlations existed between PSA and BMI (P<0.0001) and triglyceride level (P=0.01). No relationship could be found between PSA and serum cholesterol (P=0.711) or high-density lipoprotein (HDL; P =0.665). In addition, we found that serum PSA levels increased with age and decreased with BMI. Our study demonstrates that age, BMI and triglyceride levels influence the PSA level in men <50 years of age.

  12. Automated installation for gas separation and purification using the Pressure Swing Adsorption (PSA) process; Instalacao automatizada para separacao e purificacao de gases por PSA

    Energy Technology Data Exchange (ETDEWEB)

    Neves, Celia F. Cordeiro; Schvartzman, Monica M.A.M. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN), Belo Horizonte, MG (Brazil); Jordao, Elizabete [Universidade Estadual de Campinas, SP (Brazil). Dept. de Engenharia de Sistemas Quimicos e Informatica

    1999-11-01

    This paper describes the first laboratorial PSA (Pressure Swing Adsorption) unit designed and built in Brazil for gas separation by adsorption process. It consists of a stainless steel column, which was filled with zeolite 5A molecular sieve. Six solenoid valves located at the feed., product, countercurrent and high-pressure air lines were used to regulate the flow directions of different streams. Pressure and flowrate transducers and thermocouples were used to record respectively the pressure, flowrate of both feed and product stream and temperature history of the process. These instruments and the solenoid valves were joined to a programmable logic controller. By the use of a computer the unit can be automatically operated to simulate all steps in the PSA cycle and data can be easily acquired and recorded. The unit will be used to study basic parameters of PSA processes and to separate several gas mixtures. As a first goal the unit will be operated to produce oxygen-enriched air using synthetic zeolites. This PSA laboratory unit is an important step in CDTN`s objective of consolidating a research group in gas separation by adsorption processes. (author) 7 refs., 8 figs., 2 tabs.

  13. Androgen receptor isoforms in human and rat prostate

    Institute of Scientific and Technical Information of China (English)

    Shu-JieXIA; Gang-YaoHAO; Xiao-DaTANG

    2000-01-01

    Aim: To investigate the androgen receptor (AR) isoforms and its variability of expression in human and rat prostatic tissues. Methods: Human benign prostatic hyperplasia (BPH) and prostatic cancer tissues were obtained from patients undergoing prostatectomy, and rat ventral prostate was incised 3 days after castration. Forty-one AR-positive BPH specimens, 3 prostatic cancer specimens, and 6 rat prostates were used. After processing at 4℃, the tissues were examined by means of high resolution isoelectric focusing (IEF) technique to determine their AR isoforms. Results:From the prostatic specimens, 3 types of AR isoforms were detected with pI values at 6.5, 6.0, and 5.3. In human BPH tissues, 15/41 (36.6%) specimens showed all the three types of isoforms, while 19/41 (46.3%) showed 2 isoforms at various combinations and 7/41(17.1%), 1 isoform. For the 3 prostatic cancer specimens, one showed 3 isoforms, one, 2 isoforms, and the other failed to show any isoform. All rat prostatic tissues showed 2 isoforms at different combinations. Binding of 3H-dihydrotestosterone (DHT) to the isoforms was inhibited by the addition of 100-fold excess of DHT or testosterone, but not progesterone, oestradiol or diethylstilboestrol. Conclusion: AR isoforms are different in different patients. Although their genesis is not clear, the therapeutic implication of the present observation appears to be interesting, that may help clarifying the individual differences in the response to hormonal therapy.(Asian J Androl 2000 Dec;2:307-310)

  14. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone

    OpenAIRE

    SALIDO-GUADARRAMA, ALBERTO IVAN; MORALES-MONTOR, JORGE GUSTAVO; Rangel-Escareño, Claudia; Langley, Elizabeth; Peralta-Zaragoza, Oscar; COLIN, JOSE LUIS CRUZ; Rodriguez-dorantes, Mauricio

    2016-01-01

    At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer (PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia (BPH) with PSA levels in the ʻgray areaʼ (4–10 ng/ml) are currently subjected to unnecessary biopsy due to overdiagnosis. Certain microRNAs (miRs) have been proven to be useful biomarkers, several of which are detectable in bodily fluids. The present study identified and validated a urinary miR-based signature to ...

  15. Establishment of Infrastructure for Domestic-Specific Level 3 PSA based on MACCS2

    International Nuclear Information System (INIS)

    Research activities related to the Level 3 PSA have naturally disappeared since the use of risk surrogates. Recently, Level 3 PSA was only performed to the extent of the purpose of operating license for the plant under construction. Since the Fukushima accident, concern about a comprehensive site-specific Level 3 PSA has been raised for some compelling reasons, especially the evaluation of the domestic multi-unit site risk effect including other site radiological sources (e.g., spent fuel pool, multi-units). Unfortunately, there are no domestic-specific consequence analysis code and input database required to perform a site-specific Level 3 PSA. The paper focuses on the development of the input data management system for domestic-specific Level 3 PSA based MACCS2 (MELCOR Accident Consequence Code System). The authors call it KOSCA-MACCS2 (Korea Off-Site Consequence Analysis based in MACCS2). It serves as an integrated platform for a domestic-specific Level 3 PSA. Also, it provides the pre-processing modules to automatically generate MACCS2 input from diverse types of the domestic-specific data including numerical map data, e.g., meteorological data, numerical population map, digital land use map, economic statistics and so on. Note that some functions should be still developed and added on it, e.g., post-processing module to convert MACCS2 outputs to graphic report forms, and so on. Henceforth, it is necessary to develop a Korean-specific Level 3 PSA code as a substitution for the foreign software, MACCS2

  16. Establishment of Infrastructure for Domestic-Specific Level 3 PSA based on MACCS2

    Energy Technology Data Exchange (ETDEWEB)

    Jang, Seung-Cheol; Han, Seok-Jung; Choi, Sun-Yeong; Lee, Seung-Jun [KAERI, Daejeon (Korea, Republic of); Kim, Wan-Seob [Korea Reliability Technology and System, Daejeon (Korea, Republic of)

    2015-05-15

    Research activities related to the Level 3 PSA have naturally disappeared since the use of risk surrogates. Recently, Level 3 PSA was only performed to the extent of the purpose of operating license for the plant under construction. Since the Fukushima accident, concern about a comprehensive site-specific Level 3 PSA has been raised for some compelling reasons, especially the evaluation of the domestic multi-unit site risk effect including other site radiological sources (e.g., spent fuel pool, multi-units). Unfortunately, there are no domestic-specific consequence analysis code and input database required to perform a site-specific Level 3 PSA. The paper focuses on the development of the input data management system for domestic-specific Level 3 PSA based MACCS2 (MELCOR Accident Consequence Code System). The authors call it KOSCA-MACCS2 (Korea Off-Site Consequence Analysis based in MACCS2). It serves as an integrated platform for a domestic-specific Level 3 PSA. Also, it provides the pre-processing modules to automatically generate MACCS2 input from diverse types of the domestic-specific data including numerical map data, e.g., meteorological data, numerical population map, digital land use map, economic statistics and so on. Note that some functions should be still developed and added on it, e.g., post-processing module to convert MACCS2 outputs to graphic report forms, and so on. Henceforth, it is necessary to develop a Korean-specific Level 3 PSA code as a substitution for the foreign software, MACCS2.

  17. The new Planetary Science Archive (PSA): Exploration and discovery of scientific datasets from ESA's planetary missions

    Science.gov (United States)

    Martinez, Santa; Besse, Sebastien; Heather, Dave; Barbarisi, Isa; Arviset, Christophe; De Marchi, Guido; Barthelemy, Maud; Docasal, Ruben; Fraga, Diego; Grotheer, Emmanuel; Lim, Tanya; Macfarlane, Alan; Rios, Carlos; Vallejo, Fran; Saiz, Jaime; ESDC (European Space Data Centre) team

    2016-10-01

    The Planetary Science Archive (PSA) is the European Space Agency's (ESA) repository of science data from all planetary science and exploration missions. The PSA provides access to scientific datasets through various interfaces at http://archives.esac.esa.int/psa. All datasets are scientifically peer-reviewed by independent scientists, and are compliant with the Planetary Data System (PDS) standards. The PSA is currently implementing a number of significant improvements, mostly driven by the evolution of the PDS standard, and the growing need for better interfaces and advanced applications to support science exploitation. The newly designed PSA will enhance the user experience and will significantly reduce the complexity for users to find their data promoting one-click access to the scientific datasets with more specialised views when needed. This includes a better integration with Planetary GIS analysis tools and Planetary interoperability services (search and retrieve data, supporting e.g. PDAP, EPN-TAP). It will be also up-to-date with versions 3 and 4 of the PDS standards, as PDS4 will be used for ESA's ExoMars and upcoming BepiColombo missions. Users will have direct access to documentation, information and tools that are relevant to the scientific use of the dataset, including ancillary datasets, Software Interface Specification (SIS) documents, and any tools/help that the PSA team can provide. A login mechanism will provide additional functionalities to the users to aid / ease their searches (e.g. saving queries, managing default views). This contribution will introduce the new PSA, its key features and access interfaces.

  18. Low free to total PSA ratio is not a good discriminator of chronic prostatitis and prostate cancer: An Indian experience

    Directory of Open Access Journals (Sweden)

    V Thakur

    2014-01-01

    Full Text Available Aims: To find out the utility of free to total PSA ratio in discriminating chronic prostatitis and prostate cancer. Setting and design: The patients visited urology clinics at Batra Hospital and Medical Research Center, New Delhi. Background: The use of serum free to total PSA as a diagnostic tool for prostate cancer has led to early detection of prostate cancer; however, the effect of inflammation on f/t PSA ratio restricts its use in early detection of cancer. Materials and Methods: The study was conducted in age related 101 patients which include 27 carcinoma patients (group I, 34 BPH patients (group II and 40 chronic prostatitis patients (group III. Serum total PSA (tPSA and free PSA (fPSA were analyzed on Elecsys 2010. These were compared with histological reports of biopsy specimen. Other biochemistry tests were done on Randox Imola. P Value was calculated using one way ANOVA with posthoc Bonferroni analysis. Results: Serum total PSA levels were comparable in group I and III and were higher than group II (P < 0.049. Serum fPSA in group I was not significantly different from group II and III, However, group II has higher levels than group III (P < 0.035. Difference was significant for f/t PSA ratio in group I and II (P < 0.00 and group II and III (P < 0.000.Group I and III were with comparable levels (P < 0.807. Conclusions: f/t PSA ratio is not a good discriminator for malignancy and chronic prostatitis. This limitation of f/t PSA ratio must be taken into consideration while interpreting the results clinically.

  19. Role of HLA class I antigens in the development of psoriatic arthritis and its clinical presentation

    Directory of Open Access Journals (Sweden)

    Irina Aleksandrovna Troshkina

    2012-01-01

    Full Text Available Objective: to investigate the association of HLA Class I antigens with the predisposition to psoriatic arthritis (PsA and the severity and types of articular syndrome in PsA. Subjects and methods. The investigation enrolled 99 patients (56 females and 43 males aged 43.5+13 years with PA with a median duration of 2 (range 0.8-10 years. An oligoarthritic type was observed in 28 patients, polyarthritic, distal, and spondyloarthritic types were present in 28, 39, and 10 patients, respectively. Two patient groups were formed according to the age at onset of psoriasis: 1 71 patients aged less than 40 years and 2 23 patients aged over 40 years. Results. As compared with the control group, the patients with PsA were found to have a higher frequency of HLA-B13 (odds ratio [OR] 2.72; p < 0.004, HLA-В16 (OR 3.95; p < 0.0001, and HLA-B27 (OR 3.2; p < 0.003. There was an association of the types of joint injury with HLA antigens: the distal type with HLA-B13 (OR 3.38; p < 0.02 and HLA-В16 (OR 3.95; p < 0.01, the polyarthritic type with HLA-В16 (OR 5.90; p < 0.0001 and HLA-B27 (OR 3.26; p < 0.01, and the spondyloarthritic type with HLA-B27 (OR 6.32; p < 0.001. The young onset of psoriasis was associated with HLA-B13 (OR 3.29; p < 0.001. The detection rate of the B38 antigen (the subtype of HLA-B16 was higher in all X-ray stages of PsA and was 16.4% in Stages I-IIA, 25% in Stage IIB, and 40.9% in Stages III-IV versus 8.7% in the control group, the magnitude of the association being increased with the higher degree of joint destruction. Conclusion. The detailed analysis of the investigation revealed that HLA system antigens were differently involved in the development of PsA and clinical types of articular syndrome.

  20. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer

    DEFF Research Database (Denmark)

    Martínez-Piñeiro, Luis; Schalken, Jack A; Cabri, Patrick;

    2014-01-01

    OBJECTIVE: To assess prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG scores in patients with advanced and metastatic prostate cancer at baseline and after 6 months of treatment with triptorelin 22.5 mg, and analyse these scores in patient-groups defined by different disease characteristics...... change at 6 months, according to baseline variables. Other outcome measures included urinary PCA3 and TMPRSS2-ERG scores and statuses, and serum testosterone and prostate-specific antigen (PSA) levels at baseline and at 1, 3 and 6 months after initiation of ADT. Safety was assessed by recording adverse...... metastasis or unknown metastasis status. TMPRSS2-ERG scores ≥35 were considered positive (n = 149 [51.6%]). Age, presence of metastasis, PSA level and Gleason score at baseline were not associated with a significant difference in the proportion of TMPRSS2-ERG-positive scores. The median serum PSA levels...

  1. Prostate-specific antigen levels are higher in African-American than in white patients in a multicenter registration study: Results of RTOG 94-12

    International Nuclear Information System (INIS)

    Purpose: To compare serum prostate-specific antigen (PSA) levels in a national sample of African-American and white men with prostate cancer, and to attempt to explain any differences by using self-reported individual-level socioeconomic status adjustments. Methods and Materials: During 4((1)/(2)) months in 1994-95, 709 patients with nonmetastatic prostate cancer were enrolled in this prospective study; 17.5% were African-American and 82.5% were white. Information about clinical stage, tumor grade, pretreatment PSA, type of insurance, and educational and income status was obtained. Serum PSA levels were measured and racial differences were found; how the differences were influenced by other patient- or tumor-related factors and if the differences could be explained by socioeconomic status disparities were determined. In univariate analyses, factors associated with the mean PSA levels were studied; log-converted values were used to yield a normal distribution. Multivariate analyses were done on log-linear models for description of association patterns among various categorical variables; a perfectly fitted model should have a correlation value (CV) of 1.0. Results: The mean PSA level was higher in African-Americans (14.68 ng/ml) than in whites (9.82 ng/ml) (p = 0.001). Clinical stage (p = 0.001), Gleason sum tumor grade (p = 0.0001), educational level (p = 0.001), and household income (p = 0.03) were also associated with mean PSA levels; age, type of biopsy, and insurance status were not. Disease stage (p = 0.0001), grade (p 0.0001), education (p = 0.07), and income (p = 0.02) were all associated with PSA levels for whites, but none of these factors were important for African-Americans (all p values > 0.1). The best fitted log-linear model (CV = 0.99) contained PSA ( 20), Gleason sum grade (2-5, 6-7, and 8-10), race, and two interactions: PSA by race (p = 0.0012) and PSA by Gleason sum (p = 0.0001). Models replacing race for either income (CV = 0.82) or education

  2. Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score

    Science.gov (United States)

    Fang, Dong; Ren, Da; Zhao, Chenglin; Li, Xuesong; Yu, Wei; Wang, Rui; Wang, Huihui; Xi, Chenguang; He, Qun; Wang, Xiaoying; Xin, Zhongcheng; Zhou, Liqun

    2015-01-01

    Purpose. To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA) 4–10 ng/mL and develop a risk-stratification score model. Methods. The data of 345 patients who underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE), prostate volume (PV), magnetic resonance imaging (MRI), and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa) and high grade PCa (HGPCa, Gleason Score ≥ 7). Results. The median PSA was 7.15 (IQR 5.91–8.45) ng/mL. Overall 138 patients (40.0%) were shown to have PCa, including 100 patients (29.0%) with HGPCa. Smaller PV, elder age, MRI results, and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a “PAMD” score which combined the four factors to categorize patients into three risk groups, and the model performed good predictive sensitivity and specificity. Conclusion. The prevalence of prostate cancer in Chinese patients with PSA 4–10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI, and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making. PMID:26557679

  3. Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score

    Directory of Open Access Journals (Sweden)

    Dong Fang

    2015-01-01

    Full Text Available Purpose. To elucidate the characteristics and risk factors for positive biopsy outcomes in Chinese patients with prostate specific antigen (PSA 4–10 ng/mL and develop a risk-stratification score model. Methods. The data of 345 patients who underwent transrectal ultrasound-guided prostate biopsy between 2011 and 2013 was retrospectively analyzed. Digital rectal examination (DRE, prostate volume (PV, magnetic resonance imaging (MRI, and smoking status were also collected. Positive biopsy outcomes were defined as prostate cancer (PCa and high grade PCa (HGPCa, Gleason Score≥7. Results. The median PSA was 7.15 (IQR 5.91–8.45 ng/mL. Overall 138 patients (40.0% were shown to have PCa, including 100 patients (29.0% with HGPCa. Smaller PV, elder age, MRI results, and positive DRE were proved to be predictive factors for positive biopsy outcomes in both univariate and multivariate analysis. We developed a “PAMD” score which combined the four factors to categorize patients into three risk groups, and the model performed good predictive sensitivity and specificity. Conclusion. The prevalence of prostate cancer in Chinese patients with PSA 4–10 ng/mL was 40%, including 29% patients with high grade disease. DRE, age, MRI, and PV were predictive factors for positive biopsy outcomes, and the PAMD score model could be utilized for risk-stratification and decision-making.

  4. Comprehensive evaluation of new probabilistic safety analyses (PSA) for nuclear power stations outside Germany and status report on safety engineering

    International Nuclear Information System (INIS)

    This report was prepared on behalf of the Minister of Environment, Nature Conservation and Nuclear Safety. It summarizes the results of an analysis of the state of the art of foreign Probabilistic Safety Assessments (PSA) for nuclear power plants. Main features of selected PSA documents, characterizing methods and their application within the framework of operational safety assessment, are presented as well as insights gained from discussions with utilities and an authority. German examples of PSA were compared to the foreign analyses using experiences of the TUeV Nord e.V. from reviewing PSA. This comparison covers PSA of level 1. It was found that German PSA methods are generally comparable to the foreign approaches. Nevertheless differences were found with respect to the scope of operational states covered by the analyses, the details down to which human error analyses were performed as well as some special issues. The foreign examples demonstrate an extended application of PSA within the operational safety management. Experiences that were gained within this process over years form an appropriate basis for the establishment of probabilistic safety criteria as well as procedures for incorporating PSA into the operational safety evaluation process. A procedure is proposed for further performing and evaluating PSA and their results in Germany. (orig.)

  5. Research on the improvement of nuclear safety -Improvement of level 1 PSA computer code package-

    Energy Technology Data Exchange (ETDEWEB)

    Park, Chang Kyoo; Kim, Tae Woon; Kim, Kil Yoo; Han, Sang Hoon; Jung, Won Dae; Jang, Seung Chul; Yang, Joon Un; Choi, Yung; Sung, Tae Yong; Son, Yung Suk; Park, Won Suk; Jung, Kwang Sub; Kang Dae Il; Park, Jin Heui; Hwang, Mi Jung; Hah, Jae Joo [Korea Atomic Energy Research Institute, Taejon (Korea, Republic of)

    1995-07-01

    This year is the third year of the Government-sponsored mid- and long-term nuclear power technology development project. The scope of this sub project titled on `The improvement of level-1 PSA computer codes` is divided into three main activities : (1) Methodology development on the underdeveloped fields such as risk assessment technology for plant shutdown and low power situations, (2) Computer code package development for level-1 PSA, (3) Applications of new technologies to reactor safety assessment. At first, in this area of shutdown risk assessment technology development, plant outage experiences of domestic plants are reviewed and plant operating states (POS) are decided. A sample core damage frequency is estimated for over draining event in RCS low water inventory i.e. mid-loop operation. Human reliability analysis and thermal hydraulic support analysis are identified to be needed to reduce uncertainty. Two design improvement alternatives are evaluated using PSA technique for mid-loop operation situation: one is use of containment spray system as backup of shutdown cooling system and the other is installation of two independent level indication system. Procedure change is identified more preferable option to hardware modification in the core damage frequency point of view. Next, level-1 PSA code KIRAP is converted to PC-windows environment. For the improvement of efficiency in performing PSA, the fast cutest generation algorithm and an analytical technique for handling logical loop in fault tree modeling are developed. 48 figs, 15 tabs, 59 refs. (Author).

  6. Application of PSA methodology to design improvement of JAERI Passive Safety Reactor (JPSR)

    International Nuclear Information System (INIS)

    A probabilistic safety assessment (PSA) technique was applied to the design of JAERI Passive Safety Reactor (JPSR). A PSA was performed to clarify safety features and identify vulnerabilities of the original design. Based on the PSA results and considering thermal-hydraulic analyses and experiments, the JPSR design was improved to enhance plant safety. The improved design was re-evaluated with the PSA. Initiating events selected in this study were: large-break LOCA, medium- and small-break LOCAs, SGTR, main steam line break, loss of offsite power, loss of feed water, and other transients. Fault tree analyses were used to evaluate the system unavailabilities. The total core damage frequency due to internal events was estimated to be less than 10-7/RY. The contribution of high frequency non-LOCA events could be significantly reduced by the design modification. The dominant initiating event was the small break LOCA and the dominant sequence was the failure of residual heat removal system. The present study indicated that the improved JPSR design has sufficient safety margin and the PSA methodology is very effective to improve reactor safety systems in a conceptual design phase. (author)

  7. A quantitative study on important factors of the PSA of safety-critical digital systems

    International Nuclear Information System (INIS)

    This paper quantitatively presents the effects of important factors of the probabilistic safety assessment (PSA) of safety-critical digital systems. The result which is quantified using fault tree analysis methodology shows that these factors remarkably affect the system safety. In this paper we list the factors which should be represented by the model for PSA. Based on the PSA experience, we select three important factors which are expected to dominate the system unavailability. They are the avoidance of common cause failure, the coverage of fault tolerant mechanisms and software failure probability. We quantitatively demonstrate the effect of these three factors. The broader usage of digital equipment in nuclear power plants gives rise to the safety problems. Even though conventional PSA methods are immature for applying to microprocessor-based digital systems, practical needs force us to apply it because the result of PSA plays an important role in proving the safety of a designed system. We expect the analysis result to provide valuable feedback to the designers of digital safety-critical systems

  8. Use of PSA in the regulatory process. Report of the specialist's meeting. Working material

    International Nuclear Information System (INIS)

    The objective of this meeting was to focus on the role of the regulator in relation to PSA, to give a picture of the present status, and near term plans, of the requirements placed on licensees and of the uses, formal and informal, made of PSA in regulatory decision making. One such use, in which there is currently much interest, is known as Risk-Based Regulation. This term has various connotations but essentially refers to a more flexible and efficient application of Technical Specifications in the interests of gains in both economy and safety. The position in many countries is one of change in the use of PSA by regulators, and hence any report can only give a snapshot in time. It has to be noted that a number of countries, with important nuclear power programmes, were not represented at the meeting, and so the overall picture is not as comprehensive as might have been hoped. The field of the discussion in the meeting was divided into three areas, progressed in three working groups, namely: Regulatory requirements related to PSA, Regulatory uses of PSA, and Risk-Based Regulation. The outcomes are covered in the next three sections. The fifth section of this report gives the overall conclusions of the meeting and the final section makes some recommendations for future IAEA activities in these areas. Refs, figs, tabs

  9. 无症状炎症性前列腺炎与血清 PSA 水平的关系--防城港地区男性健康大型横断面调查%The relationship between asymptomatic inflammatory prostatitis and serum PSA level-A large prevalence survey of Fangchenggang area male health

    Institute of Scientific and Technical Information of China (English)

    张志甫; 吴春磊; 陆铮; 莫曾南

    2014-01-01

    Objective To investigate the relationship between asymptomatic inflammatory prostatitis (AIP)and serum prostate specific antigen (PSA). Methods Data collection was conducted in the Medical Examination Centre of Fangchenggang First People's Hospital.During the physical examination,trained physi-cians administered a standard questionnaire,basic data including National Institutes of Health Chronic Prostati-tis Symptom Index (NIH-CPSI),demographic information (age,education,occupation,etc),history of dis-ease,and lifestyle risk factors (smoking,alcohol consumption,and physical activity),and health status were collected using a standardized questionnaire.A trained profession conducted the anthtopometric parameters measurements for the participants.8 h-fasting vein blood was drawn and then the biochemical indexes [PSA, triglyceride (TG),high density cholesterol-cholesterol (HDL-C),and fasting blood glucose]were meas-ured.The expressed prostatic secretions (EPS)were collected and then were smeared on a glass slide for counting the mean WBC count of EPS.According to the NIH-CPSI score,and presence of inflammation,the participants were divided into a NIH-IV prostatitis group and a healthy group. Results The mean value of serum PSA in the healthy group and the NIH-IV prostatitis group were 0.91 ng/ml and 1.27 ng/ml,the standard deviation was 0.79 ng/ml,and 1.52 ng/ml,there were statistically significant differences (P <0.001).In NIH-IV prostatitis group,the scores of age,TG,diastolic blood pressure (DBP),systolic blood pressure (SBP),hypertension,education status,physical activity were higher than those in the healthy group. NIH-IV prostatitis (WBC≥3+)group compared to healthy group,along with the elevated PSA the OR value was also increased,the OR value was 1.078,3.589,4.406,respectively.In PSAQ4,with the elevation of in-flammation the OR value also increased.Respectively in age,education status,dyslipidemia,diabetes,high blood pressure

  10. PSA e medidas antropométricas em índios da Amazônia: avaliação da comunidade Parkatejê PSA and anthropometric measurements among Amazon Indians: an evaluation of the Parkatejê community

    Directory of Open Access Journals (Sweden)

    Homero Oliveira de Arruda

    2003-10-01

    Full Text Available OBJETIVO: O rastreamento com o PSA (antígeno prostático específico para detecção precoce de câncer de próstata em uma comunidade nativa tem grande importância epidemiológica. Assim, realizou-se estudo com objetivo de verificar a ocorrência do câncer da próstata em uma tribo indígena da Amazônia e uma possível relação entre o aculturamento, a presença de sobrepeso (índice de massa corporal e o aparecimento da doença. MÉTODOS: Foi realizado um levantamento dos hábitos e medidas antropométricas em 22 homens com idade presumida maior de 50 anos, de uma tribo isolada de 363 índios, autodenominados Parkatejê e Kikatêjê, vivendo na região Amazônica (Pará. Além dos exames físico e hematológicos, foram realizadas dosagens de PSA total e PSA livre. RESULTADO: Os níveis séricos de PSA total variaram de 0,35 a 25,8 ng/ml. Três nativos apresentaram PSA maior que 4,0 ng/ml e outros dois evidenciaram PSA entre 2,5 e 4,0 ng/ml. Biopsia prostática em dois nativos revelou a presença de adenocarcinoma de próstata em um e neoplasia intraepitelial em outro. Sobrepeso com índice de massa corporal >25 Kg/m² e relação cintura-quadril >0,9 foram observados em 68,1% e 72,7% do grupo estudado. CONCLUSÕES: Mudanças nutricionais decorrentes do contato com a civilização, como substituição da caça e fibras vegetais por alimentos mais calóricos, estão aumentando a freqüência de sobrepeso na comunidade indígena. Devido à associação entre incidência de câncer de próstata, dieta gordurosa e menor atividade física, pode-se presumir que o futuro testemunhará mais casos da neoplasia prostática, visto que vários de seus membros já evidenciaram altos níveis séricos de PSA.OBJECTIVE: PSA (prostate-specific antigen screening for early detection of prostate cancer in a native community is of great epidemiological importance. The study was conducted with the objective of verifying the occurrence of prostate cancer among

  11. Evidence for leptin receptor isoforms heteromerization at the cell surface.

    Science.gov (United States)

    Bacart, Johan; Leloire, Audrey; Levoye, Angélique; Froguel, Philippe; Jockers, Ralf; Couturier, Cyril

    2010-06-01

    Leptin mediates its metabolic effects through several leptin receptor (LEP-R) isoforms. In humans, long (LEPRb) and short (LEPRa,c,d) isoforms are generated by alternative splicing. Most of leptin's effects are believed to be mediated by the OB-Rb isoform. However, the role of short LEPR isoforms and the possible existence of heteromers between different isoforms are poorly understood. Using BRET1 and optimized co-immunoprecipitation, we observed LEPRa/b and LEPRb/c heteromers located at the plasma membrane and stabilized by leptin. Given the widespread coexpression of LEPRa and LEPRb, our results suggest that LEPRa/b heteromers may represent a major receptor species in most tissues.

  12. Process optimization of PSA way Oxygen concentrator for electric power saving

    International Nuclear Information System (INIS)

    As the importance of low power design is emphasized, power consumption became one of the standards that represent the performance of the system. The purpose of this study is to decide design variable that minimize power consumption for the oxygen concentrator in two bed-one compressor 8 step PSA process that has above 90% purity at 3lpm by using given constants and selected parameters. Setting selected parameters as cycle time and equalization time, optimization for PSA process in the oxygen concentrator is progressed. For this, we need to know the features and basic principals of PSA process and to deduce objective function of performance analysis. Validations for objective function and lots of experiments are needed too. By using the characteristic curve of the compressor and the pressure curve of the process for 1 cycle, objective function was set. After theoretical 2 dimensional optimized paths was obtained. And then, by experiment, theoretical optimized path was verified

  13. Assessment of modern methods of human factor reliability analysis in PSA studies

    International Nuclear Information System (INIS)

    The report is structured as follows: Classical terms and objects (Probabilistic safety assessment as a framework for human reliability assessment; Human failure within the PSA model; Basic types of operator failure modelled in a PSA study and analyzed by HRA methods; Qualitative analysis of human reliability; Quantitative analysis of human reliability used; Process of analysis of nuclear reactor operator reliability in a PSA study); New terms and objects (Analysis of dependences; Errors of omission; Errors of commission; Error forcing context); and Overview and brief assessment of human reliability analysis (Basic characteristics of the methods; Assets and drawbacks of the use of each of HRA method; History and prospects of the use of the methods). (P.A.)

  14. Isolation and characterization of wild-type lipoxygenase LOX(Psa)1 from Pleurotus sapidus.

    Science.gov (United States)

    Plagemann, Ina; Krings, Ulrich; Berger, Ralf G

    2014-01-01

    The lipoxygenase LOX(Psa) 1 of Pleurotus sapidus, originally investigated because of its ability to oxidize (+)-valencene to the valuable grapefruit aroma (+)-nootkatone, was isolated from the peptidase-rich lyophilisate using a three-step purification scheme including preparative isoelectric focusing and chromatographic techniques. Nano-liquid chromatography electrospray ionization tandem mass spectrometry (nLC-ESI-MS/MS) of the purified enzyme and peptide mass fingerprint analysis gave 38 peptides of the lipoxygenase from P. sapidus. Nearly 50% of the 643 amino acids long sequence encoded by the cDNA was covered. Both terminal peptides of the native LOX(Psa) 1 were identified by de novo sequencing, and the postulated molecular mass of 72.5 kDa was confirmed. With linoleic acid as the substrate, the LOX(Psa)1 showed a specific activity of 113 U mg(-1) and maximal activity at pH 7.0 and 30 degrees C, respectively. PMID:24873036

  15. Application of probabilistic safety analysis (PSA) approach to structuring accident mitigation systems of a PWR

    International Nuclear Information System (INIS)

    The safety evaluation technology of PWRs has already been improved substantially because of large-scale safety verification tests and improvement of accuracy in analyses. However, for structuring accident mitigation systems (AMS), the selection of appropriate systems from various AMS candidates mainly depends on engineering judgements by design engineers. So systematic designing process should be established. Reliability of each AMS forms the basis for reliability of safety plant design as a whole. Therefore, explicitly understanding characteristics of each AMS's reliability is very important for safety design. Based on these facts as a background, the limitation of improving reliability by strengthening redundancy of AMS mainly consisting of active components was clarified by applying PSA. At the same time, reliability and other characteristics of AMS mainly consisting of passive components were also clarified with PSA. Through these studies, it is proved that the application of PSA for structuring AMS is effective. (author)

  16. Application of PSA to Assess the Safety Level of Nuclear Power Plants

    International Nuclear Information System (INIS)

    This paper reviews the application of PSA in German nuclear power plant regulation. From a fundamental point of view, it has to be mentioned that as stipulated in the corresponding requirements, regulatory decision making in Germany is primarily based on deterministic analyses and evaluations. Therefore, PSA is not used as a stand alone but as a supplementary basis. In this context PSA has developed a valuable tool with continuously growing importance. Level 1+ PSAs are now elaborated for all German nuclear power plants in operation, most of them are already reviewed by the competent supervisory authority and its experts. Current research activities on the federal level primarily concentrate on the further development of the methodology in the areas human factor, common cause failures, accident management measures and reduction of uncertainties in methods and data. (author)

  17. Data analysis treatment in the Juragua Nuclear Power Plant preoperational PSA

    International Nuclear Information System (INIS)

    Data Analysis is an important task within Probabilistic safety Assessment,. which usually determines the level of detail of the analysis, being the way to feed the PSA with the operational experience of the Nuclear Power Plant analysed. In this paper the role of the Data Analysis Task as part of the PSA process and the different kinds of data to be estimated are explained. A description is presented of the organization of the data Analysis in the Juragua NPP Preoperational PSA, the information sources and the criteria handled for the estimation of the different kinds of Data. The Generic Data Base adopted for equipment failures and the state of the generic data issue for VVER reactors and its prospects are also dealt with. The paper concludes with suggestions for the further development of Juragua NPP generic Data Base

  18. Recent Research on Natural Hazards PSA in Germany and Future Needs

    International Nuclear Information System (INIS)

    This contribution presents results of recent research and development activities with respect to probabilistic assessment of natural external hazards for nuclear power plants (NPP) in Germany. The German PSA Guideline and, in particular, its supplementary technical documents on PSA methods and data published in 2005 require probabilistic safety analyses (PSA) to be carried out in the frame of periodic safety reviews for nuclear power plants. With respect to external hazards this also includes to perform PSA for explosion pressure waves, aircraft crash, external flooding, and seismic PSA. In general, a graded approach is applied. Seismic PSAs, for example, are required for sites with design basis earthquake (DBE) intensities exceeding VII on the MSK or EMS scale, whereas for sites with lower seismic hazard, simplified approaches are acceptable. While methods are explicitly available for seismic and flooding PSA, this is not the case for other external hazards. Event combinations of natural external hazards with other events have also not yet been considered in external hazards PSA. Some related enhancements have taken place recently, several activities are ongoing. Various recent developments, such as results and findings of investigating the Fukushima Daiichi NPP accident in March 2011, concern the consideration of dependencies among different hazards or initiating events in the analysis. In this context, proposals for modeling different types of dependencies will be made. The dependencies to be mentioned are those among initiating events occurring simultaneously as consequence of a postulated external hazard, dependencies among the initial hazard and consequential hazards or events, such as fires, explosions, flooding, etc., and finally dependencies with respect to failures of structures, systems and components (SSC). Starting point of any Hazards PSA is a site-specific probabilistic hazard assessment (PHA) that establishes a quantitative relationship between the

  19. fPSA/tPSA 及 PSAD 在前列腺疾病诊断中的价值%The Value of fPSA/tPSA and PSAD in the Diagnosis of Prostatic Diseases

    Institute of Scientific and Technical Information of China (English)

    何文正; 张红; 纪萌; 高佃军

    2015-01-01

    [ ABSTRACT] Objective To explore fPSA/tPSA and PSAD's value in the diagnosis of prostatic diseases.Meth-ods 458 patients with prostatic diseases were collected,including prostatitis,benign prostatic hyperplasia and the patho-logical diagnosis of prostate malignant tumor,and then calculated example fPSA/tPSA,PSAD values.Results Fifty-two cases of typeⅠⅡprostatitis were 6.01 ±3.25,0.31 ±0.22,0.24 ±0.33;75 cases of tpyeⅢ,Ⅳprostatitis group were 4.16 ±1.03,0.24 ±0.15,0.20 ±0.17;234 cases of benign prostatic hyperplasia group were 17.25 ±3.87,0.31 ±0. 27,0.35 ±0.12;97 cases of prostate cancer group were 51.35 ±49.23,0.13 ±0.11,0.69 ±0.12.Conclusion The conjoint analysis of fPSA/tPSA and PSAD in the diagnosis of prostate disease is superior to pure use of PSA.%目的:探究游离PSA( fPSA)和总PSA( tPSA)的比值( fPSA/tPSA)及前列腺抗原密度( PSAD)在前列腺疾病诊断中的价值。方法收集前列腺炎、良性前列腺增生、经病理明确诊断的前列腺恶性肿瘤患者共458例的tPSA并计算各例fPSA/tPSA,PSAD值。结果458例患者中52例Ⅰ,Ⅱ型前列腺炎组为6.01±3.25,0.31±0.22,0.24±0.33;75例Ⅲ,Ⅳ型前列腺炎组为4.16±1.03,0.24±0.15,0.20±0.17;234例良性前列腺增生组为17.25±3.87,0.31±0.27,0.35±0.12;97例前列腺癌组为51.35±49.23,0.13±0.11,0.69±0.12。结论 fPSA/tPSA及PSAD的联合分析在前列腺疾病的诊断中明显优于单纯使用PSA。

  20. Development and application of probabilistic safety assessment PSA in Daya Bay Nuclear Power Station

    International Nuclear Information System (INIS)

    This paper discusses the development and application of Level 1 PSA used for safety review, risk monitoring and on line maintenance of the nuclear power plant. PSA development includes the analysis of event tree, fault tree, FMEA, PSA quantification and the equipment reliability database. We have collected and processed the reliability data of external power source, the equipment reliability data and the initial event frequency. The thermal-hydraulics analysis of some important events and accidents, human factor analysis, and the calculation of human error probability have been made. During the development of event trees and fault trees, the effect of some support systems such as compressed air distribution system, ventilation system and electrical system have been taken into account. The system manuals, operation procedures and emergency operating procedures of Daya Bay NPP are referred to in this project. The operators of the NPP were involved in the establishment of all event trees and fault trees analysis. Furthermore, we have accepted the suggestion of IAEA experts, completed the logic chart of initial events to the initial events analysis of Daya Bay NPP, and optimized the code system of PSA model again. Together with the development of the reliability database, by absorbing the advanced experience of EDF, we have gained the reports about equipment's classifying, function and experience feedback information of Daya Bay NPP. According to the quantitative calculation of the latest Level 1 PSA Model of Daya Bay NPP, the results of Core Damage Frequency (CDF) is: CDF = 2.13E-5/reactor . year. The latest PSA Model of Daya Bay NPP includes: 1) 12 sorts of initial events, 67 sub-initial events, 70 fault trees; 2) 25 nuclear safety related systems were developed by fault trees and FMEA ; 3) 2609 fault tree logic gates; 4) 2146 basic events; 5) 680 core damage accident sequences. (authors)

  1. Deforestation Impacts of Environmental Services Payments: Costa Rica’s PSA Program 2000–2005

    OpenAIRE

    Robalino, Juan; Pfaff, Alexander; Sanchez-Azofefia, G. Arturo; Alpizar, Francisco; Leon, Carlos; Rodriguez, Carlos Manuel

    2008-01-01

    Costa Rica’s environmental services payments program (Pagos por Servicios Ambientales, or PSA) started in 1997 and was the true pioneer in this area. It is broadly cited and has led to numerous calls for emulating its approach in various ways. It has itself evolved over time, with acknowledged shifts in focus. To measure the impacts of changed implementation, following earlier work on the 1997–2000 payments (Sánchez-Azofeifa et al. 2007; Pfaff et al. 2007), we evaluated the impact of the PSA ...

  2. Abnormal antigens in breast cancer tissues and production of monoclonal antibodies against one of these antigens

    International Nuclear Information System (INIS)

    Breast cancer is associated with up regulation, down regulation of normal antigens or abnormal antigens. These antigens are very useful candidates as targets for the different breast cancer therapies and for vaccination trials. This study was done to characterize abnormal antigens, extract one of them and to produce monoclonal antibodies against the extracted antigen. One hundred and twenty Sudanese female patients were included in this study after informed consent. The mean age was 47. 2 years (16-80). Two tissue samples were obtained from each patient and they were confirmed as normal and cancerous breast tissues microscopically. 2D PAGE was used to analyze the protein content of samples. LC/MS and nr. fast a database search were used for separation and indentification of the abnormal proteins. Three different patterns of 2D Page results were obtained, the first pattern involved detection of four abnormal proteins in 26.7% of the patient cancerous tissues while they were undetected in the normal tissues of the same patients. In the second 2D PAGE result pattern the cancerous and the normal tissues of 67.5% patients were identical and they did not contain the four abnormal proteins while the third 2D PAGE pattern involved the presence of two abnormal antigens (from the four) in the cancerous tissues of 5.8% of the patients and they were absent from the normal tissues of the same patients. The four abnormal proteins were identified as, human Thioredoxin (D60nmutant), x-ray crystal structure of human galectin-1, retrocopy of tropomyosin 3(rc TPM3) and beta-tropomyosin (isoform 2). The primary and the secondary structures were obtained from the SWISSPROT and the PDB databases. Beta tropomyosin spot was extracted and used as antigen for monoclonal antibody production. Monoclonal antibody against beta- tropomyosin with a concentration of 0.35 mg/ml and a G11 anti beta-tropomyosin hybridoma cell line were produced. The monoclonal antibody was with single bad and

  3. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival. Results of a retrospective study

    Energy Technology Data Exchange (ETDEWEB)

    Siegmann, Alessandra; Faehndrich, Julia; Lohm, Gunnar; Hinkelbein, Wolfgang [Charite Universitaetsmedizin, Berlin (Germany). Dept. of Radiation Oncology; Bottke, Dirk; Bartkowiak, Detlef; Wiegel, Thomas [University Hospital Ulm (Germany). Dept. of Radiation Oncology; Miller, Kurt [Charite Universitaetsmedizin, Berlin (Germany). Dept. of Urology

    2011-08-15

    The optimal dose for salvage radiotherapy (SRT) after radical prostatectomy (RP) is still not defined. It should be at least 66 Gy. In the present study, the suitability of PSA regression as a selection criterion for an SRT dose escalation to 70.2 Gy was examined. Between 1997 and 2007, 301 prostate cancer patients received SRT after RP at the Charite - University Medicine Berlin, Campus Benjamin Franklin. None of the patients had antihormone therapy prior to SRT. A total of 234 patients received 66.6 Gy. From 2002 on, 67 patients with a PSA decrease during SRT were irradiated with 70.2 Gy. The influence of this selection and dose escalation on freedom from biochemical progression (bNED) was analyzed. The median follow-up of the whole group was 30 months, the median pre-SRT PSA was 0.28 ng/ml. Of the patients, 27% (82/301) developed biochemical progression, 31% from the 66.6 Gy cohort (73/292) and 13% from the 70.2 Gy cohort (9/67) (p = 0.01). The calculated 2-years bNED was 74% for the whole group, 88% vs. 71% after 70.2 Gy and 66.6 Gy, respectively (p = 0.01). In a multivariate analysis, the total dose (p = 0.017), the re-achievement of an undetectable PSA after SRT (p = 0.005), and the infiltration of the seminal vesicles (p = 0.049) were independent parameters of bNED. Our analysis suggests that patient selection during SRT for a dose escalation to 70.2 Gy can improve the freedom from biochemical progression in patients with SRT after RP. (orig.)

  4. Association of GPs' risk attitudes, level of empathy, and burnout status with PSA testing in primary care

    DEFF Research Database (Denmark)

    Pedersen, Anette F; Carlsen, Anders H; Vedsted, Peter

    2015-01-01

    Denne artikel undersøger, om variationen i raten af PSA-tests mellem alment praktiserende læger kan forklares af psykologiske faktorer som f.eks. lægens risikovillighed. Resultaterne viser, at lægens risikovillighed influerer på raten af PSA-tests. Forfatterne finder blandt andet, at patienter, s...

  5. Improvement of Initiating Events Analsis in Low-Power and Shutdown PSA for Korea Standard Nuclear Power Plant

    Energy Technology Data Exchange (ETDEWEB)

    Park, Jin Jee; Jang, Seung Chul; Lim, Ho Gon

    2005-04-15

    In this study, we have improved the methodology of the initiating event identification for the KSNP LPSD PSA to complement the deficiency obtained from Review of KSNP LPSD PSA Mode based on ANS LPSD PSA Standard. To improve the quality of initiating event analysis, we integrated three systematic approachs for this purpose such as Master Logic Diagram, the empirical approach using domestic and international operating experience and the engineering approach. And we have identified 22 initiation events finally. We could got a basis and satisfied a structured, systematic process for initiating event identification demanded in ANS LPSD PSA Standard. But the sufficient completeness of initiating event analysis for LPSD PSA, the domestic low power and shutdown operating experience for overhaul and un-planed outages analysis is also needed.

  6. Myophilin of Echinococcus granulosus: isoforms and phosphorylation by protein kinase C.

    Science.gov (United States)

    Martin, R M; Csar, X F; Gasser, R B; Felleisen, R; Lightowlers, M W

    1997-08-01

    Myophilin is a muscle-associated antigen of the taeniid cestode Echinococcus granulosus. This protein shows a high amino acid sequence homology with calponins and calponin-like proteins, which are proposed to be associated with the regulation of smooth muscle contraction. In order to provide supportive evidence for a relationship between these proteins, we characterized myophilin using electrophoretic, biochemical and molecular biological approaches. Two-dimensional protein electrophoretic separation of E. granulosus larval proteins defined 4 isoelectric isoforms of myophilin (alpha, beta, gamma and delta), which appeared to be a consequence of post-translational modification of a single gene product. It was also demonstrated biochemically that E. granulosus myophilin undergoes specific phosphorylation in vitro by protein kinase C (PKC). Finally, myophilin homologues were identified in extracts of Taenia hydatigena and T. ovis by immunoblot. A partial cDNA of the closely related species, E. multilocularis, was isolated by cloning procedures and showed 99% homology with the E. granulosus myophilin gene. The similarities of E. granulosus myophilin with calponins in their tissue localization, protein isoforms patterns, ability to be phosphorylated in vitro by PKC, and the relatively conserved nature of the protein among related parasites suggest that myophilin may be associated with smooth muscle contraction.

  7. HLA-G5 and G7 Isoforms in Pregnant Women.

    Directory of Open Access Journals (Sweden)

    Saeid Abediankenari

    2015-04-01

    Full Text Available Human leukocyte antigen-G which is an immune tolerance effecter molecule has an important role in the maintenance of fetus during pregnancy. Abortion is one of the complications of pregnancy period.  In this research, we have studied levels of HLA-G 5, HLA-G7 isoforms in the abortion-threatened pregnant women in comparison with controls. In a case-control study, 101 abortion-threatened women and 101 healthy pregnant women (healthy controls with age range 21-32 years were studied. Gene expression of HLA-5 and HLA-7 isoforms was analyzed by real-time polymerase chain reaction after mRNA extraction and cDNA synthesis. The results indicated that HLA-G5 was significantly lower in abortion-threatened women in comparison with the control group whereas HLA-G7 was not significantly differentbetween the 2 groups. HLA-G is a vital molecule during pregnancy that can be a key factor in prevention of abortion. It is concluded that determination of HLA-G5 can be of value in pregnancy.

  8. Prostate cancer detection upon transrectal ultrasound-guided biopsy in relation to digital rectal examination and prostate-specific antigen level: what to expect in the Chinese population?

    Directory of Open Access Journals (Sweden)

    Jeremy YC Teoh

    2015-01-01

    Full Text Available We investigated the prostate cancer detection rates upon transrectal ultrasound (TRUS-guided biopsy in relation to digital rectal examination (DRE and prostate-specific antigen (PSA, and risk factors of prostate cancer detection in the Chinese population. Data from all consecutive Chinese men who underwent first TRUS-guided prostate biopsy from year 2000 to 2013 was retrieved from our database. The prostate cancer detection rates with reference to DRE finding and PSA level of 50 ng ml−1 were investigated. Multivariate logistic regression analyses were performed to investigate for potential risk factors of prostate cancer detection. A total of 2606 Chinese men were included. In patients with normal DRE, the cancer detection rates were 8.6%, 13.4%, 21.8%, 41.7% and 85.2% in patients with PSA 50 ng ml−1 respectively. In patients with abnormal DRE, the cancer detection rates were 12.4%, 30.2%, 52.7%, 80.6% and 96.4% in patients with PSA 50 ng ml−1 respectively. Older age, smaller prostate volume, larger number of biopsy cores, presence of abnormal DRE finding and higher PSA level were associated with increased risk of prostate cancer detection upon multivariate logistic regression analyses (P < 0.001. Chinese men appeared to have lower prostate cancer detection rates when compared to the Western population. Taking the different risk factors into account, an individualized approach to the decision of TRUS-guided biopsy can be adopted.

  9. An antibody to de-N-acetyl sialic acid containing-polysialic acid identifies an intracellular antigen and induces apoptosis in human cancer cell lines.

    Directory of Open Access Journals (Sweden)

    Lindsay M Steirer

    Full Text Available Polysialic acid (PSA, an α2,8-linked homopolymer of N-acetylneuraminic acid (Neu5Ac, is developmentally regulated and its expression is thought to be restricted to a few tissues in adults. Recently, we showed that two human pathogens expressed a derivative of PSA containing de-N-acetyl sialic acid residues (NeuPSA. Here we show that an epitope identified by the anti-NeuPSA monoclonal antibody, SEAM 3 (SEAM 3-reactive antigen or S3RA, is expressed in human melanomas, and also intracellularly in a human melanoma cell line (SK-MEL-28, a human T cell leukemia cell line (Jurkat, and two neuroblastoma cell lines (CHP-134 and SH-SY5Y. SEAM 3 binding induced apoptosis in the four cell lines tested. The unusual intracellular distribution of S3RA was similar to that described for the PSA polysialyltransferases, STX and PST, which are also expressed in the four cell lines used here. Interestingly, suppression of PST mRNA expression by transfection of SK-MEL-28 cells with PST-specific short interfering RNA (siRNA resulted in decreased SEAM 3 binding. The results suggest further studies of the utility of antibodies such as SEAM 3 as therapeutic agents for certain malignancies.

  10. p53 Family: Role of Protein Isoforms in Human Cancer

    Directory of Open Access Journals (Sweden)

    Jinxiong Wei

    2012-01-01

    Full Text Available TP53, TP63, and TP73 genes comprise the p53 family. Each gene produces protein isoforms through multiple mechanisms including extensive alternative mRNA splicing. Accumulating evidence shows that these isoforms play a critical role in the regulation of many biological processes in normal cells. Their abnormal expression contributes to tumorigenesis and has a profound effect on tumor response to curative therapy. This paper is an overview of isoform diversity in the p53 family and its role in cancer.

  11. National STD Awareness Month and GYT: Get Yourself Tested PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-03-03

    April is National STD Awareness Month. In this PSA, native communities, especially adolescents and young adults, are encouraged to get educated, tested, and treated by visiting gytnow.org.  Created: 3/3/2011 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention.   Date Released: 3/3/2011.

  12. CDC: Tips from Former Smokers – Cessation PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-04-04

    You can quit smoking! This inspiring 30 second PSA features three people who successfully quit smoking after many years. They share their practical tips on how to quit for good.  Created: 4/4/2012 by Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion.   Date Released: 4/4/2012.

  13. State of the art on the probabilistic safety assessment (P.S.A.)

    International Nuclear Information System (INIS)

    The use of Probabilistic Safety Assessment (PSA) is internationally increasing as a means of assessing and improving the safety of nuclear and non-nuclear facilities. To support the development of a competence on Probabilistic Safety Assessment, a set of states of the art regarding these tools and their use has been made between 2001 and 2005, in particular on the following topics: - Definition of the PSA of level 1, 2 and 3; - Use of PSA in support to design and operation of nuclear plants (risk-informed applications); - Applications to Non Reactor Nuclear Facilities. The report compiled in a single document these states of the art in order to ensure a broader use; this work has been done in the frame of the Project 'Reliability and Safety of Nuclear Facility' of the Nuclear Development and Innovation Division of the Nuclear Energy Division. As some of these states of the art have been made in support to exchanges with international partners and were written in English, a section of this document is written in English. This work is now applied concretely in support to the design of 4. Generation nuclear systems as Sodium-cooled Fast Reactors and especially Gas-cooled Fast Reactor, that have been the subject of communications during the conferences ANS (Annual Meeting 2007), PSA'08, ICCAP'08 and in the journal Science and Technology of Nuclear Installations. (authors)

  14. Cancer - What You Don't Know Can Kill You PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-07-22

    This 60 second PSA is based on the July 2010 CDC Vital Signs report which provides information on colorectal and breast cancer and the importance of getting screened.  Created: 7/22/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 7/22/2010.

  15. PSA discriminator influence on (222)Rn efficiency detection in waters by liquid scintillation counting.

    Science.gov (United States)

    Stojković, Ivana; Todorović, Nataša; Nikolov, Jovana; Tenjović, Branislava

    2016-06-01

    A procedure for the (222)Rn determination in aqueous samples using liquid scintillation counting (LSC) was evaluated and optimized. Measurements were performed by ultra-low background spectrometer Quantulus 1220™ equipped with PSA (Pulse Shape Analysis) circuit which discriminates alpha/beta spectra. Since calibration procedure is carried out with (226)Ra standard, which has both alpha and beta progenies, it is clear that PSA discriminator has vital importance in order to provide precise spectra separation. Improvement of calibration procedure was done through investigation of PSA discriminator level and, consequentially, the activity of (226)Ra calibration standard influence on (222)Rn efficiency detection. Quench effects on generated spectra i.e. determination of radon efficiency detection were also investigated with quench calibration curve obtained. Radon determination in waters based on modified procedure according to the activity of (226)Ra standard used, dependent on PSA setup, was evaluated with prepared (226)Ra solution samples and drinking water samples with assessment of measurement uncertainty variation included. PMID:27016710

  16. The application of the PSA important measures in risk-informed administrations

    International Nuclear Information System (INIS)

    The importance measures analyses of PSA are main approaches during the risk-informed administrations. This paper reviews kinds of importance measures, mainly researches the meaning of the FV and RAW importance measures, and introduces the applications of importance measures in the in-service testing and categorization of SSCs, finally, discusses the limitations of the importance measures analyses. (authors)

  17. Total Order Reliability in PSA: Importance of Basic Events and Systems

    Energy Technology Data Exchange (ETDEWEB)

    E. Borgonovo; C. Smith

    2010-06-01

    The purpose of this work is twofold. First, to formalize the properties of the total order reliability importance measure for PSA models. Second, to extend the definition of the total order importance measure to groups of basic events. This allows one to obtain the importance of systems and to address the relevance of interactions among systems.

  18. The relevance of PSA during shutdown conditions for the Angra-1 NPP

    International Nuclear Information System (INIS)

    In view of the issuance of the Authorization for Permanent Operation of the Angra-1 Nuclear Power Plant, the Brazilian Regulatory Body (CNEN) is requiring a Probabilistic Safety Assessment (PSA) level 1 to be performed by the Utility (FURNAS), which should consider shutdown conditions within its scope. Angra-1 PSA is part of a Safety Improvement Programme under implementation. An analysis of Angra-1 power history, covering the last eight years of operation, has shown that 56.7% of this period corresponds to shutdown operational modes. Regarding the same period, an Analysis of Angra-1 operational experience was performed to select potential initiating events during shutdown conditions. Within the Safety Improvement Programme, a complete review of Angra-1 Technical Specifications should be carried out making use of the PSA results. The inclusion of Limiting Conditions for Operation during shutdown modes is expected to be recommended. The objective of this article is to point out, based on an analysis of Angra-1 operational experience and power history, covering the last three cycles, the relevance of requiring shutdown conditions to be included in the Angra-1 PSA scope. (author). 15 refs

  19. Level 3 PSA and it's implementation for PWR accident

    International Nuclear Information System (INIS)

    Reactor safety assessment of nuclear power plants using probabilistic assessment methodology is most important in addition to the deterministic assessment. The methodology of Level 3 Probabilistic Safety Assessment (PSA) is especially required to estimate severe accident or beyond design basis accidents of nuclear power plants. This method is carried out after the Fukushima accident. In this research, the postulations beyond design basis accidents of PWR AP - 1000 would be taken, and simulated at West Bangka sample site. The series of calculations performed are: calculate the source terms of the core damaged, modeling of meteorological conditions and environmental site, exposure pathway modeling, analysis of radionuclide dispersion and transport phenomena in the environment, radionuclide deposition analysis, analysis of radiation dose, protection & mitigation analysis, and risk analysis. The assessment uses a series of subsystems on PC Cosyma software. The results prove that the safety assessment using Level 3 PSA methodology is very effective and comprehensive estimate the impact, consequences, risks, nuclear emergency preparedness, and the reactor accident management especially for severe accidents or beyond design basis accidents of nuclear power plants. The results of the assessment can be used as a feedback to safety assessment of Level 1 PSA and Level 2 PSA. (author)

  20. MMOSA – A new approach of the human and organizational factor analysis in PSA

    International Nuclear Information System (INIS)

    The results of many Probabilistic Safety Assessment (PSA) studies show a very significant contribution of human errors to nuclear installations failure. This paper is intended to analyze both the human performance importance in PSA studies and the elements that influence it. Starting from Man–Machine–Organization System (MMOS) concept a new approach (MMOSA) was developed to allow an explicit incorporation of the human and organizational factor in PSA studies. This method uses old techniques from Human Reliability Analysis (HRA) methods (THERP, SPAR-H) and new techniques to analyze human performance. The main novelty included in MMOSA is the identification of the machine–organization interfaces (maintenance, modification and aging management plan and state of man–machine interface) and the human performance evaluation based on them. A detailed result of the Human Performance Analysis (HPA) using the MMOSA methodology can identify any serious deficiencies of human performance which can usually be corrected through the improvement of the related MMOS interfaces. - Highlights: • MMOSA allows the incorporation of the human and organizational factor in PSA. • The method uses old techniques and new techniques to analyze human performance. • The main novelty is the identification of the machine–organization interfaces. • The MMOSA methodology identifies any serious deficiencies which can be corrected

  1. Improvement of the LOCA PSA model using a beat-estimate thermal-hydraulic analysis

    International Nuclear Information System (INIS)

    Probabilistic Safety Assessment (PSA) has been widely used to estimate the overall safety of nuclear power plants (NPP) and it provides base information for risk informed application (RIA) and risk informed regulation (RIR). For the effective and correct use of PSA in RIA/RIR related decision making, the risk estimated by a PSA model should be as realistic as possible. In this work, a best-estimate thermal-hydraulic analysis of loss-of-coolant accidents (LOCAs) for the Hanul Nuclear Units 3 and 4 is first carried out in a systematic way. That is, the behaviors of peak cladding temperature (PCT) were analyzed with various combinations of break sizes, the operating conditions of safety systems, and the operator's action time for aggressive secondary cooling. Thereafter, the results of the thermal-hydraulic analysis have been reflected in the improvement of the PSA model by changing both accident sequences and success criteria of the event trees for the LOCA scenarios.

  2. The Obesity Epidemic – What Can Be Done? PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-08-03

    This 60 second PSA is based on the August 2010 CDC Vital Signs report which provides information on obesity and what you can do to help fight the epidemic.  Created: 8/3/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 8/3/2010.

  3. Mouse Brain PSA-NCAM Levels Are Altered by Graded-Controlled Cortical Impact Injury

    Directory of Open Access Journals (Sweden)

    Craig S. Budinich

    2012-01-01

    Full Text Available Traumatic brain injury (TBI is a worldwide endemic that results in unacceptably high morbidity and mortality. Secondary injury processes following primary injury are composed of intricate interactions between assorted molecules that ultimately dictate the degree of longer-term neurological deficits. One comparatively unexplored molecule that may contribute to exacerbation of injury or enhancement of recovery is the posttranslationally modified polysialic acid form of neural cell adhesion molecule, PSA-NCAM. This molecule is a critical modulator of central nervous system plasticity and reorganization after injury. In this study, we used controlled cortical impact (CCI to produce moderate or severe TBI in the mouse. Immunoblotting and immunohistochemical analysis were used to track the early (2, 24, and 48 hour and late (1 and 3 week time course and location of changes in the levels of PSA-NCAM after TBI. Variable and heterogeneous short- and long-term increases or decreases in expression were found. In general, alterations in PSA-NCAM levels were seen in the cerebral cortex immediately after injury, and these reductions persisted in brain regions distal to the primary injury site, especially after severe injury. This information provides a starting point to dissect the role of PSA-NCAM in TBI-related pathology and recovery.

  4. Study on communicating risk information obtained from PSA within nuclear power plants

    International Nuclear Information System (INIS)

    In this study, the communication of PSA information in nuclear power plants (NPPs), namely, how the risk information obtained from the probabilistic safety assessment (PSA) should be presented and communicated to plant personnel, was examined assuming that the safety management system based on the risk information was introduced to NPPs. This is called PSA communication. First, when risk-informed safety management is to be introduced into NPPs, plant personnel should have sufficient related knowledge. In order to provide such knowledge to the personnel through training, risk information is classified into three types: basic information, detailed information and task information. A hierarchical risk information summary for reporting, coordinating and communicating tasks is proposed. In this summary, the concerns of those who have received the information are placed at the top and the related risk information positioned below. At the same time, and by way of a trial, the risk information relating to on-line maintenance (OLM) is prepared. In order to enhance the safety-consciousness and the safety of the entire plant, specific plans such as 'risk tags' which indicate the safety significance of equipment is proposed. Finally, a guideline providing examination procedures for developing detailed PSA communication plans is introduced. (author)

  5. Overexpression and purification of folded domain of prostate cancer related proteins MSMB and PSA.

    Science.gov (United States)

    Tiwary, Mohini; Agarwal, Nipanshu; Dinda, Amit; Yadav, Subhash C

    2016-05-01

    Overexpression of domains of a human protein using recombinant DNA technology has been challenging because individual domains intend to accumulate as non-soluble aggregate when expressed separately. Studies on identifying right sequences for a domain to be able to fold independently may help understand the folding pattern and underlying protein-engineering events to isolate the functional domains of a protein. In this report, individual domains of prostate cancer related biomarkers; MSMB and PSA were overexpressed in bacterial system and purified in their folded forms using affinity chromatography. The western blotting experiment using domain specific antibodies further confirmed these proteins. The designed nucleotide sequences domains were truncated using fold index software and folding were predicted by phyre2 and I-TASSER software. Other parameters were optimized for their overexpression and purification using Co-NTA affinity chromatography. Purified domains of each protein showed secondary structures such as α + β type for PSA, α/β and β type for the each domains of PSA and MSMB respectively. This is the first report on producing PSA and MSMB individual domains in functional folded forms. This study may help produce the folded domain of many such proteins to be used for better diagnostic purpose. PMID:27038170

  6. Don't Sell Tobacco to Minors: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-07-08

    PSA helps raise retailers awareness of the new federal tobacco regulations related to sale of cigarettes and smokeless tobacco products to people under 18.  Created: 7/8/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 7/8/2010.

  7. Graphic Health Warnings for Cigarettes: What You Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-11-18

    PSA about new graphic health warnings for cigarette packages and advertisements.  Created: 11/18/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 11/18/2010.

  8. New Hope for Stopping HIV - Testing and Medical Care Save Lives PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-11-29

    This 60 second PSA is based on the December 2011 CDC Vital Signs report, "HIV Prevention through Care and Treatment" that shares new hope for preventing HIV and improving the health of people with HIV.  Created: 11/29/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 11/29/2011.

  9. Unpackaged Cigarettes and Smokeless Tobacco: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-10-28

    This PSA helps retailers understand new federal regulations surrounding the sale of unpackaged cigarettes and smokeless tobacco.  Created: 10/28/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 10/28/2010.

  10. Tools Related to the Federal Tobacco Products Regulations: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-09-16

    PSA to announce a new mobile text message program that will help raise retailers' awareness of the new federal tobacco regulations.  Created: 9/16/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 9/16/2010.

  11. Put Out the Myth: There Is No Such Thing as a Safe Cigarette PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-07-21

    PSA helps raise retailers' and manufacturers' awareness of the new federal tobacco regulations related to the production and sale of cigarettes labeled as "light," "low," or "mild.".  Created: 7/21/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 7/21/2010.

  12. Patients with Central Lines - What You Need to Know to Avoid a Bloodstream Infection PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-03-01

    This 60 second PSA is based on the March, 2011 CDC Vital Signs report which indicates bloodstream infections in patients with central lines are largely preventable when healthcare providers use CDC-recommended infection control steps.  Created: 3/1/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 3/1/2011.

  13. Electrochemical immunoassay for the prostate specific antigen using a reduced graphene oxide functionalized with a high molecular-weight silk peptide

    International Nuclear Information System (INIS)

    High molecular-weight silk peptide (SP) was used to functionalize the surface of nanosheets of reduced graphene oxide (rGO). The SP-rGO nanocomposite was then mixed with mouse anti-human prostate specific antigen monoclonal antibody (anti-PSA) and coated onto a glassy carbon electrode to fabricate an immunosensor. By using the hexacyanoferrate redox system as electroactive probe, the immunosensor was characterized by voltammetry and electrochemical impedance spectroscopy. The peak current, measured at the potential of 0.24 V (vs. SCE), is distinctly reduced after binding prostate specific antigen (PSA). Response (measured by differential pulse voltammetry) is linearly related to PSA concentration in the range from 0.1 to 5.0 ng · mL−1 and from 5.0 to 80.0 ng∙mL−1, and the detection limit is 53 pg∙mL−1 (at an SNR of 3). The immunosensor was successfully applied to the determination of PSA in clinical serum samples, and the results were found to agree well with those obtained with an enzyme-linked immunosorbent assay. (author)

  14. Applicability of PSA Issues for Risk Assessment during Optimisation of In-Service Inspection

    International Nuclear Information System (INIS)

    The current codes determining periodicity of in-service inspection of the NPP equipment have been formed using deterministic approaches and have an unnecessary degree of conservatism. A perspective direction of perfection of normative base is decision making on a basis of risk-informed methodologies. It allows to increase safety of NPP equipment's operation and to optimise programs on inspection of the equipment subject to limited resources by focusing efforts on the most safety significant elements of the equipment. It is internationally accepted that methodology of the probabilistic safety analysis (PSA) is the most universal and comprehensive tool focused on the general assessment of safety of NPP as a whole. By now, PSA Level 1 is fulfilled for all pilot units of the Ukrainian NPPs that is a valuable result, which should be taken into account at an assessment of reliability of the equipment. However, specificity of PSA methodology should be taken into account at the decision of the particular tasks aimed at optimisation of maintenance of the equipment within individual systems. The estimation of the contribution to core damage frequency (CDF) is a PSA issue usually used to assess the significance of consequences of failure of a system/equipment during risk-informed decision-making. This work shows that above factor is only a part of assessment of the significance of consequences as core damage can be expressed in different amount of the damaged fuel elements and, hence, severity of consequences. Besides CDF is directly affected only by active elements which failure can be an initiating event. PSA methodology uses averaged reliability factors of the equipment for all possible operating modes occurring at transitive accident process. Here, there are limited opportunities to account impact of periodicity of maintenance of the equipment on reliability and to predict impact of change of the inspection program. PSA methodology does not allow taking into account

  15. Construction of Smac gene-containing and human prostate specific antigen promoter-regulated vector and its expression

    Institute of Scientific and Technical Information of China (English)

    Yu Wu; Fuqing Zeng; Liang Wang; Yanbo Wang; Guiyi Liao

    2007-01-01

    Objective: To construct an eukaryotic expression vector containing Smac gene and study the expression efficiency and specificity of prostate specific antigen(PSA) enhancer/promoter in a possible targeted gene therapy scheme for prostate cancer. Methods: PSA enhancer (PSAE) and promoter (PSAP) sequences were amplified using PCR method. CMV and T7 promoters were deleted from pcDNA3.1-Smac and replaced by the two specific fragments to generate pPSAE-PSAP-Smac. After transfection into different cell lines, the status of cells was observed. And then, we determined the relative concentration of Smac mRNA in RT-PCR. Results: The recombinant plasmid of pPSAE-PSAP-Smac was successfully constructed. And only the prostate cancer cell line PC-3 was suppressed after transfection with pPSAE-PSAP-Smac. However, other nonprostate lines were not. Moreover,the concentration of Smac mRNA regulated by PSA promoter and enhancer was higher in comparison to the CMV promoter-driven control vectors. Conclusion: An expression vector containing the Smac gene (based on elements of the PSA gene regulatory sequences) has been developed and shown to function in prostate cancer cell lines which provides a solid platform for launching clinical studies.

  16. Usefulness of Total PSA Value in Prostate Diseases Diagnosis

    Science.gov (United States)

    Prcic, Alden; Begic, Edin; Hiros, Mustafa

    2016-01-01

    Introduction: Analysis of total value of prostate specific antigen (PSAT), with the unavoidable digital rectal examination (DRE) is the basis of prostate cancer detection. Aim: The aim of this study was to determine the specificity and sensitivity of the total value of PSAT in the diagnosis of prostate cancer. The aim was also to determine the significance of PSAT in diagnosis of benign prostate hyperplasia, precancerous conditions and inflammatory and atrophic changes of the prostate. Material and methods: Data were collected from the “Register of PH biopsy” of Clinic of Urology, CCU Sarajevo. Results: Analysis of correlation between the diagnosis and the PSAT value shows statistically significant negative correlation (r =-0,186; p = 0.006) in the sense that the value of the PSAT is highest in cancer patients, and the lowest in patients with benign prostatic hyperplasia. PSAT increases with age (r = 0.152; p = 0.025). For prostate cancer optimal sensitivity and specificity for PSAT value occurs at cut off value of> 8.6 ng /mL. Values lower than 2 ng/mL and higher than 10 ng/mL are most specific, and PPV increases with increasing value of PSAT. PSAT at values of 10 ng/mL are at high levels of specificity, and value > 10 ng / mL is also of high sensitivity in the detection of prostate cancer, and in this moment these values represent the optimal mode for the subsequent treatment. Conclusion: PSAT has a relative significance in the detection of prostate cancer, and should not be used as a guideline without DRE. PMID:27482127

  17. Gleason score as predictor of clinicopathologic findings and biochemical (PSA progression following radical prostatectomy

    Directory of Open Access Journals (Sweden)

    Marbele S. Guimaraes

    2008-02-01

    Full Text Available OBJECTIVE: There is evidence showing that Gleason grading of prostatic adenocarcinoma is one of the most powerful predictors of biological behavior and one of the most influential factors used to determine treatment for prostate cancer. The aim of the current study was to compare the Gleason score for needle biopsy to the Gleason score for the correspondent surgical specimen, find any possible difference in the biochemical (PSA progression following surgery in upgraded cases, correlate Gleason score in the specimens to several clinicopathologic variables, and compare outcomes between patients with low-grade vs. high-grade Gleason and Gleason scores 3+4 vs. 4+3. MATERIALS AND METHODS: The study population consisted of 200 consecutive patients submitted to radical prostatectomy. Biochemical progression was defined as PSA > 0.2 ng/mL. Time to PSA progression was studied using the Kaplan-Meier product-limit analysis. RESULTS: In 47.1% of the cases, there was an exact correlation and 40.6% of cases were underestimated in the biopsies. Half of the tumors graded Gleason 6 at biopsy were Gleason score 7 at surgery. These upgraded tumors had outcomes similar to tumors with Gleason score 7 in both biopsy and surgery. There was a positive correlation of high-grade Gleason score in the surgical specimens to higher preoperative PSA, more extensive tumors, positive margins and more advanced pathologic staging. Tumors with a Gleason score > 7 have lower PSA progression-free survival vs. Gleason scores < 7. In this series, there was no significant difference when comparing Gleason scores of 3+4 vs. 4+3. CONCLUSIONS: The findings support the importance of Gleason grading for nomograms, which are used by clinicians to counsel individual patients and help them make important decisions regarding their disease.

  18. The Impact of Free/Total PSA Ratio on Prostate Cancer Diagnosis in Patients with PSA Level Between 2,5-10 mg/dl Undergoing Transrectal Prostate Biopsy

    Directory of Open Access Journals (Sweden)

    Nevzat Sener

    2014-02-01

    Full Text Available Aim:  In this study, we aimed to compare the outcomes of pathologic results of patients underwent transrectal prostate biopsy (TRIB with free/total PSA ratio. Material and Method: Patients having a PSA level between 2.5-10 ng/ml and underwent TRIB were retrospectively analyzed. Patients were divided into two groups as having a free/total PSA ratio below and over 20%. The ratio below 20% was in Group 1 and over 20% were in Group 2. Results: There were 60 patients in Group 1 and 82 patients in Group 2. PSA levels were 7,45 ± 2,14 and 6,31 ± 1,89 for groups 1 and 2, respectively (p=0.067. Fourteen patients in Group 1 (23% and 15 patients in Group 2 (18% were diagnosed with prostate cancer. Sensitivity was 100% and specificity was 23% when PSA level was between 2.5 and 10. Discussion: Free/Total PSA ratio can be applied to PSA levels between 2.5 and 10. Even though it has a low specificity, with high sensitivity, it can be used in urologic practice.

  19. Changes in concentrations of zinc and PSA EPS of patients withⅢA prostatitis and the clinical significance%Ⅲa 型前列腺炎患者 EPS 中锌离子、PSA 浓度变化及其临床意义

    Institute of Scientific and Technical Information of China (English)

    陈曦; 莫林键; 汪小明; 张迅; 李广裕; 黄珊; 蒋捷; 覃春宁

    2015-01-01

    Objective To observe the changes in concentrations of zinc and prostate-specific antigen ( PSA) in the expressed prostatic secretion ( EPS) of patients with ⅢA prostatitis and to investigate the clinical significance .Methods Seventy-one patients with ⅢA prostatitis ( observation group ) and 44 healthy controls ( control group ) were recruited in our study.The concentrations of zinc and PSA in EPS were determined by colorimetric analysis and enzyme -linked immunosor-bent assay (ELISA), respectively.The wet mount was examined promptly with a high-power microscope for WBC in EPS . The pH value of EPS was acquired by pH test strips .Pearson linear correlation analysis was used to determine the correla-tions between zinc concentration , PSA concentration and CPSI scores .The relationships between zinc concentration and pH value, amount of WBC were analyzed by Spearman rank correlation analysis as well as the relationships between PSA con -centration and pH value , amount of WBC .Results The zinc concentrations of the observation group and control group were respectively (155.93 ±68.65) μg/mL and (206.54 ±65.18) μg/mL, and the PSA concentrations were respectively (2.27 ±2.03) ×105 ng/mL and (3.78 ±2.84) ×105ng/mL (all P0.05).Meanwhile, there were negative correlations between PSA concentra-tion and NIH-CPSI scores including pain scores , quality of life scores and total scores ( r =-0.255, -0.217 and-0.250, respectively;all P0.05).The pH value was negatively correlated with concentrations of zinc and PSA (r=-0.429 and -0.333, respec-tively;all P0.05).Conclusions The concentrations of zinc and PSA in EPS decreased significantly in patients with ⅢA prostatitis.The detections of concentra-tions of zinc and PSA contributed to the diagnosis and disease evaluation of ⅢA prostatitis.%目的 观察ⅢA型前列腺炎患者前列腺液(EPS)中锌离子、前列腺特异性抗原(PSA)浓度变化,并探讨其临床意义. 方法 招募ⅢA型前列腺炎患者71

  20. Cell-specific expression of TLR9 isoforms in inflammation.

    Science.gov (United States)

    McKelvey, Kelly J; Highton, John; Hessian, Paul A

    2011-02-01

    Toll-like receptors (TLRs) are key pattern recognition receptors during an immune response. With five isoforms of human TLR9 described, we hypothesised that differential expression of TLR9 isoforms in different cell types would result in variable contributions to the overall input from TLR9 during inflammation. We assessed the molecular expression of the TLR9 isoforms, TLR9-A, -C and -D. In normal peripheral blood mononuclear cells, B-lymphocytes express ∼100-fold more TLR9-A transcript than monocytes or T-lymphocytes, which predominantly express the TLR9-C transcript. Switches in isoform predominance accompany B-lymphocyte development. TLR9 protein expression in rheumatoid inflammatory lesions reflected the TLR9 isoform expression by immune cells. Herein we suggest that B-lymphocytes and plasmacytoid dendritic cells contribute the ∼3-fold higher TLR9-A transcript levels observed in inflamed synovium when compared to subcutaneous rheumatoid nodules. In contrast, macrophages and T-lymphocytes contribute the ∼4-fold higher TLR9-C transcript levels seen in nodules, compared to synovia. From protein sequence, predictions of subcellular localisation suggest TLR9-B may locate to the mitochondria, whereas TLR9-D adopts an opposing orientation in the endoplasmic reticulum. Consistent with this, structure models raise the possibility of alternative ligands for the TLR9-B and TLR9-D variants. Our results highlight differences in the expression of human TLR9 isoforms in normal and inflamed tissues, with differing contributions to inflammation.

  1. The DnaJ-like zinc finger domain protein PSA2 affects light acclimation and chloroplast development in Arabidopsis thaliana

    Directory of Open Access Journals (Sweden)

    Yan-Wen eWang

    2016-03-01

    Full Text Available The biosynthesis of chlorophylls and carotenoids and the assembly of thylakoid membranes are critical for the photoautotrophic growth of plants. Different factors are involved in these two processes. In recent years, members of the DnaJ-like zinc finger domain proteins have been found to take part in the biogenesis and/or the maintenance of plastids. One member of this family of proteins, PSA2, was recently found to localize to the thylakoid lumen and regulate the accumulation of photosystem I. In this study, we report that the silencing of PSA2 in Arabidopsis thaliana resulted in variegated leaves and retarded growth. Although both chlorophylls and total carotenoids decreased in the psa2 mutant, violaxanthin and zeaxanthin accumulated in the mutant seedlings grown under growth condition. Lower levels of non-photochemical quenching and electron transport rate were also found in the psa2 mutant seedlings under growth condition compared with those of the wild-type plants, indicating an impaired capability to acclimate to normal light irradiance when PSA2 was silenced. Moreover, we also observed an abnormal assembly of grana thylakoids and poorly developed stroma thylakoids in psa2 chloroplasts. Taken together, our results demonstrate that PSA2 is a member of the DnaJ-like zinc finger domain protein family that affects light acclimation and chloroplast development.

  2. An expert assistant for the treatment of human reliability analysis (HRA) for probabilistic safety analysis (PSA) purposes

    International Nuclear Information System (INIS)

    The value of Probabilistic Safety Analysis (PSA) for nuclear safety is well known and recognized. However, PSA methodology has limitations, particularly when the operator actions are involved in the PSA models. The results of the PSA performed up to now show that human actions are the main contributor to the core damage probability. The HRA intent to provide a framework to identify, analyse, quantify and incorporate the human actions into PSAs. An expert assistant for the treatment of HRA: ETHRA prototype was developed to provide a guide for PSA analysts to perform HRA's with the standards and most widely used methods to determine and quantify human actions for PSA applications and these human actions are then incorporated to fault trees and event trees. ETHRA is a system based on methods, rules and demons that include a question/answer user interface by means of checkboxes, valueboxes and forms. Subject discussed in this report is dealing with the practical implementation and use of ETHRA prototype to PSA applications. (author). 5 refs, 1 fig

  3. A Nucleus-Encoded Chloroplast Phosphoprotein Governs Expression of the Photosystem I Subunit PsaC in Chlamydomonas reinhardtii.

    Science.gov (United States)

    Douchi, Damien; Qu, Yujiao; Longoni, Paolo; Legendre-Lefebvre, Linnka; Johnson, Xenie; Schmitz-Linneweber, Christian; Goldschmidt-Clermont, Michel

    2016-05-01

    The nucleo-cytoplasmic compartment exerts anterograde control on chloroplast gene expression through numerous proteins that intervene at posttranscriptional steps. Here, we show that the maturation of psaC mutant (mac1) of Chlamydomonas reinhardtii is defective in photosystem I and fails to accumulate psaC mRNA. The MAC1 locus encodes a member of the Half-A-Tetratricopeptide (HAT) family of super-helical repeat proteins, some of which are involved in RNA transactions. The Mac1 protein localizes to the chloroplast in the soluble fraction. MAC1 acts through the 5' untranslated region of psaC transcripts and is required for their stability. Small RNAs that map to the 5'end of psaC RNA in the wild type but not in the mac1 mutant are inferred to represent footprints of MAC1-dependent protein binding, and Mac1 expressed in bacteria binds RNA in vitro. A coordinate response to iron deficiency, which leads to dismantling of the photosynthetic electron transfer chain and in particular of photosystem I, also causes a decrease of Mac1. Overexpression of Mac1 leads to a parallel increase in psaC mRNA but not in PsaC protein, suggesting that Mac1 may be limiting for psaC mRNA accumulation but that other processes regulate protein accumulation. Furthermore, Mac 1 is differentially phosphorylated in response to iron availability and to conditions that alter the redox balance of the electron transfer chain. PMID:27113776

  4. [11C]choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy

    International Nuclear Information System (INIS)

    The accuracy of positron emission tomography (PET)/CT with [11C]choline for the detection of prostate cancer is not well established. We assessed the dependence of [11C]choline maximum standardized uptake values (SUVmax) in the prostate gland on cell malignancy, prostate-specific antigen (PSA) levels, Gleason score, tumour stage and anti-androgenic hormonal therapy. In this prospective study, PET/CT with [11C]choline was performed in 19 prostate cancer patients who subsequently underwent prostatectomy with histologic sextant analysis (group A) and in six prostate cancer patients before and after anti-androgenic hormonal therapy (bicalutamide 150 mg/day; median treatment of 4 months; group B). In group A, based on a sextant analysis with a [11C]choline SUVmax cutoff of 2.5 (as derived from a receiver-operating characteristic analysis), PET/CT showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 72, 43, 64, 51 and 60%, respectively. In the patient-by-patient analysis, no significant correlation was detected between SUVmax and PSA levels, Gleason score or pathological stage. On the contrary, a significant (P max and anti-androgenic therapy both in univariate (r 2 = 0.24) and multivariate (r 2 = 0.48) analyses. Prostate [11C]choline uptake after bicalutamide therapy significantly (P 11C]choline is not suitable for the initial diagnosis and local staging of prostate cancer. PET/CT with [11C]choline could be used to monitor the response to anti-androgenic therapy. (orig.)

  5. Structural diversity and evolution of the N-terminal isoform-specific region of ecdysone receptor-A and -B1 isoforms in insects

    Directory of Open Access Journals (Sweden)

    Kubo Takeo

    2010-02-01

    Full Text Available Abstract Background The ecdysone receptor (EcR regulates various cellular responses to ecdysteroids during insect development. Insects have multiple EcR isoforms with different N-terminal A/B domains that contain the isoform-specific activation function (AF-1 region. Although distinct physiologic functions of the EcR isoforms have been characterized in higher holometabolous insects, they remain unclear in basal direct-developing insects, in which only A isoform has been identified. To examine the structural basis of the EcR isoform-specific AF-1 regions, we performed a comprehensive structural comparison of the isoform-specific region of the EcR-A and -B1 isoforms in insects. Results The EcR isoforms were newly identified in 51 species of insects and non-insect arthropods, including direct-developing ametabolous and hemimetabolous insects. The comprehensive structural comparison revealed that the isoform-specific region of each EcR isoform contained evolutionally conserved microdomain structures and insect subgroup-specific structural modifications. The A isoform-specific region generally contained four conserved microdomains, including the SUMOylation motif and the nuclear localization signal, whereas the B1 isoform-specific region contained three conserved microdomains, including an acidic activator domain-like motif. In addition, the EcR-B1 isoform of holometabolous insects had a novel microdomain at the N-terminal end. Conclusions Given that the nuclear receptor AF-1 is involved in cofactor recruitment and transcriptional regulation, the microdomain structures identified in the isoform-specific A/B domains might function as signature motifs and/or as targets for cofactor proteins that play essential roles in the EcR isoform-specific AF-1 regions. Moreover, the novel microdomain in the isoform-specific region of the holometabolous insect EcR-B1 isoform suggests that the holometabolous insect EcR-B1 acquired additional transcriptional

  6. An Inexpensive, Fast and Sensitive Quantitative Lateral Flow Magneto-Immunoassay for Total Prostate Specific Antigen

    Directory of Open Access Journals (Sweden)

    Jacqueline M. Barnett

    2014-07-01

    Full Text Available We describe the detection characteristics of a device the Resonant Coil Magnetometer (RCM to quantify paramagnetic particles (PMPs in immunochromatographic (lateral flow assays. Lateral flow assays were developed using PMPs for the measurement of total prostate specific antigen (PSA in serum samples. A detection limit of 0.8 ng/mL was achieved for total PSA using the RCM and is at clinically significant concentrations. Comparison of data obtained in a pilot study from the analysis of serum samples with commercially available immunoassays shows good agreement. The development of a quantitative magneto-immunoassay in lateral flow format for total PSA suggests the potential of the RCM to operate with many immunoassay formats. The RCM has the potential to be modified to quantify multiple analytes in this format. This research shows promise for the development of an inexpensive device capable of quantifying multiple analytes at the point-of-care using a magneto-immunoassay in lateral flow format.

  7. Clinical Application of Prostate - specific Antigen Detection in Prostate Diseases%前列腺特异性抗原检测在前列腺疾病中的临床应用

    Institute of Scientific and Technical Information of China (English)

    杨望君; 潘美秋

    2011-01-01

    目的 探讨血清前列腺特异性抗原(PSA)在前列腺疾病诊断中的意义.方法 采用放射免疫法对健康对照组60例、前列腺良性疾病组82例、前列腺癌组53例进行血清PSA测定,并对前列腺癌患者手术前后血清PSA测定比较其差异.结果 前列腺癌组t-PSA、f-PSA和f-PSA百分率测定结果均明显高于对照组,差异有统计学意义(P<0.01),前列腺癌患者手术前后血清t--PSA和f-PSA和f-PSA百分率比较,差异有统计学意义(P<0.01).结论 血清PSA检测在前列腺疾病诊断中有重要意义,是疗效监测、评估预后的重要指标.%Objective To explore the senm prostate specific antigen (PSA) in the diagnosis of prostate diseases. Methods Serum PSA levels of healthy control group (n= 60), benign prostate disease group (n=82), and prostate cancer group (n=53) were detected by radioimmunoassay method. And the difference in serum PSA levels of prostate cancer patients was compared before and after the operation. Results The determination results showed that serum t - PSA, f -PSA and percentage of f - PSA in prostate cancer group were significantly higher than those in healthy control group, and the difference was statistically significant (P<0.01). There were statistically significant differences in serum t - PSA, f- PSA and percentage of f - PSA of prostate cancer patients between before and after the operation (P< 0.01). Conclusions It is of great significance to detect serum PSA level in the diagnosis of prostate diseases, which is an important indicator in monitoring the therapeutic effect and evaluating the prognosis.

  8. Prostate-specific antigen as a risk factor for skeletal metastasis in native ethnic African Men with prostate cancer : a case control study

    OpenAIRE

    Qureshi, Ayman; Makhdomi, Khalid; Stones, William

    2016-01-01

    Prostate cancer is the commonest non cutaneous cancer in males. Men of African origin are at significantly higher risk as reflected in higher incidence and mortality rates in this racial group. Metastases incidence increases in parallel with serum levels of Prostate Specific Antigen (PSA), contributing significantly to morbidity and mortality. Staging of disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions they may be omitted in some situations in pat...

  9. Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia

    OpenAIRE

    Kim, Jong Min; Song, Phil Hyun; Kim, Hyun Tae; Moon, Ki Hak

    2011-01-01

    Purpose We examined the correlation between body mass index (BMI) as a marker of obesity and prostate-specific antigen (PSA), prostate volume (PV), and International Prostate Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH). Materials and Methods From January 2008 to December 2008, we examined 258 patients diagnosed with BPH. Patients taking 5α-reductase inhibitors or those diagnosed with prostate cancer were excluded from this study. BPH was defined as PV≥25 ml and IP...

  10. Simulation of Unique Pressure Changing Steps and Situations in Psa Processes

    Science.gov (United States)

    Ebner, Armin D.; Mehrotra, Amal; Knox, James C.; LeVan, Douglas; Ritter, James A.

    2007-01-01

    A more rigorous cyclic adsorption process simulator is being developed for use in the development and understanding of new and existing PSA processes. Unique features of this new version of the simulator that Ritter and co-workers have been developing for the past decade or so include: multiple absorbent layers in each bed, pressure drop in the column, valves for entering and exiting flows and predicting real-time pressurization and depressurization rates, ability to account for choked flow conditions, ability to pressurize and depressurize simultaneously from both ends of the columns, ability to equalize between multiple pairs of columns, ability to equalize simultaneously from both ends of pairs of columns, and ability to handle very large pressure ratios and hence velocities associated with deep vacuum systems. These changes to the simulator now provide for unique opportunities to study the effects of novel pressure changing steps and extreme process conditions on the performance of virtually any commercial or developmental PSA process. This presentation will provide an overview of the cyclic adsorption process simulator equations and algorithms used in the new adaptation. It will focus primarily on the novel pressure changing steps and their effects on the performance of a PSA system that epitomizes the extremes of PSA process design and operation. This PSA process is a sorbent-based atmosphere revitalization (SBAR) system that NASA is developing for new manned exploration vehicles. This SBAR system consists of a 2-bed 3-step 3-layer system that operates between atmospheric pressure and the vacuum of space, evacuates from both ends of the column simultaneously, experiences choked flow conditions during pressure changing steps, and experiences a continuously changing feed composition, as it removes metabolic CO2 and H20 from a closed and fixed volume, i.e., the spacecraft cabin. Important process performance indicators of this SBAR system are size, and the

  11. Human reliability analysis during PSA at Trillo NPP: main characteristics and analysis of diagnostic errors

    International Nuclear Information System (INIS)

    The design difference between Trillo NPP and other Spanish nuclear power plants (basic Westinghouse and General Electric designs) were made clear in the Human Reliability Analysis of the Probabilistic Safety Analysis (PSA) for Trillo NPP. The object of this paper is to describe the most significant characteristics of the Human Reliability Analysis carried out in the PSA, with special emphasis on the possible diagnostic errors and their consequences, based on the characteristics in the Emergency Operations Manual for Trillo NPP. - In the case of human errors before the initiating event (type 1), the existence of four redundancies in most of the plant safety systems, means that the impact of this type or error on the final results of the PSA is insignificant. However, in the case common cause errors, especially in certain calibration errors, some actions are significant in the final equation for core damage - The number of human actions that the operator has to carry out during the accidents (type 3) modelled, is relatively small in comparison with this value in other PSAs. This is basically due to the high level of automation at Rillo NPP - The Plant Operations Manual cannot be strictly considered to be a symptoms-based procedure. The operation Group must select the chapter from the Operations Manual to be followed, after having diagnosed the perturbing event, using for this purpose and Emergency and Anomaly Decision Tree (M.O.3.0.1) based on the different indications, alarms and symptoms present in the plant after the perturbing event. For this reason, it was decided to analyse the possible diagnosis errors. In the bibliography on diagnosis and commission errors available at the present time, there is no precise methodology for the analysis of this type of error and its incorporation into PSAs. The method used in the PSA for Trillo y NPP to evaluate this type of interaction, is to develop a Diagnosis Error Table, the object of which is to identify the situations in

  12. First Prototype of a Web Map Interface for ESA's Planetary Science Archive (PSA)

    Science.gov (United States)

    Manaud, N.; Gonzalez, J.

    2014-04-01

    We present a first prototype of a Web Map Interface that will serve as a proof of concept and design for ESA's future fully web-based Planetary Science Archive (PSA) User Interface. The PSA is ESA's planetary science archiving authority and central repository for all scientific and engineering data returned by ESA's Solar System missions [1]. All data are compliant with NASA's Planetary Data System (PDS) Standards and are accessible through several interfaces [2]: in addition to serving all public data via FTP and the Planetary Data Access Protocol (PDAP), a Java-based User Interface provides advanced search, preview, download, notification and delivery-basket functionality. It allows the user to query and visualise instrument observations footprints using a map-based interface (currently only available for Mars Express HRSC and OMEGA instruments). During the last decade, the planetary mapping science community has increasingly been adopting Geographic Information System (GIS) tools and standards, originally developed for and used in Earth science. There is an ongoing effort to produce and share cartographic products through Open Geospatial Consortium (OGC) Web Services, or as standalone data sets, so that they can be readily used in existing GIS applications [3,4,5]. Previous studies conducted at ESAC [6,7] have helped identify the needs of Planetary GIS users, and define key areas of improvement for the future Web PSA User Interface. Its web map interface shall will provide access to the full geospatial content of the PSA, including (1) observation geometry footprints of all remote sensing instruments, and (2) all georeferenced cartographic products, such as HRSC map-projected data or OMEGA global maps from Mars Express. It shall aim to provide a rich user experience for search and visualisation of this content using modern and interactive web mapping technology. A comprehensive set of built-in context maps from external sources, such as MOLA topography, TES

  13. Bioimpedance and chronoamperometry as an adjunct to prostate-specific antigen screening for prostate cancer

    Directory of Open Access Journals (Sweden)

    Abreu DS

    2011-04-01

    Full Text Available Darci Schiavon de AbreuDepartment of Urology, Hospital Unimed de Limeira, Sao Paulo, BrazilBackground: Bioimpedance is an electrical property of living tissue that has been shown to be a safe technique when used in a number of biomedical applications. The aim of this research was to assess the utility of bioimpedance measurement as a rapid, cost-effective, and noninvasive adjunct to digital rectal examination and PSA in differentiating tumor from normal prostatic tissue.Methods: Three hundred men were examined for signs and symptoms of prostate disorders. 147 patients with a digital rectal examination indicating a positive result underwent a prostate-specific antigen (PSA test. A biopsy was advised for 103 of the men, of whom 50 completed the study. Before undergoing biopsy, an examination with the EIS (electro interstitial scan system using bioimpedance and chronoamperometry was performed. In reference to the biopsy results (negative or positive, a statistical analysis of the EIS data and PSA was conducted using receiver operating characteristic curves to determine the specificity and sensitivity of each test.Results: The PSA test had a sensitivity of 73.9% and specificity of 51.9% using a cutoff value >4 and a sensitivity of 52.2% and specificity of 81.5% using a cutoff value ≥5.7 and P = 0.03. The delta of the electrical conductivity (DE of the left foot-right foot pathway had a sensitivity of 62.5% and specificity of 85.2%, with a cutoff value ≤-5 and P = 0.0001. Algorithms comprising the delta of electrical conductivity and PSA showed a sensitivity of 91.5% and a specificity of 59.3%, with a cutoff value ≤-10.52 and P = 0.0003.Conclusion: The EIS system had a very good specificity of 85.2%. However, the sensitivity of 62.5% would be a problem. Using a PSA reference >4.1 ng/mL, the adjunctive use of bioimpedance and chronoamperometry provided by EIS technology could raise the sensitivity from 73.9% to 91.5% and the specificity from 51

  14. Distinct functional interactions between actin isoforms and nonsarcomeric myosins.

    Directory of Open Access Journals (Sweden)

    Mirco Müller

    Full Text Available Despite their near sequence identity, actin isoforms cannot completely replace each other in vivo and show marked differences in their tissue-specific and subcellular localization. Little is known about isoform-specific differences in their interactions with myosin motors and other actin-binding proteins. Mammalian cytoplasmic β- and γ-actin interact with nonsarcomeric conventional myosins such as the members of the nonmuscle myosin-2 family and myosin-7A. These interactions support a wide range of cellular processes including cytokinesis, maintenance of cell polarity, cell adhesion, migration, and mechano-electrical transduction. To elucidate differences in the ability of isoactins to bind and stimulate the enzymatic activity of individual myosin isoforms, we characterized the interactions of human skeletal muscle α-actin, cytoplasmic β-actin, and cytoplasmic γ-actin with human myosin-7A and nonmuscle myosins-2A, -2B and -2C1. In the case of nonmuscle myosins-2A and -2B, the interaction with either cytoplasmic actin isoform results in 4-fold greater stimulation of myosin ATPase activity than was observed in the presence of α-skeletal muscle actin. Nonmuscle myosin-2C1 is most potently activated by β-actin and myosin-7A by γ-actin. Our results indicate that β- and γ-actin isoforms contribute to the modulation of nonmuscle myosin-2 and myosin-7A activity and thereby to the spatial and temporal regulation of cytoskeletal dynamics. FRET-based analyses show efficient copolymerization abilities for the actin isoforms in vitro. Experiments with hybrid actin filaments show that the extent of actomyosin coupling efficiency can be regulated by the isoform composition of actin filaments.

  15. Study on the PSA-ANFIS method for back analysis of displacement%位移反分析的PSA-ANFIS方法研究

    Institute of Scientific and Technical Information of China (English)

    张志军; 章求才; 贺桂成; 丁德馨

    2014-01-01

    地下工程中,通常采用位移反分析方法来确定围岩的力学参数,而现有的位移反分析方法均存在诸多不足之处,为此,采用模式搜索算法、自适应神经模糊推理系统以及正交试验设计方法,建立了位移反分析的PSA-ANFIS方法;同时还对一标准弹塑性问题进行了解析计算,得到了相应的训练数据对、检测数据对和预测数据对;最后采用此方法对该弹塑性问题的力学参数进行了反演.反演结果表明,所建立的位移反分析的PSA-ANFIS方法除了能够充分发挥ANFIS的各种优点外,还能有效地减少模型建立和参数调节过程中的人为干预,因此是一种优异的位移反分析方法.

  16. An application of PSA techniques to on-line maintenance program. A feasibility study of maintenance strategy during plant operation using PSA techniques

    International Nuclear Information System (INIS)

    This study confirms an on-line maintenance possibility for a Japanese NPP from a plant risk management point of view. One-line maintenance has already been planned and executed in some NPPs in the United States. The problem preceding on-line maintenance is how to keep a certain level of plant safety with out of service condition, safety-related systems and components, during maintenance. Deterministically, the technical specification defines unplanned maintenance periods of safety related standby systems. Probabilistically, this principle is able to be verified by utilizing PSA technology. In this study a PSA method for Japanese PWR plants is applied to improve plant availability, and to investigate safety issues associated with on-line maintenance strategy, system configuration, management and financial advantage regarding Japanese plant constraints. On-line maintenance is one of the risk management activities to improve safety and manpower workload during shutdown. As a result of this study, core damage frequency can show that on-line maintenance of some safety related systems is able to be performed and that of other safety related systems, not. On-line maintenance for Japanese NPPs utilizing risk method, will be introducing maintenance programs during power operation, like as performed in the United States. It will be important to prepare guidelines for on-line maintenance principles for further risk management programs. (author)

  17. Living PSA program: LIPSAS development for safety management of an LMFBR plant

    Energy Technology Data Exchange (ETDEWEB)

    Aizawa, Kiyoto [Power Reactor and Nuclear Fuel Development Corp., Tokyo (Japan); Nakai, Ryodai [O-arai Engineering Center, Ibaraki (Japan)

    1994-12-31

    During construction and subsequent operation of a nuclear power plant, many changes occur in components, systems and operating procedures, which continuously modify the configuration of the power plant. A living PSA program can assess and manage safety-related operations and plant changes by adequately reproducing plant models and structured databases corresponding to the changes in system configuration. A living PSA system, LIPSAS, has been developed for the Japanese prototype liquid metal-cooled fast-breeder reactor (LMFBR), Monju, which is in the preoperation functional test stage. In order to utilize the LIPSAS as a risk management tool, equations for the schematic time history of the plant risk level and the relative risk criteria have been developed. Experience with LIPSAS shows that this program is a prospective tool to support decisions that affect plant safety, although a continuing and significant resource commitment of the operations staff at the site is still required. (author).

  18. Preparation and properties of UV curable acrylic PSA by vinyl bonded graphene oxide

    Science.gov (United States)

    Pang, Beili; Ryu, Chong-Min; Jin, Xin; Kim, Hyung-Il

    2013-11-01

    Acrylic pressure sensitive adhesives (PSAs) with higher thermal stability for thin wafer handling were successfully prepared by forming composite with the graphene oxide (GO) nanoparticles modified to have vinyl groups via subsequent reaction with isophorone diisocyanate and 2-hydroxyethyl methacrylate. The acrylic copolymer was synthesized as a base resin for PSAs by solution radical polymerization of ethyl acrylate, 2-ethylhexyl acrylate, and acrylic acid followed by further modification with GMA to have the vinyl groups available for UV curing. The peel strength of PSA decreased with the increase of gel content which was dependent on both modified GO content and UV dose. Thermal stability of UV-cured PSA was improved noticeably with increasing the modified GO content mainly due to the strong and extensive interfacial bonding formed between the acrylic copolymer matrix and GO fillers

  19. Optimized design of PSA nitrogen-manufacturing system based on PLC

    Science.gov (United States)

    Nie, Zongyao; Ma, Xiushui; Jiang, Jun

    2011-05-01

    Firstly introducing principle and technological process of PSA nitrogen-manufacturing system, on condition of its high air consumption and weak in nitrogen-manufacturing system at present. We repeatedly studied the controlled object in this process, analyzed the PLC procedure based on the program rule of PLC of Siemens S7-200 series, then re-program PLC procedure without altering the nitrogen production technique of PSA nitrogen-manufacturing system. At the same time, in order to improve the operation efficiency of the response of action, we also did experiment and demonstration in the consistency of the I/O port and peripheral equipment. In this paper, through optimization of hardware and software design, the nitrogen producing cost was calculated at RMB 0.35 per m3, declined by 12% from the original RMB 0.4 per m3.

  20. Use of PSA Level 2 analysis for improving containment performance. Report of a technical committee meeting

    International Nuclear Information System (INIS)

    In order to discuss and exchange experience on different aspects of methods associated with Level 2 PSA and its applications for improving containment performance, the IAEA held a Technical Committee meeting in Vienna in December 1996. The meeting, which was attended by 26 participants from 20 Member States, provided a broad forum for discussion. The meeting addressed the issues related to the actual performance of Level 2 PSA studies as well as the insights gained from applications to improve containment performance. Particular attention was given to studies and applications for WWER type reactors, for which Level 2 work is still in its early stages, and for channel type reactors where modelling of accident progression is complex and significantly different from vessel type light water reactors. This TECDOC contains the papers presented at the meeting and the results of extensive discussions which were held in specific working groups

  1. Estimation Of Source Term For Indian PHWRS (KAPS) As Part Of PSA Level-2 Study

    International Nuclear Information System (INIS)

    Source Term (ST) is generally known as the amount of the radio-nuclides(fission products along with activation and Actinides) that can be released from a nuclear power plant in an accident. The ST can be more accurately defined as the quantity, timing, composition, chemical and physical form of radio-nuclides. The amount of radio-nuclides is a fundamental parameter to estimate the consequences of an accident on individuals and environment. A quantitative estimation of the ST is of importance for assessing the effectiveness of safety design features and for the planning of post accident emergency measures in the public domain. The PSA Level-1 study for IPHWRs(KAPS) was completed in 2002 and an attempt was made to estimate the ST for different accident scenarios as part of PSA Level-2 study. The scope of this paper is limited to estimate the ST for Indian Pressurized Heavy Water Reactors (IPHWRs) in accident conditions. (authors)

  2. Window-based computer code package CONPAS for an integrated level 2 PSA

    International Nuclear Information System (INIS)

    A PC window-based computer code. CONPAS (CONtainment Performance Analysis System), has been developed to integrate the numerical, graphical, and results-operation aspects of Level2 probabilistic safety assessments (PSA) for nuclear power plants automatically. As a main logic for accident progression analysis, it employs a concept of the small containment phenomenological event tree (CPET) helpful to trace out visually individual accident progressions and of the large supporting event tree (LSET) for its detailed quantification. Compared with other existing computer codes for Level 2 PSA, the CONPAS code provides several advanced features: computational aspects including systematic uncertainty analysis, importance analysis, and sensitivity analysis, reporting aspects including tabling and graphic, and user-friend interface

  3. Development of Integrated Analytical Tools for Level-2 PSA of LMFBR

    International Nuclear Information System (INIS)

    JNES has developed own safety analysis methods for LMFBR to make safety analyses independently from the applicant to support the regulatory body. The area of these computer codes covers the plant response phase, the core disruption phase and the containment vessel response phase of severe accidents. In addition to the codes, the PRD (Phenomenological Relationship Diagram) method was figured out as a logical method to identify the probability distributions of blanching points in event trees for level-2 PSA. After validation of these codes using various experimental data and many trial calculations to actual reactor system, the prepared tools were applied to the level-2 PSA of Monju to evaluate the effectiveness of accident management measures of Monju. (author)

  4. Reliability of piping system components. Volume 1: Piping reliability - A resource document for PSA applications

    Energy Technology Data Exchange (ETDEWEB)

    Nyman, R.; Erixon, S.; Tomic, B.; Lydell, B.

    1995-12-01

    SKI has undertaken a multi-year research project to establish a comprehensive passive component failure database, validate failure rate parameter estimates and establish a model framework for integrating passive component failures in existing PSAs. Phase 1 of the project produced a relational database on worldwide piping system failure events in the nuclear and chemical industries. This phase 2 report gives a graphical presentation of piping system operating experience, and compares key failure mechanisms in commercial nuclear power plants and chemical process industry. Inadequacies of traditional PSA methodology are addressed, with directions for PSA methodology enhancements. A data-driven-and-systems-oriented analysis approach is proposed to enable assignment of unique identities to risk-significant piping system component failures. Sufficient operating experience does exist to generate quality data on piping failures. Passive component failures should be addressed by today`s PSAs to allow for aging analysis and effective, on-line risk management. 111 refs, 36 figs, 20 tabs.

  5. Take Charge. Take the Test. "Look Out For Yourself" PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-03-07

    As part of the Take Charge. Take the Test. campaign, this 60 second PSA encourages African American women to get tested for HIV. Locations for a free HIV test can be found by visiting hivtest.org/takecharge or calling 1-800-CDC-INFO (1-800-232-4636).  Created: 3/7/2012 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 3/7/2012.

  6. The Tobacco Use Epidemic - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2010-09-07

    This PSA is based on the September, 2010 CDC Vital Signs report which indicates that, despite the dangers of tobacco use, about 46.6 million adults in the U.S. smoke, and 88 million nonsmokers are exposed to secondhand smoke. .  Created: 9/7/2010 by Centers for Disease Control and Prevention (CDC).   Date Released: 9/7/2010.

  7. Making Food Safer to Eat - What You Need to Know PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2011-06-07

    This 60 second Public Service Announcement (PSA) is based on the June, 2011 CDC Vital Signs report. One in six Americans gets sick from eating contaminated food each year. To reduce your risk, remember to clean, separate, cook, and chill.  Created: 6/7/2011 by Centers for Disease Control and Prevention (CDC).   Date Released: 6/7/2011.

  8. CDC: Tips from Former Smokers – Jessica PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2012-04-04

    Exposure to secondhand smoke can trigger a life-threatening asthma attack. This 30 second PSA features Jessica, a mother with a young son who suffers from asthma attacks triggered by secondhand smoke exposure.  Created: 4/4/2012 by Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion.   Date Released: 4/4/2012.

  9. Binge Drinking – Nationwide Problem, Local Solutions PSA (:60)

    Centers for Disease Control (CDC) Podcasts

    2012-01-03

    This 60 second PSA is based on the January 2012 CDC Vital Signs report. One in six adults binge drinks about four times a month. It's a problem nationwide but community-based strategies, such as reducing access to alcohol and increasing the price, can prevent binge drinking.  Created: 1/3/2012 by Centers for Disease Control and Prevention (CDC).   Date Released: 1/3/2012.

  10. Guidelines for reliability analysis of digital systems in PSA context - Phase 2 Status report

    Energy Technology Data Exchange (ETDEWEB)

    Authen, S. (Risk Pilot AB, Stockholm (Sweden)); Gustafsson, J. (Royal Institute of Technology (Sweden)); Holmberg, J.-E. (VTT Technical Research Centre of Finland (Finland))

    2012-02-15

    The OECD/NEA CSNI Working Group on Risk Assessment (WGRisk) has set up a task group called DIGREL to develop a taxonomy of failure modes of digital components for the purposes of probabilistic safety assessment (PSA). A parallel Nordic activity carried out a pre-study where a comparison of Nordic experiences and a literature review were performed. The study showed a wide range of approaches and solutions to the challenges given by digital I and C. In 2011, a proposal for the failure modes taxonomy was defined. This is based on a set of requirements agreed on the purpose of the taxonomy. The following levels of details can be distinguished from the hardware point of view: (1) the entire system, (2) a division, (3) processing units (and cabinets), (4) modules, i.e. subcomponents of processing units and (5) generic components, i.e. subcomponents of modules. Module level seems to be the most appropriate from the PSA modelling point of view. The software failure modes taxonomy is still an open issue. An existing simplified PSA model has been complemented with fault tree models for a four-redundant distributed protection system in order to study and demonstrate the effect of design features and modelling approaches. The example shows that even rather simple I and C design leads to rather complex model despite of the fact that many things have been simplified and only a few protection signals are considered. One lesson from the example is that the Alpha factor model should be used to model common cause failures instead of the Beta factor model. Two options were developed to the comparison of different fail-safe principles. The role of detectable and undetectable failure modes with respect to the failed versus spurious actuations can be clearly seen in the results, showing the importance to model these features in PSA. (Author)

  11. We Can Stop HIV One Conversation at a Time Radio PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2014-08-27

    As part of the We Can Stop HIV One Conversation at a Time campaign, this 30 second PSA encourages Hispanics/Latinos to talk openly about HIV and AIDS with their families, friends, partners, and communities.  Created: 8/27/2014 by National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP).   Date Released: 8/27/2014.

  12. 浅谈PSA中的相关性分析%Discussion of Relativity Analysis in PSA

    Institute of Scientific and Technical Information of China (English)

    依岩; 柴国旱; 李春

    2005-01-01

    相关性广泛存在于核电厂的设计和运行之中,它对核电厂概率安全评价(PSA)结果有重要的贡献.本文介绍了PSA中相关性评价的方法,并结合中国已有的工程实践进行了分析.

  13. Summary of the data collection and analysis process used for Temelin NPP PSA project

    International Nuclear Information System (INIS)

    The Temelin NPP is a WWER-1000/320 two unit plant under construction. This paper briefly discusses the characteristics of data sources that were used to estimate the initiating event frequencies, component reliability parameters, unavailabilities due to maintenance, common cause failure probabilities and human error probabilities in the frame of Temelin PSA Project covering Level 1 for both at power and non power modes of operation, external events and the Level 2 analysis. (authors)

  14. Guidelines for reliability analysis of digital systems in PSA context - Phase 2 Status report

    International Nuclear Information System (INIS)

    The OECD/NEA CSNI Working Group on Risk Assessment (WGRisk) has set up a task group called DIGREL to develop a taxonomy of failure modes of digital components for the purposes of probabilistic safety assessment (PSA). A parallel Nordic activity carried out a pre-study where a comparison of Nordic experiences and a literature review were performed. The study showed a wide range of approaches and solutions to the challenges given by digital I and C. In 2011, a proposal for the failure modes taxonomy was defined. This is based on a set of requirements agreed on the purpose of the taxonomy. The following levels of details can be distinguished from the hardware point of view: (1) the entire system, (2) a division, (3) processing units (and cabinets), (4) modules, i.e. subcomponents of processing units and (5) generic components, i.e. subcomponents of modules. Module level seems to be the most appropriate from the PSA modelling point of view. The software failure modes taxonomy is still an open issue. An existing simplified PSA model has been complemented with fault tree models for a four-redundant distributed protection system in order to study and demonstrate the effect of design features and modelling approaches. The example shows that even rather simple I and C design leads to rather complex model despite of the fact that many things have been simplified and only a few protection signals are considered. One lesson from the example is that the Alpha factor model should be used to model common cause failures instead of the Beta factor model. Two options were developed to the comparison of different fail-safe principles. The role of detectable and undetectable failure modes with respect to the failed versus spurious actuations can be clearly seen in the results, showing the importance to model these features in PSA. (Author)

  15. Face-to-face Tobacco Sales: What Retailers Need to Know PSA (:30)

    Centers for Disease Control (CDC) Podcasts

    2010-09-30

    PSA to help raise retailers' awareness of the new federal tobacco regulations related to the sale of cigarettes and smokeless tobacco products to people under 18 and the requirement to sell products face-to-face.  Created: 9/30/2010 by The CDC Division of News and Electronic Media and the FDA Center for Tobacco Products.   Date Released: 9/30/2010.

  16. Hiperplasia Prostática Benigna e PSA: o efeito dominó Benign prostatic hyperplasia and PSA: the domino effect Hiperplasia benigna de prostata y PSA: el efecto dominó

    OpenAIRE

    José Agostinho Santos

    2012-01-01

    Após a publicação de uma recomendação contra o rastreio câncer prostático pela U.S. Preventive Services Task Force, a comunidade médica não poderá desvincular-se das particularidades relacionadas com o antígeno prostático específico (PSA). O enfoque dado às guidelines da Hiperplasia Prostática surge pela possível partilha, a determinado ponto da sua abordagem, de um trilho que cursa também com a solicitação ...

  17. Differential regulation of renal phospholipase C isoforms by catecholamines.

    Science.gov (United States)

    Yu, P Y; Asico, L D; Eisner, G M; Jose, P A

    1995-01-01

    Dopamine and D1 agonists and NE all increase phosphatidyl inositol-specific phospholipase C (PLC) activity, but whereas dopamine produces a natriuresis, NE has an antinatriuretic effect. To determine if catecholamines differentially regulate the expression of PLC isoforms, we infused fenoldopam, a D1 agonist, or pramipexole, a D1/D2 agonist, intravenously or infused fenoldopam or NE into the renal artery of anesthetized rats. After 3-4 h of infusion, when the expected natriuresis (fenoldopam or pramipexole) or antinatriuresis (NE) occurred, the kidneys were removed for analysis of PLC isoform protein expression activity. Western blot analysis revealed that in renal cortical membranes, fenoldopam and pramipexole increased expression of PLC beta 1 and decreased expression of PLC gamma 1; PLC delta was unchanged. In the cytosol, pramipexole and fenoldopam increased expression of both PLC beta 1 and PLC gamma 1. No effects were noted in the medulla. A preferential D1 antagonist, SKF 83742, which by itself had no effect, blocked the effects of pramipexole, thus confirming the involvement of the D1 receptor. In contrast, NE also increased PLC beta 1 but did not affect PLC gamma 1 protein expression in membranes. The changes in PLC isoform expression were accompanied by similar changes in PLC isoform activity. These studies demonstrate for the first time differential regulation of PLC isoforms by catecholamines. PMID:7814630

  18. SURVIV for survival analysis of mRNA isoform variation.

    Science.gov (United States)

    Shen, Shihao; Wang, Yuanyuan; Wang, Chengyang; Wu, Ying Nian; Xing, Yi

    2016-01-01

    The rapid accumulation of clinical RNA-seq data sets has provided the opportunity to associate mRNA isoform variations to clinical outcomes. Here we report a statistical method SURVIV (Survival analysis of mRNA Isoform Variation), designed for identifying mRNA isoform variation associated with patient survival time. A unique feature and major strength of SURVIV is that it models the measurement uncertainty of mRNA isoform ratio in RNA-seq data. Simulation studies suggest that SURVIV outperforms the conventional Cox regression survival analysis, especially for data sets with modest sequencing depth. We applied SURVIV to TCGA RNA-seq data of invasive ductal carcinoma as well as five additional cancer types. Alternative splicing-based survival predictors consistently outperform gene expression-based survival predictors, and the integration of clinical, gene expression and alternative splicing profiles leads to the best survival prediction. We anticipate that SURVIV will have broad utilities for analysing diverse types of mRNA isoform variation in large-scale clinical RNA-seq projects. PMID:27279334

  19. Is there a role for {sup 11}C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

    Energy Technology Data Exchange (ETDEWEB)

    Castellucci, Paolo [University of Bologna, Service of Nuclear Medicine, Department of Haematology-Oncology and Laboratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant' Orsola-Malpighi, Bologna (Italy); Azienda Ospedaliero-Unversitaria di Bologna Policlinico Sant' Orsola-Malpighi, UO di Medicina Nucleare, PAD. 30, Bologna (Italy); Fuccio, Chiara; Santi, Ivan; Nanni, Cristina; Allegri, Vincenzo; Montini, Gian Carlo; Ambrosini, Valentina; Boschi, Stefano; Fanti, Stefano [University of Bologna, Service of Nuclear Medicine, Department of Haematology-Oncology and Laboratory Medicine, Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant' Orsola-Malpighi, Bologna (Italy); Rubello, Domenico; Marzola, Maria Cristina [Sanata Maria della Misericordia Hospital, Department of Nuclear Medicine, Medical Physics, Radiology, Service of Nuclear Medicine, PET/CT Centre, Rovigo (Italy); Schiavina, Riccardo; Martorana, Giuseppe [University of Bologna, Service of Urology, Department of Specialist Surgery and Anaesthesiology, Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant' Orsola-Malpighi, Bologna (Italy)

    2011-01-15

    The aim of this study was to evaluate the potential usefulness of whole-body {sup 11}C-choline PET/CT in the re-staging of prostate cancer (PC) patients previously treated with radical prostatectomy (RP), who presented a mild increase of prostate-specific antigen (PSA) <1.5 ng/ml (early biochemical relapse) during follow-up (FU). We evaluated 102 consecutive patients (mean age = 68 years, range = 54-82 years) previously treated with RP and who presented during FU a mild increase of trigger PSA serum levels <1.5 ng/ml: mean 0.86 {+-} 0.40 ng/ml (range 0.2-1.5) and median 0.93 ng/ml (range 0.67-1.10). In this patient series {sup 11}C-choline PET/CT was used as the first imaging examination at the time of the detection of a mild serum PSA increase <1.5 ng/ml. {sup 11}C-Choline PET/CT was performed following standard procedures in our centre. At the time of PET/CT, 86 patients were not receiving any pharmacologic treatment, while 16 were under anti-androgenic therapy. Positive PET findings were validated by: (a) transrectal ultrasound (TRUS)-guided biopsy in cases of local recurrence, (b) surgical lymphadenectomy, (c) other imaging procedures or (d) FU lasting for at least 12 months. Univariate and multivariate analyses were used to evaluate the following variables: age, TNM staging, Gleason score, time from RP to the biochemical relapse, anti-androgen therapy at the time of {sup 11}C-choline PET/CT scan, trigger PSA value and PSA kinetics, i.e. PSA doubling time (PSAdt) and PSA velocity (PSAvel), in order to assess the significant predictive factors related to the findings of a positive {sup 11}C-choline PET/CT scan. Overall, {sup 11}C-choline PET/CT showed positive findings in 29 of 102 patients (28% of cases). In detail, {sup 11}C-choline PET/CT detected: local relapse in 7 patients, bone metastases in 13 patients (4 single and 9 multiple) and lymph node metastases in 9 patients (6 single and 3 multiple). Positive PET findings were validated by: (a) TRUS

  20. Modelling and data prerequisites for specific applications of PSA in the management of nuclear plant safety

    International Nuclear Information System (INIS)

    The IAEA has a programme which supports the performance and use of probabilistic safety assessments (PSAS) to improve nuclear safety internationally. The assistance offered in this areas by the IAEA to Member States has traditionally focused on planning, performance and peer review of PSAs. PSA activities within the IAEA's programme in the area of applications are presently being expanded. The various applications of PSAs require that PSAs being developed have certain characteristics in terms of their scope, the degree of details in the modelling, the flexibility in performing desired calculations, the quality and type of the data used, and the assumptions made in treating safety significant aspects. In many cases, existing PSAs or PSAs being completed can be extended to fulfill the requirements for uses in many applications to enhance the safety of nuclear power plants. This report provides information on how to carry such extensions by matching PSA characteristics to various applications that are being considered. This report was prepared by consultants together with the IAEA following the recommendations of a Technical Committee Meeting on PSA Requirements for Use in Safety Management, held by the IAEA in co-operation with the Swedish Nuclear Power Inspectorate in Stockholm, Sweden, 16-20 September 1991. 42 refs, 1 tab

  1. Hybrid approach for the assessment of PSA models by means of binary decision diagrams

    Energy Technology Data Exchange (ETDEWEB)

    Ibanez-Llano, Cristina, E-mail: cristina.ibanez@iit.upcomillas.e [Instituto de Investigacion Tecnologica (IIT), Escuela Tecnica Superior de Ingenieria ICAI, Universidad Pontificia Comillas, C/Santa Cruz de Marcenado 26, 28015 Madrid (Spain); Rauzy, Antoine, E-mail: Antoine.RAUZY@3ds.co [Dassault Systemes, 10 rue Marcel Dassault CS 40501, 78946 Velizy Villacoublay Cedex (France); Melendez, Enrique, E-mail: ema@csn.e [Consejo de Seguridad Nuclear (CSN), C/Justo Dorado 11, 28040 Madrid (Spain); Nieto, Francisco, E-mail: nieto@iit.upcomillas.e [Instituto de Investigacion Tecnologica (IIT), Escuela Tecnica Superior de Ingenieria ICAI, Universidad Pontificia Comillas, C/Santa Cruz de Marcenado 26, 28015 Madrid (Spain)

    2010-10-15

    Binary decision diagrams are a well-known alternative to the minimal cutsets approach to assess the reliability Boolean models. They have been applied successfully to improve the fault trees models assessment. However, its application to solve large models, and in particular the event trees coming from the PSA studies of the nuclear industry, remains to date out of reach of an exact evaluation. For many real PSA models it may be not possible to compute the BDD within reasonable amount of time and memory without considering the truncation or simplification of the model. This paper presents a new approach to estimate the exact probabilistic quantification results (probability/frequency) based on combining the calculation of the MCS and the truncation limits, with the BDD approach, in order to have a better control on the reduction of the model and to properly account for the success branches. The added value of this methodology is that it is possible to ensure a real confidence interval of the exact value and therefore an explicit knowledge of the error bound. Moreover, it can be used to measure the acceptability of the results obtained with traditional techniques. The new method was applied to a real life PSA study and the results obtained confirm the applicability of the methodology and open a new viewpoint for further developments.

  2. Analytical tool for the periodic safety analysis of NPP according to the PSA guideline. Vol. 1

    International Nuclear Information System (INIS)

    The SAIS (Safety Analysis and Informationssystem) Programme System is based on an integrated data base, which consists of a plant-data and a PSA related data part. Using SAIS analyses can be performed by special tools, which are connected directly to the data base. Two main editors, RISA+ and DEDIT, are used for data base management. The access to the data base is done via different types of pages, which are displayed on a displayed on a computer screen. The pages are called data sheets. Sets of input and output data sheets were implemented, such as system or component data sheets, fault trees or event trees. All input information, models and results needed for updated results of PSA (Living PSA) can be stored in the SAIS. The programme system contains the editor KVIEW which guarantees consistency of the stored data, e.g. with respect to names and codes of components and events. The information contained in the data base are called in by a standardized users guide programme, called Page Editor. (Brunsbuettel on reference NPP). (orig./HP)

  3. Evaluation of BDB accident management in PSA for recent German 1300 MW PWRs (Konvoi)

    International Nuclear Information System (INIS)

    The Siemens AG/KWU has been performing the probabilistic safety assessment (PSA) for the nuclear power plants (NPPs) for more than 25 years for purposes of design optimization, safety research and special licensing issues. Focus of the PSA application nowadays is towards development of advanced NPPs such as EPR and 1,000 MW BWR, periodic safety review of operating plants, development and implementation of BDB (beyond design basis)-AM (accident management) measure, and so on. Here were discussed on the last two topics. As a results, PSA gave underline of high safety level on basic design in a plant expressed by the already low hazard states frequency and the balanced design, and it was recognized that efficiency of the BDB emergency measures and procedures expressed reduction of frequency required for plant damage states, importance of the emergency procedures for mitigating damage potential of reactor coolant pressure boundary failure under pressed conditions, and representation of backfitted BDB AM measures for an additional level in multi-level safety concept of the plants. (G.K.)

  4. Review of UCN 3,4 PSA model based on NEI PRA peer review process guidance, rev.0

    International Nuclear Information System (INIS)

    Recently, under the de-regulation environment, nuclear industry has attempted various approaches to improve the economics of Nuclear Power Plants (NPP). One of these efforts is the Risk Informed/Performance-Based Operation (RIPBO). This approach uses the risk and performance information to manage the resources effectively and efficiently that are used in the operation of NPP. In RIPBO, PSA quality is one of the most important things. The nuclear industry and regulatory body of U.S.A have developed a measure to evaluate the quality of PSA. NEI (Nuclear Energy Institute) has developed a guidance called 'NEI PRA Peer Review Guidance,' and NRC (Nuclear Regulatory Committee) and ASME have developed the 'PRA Standard.' In Korea, several projects are on going now, such as the extension of AOT/STI of RPS/ESFAS, Risk-Informed In-Service Inspection (RI-ISI). However, in Korea, there have been no attempts to evaluate the quality of PSA model itself. Therefore, we cannot be sure about the quality of PSA whether or not the present PSA model can be used for the risk-informed applications such as mentioned above. We can say that the evaluation of PSA model quality is the basis for the RIPBO. In this report, we have evaluated the quality of PSA model for Ulchin 3 and 4 units based on the NEI guidance. We, also, have derived what items are to be improved to upgrade the quality of PSA model and how it can be improved. This report can be used as the base of RIPBO work in Korea. The review result based on ASME Standard is published as the separated technical report of KAERI

  5. Age-specific reference values for serum prostate-specific antigen in a community-based population of healthy Swedish men.

    Science.gov (United States)

    Löfman, O; Lindahl, T; Varenhorst, E

    1997-05-01

    To establish normal reference values for prostate-specific antigen (PSA) in a Swedish population we investigated 878 healthy men, 56-75 years of age. They were randomly selected from a population of 9171 males in this group. Cancer of the prostate was excluded by digital rectal examination. When digital rectal examination was suspicious for carcinoma of the prostate and/or serum PSA > 4 micrograms l-1, fine-needle aspiration biopsy was performed. Central values, values of variance and reference limits were defined by a non-parametric method in four age groups. A strong positive correlation between PSA values and age was found and the variance increased with age. The relationship between PSA value and age was non-linear. For the age group 56-60 the upper reference limit (95th percentile) was 4.6 micrograms l-1 (confidence interval, CI: 3.9-5.5). For the age groups 61-65, 66-70 and 71-75 the corresponding values were 4.4 (3.8-5.2), 7.6 (6.5-8.9) and 8.4 micrograms l-1 (7.2-9.8) respectively. For the age groups studied the increment over time of the PSA value was 2-8% per year depending on age, with an average increment per year over 15 years of 4.3%. Overall, 11% of our reference sample had a serum PSA level > 4 micrograms l-1. We consider our study population to be representative for a normal Swedish male population in these age groups. PMID:9238758

  6. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage

    International Nuclear Information System (INIS)

    Purpose: Ideal candidates for 3D dose escalation conformal radiation or external beam + implant therapy are identified on the basis of the prostate-specific antigen (PSA) level, biopsy Gleason score, and the 1992 American Joint Commission Cancer (AJCC) clinical T-stage. Methods and Materials: The pathologic findings of 1742 men with clinical stage T1c,2 prostate cancer managed with a radical prostatectomy (RP) between 1990 and 1998 were subjected to a logistic regression multivariable analysis. The endpoints examined included pathologic organ-confined (OC), specimen-confined (SC), and margin (M) or seminal vesicle (SV) positive disease. SC disease was defined as extracapsular extension (ECE) with a negative surgical margin. The clinical factors tested included PSA level, biopsy Gleason score, and the 1992 AJCC clinical T-stage. PSA failure-free (bNED) survival was calculated according to the method of Kaplan and Meier. Results: Significant negative predictors of pathologic OC-disease or positive predictors of M+ or SV+ disease included a PSA > 10 ng/ml (p + or SV+ disease respectively. Conclusions: Patients most likely to derive a survival benefit from the improved local control possible using dose escalation techniques were those who had both a low risk of having occult micrometastatic disease (+ or SV+) and a reasonable likelihood of remaining disease-free after RP (>50% 5-year bNED). These patients included those having T1c, 2a, PSA > 10-15 ng/ml, and biopsy Gleason ≤6 or T1c, 2a, 2b, PSA ≤ 10 ng/ml, and biopsy Gleason ≤ 7 prostate cancer

  7. 血清T-PSA、F/T诊断前列腺肿瘤及其阳性预警值研究%Serum T-PSA , F/T ratio in diagnosis of prostatic cancer and its positive alarm value

    Institute of Scientific and Technical Information of China (English)

    陈国军; 陆建红; 杨勇; 董长林

    2005-01-01

    目的研究血清前列腺特异性抗原(Prostate specific antigen,PSA)、游离前列腺抗原(Free prostate specific antigen,F-PSA)与总前列腺抗原(Total prostate specific antigen,T-PSA)之比值(F/T)对前列腺肿瘤(Prostate cancer,PCa)的诊断价值和阳性预警值.方法应用化学发光法检测健康对照组60例,前列腺增生(Benign prostate hyperplasia,BPH)78例,慢性前列腺炎(Chronic prostateinflammatory,CPI)80例和PCa患者53例的血清T-PSA、F-PSA含量并计算其F/T值和对各组的检测结果进行比较分析.结果PCa组的T-PSA均值明显高于其他3组、其F/T值明显低于其他3组(P<0.01);BPH组、CPI组和健康对照组间F/T值无差异(P>0.05);BPH组与CPI组间T-PSA无差异(P>0.05),但高于健康对照组(P<0.01).当T-PSA在4.0~10.0 ng/ml时,3组研究对象间的T-PSA值无差异(P>0.05).以T-PSA≥4.0 ng/ml和T-PSA≥30.0 ng/ml为界区分前列腺良恶性疾病,PCa诊断敏感性分别为100%、47.2%,特异性分别为35.3%、100.0%;当F/T≤0.20和F/T≤0.15时,PCa诊断敏感性分别为96.2%、90.6%,特异性分别为43.6%、62.3%.结论 T-PSA结合F/T可提高PCa的诊断能力,当T-PSA异常且F/T≤0.20时必须定期随访、检查,以便及时得到明确诊治.

  8. Fault tree conditioning methods to trace system configuration changes for the application to low-power/shutdown PSA

    International Nuclear Information System (INIS)

    There have been few Probabilistic Safety Assessments (PSAs) for a whole low power and shutdown (LPSD) period since the difficulties and the cost for these assessments are considerable when compared with those for a normal operation period. The frequent changes in system configurations and the reactor coolant system (RCS) states make it difficult to estimate a risk for the LPSD period. We propose a new fault tree (FT) construction method for the LPSD PSA by using reference FTs, usually for a full-power mode, and by applying conditioning methods to the reference FTs. The conditioning method includes a condition gate function, an alternative FT structure, and the substitutions of an event to a reference FT. We used the FT of a full power PSA as the starting point to maintain a consistency between the full-power and the LPSD PSA model. Maintaining the original structure of the FT for a full-power PSA and providing flexibility to the developed FT for the LPSD are the key factors of the present study. The developed method was applied to the LPSD PSA model of the UCN 3 and 4 units in Korea, which showed that the FTs for the LPSD PSA model of a nuclear power plant (NPP) can be generated easily from those for a full-power mode as well as maintaining a consistency between the two models.

  9. Proteogenomic Analysis Identifies a Novel Human SHANK3 Isoform

    Directory of Open Access Journals (Sweden)

    Fahad Benthani

    2015-05-01

    Full Text Available Mutations of the SHANK3 gene have been associated with autism spectrum disorder. Individuals harboring different SHANK3 mutations display considerable heterogeneity in their cognitive impairment, likely due to the high SHANK3 transcriptional diversity. In this study, we report a novel interaction between the Mutated in colorectal cancer (MCC protein and a newly identified SHANK3 protein isoform in human colon cancer cells and mouse brain tissue. Hence, our proteogenomic analysis identifies a new human long isoform of the key synaptic protein SHANK3 that was not predicted by the human reference genome. Taken together, our findings describe a potential new role for MCC in neurons, a new human SHANK3 long isoform and, importantly, highlight the use of proteomic data towards the re-annotation of GC-rich genomic regions.

  10. Laminin isoforms in endothelial and perivascular basement membranes

    Science.gov (United States)

    Yousif, Lema F.; Di Russo, Jacopo; Sorokin, Lydia

    2013-01-01

    Laminins, one of the major functional components of basement membranes, are found underlying endothelium, and encasing pericytes and smooth muscle cells in the vessel wall. Depending on the type of blood vessel (capillary, venule, postcapillary venule, vein or artery) and their maturation state, both the endothelial and mural cell phenotype vary, with associated changes in laminin isoform expression. Laminins containing the α4 and α5 chains are the major isoforms found in the vessel wall, with the added contribution of laminin α2 in larger vessels. We here summarize current data on the precise localization of these laminin isoforms and their receptors in the different layers of the vessel wall, and their potential contribution to vascular homeostasis. PMID:23263631

  11. Oxygenation properties and isoform diversity of snake hemoglobins

    DEFF Research Database (Denmark)

    Storz, Jay F.; Natarajan, Chandrasekhar; Moriyama, Hideaki;

    2015-01-01

    Available data suggest that snake hemoglobins (Hbs) are characterized by a combination of unusual structural and functional properties relative to the Hbs of other amniote vertebrates, including oxygenation-linked tetramer- dimer dissociation. However, standardized comparative data are lacking...... for snake Hbs, and the Hb isoform composition of snake red blood cells has not been systematically characterized. Here we present the results of an integrated analysis of snake Hbs and the underlying - and -type globin genes to characterize 1) Hb isoform composition of definitive erythrocytes, and 2......) the oxygenation properties of isolated isoforms as well as composite hemolysates. We used species from three families as subjects for experimental studies of Hb function: South American rattlesnake, Crotalus durissus (Viperidae); Indian python, Python molurus (Pythonidae); and yellow-bellied sea snake, Pelamis...

  12. Murine antigen-induced arthritis.

    NARCIS (Netherlands)

    Berg, W.B. van den; Joosten, L.A.B.; Lent, P.L.E.M. van

    2007-01-01

    Antigen induced arthritis is a unilateral T-cell driven model caused by direct injection of an antigen into the knee joint of a FCA preimmunized animal. The chronicity is determined by antigen retention in avascular structures of the joint through charge mediated binding or antibody mediated trappin

  13. Identification and characterization of novel NuMA isoforms

    Energy Technology Data Exchange (ETDEWEB)

    Wu, Jin, E-mail: petersdu2112@hotmail.com [Key Laboratory for Cell Proliferation and Regulation of the Ministry of Education, Beijing Normal University, Beijing (China); Xu, Zhe [Department of Clinical Laboratory Diagnosis, Beijing Tiantan Hospital, Capital Medical University, Beijing (China); Core Laboratory for Clinical Medical Research, Beijing Tiantan Hospital, Capital Medical University, Beijing (China); He, Dacheng [Key Laboratory for Cell Proliferation and Regulation of the Ministry of Education, Beijing Normal University, Beijing (China); Lu, Guanting, E-mail: guantlv@126.com [Beijing DnaLead Science and Technology Co., LTD, Beijing (China)

    2014-11-21

    Highlights: • Seven NuMA isoforms generated by alternative splicing were categorized into 3 groups: long, middle and short. • Both exons 15 and 16 in long NuMA were “hotspot” for alternative splicing. • Lower expression of short NuMA was observed in cancer cells compared with nonneoplastic controls. • Distinct localization pattern of short isoforms indicated different function from that of long and middle NuMA. - Abstract: The large nuclear mitotic apparatus (NuMA) has been investigated for over 30 years with functions related to the formation and maintenance of mitotic spindle poles during mitosis. However, the existence and functions of NuMA isoforms generated by alternative splicing remains unclear. In the present work, we show that at least seven NuMA isoforms (categorized into long, middle and short groups) generated by alternative splicing from a common NuMA mRNA precursor were discovered in HeLa cells and these isoforms differ mainly at the carboxyl terminus and the coiled-coil domains. Two “hotspot” exons with molecular mass of 3366-nt and 42-nt tend to be spliced during alternative splicing in long and middle groups. Furthermore, full-length coding sequences of long and middle NuMA obtained by using fusion PCR were constructed into GFP-tagged vector to illustrate their cellular localization. Long NuMA mainly localized in the nucleus with absence from nucleoli during interphase and translocated to the spindle poles in mitosis. Middle NuMA displayed the similar cell cycle-dependent distribution pattern as long NuMA. However, expression of NuMA short isoforms revealed a distinct subcellular localization. Short NuMA were present in the cytosol during the whole cycle, without colocalization with mitotic apparatus. These results have allowed us tentatively to explore a new research direction for NuMA’s various functions.

  14. Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer

    Institute of Scientific and Technical Information of China (English)

    Takumi Shiraishi; Robert H Getzenberg; Prakash Kulkarni

    2012-01-01

    The introduction of serum prostate-specific antigen (PSA) in the 1980s has dramatically altered and benefited the initial diagnosis of prostate cancer.However,the widespread use of PSA testing has resulted in overdetection and overtreatment of potentially indolent disease.Thus,a clinical dilemma today in the management of prostate cancer is to discern men with aggressive disease who need definitive treatment from men whose disease are not lethal.Although several serum and tissue biomarkers have been evaluated during the past decade,improved markers are still needed to enhance the accuracy,with which patients at risk can be discerned and treated more aggressively.The cancer/testis antigens (CTAs) are a group of proteins that are restricted to the testis in the normal adult,but are aberrantly expressed in several types of cancers.Because of their restricted expression pattern,the CTAs represent attractive biomarker candidates for cancer diagnosis/prognosis.Furthermore,several studies to date have reported the differential expression of CTAs in prostate cancer.Here,we review recent developments that demonstrate the potential of the CTAs as biomarkers to discern the aggressive phenotype of prostate cancer.

  15. A Review of Metallothionein Isoforms and their Role in Pathophysiology

    OpenAIRE

    Senthil kumar M; Manisenthil Kumar KT; Shyam Sunder A; Thirumoorthy N; Ganesh GNK; Chatterjee Malay

    2011-01-01

    Abstract The Metallothionein (MT) is a protein which has several interesting biological effects and has been demonstrated increase focus on the role of MT in various biological systems in the past three decades. The studies on the role of MT were limited with few areas like apoptosis and antioxidants in selected organs even fifty years after its discovery. Now acknowledge the exploration of various isoforms of MT such as MT-I, MT-II, MT-III and MT-IV and other isoforms in various biological s...

  16. Contribuição da densidade do PSA para predizer o câncer da próstata em pacientes com valores de PSA entre 2,6 e 10,0 ng/ml

    Directory of Open Access Journals (Sweden)

    Hugo Alexandre Sócrates de Castro

    2011-08-01

    Full Text Available OBJETIVO: Estudar o perfil dos pacientes submetidos a biópsia prostática, determinando possíveis padrões que, associados aos níveis de PSA entre 2,6 e 10,0 ng/ml, possam levar a uma diminuição de biópsias desnecessárias. MATERIAIS E MÉTODOS: De 2007 a 2009, foi realizado um estudo transversal com 1.282 indivíduos submetidos a biópsia prostática e que apresentavam níveis de PSA entre 2,6 e 10,0 ng/ml. RESULTADOS: A prevalência de câncer foi de 28,6%. Pacientes com câncer eram, em média, mais idosos, com valores de PSA e densidade de PSA mais altos e menor volume da próstata. Na análise da densidade de PSA, os pacientes com câncer tiveram média de 0,31 ng/ml/cc, enquanto nos pacientes com resultado negativo a média foi de 0,10 ng/ml/cc. Utilizando como critério de positividade para câncer o ponto de corte de densidade de PSA de 0,15 ng/ml/cc, obtivemos especificidade de 74% e sensibilidade de 70%. Para aumentar a sensibilidade é preciso reduzir o ponto de corte. Com o valor 0,09 ng/ml/cc, obtivemos sensibilidade de 84% (IC 95%: 80-87% e especificidade de 75% (IC 95%: 72-78%. CONCLUSÃO: O uso sistemático da densidade de PSA na indicação de prosseguimento da investigação do paciente com biópsia poderia reduzir a quantidade de procedimentos desnecessários.

  17. The pneumococcal surface adhesin A (PsaA) protein and its application in conjugate vaccine%肺炎球菌PsaA抗原及其在结合疫苗中的应用

    Institute of Scientific and Technical Information of China (English)

    樊小英; 薛红刚; 郭蓉; 胡菁; 卢佳丽; 朱越雄

    2011-01-01

    目的 应用基因工程技术表达和制备肺炎链球菌表面黏附素A(pneumococcal surface adhesin A,PsaA),并与细菌荚膜多糖耦联制备成多糖蛋白结合疫苗,探讨PsaA作为肺炎球菌蛋白载体在增强结合疫苗中其他细菌多糖抗原的免疫原性的同时,还能获得对肺炎球菌的抗体反应,从而达到用一种结合疫苗能诱导出针对两种细菌的抗体免疫应答的目的 .方法 从肺炎链球菌基因组中扩增psaA基因,将目的 基因插入原核表达载体pET-28a,获得重组质粒pET28a-psaA,通过转化进入大肠杆菌BL21中,经IPTG诱导,采用DEAE-阴离子交换层析法纯化基因重组rPsaA蛋白.将纯化到的rPsaA蛋白与A群脑膜炎荚膜多糖(group A meningococcal polysaccharide,GAMP)耦联成多糖蛋白结合疫苗后,用小鼠动物模型进行免疫实验,检测该疫苗的免疫原性,用ELISA法测定该疫苗在小鼠体内产生的针对肺炎球菌和脑膜炎球菌两种病原菌特异性抗原的抗体水平.结果 成功克隆基因重组表达质粒,而且表达的PsaA蛋白在载体上的组氨酸标签之前终止表达,不带有组氨酸标签,保证疫苗的安全性.SDS-PAGE技术分析表明:rPsaA蛋白高效表达,约为菌体蛋白的60%,蛋白质相对分子质量约为37×103,而且蛋白的可溶性好,不形成包涵体,用DEAE-阴离子交换层析法纯化其纯度可达80%以上.纯化到的PsaA蛋白与荚膜多糖耦联成功,应用于小鼠免疫实验,PsaA蛋白载体能显著增强A群脑膜炎荚膜多糖抗原的免疫原性,并同时产生针对肺炎球菌蛋白抗原和脑膜炎球菌多糖抗原的特异性抗体.结论 利用基因工程技术获得无组氨酸标签的PsaA蛋白,并将它与A群脑膜炎荚膜多糖耦联,可以在增强荚膜多糖抗原免疫原性的同时,提高疫苗的免疫保护效果,探讨了给儿童接种一种疫苗能同时预防肺炎和脑膜炎两种传染病的可能性.%Objective To express and purify the

  18. ApoE isoform-dependent changes in hippocampal synaptic function

    Directory of Open Access Journals (Sweden)

    Sullivan Patrick M

    2009-05-01

    Full Text Available Abstract The lipoprotein receptor system in the hippocampus is intimately involved in the modulation of synaptic transmission and plasticity. The association of specific apoE isoform expression with human neurodegenerative disorders has focused attention on the role of these apoE isoforms in lipoprotein receptor-dependent synaptic modulation. In the present study, we used the apoE2, apoE3 and apoE4 targeted replacement (TR mice along with recombinant human apoE isoforms to determine the role of apoE isoforms in hippocampus area CA1 synaptic function. While synaptic transmission is unaffected by apoE isoform, long-term potentiation (LTP is significantly enhanced in apoE4 TR mice versus apoE2 TR mice. ApoE isoform-dependent differences in LTP induction require NMDA-receptor function, and apoE isoform expression alters activation of both ERK and JNK signal transduction. Acute application of specific apoE isoforms also alters LTP induction while decreasing NMDA-receptor mediated field potentials. Furthermore, acute apoE isoform application does not have the same effects on ERK and JNK activation. These findings demonstrate specific, isoform-dependent effects of human apoE isoforms on adult hippocampus synaptic plasticity and highlight mechanistic differences between chronic apoE isoform expression and acute apoE isoform exposure.

  19. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.

    Science.gov (United States)

    Salido-Guadarrama, Alberto Ivan; Morales-Montor, Jorge Gustavo; Rangel-Escareño, Claudia; Langley, Elizabeth; Peralta-Zaragoza, Oscar; Cruz Colin, Jose Luis; Rodriguez-Dorantes, Mauricio

    2016-06-01

    At present, prostate-specific antigen (PSA) is used as a clinical biomarker for prostate cancer (PCa) diagnosis; however, a large number of patients with benign prostate hyperplasia (BPH) with PSA levels in the 'gray area' (4-10 ng/ml) are currently subjected to unnecessary biopsy due to overdiagnosis. Certain microRNAs (miRs) have been proven to be useful biomarkers, several of which are detectable in bodily fluids. The present study identified and validated a urinary miR‑based signature to enhance the specificity of PCa diagnosis and to reduce the number of patients with benign conditions undergoing biopsy. Seventy‑three urine samples from Mexican patients with diagnosis of PCa with a Gleason score ≥7 and 70 patients diagnosed with BPH were collected after digital rectal examination (DRE) of the prostate. miR expression profiles were determined using TaqMan Low Density Array experiments, and normalized Ct values for the miRs were compared between PCa and BPH groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate whether miR detection in urine is suitable for distinguishing patients with PCa from those with BPH. The identified miR‑100/200b signature was significantly correlated with PCa. Using a multivariable logistic regression approach, a base model including the clinical variables age, prostate‑specific antigen (PSA), the percentage of free PSA and DRE was generated, and a second base model additionally contained the miR‑100/200b signature. ROC analysis demonstrated that the combined model significantly outperformed the capacity of PSA (P<0.001) and the base model (P=0.01) to discriminate between PCa and BPH patients. In terms of evaluation of the sub‑group of patients in the gray zone of PSA levels, the performance of the combined model for predicting PCa cases was significantly superior to PSA level determination (P<0.001) and the base model (P=0.009). In addition, decision curve analysis demonstrated that the

  20. Construction of cell surface-engineered yeasts displaying antigen to detect antibodies by immunofluorescence and yeast-ELISA.

    Science.gov (United States)

    Tang, Yu Qian; Han, Shuang Yan; Zheng, Hong; Wu, Lin; Ueda, Mitsuyoshi; Wang, Xiao Ning; Lin, Ying

    2008-07-01

    In order to detect monoclonal antibodies (MAbs) from insufficient and unavailable human proteins, yeast cells were engineered to display human antigens on their surface and consequently endowed with the ability to specifically bind antibodies. Thus, a fusion gene for the expression of the human proteasome subunit alpha 6 (hPSA6) and human profilin I (hProI) were assembled, respectively, with a His.tag marker at the C-terminal and displayed on yeast surface. With anti-His.tag MAb as the primary antibody and the fluorescein isothiocyanate-conjugated goat anti-mouse Immunoglobulin G as the second antibody, the surface display of hPSA6 and hProI were verified by immunofluorescence labeling. The antigen-displayed yeast particles were used for MAbs detection from ascites through both immunofluorescence and yeast-enzyme-linked immunosorbent assay (ELISA) methods. The results were verified by Western blotting and indirect ELISA. By improving the sensitivity, the novel MAbs detection can be applied in the generation and screening of positive hybridoma. It is suggested that by combining the DNA immunization, the present study can evolve into a quick and protein-free way of MAbs production for insufficient and unavailable antigen. PMID:18542951